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Abstract 
Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of chronic myeloid 
leukemia (CML), however, fail to cure the disease due to the persistence of a refractory 
fraction of stem/progenitor cells. Autophagy is a recycling mechanism utilised by the cell 
as a survival mechanism under stressful conditions, and its induction has been suggested to 
have a cytoprotective role in cancer cells. 
In this study we demonstrate that autophagy is triggered in CML upon TKI-mediated 
inhibition of BCR-ABL, and protects from cell death. In order to evaluate if specific 
autophagy inhibition enhances TKI effects, we stably transduced primary CML 
stem/progenitor cells with a vector carrying a short-hairpin against the key autophagy gene 
ATG7. Knock-down of basal ATG7/autophagy levels in CML stem/progenitor cells 
inhibited by approximately 50% the survival of the cells in a clonogenic assay, and 
reduced by 75% their erythroid differentiation potential. Furthermore, ATG7 knock-down 
enhanced the effects of TKIs imatinib (IM; 1st), dasatinib (DAS; 2nd), nilotinib (NIL; 2nd) 
and ponatinib (PON; 3rd generation), reducing by 92-98% the survival of these cells in a 
clonogenic assay. In contrast, ATG7 knock-down in normal stem cells, with or without 
TKI treatment, did not have a significant effect on survival and proliferation.  
ATG7 was also knocked-down in final disease stage, blast crisis (BC), patient-derived 
K562 and KCL22 cell lines. Both cell lines appeared to depend significantly on autophagy 
for survival as indicated by high apoptosis levels (70-100%) after ATG7 knock-down. 
Interestingly, ATG7 knock-down cells appeared to be more differentiated compared to the 
control (scrambled shRNA).  
Our findings suggest a role for basal autophagy in the survival, differentiation decisions 
and clonogenicity of CML cells, and support the combined use of autophagy inhibition 
with TKIs for the eradication of CML stem/progenitor cells. This could be partially 
attributed to a bypass of the differentiation block upon autophagy inhibition, which 
facilitates TKI-targeting. We underline the necessity for the development of specific 
autophagy inhibitors that in combination with TKIs could potentially eradicate the fraction 
of persistent CML stem/progenitor cells and offer a curative option for CML patients. 
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RT-STA Reverse Transcriptase Specific Target Amplification 
SAHA Suberoylanilide Hydroxamic Acid 
SAP Shrimp Alkaline Phosphatase  
Sca Stem Cell Antigen 1 
SCF Stem Cell Factor 
SCT Stem Cell Transplantation   
SDS Sodium Dodecyl Sulfate 
SEM Standard Error Of The Mean 
SFKs SRC Family Kinases 
SFM Serum Free Medium  
SH1 SRC Homology Domain 1  
SHC  SRC Homology Containing Protein  
shRNA Short-Hairpin RNA 
siRNA Small Interfering RNA 
SMO Smoothened  
SNP Single Nucleotide Polymorphism 
SoS  Son Of Sevenless  
SQSTM1 Sequestosome 1  
SSC Side-Angle Light Scatter  
ST-HSCs Short-Term Haemopoietic Stem Cells  
STAT Signal Transducer And Activator Of Transcription  
SYP  Synaptophysin  
tATG5 Trancuated ATG5 
TBE Tris/Borate/EDTA 
TBS Tris-Buffered Saline 
TBST TBS-Tween 
TEMED Tetramethylethylenediamine 
TIE2 Immunoglobulin-Like And EGF-Like Domains 2  
TKIs Tyrosine Kinase Inhibitors 
TPO Thrombopoietin  
TSC2 Tuberous Sclerosis Protein 2  
UBA Ubiquitin-Associated  
UBL Ubiquitin-Like 
ULK1/2 Unc-51- Like Kinase 1/2 
UV Ultraviolet 
UVRAG UV Irradiation Resistance-Associated Gene 
VPS34 Vacuolar Protein Sorting 34 
WHO World Health Organisation 
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WM Wortmannin  
WT Wild Type 
µ-bcr µ BCR Region 
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1 Introduction 
1.1 Haemopoiesis and haemopoietic stem cells 
Haemopoiesis is the process that refers to the production of the blood cellular components. 
In 1961, Till and McCulloch demonstrated the existence of clonogenic bone marrow (BM) 
cells that could give rise to multilineage haemopoietic colonies in the spleen of lethally 
irradiated mice. Some of these colonies contained a subset of clonogenic cells that could 
reconstitute haemopoiesis of irradiated mice at secondary transplants [1]. It was proposed 
that these cells are haemopoietic stem cells (HSCs), i.e. cells that at single cell level have 
the properties of self-renewal and multilineage differentiation [2-5]. 
During mammalian embryonic development the sites of haemopoietic potential are 
constantly shifting and sequentially include the yolk sac, the aorta, gonads and 
mesonephros (AGM) region, the placenta and the foetal liver. Based on mouse 
transplantation experiments, it has been suggested that the first HSCs bearing the 
characteristic hallmarks (self-renewal, multipotency, migration and apoptosis), appear at 
the AGM region of the embryo 11 days post coitum [6].  Shortly before birth, the HSCs 
migrate from the primary foetal haemopoietic centre, the liver, to the primary adult 
haemopoietic centre, the BM, where they engraft and self-renew. 
HSCs are relatively rare, accounting for approximately 0.05% of the total BM cells [7]. 
They are multipotent cells that can differentiate into all types of mature blood cells by 
residing on top of a hierarchy of progenitors that progressively commit to several or one 
lineage (Figure 1-1) [8]. However, terminally differentiated blood cells are predominantly 
short lived within the circulation and, therefore, need to be constantly replaced. In order to 
prevent exhaustion of the BM cell pool, the HSCs proliferate and self-renew. Through 
asymmetric division, an HSC gives rise to a non-self-renewing oligolineage haemopoietic 
progenitor cell (HPC) and an identical daughter cell that retains all the primitive stem cell 
features [9].  HSCs can also self-renew through symmetrical division, generating two 
identical HSCs that will contribute towards the maintenance of the HSC compartment. 
During or after the division of an HSC, each of the daughter cells has to decide its fate and 
it is believed that this decision largely depends on the environment, known also as the stem 
cell niche [10]. 
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Figure 1-1: The haemopoietic hierarchy 
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Long-term HSCs (LT-HSCs) sit at the top of the hierarchy and have unlimited self-renewal 
capacity, unlike the short-term HSCs (ST-HSCs), which have limited self-renewal 
capacity. Upon activation, HSCs divide and generate multipotent progenitors (MPPs) that 
can further differentiate to common lymphoid progenitors (CLPs) or common myeloid 
progenitors (CMPs). Subsequently, CLPs can differentiate into lymphoid lineages and 
CMPs into myeloid lineages, as shown above. 
Functional analyses of HSCs can be performed by in vitro or in vivo experiments. The 
colony-forming cell (CFC) and long-term culture initiating-cell (LTC-IC) are in vitro 
assays used to evaluate the potential of HPCs and HSCs respectively [11, 12]. In vivo 
experiments involve mainly the BM engraftment of non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) mice to demonstrate the ability of HSCs to reconstitute 
haemopoiesis [13]. One of the most important advances for in vivo functional analyses was 
the enablement of the isolation of HSCs by fluorescence-activated cell sorting (FACS) 
depending on the cell surface marker profile. In 1988, Sprangrude and colleagues isolated 
HSCs from the BM of mice, and concluded that the phenotype of the HSCs that could 
reconstitute haemopoiesis long-term was Thy1low [also known as (aka) cluster of 
differentiation 90 (CD90)], Lin- (lineage cocktail 1), and Sca1+ (stem cell antigen 1) [2]. 
Transplantation experiments focusing on the ability of HSCs subpopulations to engraft the 
BM of lethally irradiated mice showed that the population Sprangrude and colleagues had 
identified contained different HSC subsets, all capable of differentiating into lymphoid and 
myeloid lineages but with different self-renewal and reconstitution capability [3, 14]. In 
1996, Osawa and colleagues first demonstrated that injection of a single HSC could 
reconstitute the long-term the haemopoiesis of a lethally irradiated recipient [5] and based 
on this foundation, following studies classified HSCs into three functional subsets: (i) the 
LT-HSCs, that reside in BM niches and can provide life-long haemopoiesis due to their 
ability of indefinite self-renewal, (ii) the ST-HSCs that have the ability to self-renew for a 
defined interval and can transiently reconstitute haemopoiesis [3], and (iii) the MPP cells 
which have undetectable or no ability to self-renew [14]. It should also be mentioned that 
the cycle status among these subsets differs as well; the majority of LT-HSCs are quiescent 
(G0 phase) [15-17] while a significant fraction of ST-HSCs and MPPs are in cycle under 
homeostatic conditions [1]. Using mathematical model analysis it was predicted that a 
HSC divides about once every year, with the limit of 70 divisions throughout its lifetime 
[18]. This extended cell cycle arrest represents a homeostatic mechanism to ensure that the 
stem cell pool will not be severely depleted and also allows for repair of any DNA damage 
that may occur.  
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Human HSCs were isolated and validated by similar techniques previously used for mouse 
HSCs with the help of antibodies targeting cell surface markers. The CD molecules have 
been extensively used as markers because they feature different cell types and stages of 
differentiation. In the early 1990s it was noticed that during maturation the levels of CD34 
antigen expression in cells from adult BM were decreasing while simultaneously 
increasing for the CD38 [19]. A few years later, DiGiusto and colleagues reported in foetal 
BM, that CD34 expression decreases with the commitment of HPCs to specific lineages 
and cells expressing higher levels of CD34 were more primitive [20]. Therefore, the first 
cell surface marker used for the enrichment of human HSCs was the CD34 antigen, a 115-
kilodaltons (Kd) type I transmembrane glycoprotein. The CD34+ compartment contains 
multilineage primitive HSCs that have the ability to reconstitute haemopoiesis [21]. 
Despite its indisputable significance as a marker for stem cells, little is known about the 
function and regulation of CD34. It has been suggested that it may play a role in adhesion 
of leukocytes and haemopoietic cells, cell localisation, and signal transduction, including 
prevention of terminal differentiation [22]. Another marker used for the characterisation of 
HSCs is the CD38 antigen, a transmembrane glycoprotein used initially as a marker of 
lymphoid differentiation [23]. Its expression correlates with differentiation since levels of 
CD38 increase progressively during the process of maturation [19]. The use of CD38 as a 
marker allows for further identification of the HSC subpopulations; the CD34+CD38+ 
compartment includes the ST-HSCs, while the CD34+CD38- the LT-HSCs [24]. The cell 
surface profile of HSCs is also defined by the presence of receptors that promote 
quiescence and help the anchorage in the niche. Such receptors include the tyrosine kinase 
c-KIT (aka CD117), immunoglobulin-like and EGF-like domains 2 (TIE2) receptors, the 
CXC-chemokine receptor 4 (CXCR4), that via binding niche cell-secreted ligands, 
ultimately, promote cell cycle arrest (Table 1-1) [25]. The quiescence of HSCs is also 
regulated by intracellular proteins and transcription factors [25].  
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Cell Type Phenotype 
HSC CD34+ Lin-  
CD38- CD33- 
HLA-DRlow  
c-Kit+ 
CD133+ 
CD90+ 
MPP and lineage 
committed 
progenitors 
CD34+ Lin+/- 
CD38+ CD33+ 
HLA-DRhigh 
Mature  CD34- Lin+  
 
Table 1-1: Human haemopoietic system lineage marker phenotypes 
 
It has been suggested that HSCs can shift among three phases; (i) the dormant phase, 
where cells are arrested in G0 and have very low metabolism, (ii) the homeostatic phase, 
where cells are able to cycle, and (iii) the injury-activated phase, where cells are 
continuously cycling and have high metabolism. Even if the molecular events underlying 
these phases have not been elucidated so far, it has become apparent during recent years 
that decisions made regarding the fate of a stem cell depend on interactions with the niche. 
The HSCs reside within various sub-regions in the BM and their function may actually 
depend on their exact localisation. Intravital microscopy has revealed that HSCs appear to 
be inherent in the periosteal region of calvarium marrow [26]. Stem cell niches include 
several cellular components, including osteoblasts, osteoclasts, CXCL12-abundant 
reticular cells, and vascular endothelial-cadherin+ sinusoidal endothelial cells [25]. It has 
been proposed that gradients from osteoblast-secreted factors may regulate the niche and 
its size [27, 28], as well as the quiescence status of the HSCs [29]. On the other hand, there 
are studies underlining the importance of the vascular niche and the CXCL12-regulated 
migration of the HSCs to it [30]. Nevertheless, in the calvarium the osteoblastic and 
vascular niches are not anatomically separated; therefore, arguments regarding which niche 
is more influential may be only semantic [31]. 
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1.2 The cancer stem cell hypothesis 
In 1997 Bonnet and Dick provided the first conclusive evidence for the existence of cancer 
stem cells (CSCs). They isolated different subpopulations of human acute myeloid 
leukaemia (AML) stem and progenitor cells and evaluated their capacity to initiate cancer 
after transplantation to NOD/SCID mice. Surprisingly, they observed that the target cells 
responsible for the initiation of AML resided exclusively within the CD34+CD38- 
compartment of HSCs and not the CD34+ or CD34+CD38+ subpopulations [32]. Hence, 
the primitive stem cells are the target of transforming events rather than committed 
progenitors. This concept gave rise to the CSC theory; it supports that, due to similarities 
that CSCs and HSCs present by means of phenotype and function, the CSCs must originate 
from HSCs that have accumulated mutations. Following studies on other haemopoietic and 
solid tumours [33] provided further evidence for the presence of a small number of CSCs 
that have normal stem cell characteristics, such as stable self-renewal properties, but are 
accountable for the initiation of cancer, metastasis and resistance to treatment [34]. 
However, it is still unclear if CSCs share more normal stem cell features, such as the 
ability to undergo asymmetric and symmetric divisions and how stable their phenotype is.  
On the other hand, controversies arose regarding the potential of CSCs and their origin. A 
number of scientists have been questioning the interpretation of the data generated from 
xenotransplantation experiments. They support that the proposed CSCs may not be 
responsible for the initiation of the disease but actually reflect populations of cells that 
have the ability to engraft overriding cross-species differences within stem cell niches, 
cytokine profiles or residual innate immunity [35]. Another hypothesis questioning the 
notion of CSCs, suggests that these cells could originate from progenitor or more 
differentiated cells that acquired mutations leading to the gain of self-renewal capacity 
prior or after being transformed [36]. In samples from acute promyelocytic leukaemia, a 
subtype of AML, the transforming oncogene PML-RARA was detected in CD34-CD38+ 
populations but not in the CD34+CD38- fraction [37]. Retroviral transduction of CMPs 
with the oncogene MLL-ENL conferred properties of self-renewal and induced AML 
following transplantation into irradiated mice [38]. Similar studies in other types of 
leukaemia have also suggested that in some cases the leukaemia initiating cells originate 
from progenitors rather than primitive HSCs [39-41]. In a study performed by Huntly and 
colleagues, following transduction with the MOZ-TIF2 oncogene, CMPs gained capacity 
of serial replating and AML initiation after serial transplantation [42]. However, the 
authors did not record gain of similar properties in BCR-ABL-transduced GMPs. 
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Therefore, it seems that some, but not all, oncogenes can confer leukaemia initiating 
properties in committed progenitor cells.  
Nevertheless, a constantly emerging list of papers keeps providing evidence in support of 
the CSC theory. A recent study conducted by the research group of Carlos Cordon-Cardo 
identified a subpopulation of cells expressing markers of embryonic development in 
prostate cancer patient samples that consist the core of drug resistance and tumour 
progression [43]. These cells had CSC properties, including tumour initiating potential, 
however, lacked differentiation markers and human leukocyte antigen class I (HLAI) 
antigens. They were also in higher percentages in patients with more aggressive or 
metastatic tumours. Regardless of the disputes about the origin of these cells, it is widely 
accepted that targeting these treatment-resistant cancer initiating cells would attack the 
foundation of tumour growth, and potentially offer a curative option. 
 
1.3 CML 
1.3.1 Historical overview 
In 1960, Peter Nowell and David Hungerford opened a new era in cancer research by 
providing the first evidence for a genetic link to cancer. They discovered the hallmark of 
CML; a minute abnormal chromosome present in leukocytes from CML patients [44]. This 
chromosome, designated as Philadelphia chromosome (Ph) after the city at which it was 
discovered, was not found in normal leukocytes but only in malignant cells from CML 
patients. Since then, CML has served as a paradigm disease not only for haemopoietic 
malignancies but also for other types of cancer.  
Interestingly, in 1973 Janet Rowley demonstrated that the Ph is the product of a 
translocation between chromosomes 9 and 22 [45] and a decade afterwards, it was 
determined that the genes involved were the breakpoint cluster region (BCR), whose 
product’s function is still not clear, and the v-abl Abelson murine leukaemia viral 
oncogene homolog (ABL), coding for a tyrosine kinase. The t(9;22) translocation generated 
a fusion BCR-ABL protein that had lost appropriate regulation of ABL and was 
constitutively active and therefore, could be the cause of CML. The most rigorous 
evidence validating this hypothesis came from in vivo experiments in mice, when a series 
of publications demonstrated that BCR-ABL is the cause and not the result of CML, it has 
the ability to transform cells and is both necessary and sufficient for the development and 
maintenance of the disease [46-49].  
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The first evidence that CML is a clonal disease of stem cell origin came from Fialkow and 
colleagues in 1967 [50]. Following studies by the same group on female CML patients 
heterozygous for the X-linked gene coding for glucose-6-phosphate dehydrogenase further 
established the CML stem cell theory; the disease originates from Ph+ HSCs that have the 
capacity to self-renew and constitute the disease [51, 52]. 
 
1.3.2 Disease incidence, course and progression 
CML has an incidence of about 1 in 50,000 per year, accounts for 15% of all adult 
leukaemias, and does not present with significant ethnic or geographical predisposition 
[53]. The median age of onset is 45 to 55 years, with the majority of patients being 
asymptomatic during diagnosis and discovered after routine blood tests. Presenting 
symptoms include weight loss, fever, splenomegaly, purpura, night sweats, abdominal 
fullness and gout.  
CML is characterised by evolution through a biphasic or triphasic course. The majority of 
the cases (approximately 85%) are diagnosed during the asymptomatic chronic phase (CP) 
where the cells are mainly differentiated, minimally invasive and maintain their 
functionality [53]. If left untreated, the disease inevitably progresses after three to five 
years to an intermediate accelerated phase (AP) and later to BC [54]. Nevertheless, up to a 
quarter of patients progress directly to BC without developing the intermediate AC [55]. 
AC and BC are characterised by differentiation arrest and accumulation of blast cells in the 
blood and BM (Table 1-2) [56]. Especially during BC, there is a clonal expansion of 
immature population of blasts that may have developed additional cytogenetic 
abnormalities, and exhibit enhanced proliferation and reduced susceptibility to apoptosis. 
The BC transformation can be myeloid, lymphoid or both, with median survival measured 
in months [57]. 
The progression of the disease is a complex and gradual process that represents the 
accumulation of genetic and epigenetic alterations; these may include enhanced BCR-ABL 
activity following gene amplification, increased promoter activity or other less direct 
mechanisms, such as decreased miR-203 levels, inhibition of SHP-1 phosphatase and 
inactivation of PP2A [58]. Interestingly, BCR-ABL may contribute to the progression 
process by activating mitogenic, anti-apoptotic and anti-differentiation mediators (e.g. 
MYC, JAK2, hnRNP-E2, MDM2, STAT5, BMI1 and BCL2), inhibiting tumour 
suppressors (e.g. p53 or CEBPa), or through aberrant splicing of modulators like glycogen 
synthase kinase 3 beta and PYK2 [58].  
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Feature CP AP BC 
Blast % in blood or 
BM  
<10%  10–19%  ≥ 20%  
Basophil % in blood <20%  ≥ 20% NA  
 Thrombocytosis 
(×109/L)  
≤1000 or 
responsive to 
therapy if >1000  
>1000, unresponsive to 
therapy 
NA  
Thrombocytopenia 
(×109/L)  
≥100 or related to 
therapy if <100  
<100, unrelated to 
therapy 
NA  
Splenomegaly  
Responsive to 
therapy  
Persistent or increasing, 
unresponsive to therapy 
NA  
Extramedullary blast 
tumour (chloroma)  
Absent  Absent Present 
New cytogenetic 
changes that develop 
after the initial BM 
karyotype 
Absent Present  NA  
 
 
Table 1-2: Staging system for CML according to the World Health Organisation (WHO) 
Classification 2008 (NA; not applicable) 
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1.3.3 Diagnosis and monitoring 
The disease hallmark, Ph, is found in 90-95% of CML patients, but can be also detected in 
patients with acute lymphoblastic leukemia (ALL) or AML [53]. Cytogenetic analysis for 
CML diagnosis is the gold standard method that allows for simultaneous identification of 
possible clonal evolution; however, it is a laborious and time-consuming technique. 
Moreover, 5-10% of CML patients present with cryptic rearrangements, i.e. the Ph cannot 
be demonstrated by cytogenetic analysis. In these cases the BCR-ABL fusion gene can be 
detected by fluorescent in situ hybridisation (FISH) analysis or by reverse transcriptase 
polymerase chain reaction analysis (RT-PCR). FISH and quantitative RT-PCR (qRT-PCR) 
are also used to assess the response after stem cell transplantation (SCT) or the efficacy of 
treatment monitoring minimal residual disease (MRD) in remission patients. 
 
1.3.4 BCR-ABL structure  
The BCR gene (130 kilobases; kb) codes for a 160Kd cytoplasmic protein proposed to be 
taking part in the antimicrobial defense of myeloid cells [59]; however, its function is still 
not well-defined [60]. It contains a coiled-coil (CC) oligomerisation domain [61] and a 
serine/threonine domain that is retained in all BCR-ABL fusion proteins. It also contains a 
Rho guanine–nucleotide exchange factor (Rho–GEF) homology domain, a calcium-
dependent lipid-binding site, and a Rac GTPase activating protein (Rac–GAP) domain [62, 
63]. 
The ABL gene (280kb) is transcribed into two alternative mRNA transcripts of 7kb (exon 
Ib, 2–11) and 6kb (exon Ia, 2–11) length and translated into a 145Kd protein that belongs 
to the non-receptor family of tyrosine kinases. ABL can be found mainly in the cytoplasm, 
and at lower levels in the nucleus [64, 65]. Its N-terminus includes three domains with 
homology to the SRC kinases (they regulate signal transduction in cell growth, 
differentiation and survival pathways): (i) the SRC homology domain 1 (SH1) that holds 
the tyrosine kinase activity and is absolutely essential for transformation and (ii) the SH2 
and SH3 domains that bind phosphotyrosine and proline-rich regions respectively. It also 
includes sites that facilitate the binding with DNA, adaptor proteins, and actin [66-69].  
Interacting proteins (Table 1-3) include amongst other the CrKL adaptor proteins and the 
SHPTP1 tyrosine phosphatase, a protein that interplays with the regulation of cytokine 
pathways [66, 70].  
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Binding proteins Description    
p53 Tumour suppressor protein  
Rb Tumour suppressor protein  
3BP-1 SH3 domain-containing protein  
3BP-2 SH3 domain-containing protein  
AAP-1 ABL associated protein 1   
ATM Ataxia telangiectasia mutated protein  
DNA–PK Kinase involved in DNA repair  
     
Binding proteins and 
substrates Description 
   
CrK-1/CrKL SH2 and SH3 domain-containing protein 
ABL-1 ABL interactor-1 protein   
ABL-2 ABL interactor-2 protein   
SHPTP-1 Protein tyrosine phosphatase  
RNA Pol II Large subunit of RNA polymerase II  
CAS Crk binding protein   
P62–DOK RAS–GAP associated phosphotyrosine protein 
 
Table 1-3: ABL binding proteins and substrates 
(Adapted from [71]) 
 
 
The native ABL activity is very low compared to the oncogenic BCR-ABL [72] and has 
been proposed to be enhanced by DNA damage [73, 74], progression of cell cycle to S 
phase [75], and cellular adhesion mediated by integrins [76].  
The malignant transformation ability of BCR-ABL is related to the type of fusion. 
Depending on where the breakpoints occur within the BCR and ABL genes, different-sized 
mRNA and protein isoforms are produced (Figure 1-2). BCR breakpoints may occur within 
the major (M-bcr), minor (m-bcr) or a third region designated as the µ region (µ-bcr). In 
general, the longer the sequence of BCR is retained in the fusion, the more preferable the 
prognosis is. The breakpoints are widely spread at ABL; nonetheless, due to splicing of the 
primary mRNA, BCR is almost always fused to the ABL exon 2. Therefore, depending on 
where the breakpoints occur within the BCR, different sized proteins are produced that 
have diverse capacity to transform the haemopoietic cells and lead to different phenotypes. 
In CML the dominant fusion protein is the BCR-ABLp210, while in ALL it is the BCR-
ABLp185 and in chronic neutrophilic leukaemia (CNL) BCR-ABLp230. 
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Figure 1-2: BCR, ABL structure and different fusion products 
 (Original figure, compiled from information within [77, 78]) 
 
1.3.5 BCR-ABL function 
Upon demonstration that BCR-ABL is the cause of the leukaemogenic transformation, 
extensive efforts have been undertaken in order to identify its molecular mechanism of 
action. The constitutively active tyrosine kinase BCR-ABL has a large variety of targets 
(Table 1-4), and activates a plethora of pathways that protect the cell from undergoing 
apoptosis and lead to transformation, such as the RAS, PI3K, and Janus kinases (JAK)- 
signal transducer and activator of transcription (STAT) pathways (Figure 1-3). The 
apoptotic effects of cytotoxic agents are abrogated in a BCR-ABL positive background, 
not only in cell lines but also in CD34+ patient cells [79]. Ultimately, the combined effect 
of BCR-ABL activity results in deregulated proliferation, and inhibition of apoptosis that 
promote BM hypercellularity, growth factor (GF) independence and genomic instability. 
Moreover, the altered cellular adhesion within the compartment of Ph+ HSCs and HPCs 
lead to abnormal entry of immature cells into the peripheral blood and extramedullary 
tissues. 
5’#5’# 3’####3’####
BCR#gene#
(130kb)#
ABL#gene#
(280kb)#
Exon# #e1####e1’#e2’##############################b2#b3####e19###### #Ib############Ia####a2##a3##############################################a11#Exon#
Breakpoint##
region:## ##m=bcr))))))))))))))))))))M=bcr)))μ=bcr)
)
)
Breakpoint##
region#in#CML#
BCR=ABL)mRNA!
Fusion#mRNA#
e1a2#
b2a2#
b3a2#
e19a2#
!
!
!
!
!
!
!
!
!
!
BCR# ABL# BCR=ABL#Protein#
p185Bcr=Abl#
p210Bcr=Abl#
p210Bcr=Abl#
p230Bcr=Abl#
Disease#
ALL#
CML#
CML#
CNL##
BCR=ABL#Protein#
Fusion#
BCR*ABL)gene#
  31 
 
 
 
Substrate Full Name Function  
AKT/PKB Protein kinase B  Serine/Threonine kinase  
BAD BCL-2-associated death promoter  Pro-apoptotic  
BAP-1  BCR-associated protein 1  14-3-3 protein  
BCL-XL  B-cell lymphoma-extra large  Anti-apoptotic  
CBL Casitas B-lineage lymphoma  E3-ubiquitin ligase  
CrK  Avian sarcoma virus CT10  
oncogene homolog 
Adaptor molecule  
CrKL  CrK-like protein  Adaptor molecule  
FAK  Focal adhesion kinase  Cytoskeleton  
GRB2  Growth factor receptor bound  
protein 2  
Adaptor molecule  
PI3K  Phosphatidylinositol 3- kinase  Phospholipid kinase  
PLCγ  Phospholipase Cγ  Phospholipase  
RAF  RAS-activated factor  Serine/Threonine kinase  
RAS Rat sarcoma  Small G-protein  
RAS-GAP  RAS GTPase-activating protein  Ras-GTPase activating  
SHC  SRC homology containing protein  Adaptor molecule  
SoS  Son of sevenless  Guanine nucleotide exchange 
factor  
STAT1/5  Signal transducer and activator of 
transcription 1/5 
Transcriptional activator  
SYP  Synaptophysin  Protein phosphatase  
 
Table 1-4: BCR-ABL substrates 
(Adapted from [71] and [57]) 
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Figure 1-3:  Signal transduction pathways in BCR-ABL transformed cells 
BCR N-terminus includes a CC domain necessary for dimerisation, while SH2, SH3 and proline-
rich region (PPP) of ABL interact with other proteins and bind adaptor proteins, such as the CrKL, 
forming a multiprotein complex. BCR-ABL has many downstream targets; the most important one 
includes the RAS–mitogen activated protein (MAP) kinase signaling cascade, which is important 
for the transforming activity of BCR-ABL. Other targets include PI3K, STAT5, and the MYC 
transcription factor that is a protooncogene. Farnesyl transferases (FT) transfer a farnesyl to the C-
terminal cysteine of RAS (A), promoting its binding to the cell membrane so as to activate the 
serine kinase RAF (B) that subsequently activates the MAP pathway (C). PI3K produces 
phosphatidylinositol-3,4,5-trisphosphate (PiP3); the latter is essential for the localisation of PDK1 
and AKT to the inner side of the cell membrane. Subsequently, PDK1 activates AKT (E) and AKT 
activates the mammalian target of rapamycin (mTOR) (F), which activates the p70S6 kinase and 
4E-BP1 (G), two major global regulators of gene transcription in response to growth stimuli. Note: 
this is a simplified diagram; many more associations between BCR-ABL and other signaling 
proteins have been reported. (Redrawn from [77]). 
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1.3.5.1 The GRB2 adaptor 
One of the critical events in the BCR-ABL transformation is the autophosphorylation of 
tyrosine 177 (Y177), a site emanating leukaemogenic signals through a mediator known as 
GRB2, an adaptor molecule that plays an important role in human haemopoietic progenitor 
transformation [80]. Mice carrying a mutation changing the 177 amino-acid from tyrosine 
to plenylalanine (T177F) present attenuated BCR-ABL transforming capacity and have 
extended life expectancy [81].  
 
1.3.5.2 Activation of the RAS pathway 
Y177 binds to GRB2 via its SH2 domain and facilitates the formation of complexes 
between GRB2 and SoS, leading to activation of RAS [82]. RAS refers to a family of small 
guanine-nucleotide-binding proteins (G-proteins) that are active when bound to GTP and 
inactive when bound to GDP. Chang and colleagues identified the two first members of the 
family, HRAS and KRAS, while studying two cancer-causing viruses, the Harvey sarcoma 
virus and Kirsten sarcoma virus [83]. RAS proteins sit at the beginning of a cascade of 
kinases known as RAS-RAF-MEK-MAPK pathway, and are deregulated in many cancers, 
promoting tumour growth and disease progression. GTP-bound RAS activates the 
serine/threonine-selective protein kinase RAF, which then phosphorylates MEK and 
ultimately, leads to the activation of the MAP kinase (MAPK). MAPK regulates cellular 
transcription and translation via indirect activation of the ribosomal protein S6 (RPS6) and 
interaction with a range of transcription factors.  
 
1.3.5.3 Activation of the PI3K/AKT/mTOR pathway 
The Y177/GRB2 interaction facilitates the binding of a scaffolding adaptor protein, GAB2. 
BCR-ABL mediated phosphorylation of the YXXM motif of GAB2 allows for interaction 
of the molecule with PI3K regulatory subunits and activation of the PI3K/AKT/mTOR 
pathway [84]. Interestingly, BCR-ABL transformation was diminished in mice lacking 
expression of GAB2 [84]. A recent study by Wöhrle and colleagues, provided data 
supporting that GAB2-mediated resistance to conventional CML treatment is partially 
attributed to constitutive phosphorylation of a PI3K recruitment site within GAB2 [85]. 
The PI3K/AKT/mTOR pathway partakes in the regulation of cellular functions such as 
growth, proliferation, differentiation, motility, metabolism and survival, in response to 
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extracellular cues mediated by cell surface receptors and G-proteins. Additionally, this 
pathway is activated in various cancers [86]. PI3K is an intracellular signal transducer 
enzyme and contains a regulatory subunit with an SH2 domain, and a catalytic subunit that 
catalyses the addition of a phosphate to PiP2 at the 3 position, generating PiP3. PiP3 
recruits plasma pleckstrin-homology (PH) domain-containing proteins, and acts as key 
signaling molecule [87]. AKT is a serine/threonine-specific protein kinase that contains a 
PH domain and, hence, can bind to PiP3. The localisation of AKT to the membrane after 
binding to PiP3 allows for its activation by phosphoinositide dependent kinase 1 (PDPK1) 
following phosphorylation at threonine 308 [88, 89].  
Activated AKT phosphorylates a variety of substrates that play a vital role in BCR-ABL 
mediated transformation including mTOR, a serine/threonine kinase that acts as a hub for 
signals from insulin, GFs and amino-acids [90]. It regulates a variety of processes, 
including cell growth, survival, motility, protein transcription and synthesis, as well as 
autophagy (discussed later) [91, 92].  
mTOR is the catalytic core in two complexes, mTOR complex1 (mTORC1) and 2 
(mTORC2). mTORC1 contains the mTOR, the regulatory-associated protein of mTOR 
(RAPTOR), the mammalian LST8/G-protein β-subunit like protein (mLST8/GβL), 
PRAS40 and the DEP domains interactor of mTOR (DEPTOR) [93, 94]. Two important 
effectors of mTORC1 that mediate protein synthesis are the RPS6 kinase (RPS6K) and the 
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). Upon AKT 
activation, mTORC1 phosphorylates RPS6K and this facilitates its further phosphorylation 
and activation by PDK1 [95]. The activated RPS6K activates RPS6 to initiate protein 
synthesis [96] and via a positive feedback loop, it also activates mTORC1 [97]. Moreover, 
mTORC1 enhances protein translation by phosphorylating 4E-BP1 and promoting 
disassociation from the eIF4E and activation of the cap-dependent translation [98]. Recent 
models suggest that cancer cells dependent on AKT, actually are mTORC1 “addicted” and 
rely on its activity to drive tumourigenesis [99].  
mTORC2 consists of the mTOR, the rapamycin (RAPA; aka sirolimus)-insensitive 
companion of mTOR (RICTOR), mLST8/GβL and the mammalian stress-activated protein 
kinase interacting protein 1 (mSIN1) [100, 101]. mTORC2 activates AKT via 
phosphorylation of the serine 473 [102] and also, has an important influence on the 
cytoskeleton by regulating actin, the focal adhesion proteins, protein kinase Cα (PKCα) 
and the small GTPases (RHOA, CDC42 and RAC1) .  
In the past it was believed that RAPA could target only the mTORC1 but not the mTORC2 
or AKT.  Nevertheless, a study from Sarbassov and colleagues suggests that prolonged 
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exposure to RAPA targets mTORC2 assembly and mTORC2-mediated AKT 
phosphorylation in some cell types, by reducing the amounts of available mTOR [103]. 
Currently, RAPA and its analogues – temsirolimus, everolimus and deforolimus- are tested 
in many cancer clinical trials. NVP-BEZ235 (BEZ; LC Laboratories, MA, USA) is another 
compound currently tested in clinical trials as a potential anti-cancer treatment. BEZ is a 
quinoline derivative that targets the activity of both PI3K and mTOR kinases via binding to 
the adenosine triphosphate (ATP)-binding cleft of these enzymes [104]. PI-103 is also a 
very promising dual kinase inhibitor of PI3K and mTOR [105]. 
Another significant substrate of AKT is the group of forkhead box class O (FoxO) 
transcription factors that regulate the cell cycle. Phosphorylation by AKT deactivates 
FoxOs and promotes cell survival, growth and proliferation [106]. Furthermore, AKT may 
inhibit apoptosis by phosphorylating BAD, causing it to dissociate from the BCL2/BCL-X 
complex [107]. 
The murine double minute 2 (MDM2) oncogene is translated into an E3 ubiquitin ligase 
that negatively regulates the tumour suppressor p53. It has been suggested that upon AKT 
phosphorylation, MDM2 represses the transcription of p53, allowing for cell death evasion 
[108-110]. 
 
1.3.5.4 The CrKL adaptor  
In 1994, Hoeve and colleagues identified CrKL, a 38Kd adaptor protein of BCR-ABL in 
CML cells, that could also interact with native ABL [111]. CrKL contains an SH2 domain, 
two SH3 domains and has no catalytic domain [112], and was shown to be the major BCR-
ABL phosphorylated protein in neutrophils from CML patients’ peripheral blood samples 
[113]. Later on, it was demonstrated that BCR-ABL phosphorylated CrKL on tyrosine 207 
(T207) [114]. Subsequently, the phosphorylated CrKL can form different complexes; 
through its SH2 domain it binds the CBL protein, and with its SH3 domain the BCR-ABL 
[115]. Even if the function of CrKL has not been elucidated yet, it has been proposed that 
it can bind through its SH3 domain to PI3K [116] and, in that way, exert its leukaemogenic 
effects. It has been also proposed that it contributes in integrin-mediated cell adhesion 
through binding focal adhesion proteins such as paxillin [117]. 
CrKL is a prominent substrate of BCR-ABL [118] and has been extensively used as a 
marker of BCR-ABL activity in western blot [119] and FACS assays in primitive CML 
cells from patients [120].  
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1.3.5.5 Activation of the JAK-STAT pathway 
JAKs are intracellular tyrosine kinases that mediate signals from receptors activated by 
cytokines. Upon binding of the ligand to the receptor, JAKs are activated and 
subsequently, activate the receptor. Phosphorylation of the receptor’s tyrosine residues by 
JAK allows for interaction with SH2 domain containing proteins, such as the STAT 
family. These proteins bind to the receptors and after JAK-mediated activation, form 
dimers and translocate to the nucleus where they regulate the transcription of their target 
genes [121]. 
The JAK-STAT pathway is highly upregulated in CML cells [122, 123] and one of its 
mediators, STAT5, has been suggested to be an essential factor in the BCR-ABL mediated 
leukaemogenesis [124, 125] partially by inhibiting apoptosis via regulation of BCL2 
family members, such as the induced myeloid leukaemia cell differentiation protein (MCL-
1) and BCL-XL [126, 127]. In vivo experiments in mice underline the critical role of Stat5 
in Bcr-Abl mediated CML initiation and maintenance [124, 125]. Interestingly, apart from 
its role in cell transformation, STAT5 may also contribute to the development of resistance 
and disease progression in a JAK-independent manner [128]. Introduction of dominant-
negative JAK mutants in BCR-ABL expressing cells did not suppress phosphorylation of 
STAT5, proposing that BCR-ABL could activate STAT5 through other mediators [122], 
such as the haemopoietic cell kinase (HCK) [129]. 
 
1.3.5.6 BCR-ABL growth factor mimicking 
Interleukin-3 (IL-3) and the granulocyte colony stimulating factor (G-CSF) are GFs that 
bind to HSC receptors and, following activation of pathways such as the RAS, PI3K and 
JAK-STAT, promote differentiation and proliferation [130, 131]. While normal HSCs 
cannot survive and proliferate in the absence of GFs [16, 17], transformed quiescent 
primitive cells from CML patients can grow and proliferate in vitro in a GF-independent 
manner [132]. BCR-ABL positive cells override dependence on external supplementation 
of GFs for their survival and proliferation by promoting an aberrant autocrine loop 
production of IL-3 and G-CSF [132, 133] in early progenitor cells that could deregulate 
critical cell cycle mediators [134] and lead to exit from quiescence [133]. Transplantation 
of BM cells genetically manipulated to produce IL-3 lead to the development of 
myeloproliferative disorders in a mouse model [135-137], highlighting the consequences 
of GF deregulations. Hence, the BCR-ABL mimicking of physiologic GF stimulation 
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could be responsible for a significant part of the leukaemic transformation, potentially 
through activation of STAT5 [134]. 
 
1.3.5.7 BCR-ABL alteration of the niche 
As described earlier, normal HSCs express on their surface receptors that bind ligands 
secreted from niche cells and, following adhesion to the niche, promote cell cycle arrest 
[25]. For instance, mice carrying mutations within the tyrosine kinase domain of TIE2 
receptors that bind angiopoietin, or the myeloproliferative leukaemia virus oncogene 
receptor that binds thrombopoietin (TPO), lead to HSCs detachment from the niche, 
increased cycling, and finally, HSC exhaustion [29, 138]. Integrins refer to another class of 
receptors that mediate the adhesion of HSCs to the stroma [139] and simultaneously, 
promote cell cycle arrest [140]. A possible explanation for the increased proliferation and 
circulation of CML stem and progenitor cells could be that they have altered adhesion 
properties compared to normal HSCs [2, 141, 142]. In support of this hypothesis are data 
that demonstrate suppression of CXCR4 expression in BC CML patient samples and 
evasion of adhesion [143]. Drug-mediated inhibition of the kinase activity of BCR-ABL in 
primitive CML cells co-cultured with mesenchymal stem cells (MSCs) leads to 
upregulation of CXCR4, followed by migration of the CML cells to the BM, cell cycle 
arrest and, ultimately, survival of quiescent CML progenitor cells [144]. 
 
1.3.6 CML treatment 
1.3.6.1 Historical treatment of CML 
One of the first attempts to treat CML was published by Sir Arthur Conan Doyle in 1882, 
when he was a practising physician in Birmingham. He administrated iron and quinine to a 
29-year-old patient with “leucocythaemia”, the term used for CML at the time, because he 
thought that the symptoms were attributed to a previous attack of malaria. After seeing no 
effect, he used arsenic; 1% solutions of arsenic trioxide, aka Fowler’s solution, that had 
been used since 1786 for malaria patients and diseases involving fever and shivering [145]. 
However, arsenic was used for the treatment of leukaemias since ancient times; it was used 
by Hippocrates (460-370 before Christ), who gave cancer its name from the Greek word 
"καρκίνος" (carcinos) for crab [146]. The Fowler’s solution was reported to improve the 
clinical condition of CML patients but the effects lasted only for a short period of time 
[145]. In 1903, with the introduction of radiotherapy, treatment of CML patients included 
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frequent X-ray sessions, with or without the oral administration of benzene. The 
therapeutic response to radiotherapy was great, nevertheless, soon after radiation was 
linked to the development of leukaemia.  
Surprisingly, the way to chemotherapy was opened by a warfare agent used during World 
War I, known as “mustard gas”; soldiers exposed to this gas presented very low white 
blood cell counts. Analogues of the sulphur compound contained in the gas were then 
produced for the treatment of CML. Their clinical use showed improvement of the 
treatment but not prolongation of survival [145]. Additionally, such compounds had 
substantial toxic effects. In 1953, busulphan, an oral alkylating agent, was introduced for 
the treatment of CML. Nonetheless, it was also associated with severe side effects [147]. 
By that time, CML was regarded as a fatal and incurable disease. Nevertheless, in the 
1980s the scene changed when allogeneic BM transplantation (BMT) and SCT, that had 
been previously proven effective for acute leukaemia patients [148], were used as a 
curative potential for CML patients [149]. Despite their auspicious effects, BMT and SCT 
could be offered only to 20% of CML patients due to limitations such as age, physical 
condition and matched donor availability [150]. Additionally, up to 72% of low-risk CML 
patients had a 5-year survival but this percent dropped dramatically to 20% in high-risk 
patients that had approximately 73% mortality [151]. Additionally, due to the nature of the 
procedure, allogeneic SCT patients were facing an increased risk of morbidity and 
mortality due to infections, mucositis, graft failure or graft-versus-host disease [152, 153].  
In the 1980s, the cytokine interferon α (IFNα) offered an alternative less toxic treatment 
for the management of CML, attenuating the disease symptoms, and prolonging life 
expectancy. Moreover, many patients appeared to be Ph negative following IFNα treatment 
and presented with a lower rate of blastic transformation [154]. Later, it was suggested 
IFNα mediated restoration of haemopoiesis could be attributed to recovery of adhesion of 
CML progenitors to the BM stroma [155]. 
 
1.3.6.2 The development of IM 
In the 1990s Nicholas Lydon and Brian Druker, based on rational drug design, developed a 
BCR-ABL TKI called IM (STI571, Gleevec®, Glivec®, formerly CGP 57148B; Novartis, 
USA). IM binds competitively to the N-terminal region of the ATP-binding pocket of the 
inactive form of ABL [156]. IM binding to BCR-ABL stabilises the inactive conformation 
and inhibits autophosphorylation. Therefore, IM blocks the kinase activity and the 
subsequent phosphorylation of key downstream substrates. Moreover, IM targets the c-KIT 
and PDGF receptors [157]. The specificity of IM against BCR-ABL positive cell lines and 
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patients samples was demonstrated in vitro and in vivo, with minimal toxicity to BCR-ABL 
negative cells [156, 158]. With half maximal inhibitory concentration (IC50) IM within the 
range of 0.1–0.5µm, IM inhibits BCR-ABL activity and proliferation, promoting apoptosis 
of CML cells [46].  
In 1998 an IM dose-escalating phase I trial was initiated with doses ranging from 25 to 
1000mg per day; out of the 54 patients receiving doses higher than 300mg/day, 53 
achieved complete haematologic response (CHR), 29 cytogenetic response (CyR), 17 of 
which presented major responses (0-35% Ph+ metaphase cells) [119]. Furthermore, a 
phase II clinical trial evaluated the effect of IM on late CP CML patients that had 
previously failed IFNα; 95% of the patients achieved major cytogenetic response (MCyR) 
and, after a median follow-up of 18 months, in 89% of the patients disease had not 
progressed to AP or BC [159]. In order to assess the efficacy of IM versus the standard 
therapy for CML CP patients at the time, a combination of IFNα with cytarabine (a 
chemotherapeutic agent that inhibits DNA synthesis), a phase III International Randomized 
Study of Interferon and STI571 (IRIS) was launched in 2000, recruiting 1106 patients from 
16 countries [160]. In this randomised trial, patients in the IM group were receiving 
400mg/day while patients in the IFNα group received gradually increasing doses of IFNα, 
and once the maximum tolerated dose was achieved (up to 5 x 106 U / m2 body surface 
area / day), patients received subcutaneously cytarabine (up to 40 mg / day) for 10 days 
every month. A median follow-up of 19 months revealed that McyR rates were higher in 
the IM group (IM; 87.1% versus IFNα plus cytarabine; 34.7%), as well as complete CyR 
(IM; 76.2 versus IFNα plus cytarabine; 14.5). IM was also better tolerated, and was 
associated with decreased rates of disease progression. In May 2001, IM recieved approval 
by the United States Food and Drug Administration (FDA) for the treatment of Ph+ CML 
[161].  
The 6-year data from the IRIS study further underlined the supremacy of IM; patients on 
IM had an estimated event-free survival (EFS) rate of 83%, estimated rate of freedom from 
progression to AP and BC of 93%, and estimated overall survival (EOS) of 88%, or 95% 
when only CML-related deaths were taken into account [162]. The importance of 
achieving a quick IM response (within the first 24 months after initiation of treatment) has 
been highlighted during recent years since it has been associated with increased life 
expectancy, comparable to the general population [163]. Therefore, it could be 
disheartening that almost a quarter of newly CP diagnosed patients in the IRIS trial did not 
achieve complete CyR within the first 18 months of treatment [160]. Nevertheless, the 
efficacy of IM was superior to any previous treatment, taking into account BMT and SCT 
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[164]. Hence, IM is since then used as a first-line treatment for newly diagnosed CP CML 
[161, 162, 165].  
 
1.3.6.3 IM responses 
Even if IM has an effect on the majority of CP patients, once the disease progresses to AP 
or BC, it has little or no effect. Another major drawback of IM involves the development 
of resistance. Data from 5-year follow up of CML patients receiving IM, showed that in 
7% of the patients the disease had progressed to AP or BC, 2% of which had initially 
achieved a complete CyR response and a reduction of <3-log in levels of BCR-ABL 
transcripts at 18 months [166].  
A framework of guidelines and recommendations by the European LeukaemiaNet (ELN) 
[80] and National Comprehensive Cancer Network (NCCN) [82] has been provided for the 
evaluation and classification of patient responses to optimal, suboptimal or failure. Criteria 
refer mainly to the achievement of endpoints based on haematological, cytogenetic and 
molecular responses within specific time after the initiation of treatment (Table 1-5). An 
optimal response usually refers to a 2-log reduction in BCR-ABL transcripts by 3 months 
[167] and/or major molecular response (MMR) (3-log reduction in BCR-ABL transcripts), 
by 12 months [168]. However, responses from patients on 400mg IM daily that do not 
achieve CHR by 3 months or complete CyR by 12 months are classified as failure, or 
primary resistance. Secondary resistance refers to patients that initially responded to IM 
but later lost established CHR, complete CyR, or the disease progressed to AP or BC [77], 
and can be caused by various reasons, with most prominent the development of point 
mutations within the BCR–ABL kinase domain [169]. 
In the past, a suboptimal response was described as the failure to achieve 1-log reduction 
of BCR-ABL transcripts by 6 months or a 2-log reduction by 12 months [167]. On the 
other hand, recently it was demonstrated that the frequency of suboptimal responders may 
be higher than initially estimated; 4, 8 and 40% of CML patients on 400mg/day after 6, 12 
and 18 months, respectively, fulfilled the suboptimal response criteria [170]. Nonetheless, 
identification and classification of suboptimal responses still remains unclear. By 6 months 
of treatment, suboptimal responders have EFS comparable to patients with primary 
resistance. Therefore, it is harder to decide in clinic the best treatment alternative for 
suboptimal responders. 
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Response  Criteria  
CHR  Complete normalisation of peripheral blood count: 
Leukocyte count <10 x 109 cells/L 
Platelet count <450 x 109 cells/L 
No immature cells in the peripheral blood  
No signs or symptoms of disease including 
splenomegaly  
Partial haematologic 
response  
Same as those for CHR, except: 
Persistence of immature cells, or 
Platelet count <50% of the pre-treatment count but 
>450 x 109 cells/L, or  
Persistent splenomegaly but >50% of the pre- 
treatment extent  
Complete CyR No Ph+ cells detectable by cytogenetics in the BM  
Partial CyR 1-34% Ph+ cells detectable in the BM  
 MCyR <35% Ph+ cells detectable in the BM (includes 
complete and partial CyR)  
Minor CyR 35-90% Ph+ cells detectable in the BM  
Complete molecular 
response (CMR) 
Undetectable BCR-ABL transcript by qRT-PCR, or 
 ≥4.5 log reduction compared to starting level  
MMR ≥3 log reduction of BCR-ABL transcript, or 
 <0.1% BCR-ABL transcript by qRT-PCR  
 
Table 1-5: Criteria of treatment responses in CML 
 
 
1.3.6.4 Molecular persistence 
Despite the superiority of IM versus the combination of IFNα with cytarabine in achieving 
complete CyR, only 4% of the IM treated patients achieved CMR [168]. The majority of 
the patients in the IM arm had detectable BCR-ABL transcripts, which means that a 
leukaemic clone managed to escape treatment and lead to MRD.  The question that 
subsequently arose was, if IM had eradicated all leukaemic clones in patients with CMR. 
Therefore, the STIM [171] and the Australian [172] studies were launched. In the STIM 
study IM was discontinued in 69 patients who had been in CMR for at least 2 years. 
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Approximately 58% of these patients relapsed within the first 6 months. Similarly, in the 
Australian study, it was demonstrated that even patients that maintained CMR after IM 
cessation, harboured residual leukaemia. These observations support the hypothesis that a 
fraction of leukaemic stem cells (LSCs) is refractory to IM and replenishes the disease 
upon drug withdrawal, leading to relapse.  
The inability of IM to target the persistent fraction of LSCs can be attributed to the 
quiescent status of these cells. It has been suggested that CD34+ Ph+ cells could be 
inherently insensitive to IM, since they manage to survive 10 times higher concentration 
(10µM) than the inhibitory concentration (1µM), unlike more differentiated cells [173]. 
Analysis of the reduction rates of BCR-ABL transcripts with a mathematical model 
suggests that this process is biphasic [174]. During the first phase there is a rapid decrease 
in transcripts, representing the elimination of Ph+ progenitors and more committed cells. 
However, the following second phase is much slower and illustrates the inaccessibility of 
LSCs to IM.  Hence, the restored haemopoiesis upon IM treatment seems to be attributed 
to the suppression of the proliferative capacity of these cells rather than their elimination 
[175].   
 
1.3.6.5 Mechanisms of resistance 
The diverse mechanisms of resistance development against IM were first studied in BCR-
ABL positive cell lines following prolonged treatment to progressively increasing doses, 
from suboptimal concentrations up to 1mM [176-178]. Resistance mechanisms can be 
versatile, as depicted in Figure 1-4. 
 
1.3.6.5.1 Mutations affecting the BCR-ABL kinase domain  
 
The major cause of IM resistance involves the development of point mutations that prevent 
efficient IM binding [179]. More than 100 mutations have been identified so far, the 
development of which is attributed to the genomic instability that BCR-ABL is promoting 
via DNA damage and impairment of the repair mechanisms [180]. These mutations can 
affect directly IM contact positions or indirectly, by occurring within sites that destabilise 
the inactive conformation of BCR-ABL, and impair access of IM to the ATP-binding site 
[181]. Depending on their proximity to the kinase domain and other factors, these 
mutations can induce from moderate to severe resistance with significantly increased IM 
IC50 values compared to native BCR-ABL positive cells [182, 183]. The first identified 
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IM resistance mutation leads to an exchange of threonine at position 315 to isoleucine 
(T315I), and until today, BCR-ABLT315I remains the most troublesome mutant, associated 
with a highly aggressive phenotype and poor outcome [184-186]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4: IM resistance mechanisms 
IM resistance can be attributed to a plethora of causes that vary from patient compliance (1) to the 
metabolism and bioavailability of the drug (2,3,5), as well as the development of genetic 
modifications (6,7,8) and alterations in the signaling pathways downstream of BCR–ABL (9). ( a-
1-GP: a-1-acidglycoprotein; hOCT-1: human organic cation transporter-1; MDR1: multidrug 
resistance- associated membrane transporter). (Redrawn from [187]) 
 
1.3.6.5.2 BCR–ABL overexpression 
 
BCR-ABL gene amplification and protein overexpression were demonstrated to cause IM 
resistance in cell lines [176-178] and patient samples [184, 188]. A possible explanation 
could be that the amount of IM within the cell is not sufficient for the inhibition of BCR-
ABL, and this residual activity allows the clone to survive and proliferate. On the other 
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hand, it has been suggested that high levels of BCR-ABL promote genomic instability and 
this, leads to the development of mutations that ultimately lead to the development of 
resistance. In a study performed by Tang and colleagues it was observed that BCR-ABL 
overexpression is essential for the development of mutations within the kinase domain 
[189]. However, such observations were not made in CML patient samples; out of the 66 
patients only two were identified with BCR-ABL gene amplification and the rest carried 
kinase domain mutations [190]. Nevertheless, it should be underlined that high levels of 
BCR-ABL are toxic for the cells. The first step in the development of resistance could be 
overexpression of BCR-ABL that subsequently, leads to the development of a kinase 
domain mutation. Therefore, the initial overexpressing clone would die and would not be 
detected in the samples, while a lower BCR-ABL expressing clone carrying the mutation 
would have a growth advantage and drive the resistance [189]. 
 
1.3.6.5.3 BCR-ABL-related epigenetic modifications 
 
BCR-ABL has been proposed to promote epigenetic alterations by hyperacetylating 
histone H4 [191]. Moreover, IM resistant cell lines have been proposed to have distorted 
balance between histone deacetylases (HDACs) and histone acetyltransferases (HATs) that 
subsequently, lead to abnormal acetylation of key proteins, like Hsp90 and p53 [192].  
Another hypothesis supports that IM may be able to target Ph+ cells only when in a 
specific epigenetic differentiated cell state. Carette and colleagues generated induced 
pluripotent stem cells (iPSCs) from a BCR–ABL oncogene addicted CML cell line and, 
surprisingly, after reprogramming the cells became resistant to IM and did not depend on 
BCR-ABL on survival [193]. 
 
1.3.6.5.4 Clonal evolution & activation of alternative signaling pathways 
 
BCR-ABL independence implies that the cells have acquired additional mutations and do 
not exclusively rely on BCR-ABL for survival. The development of chromosomal 
abnormalities in addition to the Ph, known as clonal evolution, is considered to be a poor 
prognostic factor. Such abnormalities are associated with genomic instability and include, 
for instance, inactivation of p53 and overexpression of c-MYC and BCR–ABL as a result 
of isochromosome 17, trisomy 8 and duplication of the Ph, respectively [179, 194, 195]. 
Alterations in various cellular pathways and mechanisms can also be responsible for BCR-
ABL-independent aberrant growth and survival. SRC activation has been suggested to 
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have a significant impact on disease progression, even in cases where IM has effectively 
suppressed BCR-ABL protein expression to undetectable levels [196]. For instance, LYN, 
an SRC related kinase, has been found to be abnormally overexpressed and activated in IM 
resistant cells that carry native, unmutated BCR-ABL and IM is efficiently suppressing 
BCR-ABL activity. Interestingly, inhibition of LYN in these IM-resistant cells reduced 
proliferation and survival while it didn’t have an effect on IM sensitive cells [197].  
Another counter-regulatory mechanism relevant to BCR-ABL independent IM resistance 
involves the adaptive autocrine secretion of the granulocyte macrophage colony-
stimulating factor (GM-CSF) via activation of the antiapoptotic JAK2/STAT5 pathway. 
JAK2 inhibition managed to override GM-CSF-induced IM resistance [198]. Additionally, 
it has been suggested that high levels of STAT5 can drive TKI resistance in a JAK2 
independent manner [128]. It has been also proposed that extended IM treatment can lead 
to epigenetic silencing of PTEN, followed by aberrant activation of the PI3K/AKT 
pathway and STAT5 signaling [199, 200]. 
 
1.3.6.5.5 Pharmacokinetics & drug delivery issues 
 
Changes with regards to the distribution of IM, such as diminished delivery, can result in 
suboptimal intracellular drug concentrations and development of resistance. This can be 
attributed to dysfunctioning drug import and export pumps on the target cell membrane, as 
well as deregulated plasma proteins and enzymes. 
ATP-binding cassette sub-family B member 1 (ABCB1) transporter, aka MDR1, is a 
transmembrane glycoprotein that belongs to the ATP-binding cassette sub-family (ABC). 
ABC transporters use the energy of ATP hydrolysis to open/close ion channels of proteins, 
including themselves, and have also been suggested to carry out other functions, such as 
translation of RNA and DNA repair [191]. It was proposed that ABCB1 upregulation could 
lead to the development of resistance due to increased drug efflux [201]. Nevertheless, 
later studies from our lab demonstrated that ABCB1 inhibition did not lead to increased 
intracellular IM concentrations [202]. Moreover, it was illustrated that ABCB1 activity is 
very low within the CD34+ fraction, and this could explain why inhibition of ABCB1 did 
not sensitize these cells to IM.  
It has been suggested that concentrations of bioavailable IM can be significantly reduced 
after binding to plasma proteins, such as the a-1-GP. This displacement affects the 
pharmacological efficiency of IM and reduces its antileukaemic activity in mouse models 
[203]. A positive correlation between a-1-GP and IM plasma levels was also established in 
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the total of 19 CP, AP and BC CML patients. Clindamycin (CLI) is an antibiotic that can 
compete with IM for binding to a-1-GP in vitro, and its administration to five CML 
patients resulted in rapid decrease of IM plasma levels [204]. Nevertheless, published data 
from our lab support that normal a-1-GP at supra-physiological concentrations, or CML-
derived a-1-GP, do not inhibit the IM effect on the proliferation of Ph+ cells in vitro [205].  
Another membrane transporter that has been associated with IM resistance is the hOCT-1. 
In 2004, Thomas and colleagues first demonstrated that inhibition of hOCT-1, but not 
hOCT-2 or hOCT-3, reduced IM uptake in CML cells [206]. Furthermore, it was illustrated 
that patients with high hOCT-1 expression levels before the initiation of IM treatment, 
presented higher responses associated with higher rates of complete CyR, EFS and EOS 
[207]. Recently, the same group identified that the hOCT-1 single nucleotide 
polymorphism (SNP) M420del is associated with less favorable IM responses, further 
supporting the importance of hOCT-1 in IM treatment [208].    
The amount of IM available depends not only on the equilibrium between influx and 
efflux, but also on the rate of its biotransformation. CYP3A (cytochrome P450, family 3, 
subfamily A) is a hepatic enzyme that metabolises IM to its active form via N-
demethylation. Data from a pilot study on in vivo CYP3A activity in 14 CML patients 
support that elevated levels of CYP3A are associated with better responses, probably 
because this allows for higher amounts of bioavailable IM [209]. Factors that alter CYP3A 
levels or function, such as gene polymorphisms, interaction with other drugs or food 
habits, may affect IM responses. 
 
1.3.6.5.6 Compliance 
 
Patient compliance is another crucial parameter affecting IM responses. A study on 169 
CML patients revealed that there is a strong correlation between patient adherence and the 
achievement of MMR and CMR [210]. Poor compliance has been associated with 
suboptimal response since patients with adherence < or = 80% did not respond at 
molecular level. This hypothesis has been further validated in a following study on 87 
patients, where compliance was monitored by a microchip incorporated at the prescription 
bottle for pill counting, over a period of 3 months [211]. Data supported the direct 
association between adherence and treatment response; strong compliance has been linked 
to high rates of achieving CMR, while poor compliance with suboptimal responses.  
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1.3.6.6 Strategies to override resistance 
1.3.6.6.1 IM dose escalation 
 
A first approach in order to overcome resistance issues was escalation of IM doses. Such 
an escalation could be beneficial in cases of BCR-ABL overexpression and/or BCR-ABL 
amplification, as well as mutations that are susceptible to higher doses of IM. Moreover, 
during the phase 1 dose-escalating trial of IM, a dose-response effect was noticed. In 2003 
Kantarjian and colleagues published a study based on 54 CML CP patients that had been 
previously treated with IM at 400mg/day and had developed resistance or relapsed [212]. 
These patients were treated with up to 800mg/day; 65% of the patients with haematologic 
resistance or relapse and 56% of those with cytogenetic resistance or relapse achieved 
partial or complete haematologic and cytogenetic responses, respectively. In another study, 
IM dose was increased to 800mg/day in 84 CML CP patients that had failed IM at 
400mg/day [213]. Complete CyR was achieved in 52% of the patients with cytogenetic 
failure and 5% of those with haematologic failure, and maintained in 88% of the patients 
beyond 2 years.  
 
1.3.6.6.2 Second-generation TKIs 
 
In an effort to override IM resistance, second generation TKIs were developed. DAS and 
NIL allow for more effective binding with BCR-ABL and can target mutant BCR-ABL 
forms that are not inhibited by IM.  
1.3.6.6.2.1 DASATINIB 
 
DAS (Sprycel®; formerly BMS-354825, Bristol-Myers Squibb, NY, USA) is a multi-
targeted kinase inhibitor with specificity against the SRC and ABL kinases, as well as c-
KIT and PDGF-R [214]. DAS has much higher affinity for ABL than IM and can target 
both its active and inactive conformations [169]. DAS is >300-fold times more potent than 
IM against cells expressing native BCR-ABL, and can target the majority of the IM-
resistant BCR- ABL isoforms harbouring mutations, with the exception of the T315I [215, 
216]. 
In 2008, Hochhaus and colleagues released the data from a phase II trial evaluating the 
efficacy of DAS in 387 CML CP patients resistant or intolerant to IM [217]. After a 
median follow-up of 15.2 months, 91% of patients receiving 70mg DAS twice daily 
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attained or maintained a CHR, 59% attained or maintained a MCyR, from which 49% 
achieved complete CyR. Following, the clinical efficacy of DAS in newly diagnosed CML 
patients was evaluated in the DASISION trial [218]. In DASISION, 519 CML CP patients 
were recruited and randomised between two treatment arms, 100 mg DAS versus 400 mg 
IM per day. After a minimum follow-up of 12 months, patients on DAS achieved 
significantly higher and faster rates of complete CyR (DAS 77% vs IM 66%; p = 0.007) 
and MMR (DAS 46% vs IM 28%; p < 0.0001). In 2006, DAS gained approval from FDA 
for the treatment of newly diagnosed adult Ph+ CML and ALL patients and patients who 
have previously found to be resistant or intolerant to prior therapy.  
Nevertheless, the efficacy of DAS at more progressed disease stages, in AP and BC 
patients, was limited; responses were poor and not long lasting [219, 220]. Additionally, 
like IM, DAS was efficient in targeting CML progenitors and more differentiated cells, 
however, failed to eliminate the persistent fraction of the quiescent leukaemic stem cells 
[221].  
 
1.3.6.6.2.2 NILOTINIB 
 
NIL (AMN107; Tasigna, Novartis, Switzerland), is a BCR-ABL TKI, that structurally 
resembles to IM, but carries a modification in a methylpiperazinyl group that allows for 
higher affinity to the inactive conformation of ABL [222]. NIL exhibits >20 times higher 
potency than IM [223], and can target in vitro all the BCR-ABL mutants whose 
conformations are inaccessible to IM, with the exception of the BCR-ABLT315I isoform 
[215, 224].  
The clinical efficacy of NIL was underlined in the ENESTnd trial, where NIL at 300mg or 
400mg twice daily was associated with better responses compared to IM at 400mg daily. A 
median 24-month follow up revealed that 71% patients at the NIL arm achieved MMR 
versus 44% at the IM arm [225]. In 2010, NIL received FDA approval for the treatment of 
adult patients with newly diagnosed Ph+ CP CML. However, NIL, like IM and DAS, 
cannot eliminate the persistent population of LSCs [226]. 
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1.3.6.6.3 Third-generation TKIs 
 
1.3.6.6.3.1 Ponatinib 
 
PON (AP24534; ARIAD, MA, USA) is a third generation pan-BCR-ABL inhibitor that 
can target all BCR-ABL mutants, including the BCR-ABLT315I, as well as FLT3 and SRC 
kinases [227]. The toxicity and safety of the clinical use of PON were explored in a phase I 
trial focused on CML patients that had previously failed a minimum of two TKIs. PON 
was well tolerated and associated with superior responses; 98% of the CML CP patients 
had a complete haematologic response, 72% had a MCyR, and 44% had a MMR [228]. 
Therefore, a phase II Ponatinib Ph+ ALL and CML Evaluation (PACE) trial was launched 
in September 2010 [229]. During the PACE trial, CP (271 patients) and AP (79 patients) 
CML patients that resistant or intolerant to DAS or NIL or harbouring the T315I mutation 
were receiving PON 45mg daily and the results were very encouraging. In July 2012, 
ARIAD announced the initiation of the phase III Evaluation of PON versus IM in CML 
(EPIC) trial that will compare the efficacy of PON with that of IM in the treatment of adult 
patients with newly diagnosed CP CML [230].  
 
1.3.6.6.3.2 Bosutinib 
  
Bosutinib (SKI-606; Pfizer, NY, USA) is a dual inhibitor of ABL and SRC, targeting 
simultaneously c-KIT and some PDGF receptor members. Bosutinib is currently tested in a 
phase III clinical trial. 
 
1.3.6.6.4 Investigational agents 
 
Aurora kinases are serine/threonine kinases that play an active role in mitosis and their 
deregulation has been associated with many cancers. These enzymes are being considered 
for treatment of CML since they inhibit, among many targets, ABL. Allosteric inhibitors 
that selectively target BCR-ABL, like GNF-5, are also under investigation [231]. A novel 
approach in inhibiting ABL refers to a class of molecules, known as “switch pocket 
inhibitors”, such as DCC-2036 (Deciphera, KS, USA) [232]. DCC-2036 exerts its effects 
by binding to two amino acids in the switch pocket of ABL that are necessary for the shift 
of BCR-ABL from the inactive to the active form.  
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Anti-CML vaccines have also been tested for the treatment of patients. Recent studies 
suggest that BCR-ABL is not a strong immunogen; therefore, research is focused on 
developing vaccines from other immunogens, such as WT1, PRTN3, HMMR, PRAME, 
SPAG9, AURKA, IL1RAP and BMI1 [233].  
 
1.3.6.6.5 Combination approaches for the elimination of the persistent CML stem cells 
 
As described above, TKIs fail to eradicate the fraction of primitive LSCs that persist and 
replenish disease. Recent studies by our lab and others, demonstrated that the LSCs may 
not be oncogene addicted [234, 235]. In such a scenario, TKIs will be completely 
ineffective in targeting these cells since their survival will not be affected by the absence of 
BCR-ABL initiated signals. Therefore, rational strategy would involve the combinational 
targeting of these cells with TKIs and other agents that target vital pathways for the 
survival of LSCs. Combinational approaches could also have an inhibitory effect on 
disease progression since this process is mainly relying on the development of secondary 
BCR-ABL independent changes such as, activation of alternative pathways and epigenetic 
alterations [58]. 
There is a series of studies investigating the benefits from the combination of IM with 
alternative reagents. For instance, HDAC inhibitors in combination with IM have been 
demonstrated to induce apoptosis in quiescent IM resistant CML progenitors in vitro, while 
in vivo administration of IM and HDAC inhibitors eradicated the LSC population in a 
mouse model [236]. Moreover, Preudhomme and colleagues demonstrated that the 
combination of peginterferon α -2a (90µg weekly) and IM (400mg daily) was superior to 
IM treatment alone (at 400mg daily) [237]. Patients presented significantly higher rates of 
superior molecular response (reduction of 4 log units or more from the baseline level) in 
the combination arm (30%) versus IM alone (14%) (P=0.001).  
Metabolic modulators have also been tested in combination with IM. Arachidonate 5-
lipoxygenase (ALOX5) is an enzyme that takes part in transforming essential fatty acids 
into leukotrienes and has been proposed to be essential for the maintenance of LSCs. In 
vivo experiments in a murine model demonstrated that BCR-ABL could not induce CML 
in an Alox5 deficient background [238]. Based on these data, a phase I trial has been 
launched in order to evaluate the clinical efficacy of IM in combination with zileuton, an 
ALOX5 inhibitor.  
Another pathway that has been suggested to be vital for the self-renewal of LSCs is the 
Hedgehog pathway. Loss of Smoothened (SMO), a vital Hedgehog pathway mediator, 
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leads to targeting of the leukaemia initiating CML stem cells and targets their ability to 
proliferate and induce the disease [239]. A phase II trial is currently investigating the 
combination of a SMO inhibitor with DAS in CML CP patients.  
 
1.4 Autophagy 
In 1963, de Duve introduced the term autophagy - from the Greek words αυτό (self) and 
φαγία (eating) - a cell survival lysosomal pathway used by eukaryotes to degrade and 
recycle cellular components, such as aged proteins and organelles, in order to recoup ATP 
and essential building blocks during nutrient and/or oxygen deprivation [240]. For a long 
time autophagy was regarded solely as a stress-induced cellular recycling mechanism. 
Nevertheless, research during the last 10 years has revealed the multifaceted role of 
autophagy; this process takes place in virtually all mammalian cells, from oocytes to 
neurons, and ensures homeostasis and quality control. Autophagy can target bulk 
cytoplasm or selective cargo, clearing damaged mitochondria (mitophagy) or peroxisomes 
(pexophagy). Additionally, autophagy takes part in various cellular processes such as 
ageing, inflammation, innate and acquired immunity, as well as differentiation [241]. 
Impairment of autophagy has been associated with the development of many diseases, 
including cancer. 
There are three different types of autophagy. Chaperone-mediated autophagy is a 
secondary response to nutrient starvation; cytosolic proteins tagged with a pentapeptide 
motif are transferred to the lysosomes and afterwards unfolded with chaperones’ 
mediation. On the other hand, during microautophagy cytoplasmic components are 
recruited directly on the lysosomal membrane, which subsequently gets introverted and/or 
segmented. 
Macroautophagy, is the most efficient autophagic clearance mechanism and the most 
common type of autophagy, therefore, hereafter macroautophagy will be referred to as 
autophagy. Through this process, cytoplasmic components are being delivered to the 
lysosomes for degradation after inclusion in de novo constructed double-membrane 
vesicles, the autophagosomes [242]. These formations are derived from the phagophores 
(aka isolation membranes), cup-shaped membranes, which are generated after the 
induction of autophagy. As the phagophores expand, they segregate cytoplasm and finally 
isolate it upon their structural completion [243]. The autophagosomes slide along 
cytoskeletal structures and fuse with lysosomes, generating the autophagolysosomes. 
Degradation of the included components and the inner autophagosomal membrane follows.            
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Autophagy is regulated by the autophagy-related genes (Atg) that have been discovered in 
S. cerevisiae. From these 31 genes, 15 are mainly required for the autophagic machinery, 
and only 11 of them have unambiguous orthologues in mammalians (Table 1-6). Most of 
these “core” Atg’s mediate the autophagosome formation [243]. 
 
 
Autophagy genes in mammals 
Gene Protein function Chromosomal 
location 
ATG1, 
ULK1 
Serine/threonine protein kinase; it may be 
involved in induction/membrane recycling 
12q24.3 
17p11.2 
ATG3 Ubiquitin-conjugating E2-like enzyme; covalently 
attaches ATG8/LC3 to PE 
3q13.2 
ATG4 Cysteine protease; cleavage of ATG8   
Xq22.1–q22.3 
(ATG4A) 
2q37.3              
(ATG4B) 
1p31.3              
(ATG4C) 
19p13.2            
(ATG4D) 
ATG5 Conjugated to ATG12; binds AT16 as part of a 
tetrameric complex of unknown function 
6q21 
ATG6, 
BECN1 
Component of the class III PI3K complex that is 
required for autophagy 
17q21 
ATG7 Homolog of the ubiquitin-activating enzyme; it 
activates both ATG8/LC3 and ATG12 
3p25.3 
ATG8,  
MAP1LC3 
Ubiquitin-like protein conjugated to PE; 
formation and expansion of the autophagosome 
 
ATG9 
Transmembrane protein; it may be involved in 
delivering membrane to the forming 
Autophagosome 
2q35                 
(ATG9A) 
7q36.1              
(ATG9B) 
ATG10 Functions as an ubiquitin-conjugating-like 
enzyme; covalently attaches ATG12 to ATG5 
5q14.1–q14.2 
ATG12 Structural similarity to ubiquitin; it is conjugated 
to an internal lysine of ATG5 
5q21–q22 
ATG16 Binds ATG5 and homo-oligomerizes to form a 
tetrameric complex 
2q37.1             
(ATG16L1) 
11q13.4           
(ATG16L2) 
 
Table 1-6: Autophagy genes in mammals 
(Table compiled from information within [244] and [240])  
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1.4.1 Molecular mechanism  
Basal autophagy occurs constantly within the majority of mammalian cells at low levels. 
Nevertheless, under conditions of starvation or stress [endoplasmic reticulum (ER) stress, 
hypoxia or oxidative stress], autophagy is induced [245]. The autophagic process can be 
divided into the following steps: initiation, autophagosome formation, fusion and 
degradation (Figure 1-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5: Overview of the autophagy process in vertebrates 
(Adapted from [246]) 
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Initiation: The mediator that sits atop the hierarchy of the autophagy initiation cascade is 
the Unc-51- like kinase 1 (ULK1), which along with the Unc-51- like kinase 2 (ULK2), 
consist the Atg1 yeast homologs. Kim and colleagues recently offered an insight about the 
regulation of ULK1 by AMPK and mTORC1 [247]. During energy sufficient conditions, 
mTORC1 is active in a RHEB-dependent manner and phosphorylates ULK1 on Ser757, 
prohibiting its interaction with AMPK. Nevertheless, upon glucose starvation, the energy 
sensor AMPK, phosphorylates tuberous sclerosis protein 2 (TSC2) and RAPTOR thus, 
inhibiting mTORC1 and mTORC1-mediated ULK1 phosphorylation. Hence, ULK1 is free 
to interact with AMPK, which phosphorylates ULK1 at Ser317 and Ser777 and activates it. 
It should be underlined however, that ULK1-mediated autophagy induction upon RAPA 
treatment or amino-acid starvation, occurs in an AMPK-independent manner. 
Regardless of nutrient conditions, the ULKs form a complex with the mammalian ATG13 
(Atg13 homolog) and the focal adhesion kinase family-interacting protein of 200Kd 
(FIP200) (Atg17 homolog) [248, 249]. Active ULKs, phosphorylate and activate the 
ATG13 and FIP200, and the activated ULK-ATG13-FIP200 complex is recruited to the 
phagophores [250]. Nonetheless, mTOR has been also suggested to directly phosphorylate 
and inactivate ATG13 under nutrient rich conditions [249]. Hence, phosphorylation of 
ATG13 by ULKs and mTOR must occur within different sites, having opposite effects.  
 
Autophagosome formation: The first step of this process refers to the nucleation of the 
phagophore. In order to achieve this, a complex comprising of the class III PI3K vacuolar 
protein sorting 34 (VPS34), the regulatory unit VPS15 (previously known as p150 in 
mammalian cells) [251, 252] and BECLIN1 (ATG6; Vps30 or Atg6 yeast homolog) [253, 
254]. Recently, a new interactor of this complex was identified; this molecule, known as 
BECLIN1-associated autophagy-related key regulator (BARKOR), has a sequence that is 
18% identical and 32% similar to the yeast Atg14 [255]. Therefore, mammalian BARKOR 
is also known as autophagy-related protein 14-like (ATG14L) protein. In yeast, there are 
two PI3K complexes; the [Vps34-Vps15-Atg6]-Atg14, which takes part in autophagy, and 
the [Vps34-Vps15-Atg6]-Vps38, which takes part in the vacuolar protein-sorting pathway 
[256].  It is believed that Atg14 and Vps38 “tag” the complexes and determine their 
function and localisation. Accordingly, in mammals the core of the PI3K complex consists 
of the VPS34-VPS15-BECLIN1 and, depending on the binding of specific interactors, 
such as ATG14L or the UV irradiation resistance-associated gene (UVRAG; Vps38 yeast 
homolog) protein, the complex gains specific functions regarding membrane trafficking. In 
the mammalian autophagy machinery, ATG14L is believed to target the PI3K complexes 
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to an ER subdomain that is essential for the autophagy [257, 258]. Hence, in both yeast and 
mammals, ATG14L is mediating the localisation of the PI3K complexes to the site of the 
autophagosome formation.  
Furthermore, the function of the PI3K complex can be regulated via interaction of 
BECLIN1 with its binding partners. The apoptosis regulator protein BCL2 can inhibit 
autophagy through interaction with the BH3-like domain in BECLIN1 [259]. This 
interaction is, however, reversed during starvation, allowing BECLIN1 to induce 
autophagy [260]. BECLIN1 has also been demonstrated to interact with UVRAG and 
activate autophagy [261].  Another BECLIN1 interactor is the activating molecule in 
BECLIN1-regulated autophagy protein 1 (AMBRA1). The PI3K core complex is docked 
to the cytoskeleton via dyneins through a BECLIN1/AMBRA1 interaction. Di Bartolomeo 
and colleagues demonstrated that upon autophagy induction, ULK1 phosphorylates 
AMBRA1, disrupting the interaction with BECLIN1 [262]. This allows the PI3K complex 
to de-attach from dyneins and reach the ER in order to initiate the autophagosome 
nucleation.  
The origin of the autophagosomal membrane still remains unclear. Some studies suggest 
that either the ER or the Golgi is the source, however, others propose both ER and 
mitochondria, or a de novo membrane generation [263].  
The expansion of the phagophore and, ultimately, the formation of the autophagosome, 
depend on two ubiquitin-like (UBL) conjugation systems; the ATG12–ATG5 and the 
ATG8–PE (phosphatidylethanolamine) [ATG8 is also known as microtubule-associated 
protein 1 light chain 3 (LC3); Atg8 yeast homolog]. The proteins with UBL activity, 
ATG12 and ATG8, undergo a cascade of conjugation with different ATG interactors 
(Figure 1-6).  
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Figure 1-6: Autophagosome elongation 
(Original figure, compiled from information within [244] and [243]).  
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seems to be the most indispensible building block for both inner and outer autophagic 
membranes [126]. 
It is believed that the expanding autophagosomes engulf bulk cytoplasmic contents in a 
non-specific manner. Nonetheless, this process can also be selective; cargo receptors 
deliver ubiquitinated substrates for autophagic degradation. Such a receptor is the 
mammalian protein p62/sequestosome 1 (SQSTM1), which contains a C-terminal 
ubiquitin-associated (UBA) domain that binds ubiquitin, and a conserved 22-amino acid 
acidic peptide motif LC3-interacting region (LIR) that allows for direct binding to human 
LC3 family members [271]. The selective recognition and degradation of p62 through 
autophagy were demonstrated by its accumulation in autophagy deficient cells [272, 273]. 
NBR1 (neighbor of BRCA1 gene 1) is another autophagy receptor containing a UBA 
domain and a LIR region [274]. NBR1 and p62 can work independently, or interact and 
form oligomers.  
 
Fusion and degradation:  Upon formation of the complete autophagosome, ATG4 
releases the outer membrane LC3 from the PE by cutting the amide bond that links them 
[275]. The mechanistic details of the autophagosome fusion with the lysosomes in order to 
form the autolysosomes or autophagolysosomes, are still not clear. Nevertheless, in 
mammals, it has been demonstrated that this process requires the presence of lysosomal 
membrane protein LAMP-2, the small GTPase RAB7 and UVRAG [276-278]. 
Following fusion, the cargo is lysed mainly by cathepsins [279]. The macromolecules have 
been digested to their monomeric units, and released to the cytosol for reuse. Nevertheless, 
this process has to be further investigated; especially, the process of the autophagic 
recycling of carbohydrates and lipids remains vastly unknown. 
 
1.4.2 Autophagy in cancer 
1.4.2.1 Autophagy and cell death 
Apoptosis, aka programmed cell death (PCD) type I, is a highly ordered process that 
recruits proteases and caspases for the dismantling of a cell. Accordingly, the extended 
vacuolisation of the cytoplasm accompanied by Golgi, ER and polyribosomes degradation 
before nuclear destruction, has been considered by many as an autophagic cell death, or 
PCD type II [280]. Along with necrosis, which is a non-ordered accidental type of death 
induced usually by external factors, apoptosis and autophagy cell death consist the three 
pathways of cell death [281]. Nevertheless, there have been arguments regarding the 
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contribution of autophagy in the process of cell death. More specifically, the Nomenclature 
Committee of Cell Death 2009 underlined that the “autophagic cell death” term “may 
misleadingly suggest a form of death occurring through autophagy, as this process often 
promotes cell survival” [241]. Hence, the use of a broader definition, such as “cell death 
occurring with autophagy” may be more suitable.  
It has now been established that disruption of apoptosis can lead to tumour initiation, 
progression or metastasis. p53 is an extensively investigated transcription factor that acts 
as a tumour suppressor and is deregulated in more than 50% of all cancers [282-284]. p53 
is involved in many cancer prevention mechanisms, including DNA repair, cell cycle 
regulation and initiation of apoptosis. In 2006, it was demonstrated that, DRAM (damage-
regulated autophagy modulator), a p53 target, is required for DNA-damage induced 
autophagy and is indispensible for p53-mediated apoptosis [284, 285]. It has been 
suggested that the p53 regulation of autophagy depends on its localisation; nuclear p53 
appears to induce autophagy at transcriptional level, whereas cytosolic p53 suppresses 
autophagy [286]. Recently, Lee and colleagues provided the first evidence for a direct 
interaction between p53 and ATG7 and a non-autophagic role for ATG7 [287]. ATG7 was 
essential during starvation for initiation of cell cycle arrest by binding to p53 and inducing 
expression of the cell cycle inhibitor p21. During starvation conditions, absence of ATG7 
resulted in increased DNA damage and reactive oxygen species (ROS), as well as 
transcriptional increase of the proapoptotic genes PUMA, NOXA, and BAX and, ultimately, 
p53-dependent apoptosis.  
Another autophagy gene interplaying with apoptosis is the ATG5, which is considered to 
be the “molecular switch” between autophagy and apoptosis. Cellular death stimulation 
and other stress factors (e.g. anticancer drugs) activate the calpains, a family of proteases, 
which cleave ATG5. The truncated ATG5 product (tATG5) triggers the release of 
mitochondrial cytochrome c and leads to an autophagosome-independent cell death [288].  
 
1.4.2.2 The autophagy paradox 
In 1999, experiments on Beclin1 haplodeficient mice associated for the first time an 
autophagy gene with tumourigenesis [254]. Following, it was demonstrated that BECLIN1 
was monoallelically deleted in 40-­‐‑70% of sporadic human breast or ovarian cancers cases 
[254], and haploinsufficient Beclin1 mice were prone to tumour development, including 
lymphoma, lung cancer and hepatocellular carcinoma [289, 290]. ATG genetically 
modified mice with compromised autophagy at whole body or tissue-specific level, 
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presented neurodegeration, muscle and liver damage, chronic inflammations and frequent 
infections, as well as the development of spontaneous tumours [291, 292]. Tissue cells 
from such ATG-/- mice had abnormal mitochondria, increased number of polyubiquinated 
protein aggregates, lipid droplets, ribosomes, perixosomes, as well as autophagy receptors 
p62 and NBR1 [291-293]. These data support the notion that autophagy acts as a tumour 
suppressor mechanism, most probably through its role in homeostasis and quality control. 
Autophagy ablation leads to ER stress and accumulation of dysfunctional proteins’ 
aggregates that have been suggested to favour tumourigenesis [294]. Furthermore, 
impairments in mitophagy lead to the accumulation of dysfunctional mitochondria and 
subsequent oxidative stress due to increased number of ROS. PINK1 and PARK2 (aka 
parkin) take part in the ubiquitination of the outer mitochondrial membrane so as to target 
damaged mitochondria for autophagic degradation [295]. These proteins are mutated in 
Parkinson’s disease, and their inactivation causes hepatocellular carcinoma in mice [296]. 
Increased ROS due to an autophagy-deficient background promote deoxyribonucleic acid 
(DNA) damage, and lead to genetic instability [287]. Interestingly, accumulation of p62 
due to impaired autophagy has been suggested to drive tumourigenesis by aberrantly 
increased ROS and oxidative DNA damage that enhance the development of acquired 
mutations and the activation of tumour-promoting pathways [297]. p62 has been proposed 
to activate the transcriptional nuclear factor-erythroid 2-related factor-2 (NRF2), which 
regulates cellular defense upon oxidative stress [298, 299]. Autophagy suppression in the 
liver of mice has been demonstrated to lead to increased p62 levels, overexpression, 
activation and translocation of Nrf2 to the nucleus, followed by transcription of the Nrf2 
gene targets and tumourigenesis [298, 300, 301]. NRF2 has been suggested to have a dual 
role in cancer; from the one hand, it protects from oxidative stress, from the other hand, its 
overexpression had been proposed to give a survival and growth advantage to tumour cells 
[302]. Finally, it has been suggested that increased ROS levels could reduce immunity 
against cancer antigen by promoting apoptosis of T-cells.  
Another potential contribution of autophagy deficiency towards development of cancer is 
through inflammatory responses. The aforementioned effects of compromised autophagy 
on oxidative and ER stress, genomic instability etc, induce prolonged tissue damage and an 
inflammatory environment [303]. Autophagy defects lead to inflammation in Crohn’s 
disease [304] and pancreatitis [305], and chronic inflammation supports cancer 
development. Loss of Beclin1 allele in mice has been shown to promote liver inflammation 
and hepatocellular carcinoma [289, 290, 306].  
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On the other hand, autophagy has been considered as a survival mechanism since its 
discovery and increasing evidence suggest that autophagy acts also as a survival 
mechanism within cancer cells. Cells in the core of the tumour or highly proliferating 
cancer cells that have surpassed the potential of their vascular niche, have to overcome 
adverse conditions such as hypoxia and limited access to nutrients and GFs [307, 308]. 
Unlike normal cells that have low basal autophagy levels, cancer cells seem to be 
“addicted” to high levels of autophagy under nutrients  replete conditions [307].  
In support of the cancer cell “autophagy addiction” hypothesis are studies demonstrating 
the autophagy dependence of RAS-driven cancers [309-311]. Data showed that autophagy 
is required for the maintenance of mitochondrial integrity, which is necessary for the 
survival of RAS-expressing cells during starvation [309]. Most importantly, tumourigenic 
ability of RAS was ablated in an autophagy deficient background [309, 311].  
 
 
 
 
 
 
Figure 1-7: The role of autophagy in cancer 
 (Adapted from [240]).  
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Taken altogether, autophagy seems to have a dual role in cancer; it can act as a tumour 
suppressor by ensuring cellular integrity, however, in established tumours it seems to 
support the survival of cancer cells [307]. Therefore, modulation of autophagy for cancer 
therapy should be context-specific and take into account the type of tumour, the stage of 
disease and the nature of the treatment [244].  
 
1.4.2.3 Inhibition of autophagy in CML 
The most commonly used autophagy inhibitors nowadays include chloroquine (CQ), and 
its derivative hydroxychloroquine (HCQ), which is associated with lower retinal toxicity 
[312, 313]. CQ has been extensively used in the clinic for malaria, as well as for 
autoimmune diseases, such as rheumatoid arthritis and systemic lupus. Both CQ and HCQ 
inhibit autophagy at a late stage, by inhibiting lysosomal acidification and preventing the 
fusion between autophagosomes and lysosomes. CQ and HCQ are not exclusive autophagy 
inhibitors and affect other cellular pathways as well. However, since these drugs are FDA-
approved, they can be used in the clinic for the inhibition of autophagy, and a number of 
clinical trials are investigating their effects in combination with other anti-cancer agents 
(Table 1-7).  
Early stage pharmacological autophagy inhibitors target the PI3K-kinases, such as the 3-­‐‑
methyladenine (3-­‐‑MA), a PI3K-III inhibitor, and wortmannin (WM), a pan-PI3K inhibitor 
[314]. Nonetheless, PI3K inhibitors may also suppress class I PI3K kinases upstream of 
mTOR, and, partially, induce autophagy. Moreover, like CQ and HCQ, PI3K inhibitors are 
not targeting autophagy solely, and some of them are associated with high toxicity at 
clinically relevant doses [315].  
Chemical autophagy inhibitors can block autophagy at the fusion stage, such as vinblastine 
and nocodazole [316], or at the degradation stage, such as ammonium chloride or 
lysosomal protease inhibitors E64d and pepstatin [279]. Another late autophagy stage 
inhibitor is bafilomycin A1, which inhibits lysosomal acidification [317]. It should also be 
mentioned, that none of these chemical inhibitors is specific to autophagy.  
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Table 1-7: Clinical trials investigating autophagy inhibition using HCQ or CQ in 
combination with anti-cancer therapies  
(Reproduced from [318])  
 
 
1.4.3 Autophagy in CML 
In 2006, Yan and colleagues demonstrated that crotoxin (CrTX), a neurotoxin with 
antitumour activity, induces apoptosis and autophagy in BC CML cell line K562 [319]. 
Inhibition of the CrTX-induced autophagy with 3-MA or ammonium chloride enhanced 
the neurotoxin's cytotoxicity. Additionally, Carew and colleagues suggested a year later 
that CQ-mediated inhibition of autophagy potentiated the effects of the HDAC inhibitor 
suberoylanilide hydroxamic acid (SAHA) in IM-resistant CML cell lines and primary cells 
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[320]. In 2008, inhibition of BCR-ABL by bafetinib, a dual BCR-ABL/LYN TKI, or IM, 
was shown to induce protective autophagy [321, 322].  
In 2009, our lab provided for the first time rigorous evidence demonstrating that TKIs 
induces autophagy in CML primary cells and its inhibition augments TKI effects [323]. IM 
treatment induced autophagy in CML cell lines and primary cells; inhibition of the IM-
induced autophagy either with CQ enhanced the effects of IM (Figure 1-8). Furthermore, 
CQ potentiated the effects of second generation TKIs, DAS and NIL. Importantly, 
induction of autophagy was demonstrated to be specific to inhibition of BCR-ABL 
activity, since IM treatment did not enhance autophagic activity in the cells carrying the 
resistant clone BCR-ABLT315I. Nevertheless, these data do not clarify if the observed effect 
on stem/progenitor cells is due to the inhibition of cellular autophagy or lysosomal activity, 
or other CQ-associated off-target effects. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8: Proposed mechanism for the role of autophagy in TKI-induced CML treatment 
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Sheng and colleagues recently shed more light regarding the mechanism by which 
inhibition of BCR-ABL is leading to induction of autophagy [324]. Oncogenic BCR-ABL 
mimicks the effects of GF and activates the PI3K/AKT pathway, which inhibits FoxO4. 
Inhibition of FoxO4 leads to increased levels of the transcription factor ATF5 and its 
target, mTOR. Subsequently, mTOR suppresses autophagy. Upon BCR-ABL inhibition, 
for example during TKI treatment, decreases PI3K/AKT signaling and FoxO4 is free to 
inhibit ATF5, leading to decreased transcription of mTOR and increase in autophagy.  
Our data regarding the protective role of autophagy in CML were supported by the 
following studies [325-329]. Most importantly, in 2011, Altman and colleagues 
demonstrated that autophagy is necessary for Bcr-Abl transformation; deletion of Atg3 in a 
mouse model prevented Bcr-Abl-mediated leukaemogenesis [330]. However, there are 
studies supporting the induction of autophagy in combination with targeting of non-BCR-
ABL related pathways for the treatment of CML [331, 332]. Resveratrol (RSV), a 
phytoalexin, has been proposed to induce apoptosis and autophagy in an AMPK-dependent 
manner, and inhibition of RSV-induced autophagy partially rescued RSV-mediated 
apoptosis within CML cells sensitive or resistant to IM [331]. Additionally, it has been 
proposed that treatment with arsenic trioxide, an autophagy inducer, has antileukaemic 
effects that are partially attributed to the autophagic degradation of BCR-ABL [333].  
 
1.4.3.1 The CHOICES clinical trial 
The findings from the study of Bellodi and colleagues provided the foundation for the 
initiation of the phase II clinical trial CHOICES (CQ and IM Combination to Eliminate 
Stem cells) clinical trial. CHOICES is a randomised trial investigating the effects of IM 
versus HCQ and IM for CML patients that have been on IM for >1 year and are in MCyR 
with residual disease detectable by qRT-PCR.  
Primary objectives include determining if the combination HCQ plus IM versus IM alone 
is more effective in terms of lowering BCR-ABL levels in CML patients with MCyR and 
residual disease detectable by qRT-PCR after at least 1 year of IM treatment, as well as 
evaluating the safety and tolerability of this regimen in these patients. 
 
Patients are randomised to 1 of 2 treatment arms: 
Arm A: Patients receive oral IM daily. Treatment repeats every 4 weeks for up to 12 
months in the absence of disease progression or unacceptable toxicity. 
Arm B: Patients receive oral IM daily and oral HCQ twice daily. Treatment repeats every 4 
weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. 
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In both arms, patients may then receive oral IM daily for another 12 months during the 
follow up period of this study. Consenting patients undergo blood sample and BM 
collection at baseline, during, and after completion of study therapy for pharmacologic and 
other laboratory studies. After completion of study treatment, patients are followed up at 3, 
6, 9, and 12 months. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Small molecule inhibitors 
IM was provided as a white powder under a Materials Transfer Agreement from Novartis 
Pharma (Basel, Switzerland). DAS was provided as a white powder under a Materials 
Transfer Agreement from Bristol-Myers Squibb (Princeton, NJ, USA). PON was provided 
as a white powder under a Materials Transfer Agreement from ARIAD Pharmaceuticals 
Inc. (Massachusetts, USA).  
Details of the suppliers, stock concentrations, and diluents of all drugs and inhibitors used 
are listed in Table 2-1. All stock aliquots were stored at -20oC, with the exception of HCQ 
and CQ, which were stored at 4oC. All small molecule inhibitors were made up fresh for 
each experiment and diluted to the appropriate concentration with appropriate medium 
prior to use. 
 
 
 
Molecule Solvent Stock 
Concentration 
Supplier 
CQ Water 100mM Sigma-Aldrich 
DAS DMSO 20mM Bristol-Myers Squibb 
HCQ PBS 100mM Sigma-Aldrich 
IM Water 100mM Novartis 
NIL DMSO 10mM Novartis 
BEZ DMSO 1mM LC Laboratories 
PON DMSO 10mM ARIAD Pharma 
RAPA EtOH 2mM Sigma-Aldrich 
 
Table 2-1: Small molecule inhibitors (dimethyl sulfoxide; DMSO, phosphate buffered saline; 
PBS, ethanol; EtOH) 
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2.1.2 Tissue culture materials 
Abbot Diagnostics, Maidenhead, 
UK  
Locus specific identifier (LS1) BCR-ABL Dual 
Colour FISH probe  
Baxter Healthcare, Nottingham, 
UK  
Sterile water  
BD Biosciences, Oxford, UK Annexin binding buffer (10X) 
Anti-human IgG allophycocyanin (APC) 
isotype control 
Anti-human IgG fluorescein isothiocyanate 
(FITC) isotype control  
Anti-human IgG phycoerythrin (PE) isotype 
control  
BD BioCoat™ - Collagen I 12-well plates 
FACS flow/FACS clean 
Mouse anti-human-annexin-V-FITC antibody 
Mouse anti-human-annexin-V-PE antibody 
Mouse anti-human-CD34-APC 
Mouse anti-human-CD38-FITC  
Mouse anti-human-annexin-V-peridinin 
chlorophyll protein (PerCP)-CyTM5.5  
PE anti-human CD235a 
Via-ProbeTM- 7 aminoactinomycin D (7-AAD) 
Chugai Pharma, London, UK  Recombinant human G-CSF  
Enzo Life Sciences, Exeter, UK Cyto-ID® Autophagy detection kit 
Gilson, Middleton, USA  Yellow and blue pipette tips  
Greiner Bio-One, Gloucestershire, 
UK  
Cryo.sTM cryotubes 
Tissue culture flasks  
(25cm2, 75cm2 and 175cm2) 
Tissue culture plates  
(6-well, 12-well, 24-well and 96-well) 
Pipettes (5mL, 10mL and 25mL) 
Invitrogen, Paisley, UK  2-mercaptoethanol 
Foetal calf serum (FCS) 
L-glutamine (200mM) 
Isocove’s modified dulbecco’s medium 
(IMDM) 
Dulbecco's modified eagle medium (DMEM) 
RPMI 1640  
Dulbecco’s PBS 
MitoTracker® Red CMXRos 
MitoSOX™ Red  
Miltenyi Biotec, Bisley, UK  CliniMACS CD34 reagent 
CliniMACS PBS/ ethylenediaminetetraacetic 
acid (EDTA) buffer  
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CliniMACS tubing set 
CD34 MicroBead kit  
Nalgene Labware, Roskilde, 
Denmark  
25 and 75cm3 non-adherent issue culture flasks 
Cryo freezing container “Mr. Frosty”  
Vacubottles 
Scottish National Blood 
Transfusion, 
Glasgow, UK  
20% Human serum albumin 
4.5% Human albumin solution (ALBA®) 
Sigma-Aldrich, Dorset, UK  5-Azacytidine (AZA) 
Bovine serum albumin (BSA)  
Carbonate-bicarbonate buffer  
DMSO 
Ficoll/histopaque solution (1.077g/mL)  
G418 
Gelatin 
Hank’s buffered salt solution – calcium and 
magnesium free (HBSS-CMF)  
Hydrochloric acid (HCl) 
Hygromycin B 
Magnesium chloride (MgCl2) 
Poly-L-lysine 
Potassium chloride (KCl) 
Puromycin (PURO) 
Sodium azide 
Trisodium citrate 
Trypan blue 
Trypsin-EDTA 
Startorius, Hannover, Germany  Minisart 0.2µM sterile filters  
Minisart 0.45µM sterile filters 
Stem Cell Technologies, British 
Columbia, Canada  
Methocult® H4434 
Methocult® H4230 
Bovine pancreatic deoxyribonuclease  
(DNase 1) 1mg/mL 
BSA/insulin/transferrin (BIT)  
Serum substitute 
Flt-3 ligand (FLT3L) 
IL-3 
IL-6 
Stem Cell Factor (SCF) 
TPO 
GM-CSF 
Macrophage inflammatory protein 1α (MIP-1α) 
Sterilin Ltd, Hounslow, UK Pastettes 
Disposable pipettes (5mL, 10mL and 25mL) 
Sterile plastic falcon tubes (15 and 50mL) 
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Thermo-Scientific, Hertfordshire, 
UK 
ON-TARGETplus SMARTpool-human ATG7 
ON-TARGETplus non-targeting pool 
 
2.1.3 Molecular biology materials 
Abcam, Cambridge, UK  Mouse anti-human-p62 antibody 
Mouse anti-human-actin antibody  
Applied Biosystems, Foster City, CA, 
USA  
GeneAmp® RNA PCR core kit 
High capacity complimentary DNA 
(cDNA) reverse transcription kit 
Nuclease free water 
TaqMan® probes  
Deoxyribonucleotide triphosphates 
(dNTPs) 
Bio-Rad Hercules, CA, USA Combs for gel casting 
Gel casting trays 
Immuno-BlotTM polyvinylidene fluoride 
(PVDF) membrane  
Immuno-StarTM WesternCTM Kit  
Bioline, London, UK HyperPAGE prestained protein marker  
Cell Signalling, New England Biolabs 
Hitchin, UK  
Anti-rabbit IgG horseradish peroxidase 
(HRP)-linked secondary antibody 
Rabbit anti-human-ATG7 antibody 
Rabbit anti-human-p-CrkL antibody 
Rabbit anti-human-LC3b antibody 
Rabbit anti-human-p-RPS6 antibody 
Rabbit anti-human-β-Tubulin antibody 
Chemical Store, University of Glasgow 
Glasgow, UK  
EtOH 
Methanol  
Chemicon International, Temecula, 
CA, USA 
10X Re-BlotTM plus strong antibody 
Stripping solution 
Eurofins MWG Operon, 
Wolverhampton, UK  
PCR primers  
Helena Biosciences, Gateshead, UK  Agarose powder  
Invitrogen, Paisley, UK  Novex® SharpTM pre-stained protein 
standard 
NuPage® MES sodium dodecyl sulfate 
(SDS) running buffer (20X) 
CellsDirectTM One-Step qRT-PCR kit  
Nupage® Novex® Bis-Tris 4-12% gel 
NuPage® transfer buffer (20X) XCell 
IITM Blot module 
Miller’s Luria Broth (LB) base® 
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Lonza, Basel, Switzerland Amaxa® cell line nucleofector® kit V 
Amaxa® human CD34+ cell 
nucleofector® kit 
New England Biolabs (NEB), 
Hertfordshire, UK 
NdeI restriction enzyme 
SpeI restriction enzyme 
Promega, Southampton, UK 100 base pair (bp) DNA ladder PCR 
loading dye (6X)  
CellTiter-Glo® luminescent cell viability 
assay 
Shrimp alkaline phosphatase (SAP) 
Qiagen, West Sussex, UK RNeasy mini kit  
QIAshredder kit 
HiSpeed® plasmid midi kit 
SG Wasseraufbereitung und 
Regenerierstation GmbH, Barsbuttel, 
Germany 
Ultra pure water system (sterile water)  
Sigma-Aldrich, Dorset, UK 0.1% Ponceau S solution 
2-glycerophosphate 
Aprotinin 
Boric acid 
CaCl2*2H2O 
EDTA 
Formaldehyde solution (36.5%)  
Leupeptin 
NP-40 
PMSF 
Protein A-sepharose®  
Sodium chloride 
Sodium fluoride 
Sodium orthovanadate 
Sodium pyrophosphate 
Tris base 
TWEEN 20 for electrophoresis 
Tetramethylethylenediamine (TEMED) 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Thermo-Scientific, Hertfordshire, UK  BCATM protein assay kit  
 
  71 
 
2.1.4 TaqMan® probes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Product No Gene Product No
18S Hs99999901 E2F1 Hs00153451
ABL1 Hs01104728 GABARAPL1 Hs00740588
APOBEC3B Hs00358981 GAPDH Hs99999905
ATG12 Hs01047860 GUSB Hs99999908
ATG13 Hs00207186 HES1 Hs00172878
ATG3 Hs00223937 HES5 Hs01387463
ATG4B Hs00367088 HIF1A Hs00936371
ATG5 Hs00169468 MAP1LC3B Hs00797944
ATG7 Hs00197348 MCL1 Hs03043899
ATM Hs01112307 MDM2 Hs00234753
BAK1 Hs00940250 p21 Hs00355782
BAX Hs00180269 p53 Hs01039246
BECN1 Hs00186838 RB Hs01078066
BID Hs00609630 SIRT1 Hs01009006
BIM Hs00708019 SIRT6 Hs00213036
BIRC5 Hs04194392 TBP Hs99999910
BRCA1 Hs01556193 TGFB1 Hs00998129
CDKN1B Hs00153277 TGFBR1 Hs00610320
CHEK2 Hs00200485 ULK1 Hs00177504
CHK1 Hs00967506 ULK2 Hs00206622
CXCL1 Hs00236937 WNT4 Hs00229142
CYCLIN D1 Hs00765553 WNT5A Hs00998537
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2.1.5 Fluorescence microscopy supplies 
Abcam, Cambridge, UK  Mouse IgG2a isotype control  
Rabbit F(ab’)2-IgG-isotype control 
Carl Zeiss, Jena, Germany  AxioVision software 
Cell Signalling, New England Biolabs, 
Hitchin, UK  
Rabbit anti-human-LC3B antibody 
Hendley, Essex, UK  Multi-spot microscope slides 
Invitrogen, Paisley, UK Alexa Fluor® 488 cholera toxin 
subunit B conjugate 
Alexa Fluor® 488 goat anti-rabbit 
IgG 
Alexa Fluor® 594 goat anti-mouse 
IgG 
Alexa Fluor® 488 phalloidin 
Sigma-Aldrich, Dorest, UK  Poly-L-lysine solution 0.1 % (w/v) 
Triton-X100  
Vector Laboratories Ltd,  
Peterborough, UK 
VECTASHIELD® mounting 
medium with 4',6-diamidino-2-
phenylindole (DAPI) 
 
2.1.6 PCR primer sequences 
TAT Forward GAAGCATCCAGGAAGTC AGCC  
TAT Reverse GCTGTCTCCGCTTCTTCC TGCC  
Human U6 Promoter 
Forward GACTATCATATGCTTACCGT 
pLKO.1 Backbone Reverse AAACCCAGGGCTGCCTTGGAAAAG 
 
2.1.7 Equipment 
Kell-Strom, Wethersfield, USA Branson 200 Ultrasonic cleaner 
Epson (UK), Hertfordshire, UK Epson perfection 4490 photo scanner 
BD Biosciences, 
San Jose, CA 
FACSAria II 
FACSCalibur 
Gilson, Middleton, USA Gilson pipetman single channel pipettes 
Weber Scientific International, 
West Sussex, UK 
Hawksley Neubauer counting chamber 
Carestream Health, 
Rochester, NY, USA 
Kodak X-OMAT 1000 
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Thermo Fisher Scientific, 
Loughborough, UK 
Multiscan EX photometer 
Lonza, Basel, Switzerland Nucleofector® II device 
Bio-Rad Hercules, CA, USA PowerPac300 
Schutron, Reutlingen, Germany Thermoshaker 
Bio-Rad Laboratories Ltd., UK Trans-Blot® SD cell 
Molecular Imager® ChemiDocTM XRS  
Carl Zeiss, Jena, Germany  Fluorescence microscope 
Light microscope 
Labtech International East 
Sussex, UK 
NanoDrop ND-1000 spectrophotometer 
Invitrogen, Paisley, UK  XCell SureLockTM mini-cell electrophoresis 
system 
 
 
2.1.8 Preparation of medium and solutions 
2.1.8.1 Tissue culture mediums and solutions 
2.1.8.1.1 RPMI++ 
RPMI 1640 440mL 
FCS 50mL 
L-glutamine (200mM) 5mL 
Penicillin/streptomycin solution 
(10,000UmL-1/10,000gmL-1) 
5mL 
 
2.1.8.1.2 DMEM++ 
DMEM 440mL 
FCS 50mL 
L-glutamine (200mM) 5mL 
Penicillin/streptomycin solution 
5mL 
(10,000UmL-1/10,000gmL-1) 
 
2.1.8.1.3 20% FCS DMEM^ 
DMEM 390mL 
FCS 100mL 
L-glutamine (200mM) 5mL 
Penicillin/streptomycin solution 
5mL 
(10,000UmL-1/10,000gmL-1) 
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2.1.8.1.4 DMEM* for maintenance of stromal cell line Sl/Sl for LTC-IC 
DMEM 500mL 
FCS 75mL 
L-glutamine 10mL 
Penicillin/streptomycin solution 10mL 
(10,000UmL-1/10,000gmL-1) 
 
2.1.8.1.5 RPMI* for maintenance of stromal cell line M2-10B4 for LTC-IC 
RPMI 1640  500mL 
FCS 50mL 
L-glutamine 10mL 
Penicillin/streptomycin solution 
(10,000UmL-1/10,000gmL-1) 
10mL 
 
2.1.8.1.6 IMDM/2% FCS 
IMDM 98mL 
FCS 2mL 
 
2.1.8.1.7 Myelocult 
Myelocult™ 100mL 
Hydrocortisone hemisuccinate  
(1x10-4M) 
1mL 
 
2.1.8.1.8 DAMP solution [for thawing cryopreserved CD34+ or mononuclear cell (MNC) 
aliquots from -150°C] 
 
 
2.1.8.1.9 Serum free medium (SFM) 
 
BIT 25mL 
L-glutamine (200mM) 1.25mL 
Penicillin/streptomycin solution 
(10,000UmL-1/10,000gmL-1) 
1.25mL 
2-mercaptoethanol (50mM) 250µL 
Low density lipoprotein (10mg/mL) 500µL 
IMDM 97.25mL 
 
DNase I  
(2 vials at approximately 2500U/1mL/vial) 
2mL 
Magnesium chloride  
(400X, 1.0M stock) 
1.25mL 
Trisodium citrate (0.155M) 53mL 
Human serum albumin  (20%, SNBTS) 25mL 
Dulbecco’s PBS (magnesium/calcium free) 418.75mL 
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2.1.8.1.10 SFM supplemented with five growth factors (SFM+5GFs) 
SFM 10mL 
IL-3 (50µg/mL) 4µL 
IL-6 (50µg/mL) 4µL 
G-CSF (20µg/mL) 10µL 
FLT3L (50µg/mL) 20µL 
SCF (50µg/mL) 20µL 
 
2.1.8.1.11 SFM supplemented with physiological growth factors (SFM+PGFs) 
SFM 10mL 
SCF (0.5µg/mL) 4µL 
G-CSF (2µg/mL) 5µL 
GM-CSF (0.1µg/mL) 20µL 
IL-6 (5µg/mL) 2µL 
LIF (0.1µg/mL) 5µL 
MIP-1α (0.1µg/mL) 20µL 
*Filter through 0.22µM filter 
 
2.1.8.1.12 20% DMSO/4.5% ALBA 
DMSO 20mL 
4.5% ALBA 80mL 
 
2.1.8.1.13 PBS/2% FCS 
PBS 490mL 
FCS 10mL 
  
2.1.8.1.14 Annexin binding buffer 
Annexin binding buffer (10X) 1mL 
distilled water (dH2O) 9mL 
 
2.1.8.1.15 Fix perm wash – PBS/1% BSA 
BSA 10g 
PBS to 1L 
 
2.1.8.1.16 IMDMm+ for the maintenance of mouse c-kit enriched cells 
IMDM 
FCS 
 
10% 
mouse SCF 40 ng/ml 
mouse IL-6 20 ng/ml 
mouse IL-3 20 ng/ml 
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2.1.8.2 Western blotting solutions 
2.1.8.2.1 Lysis buffer for protein lysates (radio-immunoprecipitation assay; RIPA) 
distilled sterile water (dsH2O) 7.75mL 
1.5M NaCl 1mL 
1M Tris-HCl 0.5mL 
150mM EDTA 333µL 
NP-40 50µL 
10% (w/v) Sodium deoxycholate 250µL 
*Immediately prior to use, one protease inhibitor 
tablet added per 10mL of buffer 
 
 
2.1.8.2.2 2X SDS Sample buffer (Laemmli) 
1.5M Tris-HCl, pH6.8 10mL 
Glycerol 30mL 
20% (w/v) SDS 6mL 
Bromophenol blue    1.8mg 
2-mercaptoethanol 15mL 
dsH2O to100
mL 
 
 
2.1.8.2.3 10X TBS buffer 
NaCl 876.6g 
Tris 121.1g 
dH2O 10L 
 
2.1.8.2.4 1X TBS-Tween (TBST) buffer 
10X Tris-buffered saline (TBS) buffer 1L 
TWEEN 20 10mL 
dH2O 8.99L 
 
2.1.8.2.5 Homemade gels 
2.1.8.2.5.1 10% Resolving gel 
dsH2O 4mL 
30% Acrylamide 3.3mL 
1.5M Tris (pH8.8) 2.5mL 
10% SDS 0.1mL 
10% APS 0.1mL 
TEMED 0.01mL 
 
2.1.8.2.5.2 15% Resolving gel 
dsH2O 2.3mL 
30% Acrylamide 5.0mL 
  77 
 
1.5M Tris (pH8.8) 2.5mL 
10% SDS 0.1mL 
10% APS 0.1mL 
TEMED 0.01mL 
 
2.1.8.2.5.3 Stacking gel 
dsH2O 1.4mL 
30% Acrylamide 0.33mL 
1.0M Tris (pH6.8) 0.25mL 
10% SDS 0.02mL 
10% APS 0.02mL 
TEMED 0.01mL 
 
2.1.8.2.6 1X NuPAGE® Running buffer 
NuPAGE® MES SDS Running Buffer (20X) 50mL 
dH2O to 1L 
 
2.1.8.2.7 1X NuPAGE® Transfer buffer 
NuPAGE® Transfer Buffer (20X) 30mL 
dH2O 510mL 
Methanol 60mL 
 
2.1.8.2.8 10X Running buffer (homemade) 
Glycine 144.1g 
Tris 30.3g 
SDS 10g 
dH2O to 2L 
pH to 8.3  
 
2.1.8.2.9 1X Running buffer (homemade) 
10X Running buffer (homemade) 100mL 
dH2O 900mL 
 
2.1.8.2.10 10X Transfer buffer (homemade) 
Glycine 144.1g 
Tris 30.3g 
dH2O to 2L 
pH to 8.3  
 
2.1.8.2.11 1X Transfer buffer (homemade) 
10X Transfer buffer (homemade) 100mL 
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Methanol 200mL 
dH2O 700mL 
 
2.1.8.2.12 5% BSA/TBST blocking buffer 
1X TBST buffer 100mL 
BSA 5g 
 
2.1.8.3 Immunofluorescence solutions 
2.1.8.3.1 3.65% Formaldehyde 
36.5% Formaldehyde solution 1mL 
PBS 9mL 
 
 
2.1.8.3.2 0.5% Triton-X-100 
Triton-X-100 250mL 
PBS 50mL 
 
 
 
2.1.8.4 PCR-based assays solutions 
2.1.8.4.1 2X RT-PCR Master Mix (10µL/assay) 
10X Reverse transcription buffer 2µL 
25X dNTPs Mix 0.8µL 
10X Reverse transcripton random primers 2µL 
Reverse transcriptase 1µL 
Nuclease free dsH2O 4.2µL 
 
2.1.8.4.2 PCR Mix (50µL) 
10X PCR Buffer 5µL 
dNTPs mix (1000µM) 10µL 
Taq polymerase 0.25µL 
Forward primer (100µM) 0.25µL 
Reverse primer (100µM) 0.25µL 
MgCl2 (25mM) 5µL 
cDNA 1µL 
Nuclease free dsH2O 28.25µL 
 
2.1.8.4.3 10X Tris/Borate/EDTA (TBE) buffer 
Boric acid 55g 
EDTA (0.5M, pH8.0) 40mL 
Tris base 108g 
dsH2O 1L 
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2.1.8.4.4 2X Reverse Transcriptase Specific Target Amplification (RT-STA) mix 
For one well: 
0.2X TaqMan® probes mix 1.4µL 
Cells direct 2X reaction 2.8µL 
SUPERase-In  0.056µL 
SuperscriptIII RT 0.112µL 
TE buffer 0.672µL 
  
2.1.8.5 Transfection solution 
2.1.8.5.1 2X HEPES-buffered saline (HBS) 
NaCl 8g  
KCl 0.37g  
Na2HPO4 106.5mg  
Dextrose 1.0g  
HEPES 5g 
dsH20 to 500mL 
pH to 7.05  
*Sterile filter through 0.45mM filter  
 
2.1.8.5.2 2M CaCl2  
CaCl2*2H2O  147g 
dsH2O to 500mL 
 
2.1.8.5.3 Transfection solution/10cm2 petri dish 
dsH20 440µL 
2X HBS 500µL 
2M CaCl2 (dropwise) 60µL 
 
2.1.8.6 Microbiology solutions 
2.1.8.6.1 LB 
Miller’s LB base® 25g 
dsH2O to 1L 
*Autoclave*  
Ampicillin (100mg/mL) 1mL 
 
2.1.8.6.2 Glycerol solution (30%) 
Glycerol 3mL 
dsH2O to 10mL 
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2.2 Methods 
2.2.1 Cell Culture  
2.2.1.1 Culture of cell lines  
The BC CML wild type (WT) cell lines K562 and KCL22 and the CLL cell line HG3, 
were all available “in-house”, and grown in suspension culture in RPMI++ medium 
(2.1.8.1.1) in tissue culture flasks. KCL22 cells expressing BCR-ABLT315I were kindly 
donated by Professor Bruno Calabretta and maintained in RPMI++. BaF3 cells (murine IL-
3 dependent pro-B cells) that stably expressed BCR-ABL, either the native p210 isoform 
or carrying the T315I kinase domain mutation, were donated as a kind gift from Professor 
Junia Melo and were also grown in RPMI++. M2-10B4 and Sl/Sl murine fibroblast cell 
lines were cultured in RPMI* (2.1.8.1.5) and DMEM* (2.1.8.1.4), respectively. Mouse c-
kit enriched MLL-ENL transformed cells were kindly donated by Dr Deniz Gezer, and 
maintained in IMDMm+ (2.1.8.1.16). 
All cell lines were maintained at 37°C with 5% CO2 in 25 or 75cm3 tissue culture flasks, 
counted and passaged every two days with warm fresh medium, to maintain a density of 
between 1x105-1x106 cells/mL.   
 
2.2.1.2 Cell proliferation assays 
2.2.1.2.1 Trypan blue dye exclusion method  
Background: The trypan blue dye exclusion method was used for cell counting and 
assessment of viability. Cells with damaged membranes are porous and absorb the trypan 
blue dye, appearing dark blue under a light microscope; viable cells with an intact 
membrane do not absorb the dye. For cell counting only the unstained cells were counted 
and the remaining stained dead cells were deemed non-viable.   
Method: Trypan blue dye was first diluted 1:10 with PBS and 90µL was added to 10µL of 
cell suspension to give a 1:10 dilution of cells. Approximately 10µL of the mixture was 
transferred to a counting chamber (improved Neubauer haemocytometer) and the four 
squares (a,b,c and d) were counted to give a statistically significant count. Number of cells 
and percent of viability were determined by using the formulas shown in Figure 2-1. 
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Figure 2-1: Trypan blue method for cell counting and viability assessment with improved 
Neubauer counting chamber 
 
2.2.1.2.2 CellTiter-Glo® Luminescent Cell Viability Assay 
Background: The CellTiter-Glo® luminescent cell viability assay [Promega, product 
number (PN) G7570] determines the number of viable cells in culture based on 
quantitation of the ATP present, which is directly proportional to the number of cells 
present in culture. The reagents generate a luminescent signal with extended half-life 
(>5h). 
Method: Culture volume containing 5000 cells was centrifuged (400 x g for 5mins) and 
resuspended in 100µL medium. The suspension was transferred to an opaque-walled 96-
well plate along with several ATP solutions (concentrations ranging from 1µM to 10nM 
ATP) for the generation of a standard curve. Medium containing no cells was used as a 
background control. The plate and its contents were equilibrated at room temperature for 
30mins, and following 100µL of reagent (prepared according to the manufacturer’s 
guidelines) was added to each well. The contents of the plate were mixed for 2mins on an 
orbital shaker, and incubated at room temperature for 10mins. Following incubation, the 
signal was recorded by a luminometer. 
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2.2.1.3 Primary samples’ collection and enrichment  
All samples were collected with the approval of the Local Research and Ethics Committee 
(LREC) and all human participants gave written informed consent.  
 
2.2.1.3.1 CML samples  
Leukapheresis samples from newly diagnosed untreated patients with CP CML were 
enriched to more than 90% CD34+ progenitors, by positive selection with CliniMACS, 
and cryopreserved. CML samples were determined to be Ph+ by FISH by Ms Elaine Allan. 
Purification of the MNC fraction from whole blood cell samples and selection of CD34+ 
cells from MNC samples were performed by Dr Alan Hair.  
 
2.2.1.3.2 non-CML samples 
Peripheral blood samples were obtained from patients undergoing autologous stem cell 
collection for either non-Hodgkin’s lymphoma or multiple myeloma. Patient stem cells 
were mobilised with G-CSF following chemotherapy and the excess CD34+ cells 
remaining after those required for clinical use were donated for research purposes.  
 
2.2.1.3.3 Cord blood (CB) samples 
CD34+ cells were isolated from fresh or cryopreserved CB samples using human MACS 
CD34 MicroBeads according to the manufacturer’s protocol (Miltenyi Biotec, Surrey, 
UK). After separation, CD34+ purity was assessed by flow cytometry. 
 
2.2.1.4 Cryopreservation of cells 
Primary CML/non-CML/CB CD34+ cells, as well as cell lines, were cryopreserved in 
liquid nitrogen at -150°C for long-term storage.  
Isolated CML/non-CML/CB CD34+ cells from fresh samples were suspended in 4.5% 
ALBA® and aliquoted in cryotubes; an equal volume of 20% DMSO in 4.5% ALBA® 
(2.1.8.1.12) was added to give a final DMSO concentration of 10%. 
Cell lines in exponential growth phase were collected and resuspended with 10% DMSO in 
FCS (5-10x106 cells/mL), and aliquoted into cryotubes. The cryotubes were transferred to 
a cryofreezing container (“Mr Frosty”) and kept at -80°C overnight to achieve a controlled 
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temperature reduction. The next day the cryotubes were transferred to a -1500C liquid 
nitrogen freezer for long-term storage.  
 
2.2.1.5 Recovery of frozen samples  
Primary CML/non-CML/CB CD34+ cells were removed from liquid nitrogen and 
immediately thawed at 37°C in a water bath until ice crystals disappeared. The cells were 
transferred to a 15mL sterile tube and recovered by adding dropwise 10mL of prewarmed 
at 37°C DAMP (2.1.8.1.8) thawing solution over a 20mins period. This step was 
performed at room temperature to enhance the activity of the DNase I, with constant 
agitation to avoid clumping of the cells. After centrifugation (120 x g for 10mins), the 
supernatant was removed and the pellet was washed twice more in DAMP (to get rid of 
remaining traces of DMSO). Subsequently, the cells were transferred to appropriate 
volume of SFM+PGFs medium (2.1.8.1.11) for CML and CB samples, or SFM+5GFs 
medium (2.1.8.1.10) for non-CML samples. The cells were seeded in a 25cm3 non-
adherent tissue culture flask at a density of approximately 1.5 x 106 cells/mL for overnight 
recovery.  
Cell lines were thawed in a 37°C water bath and recovered slowly as above but in PBS 
instead of DAMP. The cells were then washed twice with PBS (400 x g for 5mins) and 
transferred to RPMI++. Cells were plated in a 75cm3 tissue culture flask at a density of 
2x105 cells/mL (unless otherwise stated).  
 
2.2.1.6 Culture of CD34+ cells  
Following recovery from long-term liquid nitrogen storage, CML/CB cells were cultured 
in SFM+PGFs and non-CML cells in SFM+5GF, in 25 or 75cm3 non-adherent tissue 
culture flasks. The cells were seeded at an initial concentration of approximately 1.5x106 
cells/mL and maintained in an incubator at 37°C, 5% CO2. Drugs were added to each 
experiment as appropriate to the described conditions. The cells were harvested at 
indicated time-points, washed in PBS/2% FCS and aliquots were removed for performing 
cell counts, FACS analysis and RNA preparation. Wherever cell number was not 
restrictive, aliquots were taken for protein lysates. 
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2.2.2 Flow cytometry 
FACS is a quantitative technique that permits the characterisation and sorting of cells 
depending on their phenotype after staining with fluorochrome-labelled antibodies. A flow 
cytometer is equipped with lasers that supply excitation energy, as well as filters and 
detectors that detect the fluorescent emissions from the cells. Moreover, flow cytometers 
can measure the size of a cell, using forward-angle light scatter (FSC), and the granularity 
of a cell, using side-angle light scatter (SSC). All the flow cytometric analyses herein 
described were carried out on a Becton Dickinson FACSCanto. Data was analysed using 
FlowJo software. 
 
2.2.2.1 Selection of CD34+38- cells from total CD34+ samples  
CD34+ cells, prior or post transduction, were centrifuged (400 x g for 5mins) and 
resuspended in 100µl PBS/2% FCS (2.1.8.1.13). Aliquots of cells (2x104 cells per tube) 
were removed for appropriate isotype controls and used to set the detectors, so that the 
negative isotype population was placed in the first log decade for each flow cytometry 
channel. CD34-APC and CD38-PerCP positive controls (5µL of antibody per tube) were 
also set up. The remaining test cells were stained with 15µL of CD34-APC and 15µL of 
CD38-PerCP antibody and incubated for 20mins at room temperature in the dark. 
Following incubation, samples were washed twice with PBS/2% FCS (1000rpm for 
5mins). The controls were resuspended in 100µL PBS/2% FCS and the test cells were 
resuspended in 2mL PBS/2% FCS. All samples were sterile filtered through a mesh filter 
before sorting. The controls were run first and the compensation between fluorochromes 
with emission spectra overlap was adjusted. The population of CD34+CD38+ and 
CD34+38- cells were then sorted using a Becton Dickinson FACSAria.  
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Figure 2-2: Sorting the CD34+CD38- subpopulation from primary human CD34+ samples 
 The P3 gate represents the CD34+CD38+ cells and the P4 the more primitive CD34+CD38-
subpopulation. 
 
2.2.2.2 Surface antibody staining  
1x105 primary cells were collected, washed in PBS/2% FCS (400 x g for 5mins) and 
resuspended in 100µL PBS/2% FCS with appropriate antibody solution. Subsequently, the 
samples were incubated in the dark for 15mins. After incubation, the cells were washed 
twice in PBS/2% FCS (400 x g for 5mins) and analysed by FACS immediately, or kept at 
4°C until analysis. Appropriate isotype controls were used as negative controls.  
 
2.2.2.3 Apoptosis and necrosis assessment  
Background: Apoptosis and necrosis were assessed by FACS analysis after annexin V 
staining based on the principle that during early apoptosis phosphatidylserine translocates 
from the inner layer of plasma membrane to the outer layer and therefore, is available for 
binding by annexin V. Nonetheless, cells in late apoptosis continue to bind annexin V after 
loss of plasma membrane integrity. Hence, in order to differentiate between early and late 
apoptosis, cells were stained with 7-AAD, a nucleic acid dye. Late apoptotic cells were 7-
AAD positive since the integrity of plasma membrane was lost. Staining cells 
simultaneously with annexin V and 7-AAD enabled distinguishing of viable, early 
apoptotic and late apoptotic (or necrotic cells) by flow cytometry (annexin V– 7AAD–, 
annexin V+ 7AAD– and annexin V+ 7AAD+, respectively). 
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Method: Cells were incubated with 5µL annexin-V-FITC (BD, PN 560931) - or annexin-
V-PE (BD, PN560930)/ annexin-V-PerCP-CyTM5.5 (BD, PN 561431) for cells that have 
been transduced and are expressing GFP - and 10µL 7-AAD in 100µL annexin binding 
buffer  (2.1.8.1.14) for 15mins in the dark. The cells were then topped with 300µL annexin 
binding buffer and analysed by FACS within an hour, to identify percentages of necrotic 
and apoptotic cells.  
 
2.2.2.4 Cyto-ID® autophagy detection kit 
Background: Cyto-ID® autophagy detection kit (Enzo Life Sciences, PN 51031K200) 
offers evaluation of autophagic activity in live cells by FACS. It relies on the development 
of a novel dye, Cyto-ID™ green autophagy detection reagent, which selectively labels 
green vacuoles associated with the autophagy pathway, with minimal background 
lysosomal staining. The probe is a cationic amphiphilic tracer dye that rapidly partitions 
into cells in a similar manner as drugs that induce phospholipidosis.  
Method: Cell culture medium containing 105 cells was centrifuged (400 x g for 5mins) to 
pellet the cells and the supernatant was discarded. The cells were washed with PBS, 
centrifuged as before, and the supernatant was discarded. The cells were resuspended in 
95µL 1X assay buffer (1:10 dilution of 10X assay buffer in dsH2O) provided in the kit, 
and transferred to a FACS tube. 5 µL of Cyto-ID™ green autophagy detection reagent 
were added to the cell suspension and gently vortexed, followed by 15mins incubation at 
room temperature in the dark. The samples were analysed by FACS using a 488nm laser 
with the FL-1 channel for the detection of the Cyto-ID™ green autophagy detection 
reagent. Autophagic activity was estimated measuring the mean fluorescence intensity 
(MFI) value.  
 
2.2.2.5 Evaluation of mitochondrial membrane potential 
Background: MitoTracker® Red CMXRos (Invitrogen, PN M7512) is a commercially 
available cell-permeant fluorescent dye that labels active mitochondria within live cells, 
utilizing the mitochondrial membrane potential.  
Method: Target cells were washed with PBS and incubated with 200nM MitoTracker® 
Red CMXRos in PBS at 37°C in the dark for 30mins. Cells took up the dye at this stage 
since it is cell-permeable. Following, cells were centrifuged (400 x g for 5mins) and 
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resuspended in prewarmed medium. Fluorescence was detected by FACS (excitation 
wavelength  approximately 590nm). 
 
2.2.2.6 Mitochondrial superoxide measurement 
Background: Superoxide is the main form of ROS within mitochondria, produced as a by-
product during oxidative phosphorylation. MitoSOX™ Red (Invitrogen, PN M36008) is a 
cationic dye that targets specifically superoxide within mitochondria and not other ROS, 
emitting fluorescence at 599nm. 
Method: Target cells were washed with PBS and incubated with 5µM MitoSOX™ Red in 
PBS at 37°C in the dark for 30mins. Cells took up the dye at this stage since it is cell-
permeable. Following, cells were centrifuged (400 x g for 5mins) and resuspended in 
prewarmed medium. Fluorescence was detected by FACS (excitation wavelength 
approximately 590nm). 
 
2.2.3 Western blotting  
Western blotting (aka protein immunoblotting) is a robust protein analysis technique that 
identifies with specific antibodies proteins that have been separated according to their size 
by gel electrophoresis. The gel is placed then next to the membrane and application of an 
electrical current induces the proteins in the gel to move to the membrane made of 
nitrocellulose or PVDF. Therefore, the membrane represents a replica of the gel’s protein 
pattern, and allows visualisation of the protein(s) of interest after staining with a specific 
antibody coupled to an easily detectable enzyme such as HRP, a radioactive isotope or 
fluorescent dye.  
 
2.2.3.1 Protein lysate preparation  
In order to analyse the proteins of interest within a sample, the cells need to be lysed. 
There are many recipes for lysis buffers but a few will serve for most western blotting 
experiments. In brief, they differ in their ability to solubilise proteins, with those 
containing SDS and other ionic detergents considered to be the harshest and therefore most 
likely to give the highest yield. For the herein described experiments, two different lysis 
buffers were used. 
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2.2.3.1.1 RIPA buffer lysis method 
As soon the cells are lysed, proteolysis, dephosphorylation and denaturation also initiate. 
These events can be significantly inhibited by: 1) keeping the samples on ice, or at 4°C, at 
all times, and 2) by adding appropriate protease inhibitors fresh to the lysis buffer. 
Therefore, RIPA buffer (2.1.8.2.1) was prepared immediately prior to use and samples 
were processed while keeping on ice.  
Equal cell numbers from different treatment conditions were washed twice with ice cold 
PBS (400 x g for 5mins). The cells were then transferred to a 1.5mL eppendorf and washed 
again in ice cold PBS. The lysis buffer was added to the cells (50µL per 1-3x105 cells), 
mixed by pipetting up and down and incubated for 15mins on ice. Subsequently, the cell 
lysates were centrifuged (21,000 x g for 10mins at 4°C) to pellet chromatins and debris. 
The supernatants were transferred to new eppendorf tubes and stored at -20°C until use.  
 
2.2.3.1.2 2X SDS sample buffer/ Laemmli method 
Background: SDS denatures proteins by binding around their polypeptide backbone in a 
mass ratio of 1.4:1, assigning a negative charge that is proportional to their length. Hence, 
in denaturing SDS-polyacrylamide gel electrophoresis (PAGE) separations, migration is 
determined not by intrinsic electrical charge but by molecular weight. 2-mercaptoethanol is 
used as a reducing agent in the lysis buffer; it reduces disulphide bridges in proteins before 
they adopt the random-coil configuration so that all the constituent polypeptides can be 
analysed separately. Glycerol is added to the buffer to increase the density of the sample to 
be loaded and keep it at the bottom of the well, restricting overflow and uneven gel 
loading. Bromophenol blue is a small anionic dye molecule that enables the visualisation 
of the migration of proteins. 
Method: 1x106 cells from each treatment condition were washed twice with PBS (120 x g 
for 5mins) and the supernatant was carefully removed. The cell pellet was resuspended 
with 2X SDS sample/Laemmli lysis buffer (2.1.8.2.2) (200µL per 1x106 cells), mixed by 
pipetting up and down and cell lysates were stored at -20°C. Prior to use, protein samples 
were thawed, mixed by vortexing, heated at 95oC for 10mins and vortexed again before the 
loading step for best resolution. 
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2.2.3.2 Protein quantification  
Background: Bicinchoninic acid (BCA) protein assay was used to quantify RIPA-lysed 
protein samples’ concentrations according to the manufacturer’s instructions. This assay 
utilises the reduction of Cu2+ to Cu1+ by protein in an alkaline medium and detects Cu1+ by 
a reagent containing BCA in a colorimetric way. The purple product generated by this 
reaction is formed by the chelation of one Cu1+ ion with two molecules of BCA. The 
water-soluble complex absorbs strongly at 562nm and its absorbance linearly correlates 
with increasing concentrations from 20 to 2000µg/mL.  
Method: BSA standards were prepared by serially diluting 2000µg/mL BSA in dH2O. The 
following BSA concentrations were prepared: 2000, 1500, 1000, 750, 500, 250, 125, 50, 
25 and 5µg/mL and a blank (dH2O). These BSA standards were stored at - 20°C and used 
in multiple times.  
The BCATM Protein Assay Kit (Thermo-Scientific, PN 23227) was used for protein 
quantification. BCA working solution was prepared according to manufacturer’s 
instructions, by mixing thoroughly reagents A and B (50:1). 200µL of this solution was 
then added to each well of a 96-well plate. 10µL of each BSA standard concentration was 
added to each well in triplicate, and 10µL of protein samples was added in duplicate. The 
96-well plate was incubated at 37°C for 30mins and read by an enzyme-linked 
immunosorbent assay (ELISA) plate reader for absorbance at 562nm. Protein 
concentrations were calculated according to the BSA standards and equal amounts of 
protein lysates were loaded for western blotting.  
Note: The aforementioned procedure was not followed for the 2X SDS sample buffer-lysed 
protein samples since the buffer contains bromophenol blue that does not allow the 
colorimetric detection of the protein content. For these samples, equal number of cells 
from each treatment was lysed in equal amount of lysis buffer, assuming, thus, that the 
protein lysates should contain equal amounts of protein. 
 
2.2.3.3  SDS-PAGE 
Background: SDS-PAGE is a denaturing separation method used for the analysis of protein 
samples. As described above, the protein samples are in an SDS containing solution (used 
either as loading buffer for RIPA-lysed samples or as lysis sample buffer for Laemmli-
lysed samples), which binds to hydrophobic regions of the protein molecules, forcing them 
to unfold into long negatively charged polypeptide chains and become freely soluble in the 
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solution. Following the application of an electric current, the proteins migrate towards the 
positive electrode. The size and shape of the polypeptides as well as the pore-size of the 
gel matrix determine the direction, distance, and speed of migration with smaller 
polypeptides travelling more rapidly through the gel. Common gel materials are agarose (a 
polysaccharide) and acrylamide (a 3-carbon amide which is polymerised to form long 
chains with cross-links between the chains). The pore size of the gel is influenced by the 
percentage of gel material used and, in the case of acrylamide, the amount of cross-linking. 
Method: SDS-PAGE method was utilised for the separation of the proteins based on their 
size. After short centrifugation, protein samples were loaded into a Nupage® Novex® Bis-
Tris 4-12%  (Invitrogen, PN NP0321BOX) gradient gel or a homemade 10% or 15% non-
gradient gel  (2.1.8.2.5). 10µL of Novex® SharpTM Pre-stained protein standard 
(Invitrogen, PN LC5800) or HyperPAGE prestained protein marker (Bioline, PN 
BIO33066) was loaded into a well so as to determine the molecular weight of the proteins 
within the samples. Gels were run in 1X NuPAGE® MES SDS running buffer (2.1.8.2.6) 
for the precast gels, or homemade 1X running buffer (2.1.8.2.9) for the homemade gels, at 
80V for the first 30mins and at 120V for the remaining time, in a Invitrogen XCell 
SureLockTM mini-cell electrophoresis system.  
 
2.2.3.4 Transfer to PVDF membrane  
Following gel electrophoresis, proteins were transferred from the gel to a PVDF 
membrane. PVDF membrane was activated by brief soaking into methanol, followed by 
soaking in transfer buffer until completely wet. The sponges and paper towels were all 
soaked carefully in 20% methanol transfer buffer (2.1.8.2.7 or 2.1.8.2.11) before use. 
Methanol was included in the transfer buffer, for two main reasons; firstly, to maintain 
dimensional stability of gels and minimise gel swelling, and secondly, to remove SDS 
from proteins and increase protein binding to the membrane.  
The transfer sandwich was assembled as shown in Figure 2-3. Proteins were transferred at 
30V for 80mins in an XCell IITM blot module.  
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Figure 2-3:  Assemble of sandwich for transfer of proteins to PVDF membrane 
 
2.2.3.5 Immunolabelling  
In order to verify the efficiency of the proteins’ transfer onto the membrane, the transfer 
membrane was stained with 0.1% Ponceau S for a min. Ponceau S destaining of the 
membrane occurred with careful washes with dH2O. Subsequently, the membrane was 
blocked in 5% BSA/TBST blocking buffer (2.1.9.2.12) at room temperature for 30mins 
with constant agitation. After blocking, the membrane was incubated with primary 
antibody solution diluted in the blocking buffer (e.g. p-CrkL, LC3B, GAPDH, p-RPS6K; 
1:1000 dilution) overnight at 4°C with gentle rotation. The next day, the membrane was 
washed in the 1X TBST buffer (2.1.8.2.4) 3x15mins to get rid of unbound primary 
antibody and reduce background. After washes, the membrane was incubated with HRP-
conjugated secondary antibody solution (1:3000 dilution) for 1h at room temperate with 
agitation. Following secondary antibody incubation, the membrane was washed in the 1X 
TBST buffer 3x15mins to remove unbound secondary antibody. Finally, the Immuno-
StarTM WesternCTM kit (Bio-Rad, PN 170-5070) was used according to the manufacturer’s 
instructions for development of the membrane. Just before the development, the membrane 
was incubated with the mixture of equal amounts of luminol/enhancer solution and 
peroxide solutions for 3mins. HRP oxidises luminol in the presence of hydrogen peroxide 
and when oxidised luminol goes back to its initial state, and light is emitted. The enhancer 
increases signal intensity and length. At last, digital pictures of protein bands were taken 
by the Molecular Imager® ChemiDocTM XRS machine. 
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2.2.3.6 Stripping  
In order to incubate the PVDF membrane with a different primary antibody, the membrane 
was incubated in Re-BlotTM Plus Strong Antibody Stripping Solution (Chemicon, PN 
2504) (1mL of the 10X buffer was diluted with 9mL distilled water) for about 15mins with 
constant agitation at room temperature. The stripping buffer can remove antibodies bound 
to the membrane without removing proteins. The membrane was washed briefly in TBST 
and re-blocked in 5% BSA/TBST blocking buffer for 30mins before incubation with 
another primary antibody.  
 
2.2.4 Immunofluorescence microscopy  
Poly-L-lysine coated multi-spot microscope slides were prepared in advance; poly-L-lysine 
is adhesive and it facilitates suspension cells binding to glass microscope slides. Poly-L-
lysine solution (Sigma-Aldrich, PN P8920) was diluted 1:10 in distilled water, and multi-
spot microscope slides were immersed in the dilution in a coplin jar for 10mins. Excessive 
poly-L-lysine solution was removed, and the slides were air-dried and kept in a box for 
future use. 
30,000 cells per treatment were added to each well of a poly-L-lysine-coated multi-spot 
slide. Samples were allowed to adhere to the slides for 90mins in a tissue culture incubator. 
Following, the excess medium was gently removed by blotting carefully with tissue paper 
and the cells were fixed by cross-linking protein molecules with the addition of 30µL of 
the 3.65% formaldehyde solution (2.1.8.3.1) per well. The slides were incubated for 
20mins at room temperature and washed 2x5mins in PBS. Permeabilisation was performed 
by incubating the cells with 30µL of 0.5% Triton-X-100 solution (2.1.8.3.2) per well for 
10mins. Triton-X-100 solution can dissolve cellular lipid membranes to allow antibody 
access of internal proteins. After washing in PBS 2x5mins, the slides were dried and each 
spot was blocked with 30µL blocking buffer (2.1.8.2.12) for 1h at room temperature. 
LC3B antibody (Cell Signaling, PN 2775) at a concentration of 0.5µg/mL in blocking 
buffer was added to each well. 30µL of rabbit F(ab’)2-IgG-isotype (Abcam, PN ab37416; 
0.5µg/mL in blocking buffer) was  used as a control. The slides were incubated for 90mins 
at room temperature. Following incubation, the slides were washed 4x5mins with PBS. 
Subsequently, the slides were incubated with Alexa Fluor® 488 goat anti-rabbit IgG 
secondary antibody (Invitrogen, PN a-11008) (1µg/mL in blocking buffer; 30µL per spot) 
for 1h at room temperature in the dark. The slides were washed 4x5mins with PBS and 
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then air-dried. Two drops of VECTASHIELD® mounting medium with DAPI (Vector, PN 
H-1200) were added to the centre of each slide and a coverslip placed on the top. The 
coverslip was carefully pushed down, so that the mounting medium spread over each well 
of the slide and then sealed with nail varnish. The slides were stored at 4°C until analysis. 
All slides were analysed using a Zeiss Imager M1 microscope at 100x magnification using 
oil immersion and Axiovision software. Images were captured with multiple layers from 
the top to the bottom of cells with optimal distance (0.25µM) between adjacent layers. 
Captured images were subjected to deconvolution to remove non-specific fluorescence and 
sharpen images. Deconvolution was performed by utilising the deconvolution module of 
the AxioVision software; the iterative algorithm and clip normalisation methods were used.  
 
2.2.5 PCR-based assays 
PCR is a technique used to amplify a single or a few copies of a DNA piece to millions of 
copies. Usually, it includes 20-40 thermal cycles, with each cycle consisting of three steps 
including 1) denaturation of the double-stranded DNA into single strands, 2) annealing of 
primers to the single-stranded DNA and 3) extension of primers by the Taq polymerase. 
Nowadays, PCR has widespread application. 
 
2.2.5.1 Primer design  
Primers were designed with Vector NTI ® software and were verified by using the 
NCBI/Primer-Blast. The cDNA sequences were identified by searches on the Pubmed 
website, and used to design appropriate primers. The primers were about 20bp with similar 
melting temperatures between forward and reverse primers, excluding internal loops or 
primer dimers.  
 
2.2.5.2 RNA extraction 
Cells were harvested, washed in ice-cold PBS, and pelleted by centrifugation at 500 x g for 
3mins at 4°C prior to RNA extraction. The RNeasy Mini Kit (Qiagen, PN 74106) was used 
according to the manufacturer’s instructions for the extraction of the total cellular RNA. 
The concentration and quality of extracted RNA were measured with a NanoDrop ND-
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1000 spectrophotometer (Labtech International Ltd). Absorbance at 260nm quantified 
nucleic acid concentration, and RNA purity was determined by the ratio of 260/280 (1.8 to 
2.0) and 260/230 (1.8 or greater). This is because nucleic acid is detected at 260nm, while 
solvents, salts and protein are detected at 230nm and 280nm. RNA was stored diluted in 
RNase free dsH20 at -80°C. 
 
2.2.5.3 cDNA synthesis by reverse transcription 
RNA was reverse transcribed into cDNA by the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, PN 4374966) according to the manufacturer’s 
instructions. RNA samples were prepared to a concentration of 1µg per 10µl in nuclease-
free dsH20 and mixed with 10µL of 2X Reverse Transcription Master Mix (2.1.8.4.1) in a 
PCR tube to give a final concentration of 1 x RT-buffer, 4mM dNTP mix, 1xRT random 
primers, and 2.5IU/ml MultiScribe reverse transcriptase (Applied Biosystems, PN 
4311235). The 20µL mixture was run in a MastercyclerTM PCR machine (Eppendorf UK 
Ltd.). The program was 250C for 10mins, 370C for 120mins and 850C for 5secs. 
Synthesised cDNA was kept at 40C for short-term storage or at -200C for long-term 
storage. 
 
2.2.5.4 Single-cell preamplification 
CellsDirectTM One-Step qRT-PCR Kit (Invitrogen, PN 11753) was used for the 
amplification of 1-300 sorted cells. Initially, a 0.2X probe mix was prepared by adding 
1µL of each of the 20X TaqMan® probes to be used on the chip (can preamplify up to 100 
targets even if the 48.48 dynamic array chip can accommodate up to 48 probes) and 
appropriate TE volume up to 100µL total mix volume. The 0.2X probe mix was stored at -
200C up to 6 weeks. The RT-STA mix (2.1.8.4.4) was prepared each time just before the 
sort. 1 up to 300 target cells were sorted into a well with 5µL, vortexed and briefly 
centrifuged. The preamplification mixture was run in a MastercyclerTM PCR machine. The 
program was 500C for 10mins, 950C for 12mins, 950C for 15secs and 650C for 4mins, for a 
total of 18 cycles. Synthesised cDNA was kept at 4°C for short-term storage or at -20°C 
for long-term storage. The amplified cDNA was diluted 5X with TE buffer (20µL per 
well), vortexed and briefly centrifuged. Samples were stored at -200C until analysis. 
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2.2.5.5 qRT-PCR 
qRT-PCR uses the linearity of DNA amplification to determine absolute or relative 
amounts of a known sequence in a sample by monitoring DNA amplification through each 
cycle. When the DNA is in the log linear phase of amplification, the amount of 
fluorescence increases above the background. Threshold cycle (Ct) is the point at which 
the fluorescence becomes measurable. By using multiple dilutions of a known amount of 
standard DNA, a standard curve can be generated of log concentration against Ct. The 
amount of DNA or cDNA in an unknown sample can then be calculated from its Ct value. 
 
2.2.5.6 TaqMan® qRT-PCR 
Background: This method uses dual-labelled probes, which are oligonucleotides designed 
to hybridise to a complementary region of the cDNA of interest, and contain (i) a 
fluorescent reporter dye on the 5' base, and (ii) a quencher located on the 3' base. When 
irradiated, the excited fluorescent reporter dye transfers energy to the nearby quencher 
molecule rather than fluorescing, resulting in a non-fluorescent substrate. However, during 
PCR, when the polymerase extends the PCR product from the upstream primer, the 5' 
exonuclease activity of the polymerase cleaves the probe. This separates the fluorescent 
quencher and reporter dyes and fluorescence resonance energy transfer no longer occurs. 
The increase in fluorescence intensity is proportionate to the number of probe molecules 
that are cleaved. 
Method: TaqMan® qRT-PCR was performed using TaqMan® Gene Expression Assays 
(Applied Biosystems), as follows. The TaqMan® Gene Expression Assay probes (2.1.4) 
were all carrying a FAM reporter; GAPDH, GUSB, 18S and TBP were used as 
endogenous controls. In a MicroAmpTM Optical 96-well reaction plate (Applied 
Biosystems) a total volume of 25µl/reaction was prepared, containing 1X TaqMan® Gene 
Expression Mastermix (AmpliTaq Gold® DNA Polymerase, Uracil-DNA glycosylase, 
dNTPs with deoxyuridine triphosphate, ROXTM Passive Reference, in addition to buffer 
components), 1X TaqMan® Gene Expression Assay and 1µl cDNA diluted in nuclease 
free dsH2O. For each sample, each gene was assayed in triplicate, and a negative control 
containing nuclease free dsH2O in place of cDNA was included. Plate wells were capped 
and the plate centrifuged briefly. The plate was inserted into an Applied Biosystems 7900 
Fast Real-Time PCR System thermal cycler, and programmed to complete 40 cycles as 
follows: 50°C for 2mins, 95°C for 10mins, 95°C for 15secs, and 60°C for 1min. Reactions 
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were analysed using Sequence Detections Systems software version 2.3 (Applied 
Biosystems). Results for each sample were analysed by using the 2-DDCt method [334]. 
 
2.2.5.7 PCR amplification 
PCR Mix (2.1.8.4.2) was prepared in a PCR tube with GeneAmp® RNA PCR Core Kit 
according to the manufacturer’s instruction. The PCR tube was heated to 94°C for 5mins at 
first to denature all the double stranded cDNA, and then 35 cycles of 94°C for 30secs, 
52°C for 1min and 72°C for 1min were set in a PCR Thermo Cycler. After all cycles 
finished, the tubes were heated to 72°C for 5mins for final extension, and then held at 4°C.  
 
2.2.5.8 Gel electrophoresis  
The PCR products were ran in agarose gels in order to visualise individual DNA bands.  
1% agarose gels were prepared by diluting 0.5g agarose powder in 50mL of 1X TBE 
buffer (10X TBE buffer -2.1.8.4.3- diluted in dH2O). The mixture was heated in a conical 
flask in a microwave until the agarose powder had completely dissolved. When the gel 
cooled down, 1µL ethidium bromide (10mg/mL) was added and mixed well.  
Subsequently, the gel was poured into a casting tray with a comb inserted to create loading 
wells. The gel was left to set for about 30mins. The comb was removed and the gel was 
placed in a gel tank filled with 1X TBE buffer so as to cover completely the gel. 10µL of 
PCR product mixed with 2µL loading dye (6X) was loaded into each well of the gel (2µL 
of 100bp DNA ladder was loaded in a separate lane), and then the gel was run at 50V 
constant voltage. After running, the gel was viewed by an ultraviolet (UV) transilluminator 
(ChemiDoc) and photographed. 
 
2.2.5.9 High-throughput qRT-PCR (Fluidigm©) 
Background: Fluidigm© introduced in 2006 the first commercial system for digital PCR 
using nanolitre volumes, based on integrated fluidic circuits (chips) having integrated 
chambers and valves for partitioning samples. The Fluidigm© 48.48 Dynamic ArrayTM chip 
allows the validation of up to 48 genes in each of the 48 samples simultaneously. With a 
dynamic array chip, high-throughput multiplexing is easy because the integrated fluidic 
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circuit (IFC) does the work of combining samples and primer-probe sets into 2,304 PCR 
assays (48 real-time curves for each of 48 samples).  
Method: Initially, the 48.48 the dynamic array was primed in order to close the interface 
valves and prevent premature mixing of samples and assays. A plate “assays” (BioMark®) 
was prepared by loading into each well a mixture containing 3.0µl assay loading reagent 
(Fluidigm, PN 85000736) and 3.0µl of each TaqMan® gene expression assay. A ‘samples’ 
plate (BioMark®) was prepared by mixing in each well 3.0µl Taqman® Universal PCR 
Master Mix, 0.3µl 20X GE sample loading reagent (Fluidigm, PN 85000735) and 2.7µl 
from the pre-amplified cDNA mix (2.2.5.4). 5µl from each well in plate “arrays” and plate 
“samples” were loaded into separate array and sample inlets on the left and right frames of 
the chip respectively, as shown in Figure 2-4. Note that the in the number 22 sample inlet, 
the RT-STA water control was loaded. Following, the dynamic array was placed on the 
IFC controller, and software interface was used to pressure load the assay components into 
reaction chambers. Assay components were automatically combined on-chip. 
Subsequently, the dynamic array was transferred to a BioMark Real-Time PCR System for 
thermal cycling and fluorescence detection. Amplifications were carried out at 95°C for 
10mins, followed by 40 PCR cycles at 95°C (15secs) and 60°C (4mins) on the BioMark 
System. qRT-PCR analysis software was used to visualise and interact with amplification 
curves performed analysis, colour-coded heat maps, and Ct data for the run. Data was 
analysed as for qRT-PCR using GAPDH rRNA as the housekeeping gene (GUSB, 18S and 
TBP were also tested).  
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Figure 2-4: The Fluidigm© 48.48 Dynamic ArrayTM  
 
2.2.6 Statistics  
All statistical analyses were performed either with the Microsoft Office Excel software 
using the two-sided unpaired or paired Student’s t-test or the GraphPad Prism Software. P-
values less than 0.05 were considered statistically significant. The results are shown as the 
mean ± standard error of the mean (SEM).  
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2.2.7 Cellular techniques 
2.2.7.1 LTC-IC 
Background: Primitive haemopoietic cells with proliferative potential can be maintained in 
long-term bone marrow culture (LTBMC) for extended periods of time in 
microenvironment formed by supportive stromal layer. An application of LTBMC is an 
assay that measures the number of LTC-IC.  
In this assay, the cells of interest are overlaid on a supportive irradiated stromal cell 
monolayer and cultured for 5 weeks before being transferred to a CFC. The number of 
colonies counted at the end of the assay correlated with the number of LTC-IC within the 
initial test cell sample. Figure 2-5 shows a schematic diagram for the method used in the 
LTC-IC assay. 
 
 
 
 
Step 1 : Establishment of feeders 
 
Supportive stromal cell layer consisting  
of two irradiated cell lines: 
SI/SI! express SCF and IL-3 
M2-10B4 !express G-SCF and IL-3 
SI/SI M2-10B4 
Step 2 : Addition of known 
             number of test cells 
 
Step 3: Maintenance of the culture 
 
The total cultivating time is 5weeks 
with weekly change of  ½  of the medium 
 
5 weeks 
culture 
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Figure 2-5: The LTC-IC assay 
 
 
Method: LTC-IC stromal support was provided by two genetically modified murine 
fibroblast cell lines, M2-10B4 (expressing G-CSF and IL-3) and Sl/Sl (expressing SCF), 
which were kindly provided by the Terry Fox Laboratories (Vancouver, BC, Canada). 
Following thawing the cell lines were maintained in culture and when the monolayer was 
semi-confluent, the cells were trypsinised and passaged to allow for propagation of 
sufficient cells for LTC-IC. Proliferation of untransduced cells was minimised but 
supplementing the cultures on alternate weeks with hygromycin B (final concentration 
62.5µg/mL for M2-10B4 and 125µg/mL for Sl/Sl fibroblasts) and G418 (final 
concentration 400µg/mL for M2-10B4 and 800µg/mL for Sl/Sl fibroblasts). Moreover, in 
order to render them incapable of proliferation, M2-10B4 and SI/SI cells were irradiated at 
80gray prior to being seeded with the test cells. Afterwards, M2-10B4 and SI/SI fibroblasts 
were mixed in a 1:1 ratio and resuspended in hydrocortisone supplemented Myelocult™ to 
a final cell concentration of 3x105 cells/mL. 2mL of this suspension was then aliquoted 
into the required number of wells of a BD BioCoat™ - Collagen I 12-well plate (BD, PN 
354500). After 24h of incubation, the test cells were inoculated in duplicates onto the 
stromal monolayers. The cells were incubated for a total of 5 weeks at 37°C, 5% CO2 with 
weekly replacement of 1mL Myelocult™, in order to achieve a half medium change. After 
5 weeks, LTC-IC were harvested and set up in CFC assay. Culture supernatant from each 
LTC-IC well was collected in a sterile 15mL centrifuge tube. Each well was washed with 
Step%4:%Harvest%and%plate%
%
Harvest(endline(dish,(including(
adherent(and(non3adherent(cells,(and(
plate(appropriate(aliquot(in(
methylcellulose(cultures.(
%
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2mL HBSS-CMF (to remove any serum-containing Myelocult™ medium), which was also 
transferred to the collection tube. Adherent cells were detached after incubation with 1mL 
0.25% trypsin-EDTA for a maximum of 5mins and transferred to the harvest tube. 
Immediately, 2mL of IMDM/2% FCS were added to the LTC-IC well, swirled gently and 
transferred to the harvest tube. A further 2mL of HBSS-CMF was used to wash the well 
and then transferred to the harvest tube. The harvest tubes were then centrifuged (400 x g 
for 10mins). Finally, the supernatant was gently poured off and the cells were resuspended 
in the remaining supernatant. The volume of the remaining cell suspension was noted and a 
cell count was performed. 
 
2.2.7.2 CFC assay 
Duplicate committed progenitor cell assays were set up for each cell volume of each 
treatment condition at a cell concentration of 2.5x104/mL. Appropriate volume of cell 
suspension for duplicate wells was added to 3mL of MethocultTM H4434 medium for 
committed progenitor cell assays and vortexed for 15secs. After 10mins (in order to allow 
for the formed bubbles to go to the surface), 1.5mL of this mixture was transferred to a 
35mm tissue culture dish in duplicate. Each dish was gently swirled, so as to coat the 
whole surface, and then incubated for 14 days at 37°C, 5% CO2. At the end of this time, 
the number of viable colonies was counted in each dish and this allowed a comparison of 
the LTC-IC present in the different treatment conditions. 
In experiments where CFC assays were performed alone (without LTC-IC), 5000 cells 
were added to 3mL of MethocultTM methylcellulose medium and split into two 35mm 
tissue culture dishes in duplicate. The rest of the procedure was the same as described 
directly above. 
For CFC experiments with cell lines, the MethocultTM H4230 medium was used. 
 
2.2.7.3 Isolation of cell line sub-clones 
Background: In theory, all cells within a cell line are clones and therefore, should be 
genetically uniform. Nevertheless, spontaneous mutations giving a proliferation advantage 
can occur in single cells and lead to a mixed population of sub-clones carrying different 
genetic defects. In order to validate that the phenotype observed after ATG7 knock-down 
was attributed to the knock-down and not the selection of a mutation carrying K562 sub-
clone, the following approach was followed. 
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Method:  K562 cells were transduced three times with virus carrying an ATG7 or control 
short hairpin, as described at  section (§) 2.2.8.1.1. 48h after the last incubation with virus, 
successfully transduced cells were sorted based on the expression of the GFP marker. 
Single control or ATG7 knock-down GFP+ cells were sorted in individual wells of 96–
well plates with 100µL RPMI++. The presence of a single cell was verified after 
examination under a microscope.  
 
2.2.8 Gene knock-down  
A widely used approach in order to study the function and regulation of a specific gene or 
to explore its therapeutic applications, is by knocking it down, i.e. depleting/deleting the 
gene’s product, and investigating the effects it has on the cells’ phenotype. This can be 
carried out either by editing the organism’s DNA, e.g. by deleting the gene itself, or by 
degrading the gene’s product at mRNA level before it matures into a functional protein. 
The latter technique utilises small interfering RNA (siRNA) that via the RNA interference 
(RNAi) technology silence the target gene in a sequence-specific manner. These siRNAs 
can be stably introduced even to a non-dividing cell in the form of short hairpin RNA 
(shRNA)–which will be processed within the cells into siRNA- through lentiviral delivery 
and they will be integrated to the host’s genome. In order to knock-down a gene 
transiently, processed siRNA molecules can be introduced directly into the cells nucleus by 
electroporation. 
 
2.2.8.1 Lentiviral transduction 
pLKO.1-GFP-shATG7_E, pGIPZ-GFP-shATG7_1 and pGIPZ-GFP-shATG7_2 vectors 
carrying hairpins targeting ATG7 were used along with the packaging vectors psPAX2 and 
pCMV-VSV-G (see Appendix for plasmid maps). For murine samples, the pLKO.1-
PURO-shAtg7 vector was used. Vectors pLKO.1-GFP-shCtrl and pGIPZ-GFP-shCtrl 
carried scrambled - non-targeting- hairpins and were used as control.  
The plasmids pGIPZ-GFP-shATG7_1 and pGIPZ-GFP-shATG7_2, were donated by 
Professor Ravi Bhatia. The plasmid pCMV-VSV-G was kindly donated by Professor John 
Rossi. pLKO.1-PURO-shATG7 and pLKO.1-PURO-shAtg7 were donated by Professor 
Kevin Ryan. Plasmids pLKO.1-GFP-shCtrl and psPAX2 were donated by Dr Kamil Kranc. 
As described below (§2.2.9), the shATG7 hairpin was cloned into the pLKO.1-GFP 
backbone in order to be able to select by FACS the transduced cells. 
  103 
 
 
2.2.8.1.1 Transfection of HEK293 cells 
For the production of the virus, HEK293 cells were transfected using the CaCl2 method. 
The cells were set up two days before the transfection as 2x106 cells/ 10cm2 petri dish in 
10ml DMEM++ to allow them to adhere. In order to facilitate the attachment, the petri 
dishes were coated with 0.1% gelatin in dsH20. 10µg of the shRNA vector, 6.5µg psPAX2, 
and 3.0µg pCMV-VSV-G were diluted in the transfection solution (2.1.8.5). The 
transfection mixture was incubated at 370C for 30mins and then, transferred dropwise to 
the HEK293 cells. The following morning, the medium was replaced with 20% FCS 
DMEM^ (2.1.8.1.3) (to wash off the CaCl2 precipitate) and the flasks were examined under 
inverted fluorescent microscope for the presence of green cells. After 24h, the virus was 
collected as supernatant and used either directly for the transfection of primary CML/non-
CML/cord blood CD34+ cells or it was ultracentrifuged, as described below.  
 
2.2.8.1.2 Transduction of CML cells with fresh virus 
After 24h of incubation, virus-containing 20% FCS DMEM^ medium was collected from 
the HEK293 cells and used for the transduction of primary CML/non-CML/CB samples or 
cell lines. The cells were spinoculated in 5mL or 20mL of virus containing medium in 
25cm2 or 75cm2 flasks respectively (approximately 5x105 cells/mL) at 400 x g for 90mins. 
Virus transduction reagents Transdux™ (Lonza, PN LV850A-1) and polybrene (Sigma-
Aldrich, PN 107689; dilution 1:2000) were used for primary samples and cell lines, 
respectively, in order to facilitate the entrance of the virions in the target cells and increase 
the efficiency of the transduction. 15mL of fresh medium were placed on the HEK cells so 
as to produce more rounds of virus. Spinoculations were repeated at 32h, 48h and 56h. 72h 
after the first transduction, the cells were centrifuged (400 x g for 5mins) and the viral 
containing supernatant was removed. The cells were resuspended in SFM+5GFS (for non-
CML samples) or SFM+PGFs (for CML and CB samples). Transduced cells were sorted 
48h after the last incubation with virus, based on the presence of GFP, and used as 
described per experiment. 
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2.2.8.1.3 Transduction of CML cells with concentrated virus 
Concentrated virus was produced after 24h of incubation by untracentrifuging the 
supernatant 20% FCS DMEM^ medium of the transfected HEK293 cells in Beckman tubes 
at 625,000 x g for 2h in vacuum, at 40C. The supernatant was removed carefully and the 
pellet, which contained the virus particles, was resuspended in 200µL SFM. Titration of 
the virus was carried out by adding small aliquots of the concentrated virus solution (from 
2µL to 20 µL) on HT1080 cells (105 cells/well in a 6-well plate). Polybrene (dilution 
1:2000), a cationic polymer, was used to enhance the transduction of the cells. Four days 
post-transduction, the HT1080 cells were analysed by FACS and the virus titre was 
estimated by using the following formula:   
 
(105 seeded cells x %GFP+ cells) x1000/ µL virus       
Equation 2-1 
 
200µL of unconcentrated virus were also titrated in order to evaluate the efficiency of the 
ultracentrifugation.  
Primary samples were transduced with multiple of infection (MOI) 10 in the presence of 
Transdux™. This procedure was repeated after 24h. 48h after the last incubation with 
virus, the cells were centrifuged (400 x g for 5mins) and the viral containing supernatant 
was removed. The cells were resuspended in SFM+5GF (for non-CML) or SFM+PGFs 
(for CML and CB samples). Transduced cells were sorted the day after, based on the 
presence of GFP, and used as described per experiment. 
 
2.2.8.1.4 Amaxa® nucleofection 
Culture volume containing 1x106 cells was centrifuged (400 x g for 5mins) at room 
temperature. The supernatant was completely removed and the cell pellet was washed 
twice in 5mL PBS. Subsequently, the pellet was resuspended with 100µl room temperature 
Cell Lines Nucleofector® Solution V (Lonza, PN VCA-1003) - for cell lines- or Human 
CD34+ Cell Nucleofector® Solution (Lonza, PN VPA-1003) - for primary CD34+ 
samples- that included 2µg pmaxGFP® vector and 50nM control (Thermo-Scientific, PN 
D-001810-01) or ATG7 targeting siRNA pool (Thermo-Scientific, PN L-020112-00). A 
pool of four siRNAs was preferred over single siRNAs in order to mimic the natural 
silencing pathway and reduce the off-target effects. The suspension was transferred into a 
certified cuvette and sealed with a cap provided with the kit. The cuvette was inserted into 
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the Nucleofector® Cuvette Holder of a Nucleofector®II Device and the appropriate 
transfection program was chosen from the menu (T-020 for cell lines or U-008 for CD34+ 
cells). Once the program finished, the solution was transferred to 5mL of prewarmed 
medium in a 6-well plate by using the supplied pipettes. The cells were stored in a 
humidified 37°C/5% CO2 incubator until analysis. Transfected cells were sorted 48h later, 
based on the expression of GFP, and used as described per experiment. 
 
2.2.9  Cloning 
Background: In order to be able to select the successfully transduced cells, the shRNA 
vectors carry selection markers, such as genes coding for fluorescent proteins or antibiotics 
resistance. The pLKO.1-PURO-shATG7 vector carried the selection market of resistance 
to puromycin. This means that selection of the successfully transduced cells would have to 
be carried out by growing the total number of cells for 3 days in medium supplemented 
with puromycin, a technique that has mainly two drawbacks; firstly, the transduced cells 
would not be able to be selected by FACS and secondly, we do not know if the phenotype 
or biochemistry of the cells would be affected by the process selection in the presence of 
PURO. Therefore, it was decided to clone the hairpin of the pLKO.1-PURO-shATG7 in a 
pLKO.1 backbone that carried as selection gene GFP, a marker that allows for FACS 
selection and it is not relatively toxic to the cells (Figure 2-6). The shATG7 hairpin was 
“cut” from the pLKO.1-PURO-shATG7 vector and cloned into the backbone of the 
pLKO.1-GFP-shCtrl. 
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Figure 2-6: Strategy for cloning the shATG7 hairpin into the pLKO.1-GFP backbone 
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Method: In order to generate bacterial stocks carrying the plasmids of interest, competent 
bacteria were transformed with plasmids pLKO.1-PURO-shATG7 or pLKO.1-GFP-shCtrl 
and incubated overnight at 37oC on agar plates supplemented with ampicillin. The 
following day, a starter culture was formed by inoculating a single colony from each plate 
into 5mL LB (2.1.8.6.1), and incubated overnight at 37oC with constant agitation. After 
24h, each starter culture was moved to 250mL of LB and incubated at 37oC with constant 
agitation. The plasmids were collected from the cells 24h later by using the HiSpeed® 
Plasmid Midi Kit (Qiagen, PN 12643) as described by the manufacturer’s instructions; 
2mL of each culture were stored as bacterial glycerol stock (30% glycerol in dsH2O). 
Subsequently, both pLKO.1-PURO-shATG7 and pLKO.1-GFP-shCtrl were double-
digested with the restriction enzymes SpeI (NEB, PN R0133) and NdeI (NEB, R0111) at 
37oC for 3h in order to cut both plasmids in two fragments; the backbone fragments (which 
included the selection marker) and the insert fragments (which included the short hairpin). 
Following, the double-digested vector pLKO.1-GFP-shCtrl was incubated for 45min with 
SAP (Promega, PN M8201) in order to dephosphorylate its overhanging complementary 
ends and inhibit annealing between them. Hence, each plasmid was cut in two fragments; 
the approx. 6.5kb vector backbone (pLKO.1-GFP or pLKO.1-PURO) and the 
approximately 600bp insert fragment that contained the shRNA hairpin (shATG7 or 
shCtrl). Afterwards, the digestion products were separated on a 1% agarose gel. The 
fragments of interest, pLKO.1-GFP backbone and shATG7 insert, were isolated under 
long-wave UV light using a clean scalpel (short-wave UV light is not recommended 
because it may break DNA). The products were gel-purified by using the QIAquick Gel 
Extraction Kit according to manufacturer’s instructions.  The concentration and quality of 
extracted DNA were measured with a NanoDrop ND-1000 spectrophotometer. Following, 
the pLKO.1-GFP backbone and shATG7 insert fragments were ligated overnight at room 
temperature. As dephosphorylation control, pLKO.1-GFP backbone fragments were 
ligated but without adding the insert fragments. The ligation products were used for 
bacterial transformation. The dephosphorylation control presented with no colony growth, 
which confirmed that the dephosphorylation step was successful. On the other hand, 
bacteria that were transformed with the ligation product from the pLKO.1-GFP backbone 
and the shATG7 insert presented with hundreds of colonies. From these, 10 single colonies 
were randomly selected and grown overnight in 5mL LB for an initiation colony. After 
24h, plasmid was extracted from 3mL of each starter culture by using the QIAprep Spin 
Miniprep Kit according to manufacturer’s instructions. The remaining 2mL were stored as 
bacterial glycerol stock (30% glycerol dsH2O).  Following isolation, the 10 plasmid clones 
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were double digested with the SpeI and NdeI restiction enzymes in order to verify the 
presence of the insert and after electrophoresis, all of them appeared to have an insert 
(Figure 2-7). Three random clones were sent for sequencing analysis with primer that were 
flanking the shRNA area, where it was verified that all of them carried the shATG7 
sequence, without the presence of any mutations or alterations. 
 
 
 
 
Figure 2-7: Isolation of ten pLKO.1-GFP-shATG7 clones (circa; ca.) 
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2.2.10 Morphological analysis of CML cells  
Background: Morphological analyses of CML cells was performed by staining with the 
"Diff-Quik" staining kit (DADE Behring, PN130832) and examination under a light 
microscope. "Diff-Quik" is a product based on the Romanowski group of stains; the 
variants of the Romanowski group differ in the degree of oxidation of the methylene blue 
stain prior to the precipitation. The staining system incorporates an acidic red dye that 
targets the basic parts of a cell, and a dark blue/purple basic dye that is attracted to the 
acidic parts of a cell. Hydrophobic structures, like the Golgi zone, remain unstained. 
Method: 2-5x104 cells were harvested and adhered onto a slide using a Shandon Cytospin 3 
centrifuge. Following, the cells were fixed for 1min with the fixative  "Diff-Quik" and 
sequentially incubated for 1min with the dye A and dye B supplied in the kit. Finally, 
slides were briefly washed, air-dried and examined under a light microscope. 
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3 Results (I): Effects of first, second, and third 
generation TKIs on proliferation, survival and 
autophagy in CML cell lines and primary cells 
TKIs have revolutionised the treatment of CML patients, nevertheless fail to cure the 
disease due to persistence of a fraction of LSCs. Recent studies by our lab and others [234, 
235] suggest that these cells may not be oncogene addicted and, therefore, survive and 
proliferate even upon complete BCR-ABL inhibition. A new strategy in eliminating the 
refractory fraction of CML stem cells includes the combination of TKIs with agents that 
target other survival mechanisms, such as autophagy.  
In this chapter, the effects of first (IM), second (DAS) and third (PON) generation TKIs 
were investigated with regards to cell proliferation, viability, clonogenic ability and 
induction of autophagy in CML cells. In order to monitor effects induced upon exposure to 
TKIs, established human CML BC cell line models were used; these included the K562 
cell line, which carries the BCR-ABL1 e14-a2 (b3-a2) fusion gene, and the KCL22 cell 
line, that carries the BCR-ABL1 e13-a2 (b2-a2) fusion gene. KCL22 cells carrying the 
BCR-ABLT315I (KCL22T315I) mutant were utilised in order to evaluate the TKI efficacy in 
the presence of the T315I mutation, and compared to KCL22 cells carrying the native 
BCR-ABLp210 (KCL22WT). IL-3 dependent murine pro B cell line BaF3 (BaF3Parental) that 
had been transfected with BCR-ABLp210 (BaF3WT) or BCR-ABLT315I (BaF3T315I) – thus 
rendering their growth IL-3 independent- were also used for the monitoring of TKI effects 
in combination with CQ. Finally, the efficacy of PI3K/AKT/mTOR inhibitors against 
CML cells carrying the native or mutant BCR-ABL was investigated in the presence and 
absence of CQ. 
 
Experiments described in this chapter were designed with the aim to: 
1) investigate the effects of IM, DAS and PON on BCR-ABL inhibition, cell proliferation,  
    viability and clonogenic ability of CML cell lines, and CD34+ human CML cells  
2) investigate if TKI-mediated BCR-ABL inhibition leads to induction of autophagy 
3) investigate if pharmacological inhibition of autophagy with CQ or HCQ enhances the 
    efficacy of TKIs and mTOR inhibitors 
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3.1 TKIs in the proliferation, survival and autophagy of CML 
cells expressing native BCR-ABL 
3.1.1 Optimisation of IM, DAS and PON treatment to maximise 
targeting of BCR-ABL activity in K562 cells 
The aim of this section was to identify by western blot TKI concentrations that fully inhibit 
BCR-ABL activity, and to investigate the effects on the proliferation of CML cells.  
Previous studies on K562 cells have identified a proliferation half minimal inhibitory 
concentration (IC50) for IM at 400nM, for DAS at 1.5nM [335], and for PON at 4nM 
[227]. Based on these observations, it was decided to investigate the levels of BCR-ABL 
inhibition upon 24h treatment with the following TKI concentrations; 125 to 8000nM IM, 
2.5 to 160nM DAS, and 1.0 to 10000nM PON. The inhibitory effect of TKI treatment on 
BCR-ABL activity was measured by monitoring the phosphorylation levels of downstream 
effectors STAT5 and/or CrKL. Protein lysates were analysed by western blot and β-tubulin 
was included as a protein loading control. 
As illustrated in Figure 3-1A, phosphorylation of STAT5 was not affected until treatment 
with 4µM IM. Shah and colleagues [336] have reported that phosphorylation of STAT5 is 
a more sensitive marker of BCR-ABL activity compared to phosphorylation of CrKL, 
potentially due to the difference within the non-phosphorylated/phosphorylated ratio of the 
proteins at steady state. This could explain why 4µM of IM did not inhibit as effectively 
the phosphorylation of CrKL. Hence, for all subsequent experiments, it was decided to use 
IM at 5µM which is the highest clinically achievable concentration [337]. 
DAS was more potent than IM, and doses ≥20nM had a significant inhibitory effect on 
BCR-ABL, as reflected by reduced CrKL phosphorylation (Figure 3-1B). Nevertheless, 
even upon exposure to 160nM, BCR-ABL activity was not completely inhibited. Based on 
these observations it was decided to use DAS at 150nM, which is close to the maximal 
achievable plasma concentration in vivo [221].  
Finally, treatment with ≥100nM PON almost completely inhibited BCR-ABL activity and 
abolished phosphorylation of CrKL (Figure 3-1C). Therefore, for subsequent experiments, 
PON was used at the clinically achievable concentration of 100nM [228]. 
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Figure 3-1: Effect of TKI treatment on BCR-ABL activity, measured by phosphorylation of 
downstream effectors CrKL and STAT5, in K562 cells 
Western blot analysis on lysates from K562 cells treated for 24h with IM (A), DAS (B) or PON 
(C). Β-tubulin measured as loading control. 
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The effectiveness of IM, DAS and PON was also assessed with regards to cell proliferation 
potential. K562 cells were exposed to different concentrations of IM (125 to 8000nM), 
DAS (0.625 to 40nM) or PON (1 to 10000nM) and cell counts were performed every 24h 
for a total of 72h. Cell viability was established by using the trypan blue exclusion method.  
Figure 3-2 demonstrates the relative proliferation of K562 cells over 72h under continuous 
exposure to IM (A), DAS (B) and PON (C). 
Our data illustrate that IM had an antiproliferative effect on K562 cells, which became 
apparent after 48h of treatment with doses higher than 1µM. However, IM had a cytotoxic 
effect only at 8µM (p=0.03 versus input), a dose higher than the clinically achievable 
concentration. Likewise, DAS suppressed the proliferation of K562 cells following 48h of 
treatment at doses higher than 2.5nM but did not have a cytotoxic effect up to 40nM. This 
could be attributed to incomplete inhibition of BCR-ABL (see Figure 3-1B). On the other 
hand, PON was associated with strong antiproliferative and cytotoxic effects in K562 cells; 
continuous exposure for 72h to as low as 10nM reduced the number of viable cell by >60% 
compared to the input (p=0.001). 
Figure 3-2D presents the proliferation IC50 values for IM, DAS and PON (based on the 
cell count data following 72h of treatment), and are in agreement with previously 
published studies [227, 338]. Our experiments demonstrate that amongst the three TKIs 
tested, DAS and PON were more effective in inhibiting BCR-ABL activity and 
proliferation in K562 cells. IM treatment up to 8μM (higher than the clinically achievable 
concentration) did not completely inhibit phosphorylation of CrKL, unlike DAS and PON. 
Furthermore, DAS and PON presented similar proliferation IC50 and were >100fold more 
potent compared to IM. It should also be highlighted that IM and DAS were mostly 
antiproliferative, reaching maximum effect at approximately 2μM for IM and 5nM for 
DAS; drug concentration increase beyond these doses did not confer cytotoxicity up to 
8µM for IM and 40nM for DAS. On the other hand, PON had an apparent cytotoxicity at 
doses ≥10nM. It should be mentioned that IM, DAS and PON also have an inhibitory 
effect on other non-BCR-ABL kinases such as KIT, platelet-derived growth factor receptor 
(PDFGR) and others. Hence, the observation that these TKIs show different 
antiproliferative/cytotoxic effects may reflect the different effect they have on BCR-ABL-
independent targets. For instance, unlike IM, low doses of DAS have been reported to 
inhibit SRC family kinases (SFKs), including SRC, LCK, LYN, FGR, BLK, FYN, YES, 
HCK [338], and this may explain why DAS has a stronger antiproliferative effect 
compared to IM. In a similar manner, the cytotoxic effect of PON may be superior due to 
inhibition of kinases that are not targeted by IM and DAS, such as Aurora A [227]. 
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Figure 3-2: Comparison of IM, DAS and PON treatment in the proliferation of K562 cells 
K562 cells were treated with IM (A), DAS (B) or PON (C). Cell counts were performed at 24, 48 
and 72h following treatment initiation and viability was determined by using the trypan blue 
exclusion method. The number of viable cells in each treatment was compared to the input and the 
relative numbers are presented as mean±SEM (n=3). (D) Proliferation IC50 values were estimated 
based on the proliferation data after 72h of TKI treatment. (θ; p≤0.05, ϕ; p≤0.01, δ; p≤0.001, NDC; 
no drug control) 
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3.1.2 Effects of TKI-mediated BCR-ABL inhibition on autophagy  
It has been suggested that TKI-mediated BCR-ABL inhibition leads to induction of 
autophagy. In order to investigate this hypothesis, a series of experiments were designed 
for the monitoring of autophagy upon treatment of CML cells with IM, DAS or PON. 
 
3.1.2.1 Autophagy monitoring assays  
The most common mammalian autophagy marker is LC3; this is the only validated protein 
so far that stably associates with the autophagosome membranes. LC3 is cleaved at the C-
terminus by ATG4, forming the LC3-I cytosolic form. Upon induction of autophagy, 
through a cascade of reactions, LC3-I is lipidated by covalent binding to PE, generating the 
LC3-II form. LC3-II is then utilised for the construction of the inner and outer 
autophagosomal membranes. Following fusion with lysosomes, LC3-II in the inner 
membrane is degraded by lysosomal enzymes, while outer membrane-bound LC3-II is 
cleaved off by ATG4 and re-used for lipidation and loading to autophagosomes upon 
autophagy stimulation.  
Despite the continuously increasing number of publications focusing on the investigation 
of autophagy (PubMed search for “autophagy” retrieves >11,500 publications; website last 
accessed 6th of March 2013), there is still confusion regarding the acceptable methods of 
monitoring autophagy, especially in multicellular eukaryotes. Autophagy assays can be 
divided into two categories (i) assays that measure the volume of autophagic elements (e.g. 
autophagosomes or autophagolysosomes) at any stage of the process, and (ii) assays that 
monitor the flux through the pathway (i.e. complete process) (Table 3-1). It should be 
underlined that autophagy is a multi-step, highly dynamic process, described better by the 
term “autophagic flux”. Hence, increase in autophagosomes/LC3-II levels may reflect (i) 
autophagy induction with increased formation of autophagosomes, or (ii) reduced/blocked 
autophagy turnover, perhaps due to delayed trafficking to the lysosomes, reduced fusion 
between compartments or impaired lysosomal proteolytic activity. Therefore, accumulation 
of autophagosomes or LC3-II does not simplistically imply an induction in autophagy. The 
experimental and the biological context are parameters that have also to be taken into 
account when choosing upon suitable autophagy monitoring assays. Hence, it becomes 
apparent that for rigorous autophagy monitoring no single assay can be the most 
appropriate, since each method is associated with different advantages and limitations, and 
more than one assay have to be performed in order to obtain robust data. 
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Table 3-1: Recommended methods for monitoring autophagy in higher eukaryotes (Modified 
from [339]) 
 
 
Criteria Methods 
Monitoring Phagophore and Autophagosome Formation 
Electron microscopy (increase in autophagosome 
quantity) 
Quantitative electron microscopy, 
immunoelectron microscopy 
LC3 western blotting and ubiquitin-like protein 
conjugation systems (increase in the amount of 
LC3-II, and ATG12-ATG5 conjugation) 
Western blot 
Fluorescence microscopy (increase in LC3 
punctae) 
 
Fluorescence, immunofluorescence 
and immunoelectron microscopy 
mTOR and ULK1 kinase activity Western blot, immunoprecipitation or 
kinase assays 
Transcriptional regulation Northern blot or qRT-PCR 
Monitoring Autophagy by Flux Measurements 
Autophagic protein degradation Turnover of long-lived proteins 
Turnover of LC3-II Western blot ± lysosomal fusion or 
degradation inhibitors 
GFP-LC3 lysosomal delivery, and proteolysis (to 
generate free GFP) 
Fluorescence microscopy, FACS, 
western blot ±lysosomal fusion or 
degradation inhibitors 
p62 western blot 
 
Western blot with qRT-PCR or 
northern blot to assess transcription 
Autophagic sequestration assays Lysosomal accumulation by 
biochemical or multilabel 
fluorescence techniques 
Turnover of autophagic compartment 
 
Electron microscopy 
morphometry/stereology 
Autophagosome-lysosome colocalisation and 
dequenching assay 
Fluorescence microscopy 
Tandem mRFP-GFP fluorescence microscopy Fluorescence microscopy of tandem 
mRFP-GFP-LC3 
 
Tissue fractionation Centrifugation, western blot and 
electron microscopy 
 
Analyses in vivo Fluorescence microscopy and 
immunohistochemistry 
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For the purposes of this study, a detailed set of guidelines [339] about autophagy 
monitoring was taken into account when deciding upon the assays that better fit the CML 
system, and multiple assays were tested in order to validate autophagic responses. 
In the 1950s, autophagy was first described by electron microscopy (EM) [340]. 
Nowadays, EM remains the most informative method used for the morphological analysis 
and evaluation of selective and non-selective autophagic activity, allowing for the direct 
visualisation of the autophagic elements (e.g. autophagosomes and autophagolysosomes) 
(Table 3-2A). However, EM data interpretation can be misleading due to 
methodological/sampling artefacts, apart from being a laborious and expensive technique. 
Herein, two methods were used for the measurement of the volume of autophagic 
elements: (i) measurement of LC3-positive punctae per cell after staining with anti-LC3 
antibody and analysis by immunofluorescence (Table 3-2B), and (ii) measurement of LC3-
II levels by western blot (Table 3-2C).  
Currently, commercially available anti-LC3 antibodies stain both LC3-I and LC3-II. In an 
immunofluorescence assay LC3-I is diffused in the cytoplasm, whereas LC3-II appears 
punctaete since it is bound on autophagic membranes.  
In an immunoblot, incubation with anti-LC3 antibody reveals two bands: the cytosolic 
LC3-I with a size of 16Kd, and the autophagosome membrane-bound LC3-II with size of 
14Kd. Since LC3-II is PE-conjugated, its molecular weight is greater than LC3-I. 
However, due to the hydrophobic nature of PE, LC3-II migrates faster in SDS-PAGE, 
displaying a lower molecular weight compared to its actual size. 
As mentioned earlier, autophagy is a dynamic process and an increase in LC3-positive 
punctae or LC3-II levels may reflect an increase in autophagosome synthesis or a 
reduction/defect in autophagosome turnover. Therefore, we also performed autophagic flux 
assays.  
In order to monitor LC3-turnover by western blot (Table 3-2D) we included in our 
analyses control lysates harvested from cells that had been treated with inhibitors of the 
autophagic flow [341]. CQ and HCQ disrupt the completion of autophagy at late stages by 
increasing the pH within lysosomes, inhibiting the fusion between autophagosomes and 
lysosomes. In order to evaluate the autophagic flux in our samples under basal conditions, 
we compared LC3-II levels between untreated samples and samples that had been treated 
with CQ or HCQ; accumulation of LC3-II in the CQ or HCQ-treated cells would indicate 
efficient autophagic flux, while similar LC3-II levels between NDC and CQ or HCQ-
treated cells would suggest a delay or block of autophagy at a stage before autolysosome 
degradation. 
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Likewise, LC3-II levels were detected not only in TKI-treated samples, but also in cells 
treated with the combination TKI/CQ or HCQ. Similar LC3-II levels between the CQ- or 
HCQ-treated cells and the combination TKI/CQ or HCQ-treated cells would suggest that 
the treatment has no effect on the autophagic activity, while an increase in LC3-II levels in 
the combination TKI/CQ or HCQ-treated cells compared to the CQ- or HCQ-treated cells 
would indicate that the TKI treatment is inducing autophagy. 
Since (i) LC3 antibodies present different affinity for LC3-I and LC3-II, (ii) LC3-I and 
LC3-II present different expression patterns in different cell lines and tissues, and (iii) 
LC3-II has a shorter half-time life compared to LC3-I due to degradation of 
autolysosomes, determining autophagy changes based on the western blot ratio between 
LC3-I and LC3-II can give false results. Hence, in this study we decided to assess 
autophagy activity by normalising the total LC3-II levels to a loading control, such as actin 
or β-tubulin [342].  
The autophagic flux was also monitored by FACS, following staining with the Cyto-ID® 
dye that fluoresces after incorporation to autophagic elements, in the absence or presence 
of CQ or HCQ-mediated autophagy inhibition.  
Transient transfection or stable transduction of target cells with the mRFP-GFP-LC3 
construct is a very useful tool in monitoring of autophagy (Table 3-2F). LC3 protein is 
tagged with both monomeric red fluorescence protein (mRFP) and GFP. Since mRFP has a 
relatively lower pKa value (approximately 4.8) than GFP (approximately 6.2), mRFP 
fluorescence remains more stable in acidic compartments whereas GFP fluorescence is 
rapidly quenched [343]. This difference on the properties of mRFP and GFP enables 
monitoring of the autophagic turnover. Upon induction of the flux, early autophagosomes 
are synthesized (yellow-tagged as they co-express mRFP and GFP) and late 
autophagosomes undergo degradation following fusion with lysosomes (red-tagged as they 
express only mRFP; GFP is quenched). On the other hand, disrupted turnover is associated 
with increase only in yellow-tagged autophagosomes due to delay or blockade of the latter 
autophagic stages.  
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Table 3-2: Methods used for measuring autophagic elements’ volume and autophagic flux 
(AP; autophagosome, AL; autophagolysosome, EM; electron microscopy, FM; fluorescence 
microscopy,WB; western blot, FC; flow cytometry) (Modified from [344]) 
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3.1.2.2 Accumulation of autophagosome-bound LC3-II in K562 cells upon treatment 
with IM and DAS 
In order to investigate if TKIs induce autophagy in CML BC cells upon BCR-ABL 
inhibition, K562 cells were treated with IM and DAS at concentrations previously shown 
to inhibit BCR-ABL activity (see §3.1.1 for more details). Cells were exposed for 4h to 
5µM IM or 150nM DAS ±10µM CQ in order to assess the autophagic flow. As explained 
in §3.1.2.1, if TKIs induced autophagy, the TKI/CQ combination-treated cells should 
present higher levels of LC3-II compared to CQ treatment alone. Whole cell lysates were 
analysed by western blot and LC3-II protein levels were determined after densitometry and 
normalisation to β-tubulin. Calibration was performed towards the NDC arm. 
Figure 3-3 suggests that IM (A) induced synthesis of autophagosomes and promoted 
autophagy in BC K562 cells. Cells treated with IM/CQ presented higher levels of LC3-II 
(6-fold increase compared to NDC) versus CQ-alone treated cells (3.5-fold increase 
compared to NDC) (n=3). Even if this increase was not statistically significant (p=0.08), 
induction of autophagy at this level within an IM-treated cell may significantly support its 
survival in the absence of BCR-ABL signalling.  
Likewise, Figure 3-3B illustrated that LC3-II protein levels were higher in K562 cells 
treated with DAS/CQ combination (6.4-fold increase compared to NDC) compared to cells 
that had been treated with CQ only (3.7-fold increase compared to NDC) (n=2). This 
observation suggests that lipidation of LC3 is enhanced following treatment with DAS. 
Since both IM and DAS have the same mechanism of action (targeting BCR-ABL kinase 
activity), the densitometry data presented in Figure 3-3A and 3-3B were combined and 
analysed so as to further evaluate the effect of TKIs on the autophagic flux. 
As Figure 3-3C reveals, TKI-mediated BCR-ABL-inhibition led to a significant increase in 
the autophagic flow. The combination of TKI/CQ presented higher levels of LC3 lipidation 
(6-fold increase relative to the NDC) compared to CQ treatment alone (4-fold increase 
relative to the NDC), and this increase was statistically significant (p=0.02).  
Taken together, these data suggested that inhibition of BCR-ABL activity, mediated either 
by IM or DAS, is associated with an increase in the autophagic flow in K562 BC cells.   
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Figure 3-3: Accumulation of autophagosome-associated LC3-II upon IM or DAS treatment of 
K562 cells 
Western blotting was used for the analysis of LC3-II levels following 4h treatment of K562 with 
(A) 5µM IM±10µM CQ or (B) 150nM DAS±10µM CQ. Combined analysis of the data presented 
in (A) and (B) is depicted in (C). Densitometry calculations for western blot data shown were 
performed by using the Quantity One software (verifying for non-saturation and subtracting 
background). The graphs represent relative LC3-II levels (normalised to β-tubulin levels) compared 
to the no drug control (NDC) as mean±SEM of n=3 for IM and mean of n=2 for DAS. (ns; not 
significant, *; p≤0.05) 
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3.1.2.3 Accumulation of autophagosome-bound LC3-II in CP CML CD34+ cells 
upon treatment with IM, DAS or PON 
Having demonstrated that treatment with IM or DAS induces autophagy in the BC CML 
cell line K562 (§3.2.2), we investigated if TKIs induce autophagy upon inhibition of BCR-
ABL in CD34+ cells from CP CML patients.  
Primary CP CML CD34+ cells were cultured in SFM+PGFs, and treated with TKIs at 
clinically achievable concentrations that had been previously shown to effectively inhibit 
BCR-ABL activity (see §3.1.1). Cells were treated for 4h with 5µM IM, 150nM DAS, or 
100nM PON, in the absence or presence of 10µM CQ. Whole cell lysates were analysed by 
western blot and LC3-II protein levels were determined after densitometry and 
normalisation to β-tubulin. Calibration was performed towards the NDC arm. 
IM induced autophagy in CD34+ cells from a CML patient; LC3-II levels were 
significantly higher in the cells that were exposed to IM in the presence of CQ (28-fold 
increase), compared to CQ-treated alone cells (14-fold increase) (Figure 3-4A).  
Accumulation of LC3-II was also observed in CD34+ cells (n=2) upon treatment with 
DAS (Figure 3-4B). Inhibition of BCR-ABL activity was verified by complete inhibition 
of CrKL phosphorylation in both samples. This observation further highlights the efficacy 
of DAS in the inhibition of BCR-ABL activity even after short exposure time. 
Interestingly, DAS-mediated inhibition of BCR-ABL signalling was associated with 
induction of autophagy and increase in LC3 lipidation; while CQ-treated cells had a 1.98-
fold increase in LC3-II levels, DAS/CQ-treated cells presented a 2.24-fold increase. 
PON has been reported to be active against a variety of BCR-ABL mutants that are 
refractory to first and second generation TKIs [227]. However, no published study so far 
has investigated the role of PON treatment on autophagy. We first report here that 
inhibition of BCR-ABL activity upon treatment with 100nM PON, induced autophagy in 
CD34+ cells of CP CML patients (Figure 3-4C); LC3-II levels were significantly higher in 
the PON/CQ arm (1.46-fold increase) compared to CQ alone treated cells (1.31-fold 
increase), suggesting increased autophagosome synthesis.  
Densitometry data from the above mentioned protein analyses on CP CML CD34+ cells 
treated with TKIs±CQ were combined in order to evaluate overall effect of TKIs on 
autophagy. Figure 3-4D demonstrates that TKIs induced autophagy upon inhibition of 
BCR-ABL; the TKI/CQ arm was associated with higher levels of LC3-II (2.18-fold 
increase relative to the NDC) compared to CQ treatment alone (1.72-fold increase relative 
to the NDC), suggesting an approximately 27% increase of the autophagic activity 
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(average of n=4). Even if this increase is not significant by the statistical point of view 
(p=0.07), it does not necessarily mean that this level of induction in the autophagic flux 
does not have a significant effect on the biological system.  
Taken together, our results demonstrate that TKI-mediated inhibition of BCR-ABL activity 
leads to induction of autophagy. In a CP CML CD34+ sample, IM increased the 
autophagic flux by approximately 50% compared to the basal autophagy levels (IM/CQ 
versus CQ alone). On the other hand, in CP CML CD34+ cells, DAS increased 
approximately 13% the autophagic activity (average from n=2), while PON approximately 
11.4% (average from n=2). Based on the observations from the LC3-II protein analysis, IM 
induced the highest levels of autophagy, while DAS and PON exhibited similar effects. 
However, this could be sample-specific; the IM-treated CD34+ cells (sample CML284) 
demonstrated a high autophagic flux under basal conditions (comparison of LC3-II levels 
between NDC and CQ arms). The effect of IM on LC3 lipidation should be further 
investigated by protein analysis on more primary CML samples. Finally, even if combined 
data analysis from all TKIs (Figure 3-4D) did not reveal a significant increase of the 
autophagic flow upon TKI treatment, inclusion of more samples could statistically increase 
the significance of the autophagic induction since this trend is always observed after TKI 
treatment. 
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Figure 3-4: Accumulation of autophagosome-associated LC3-II upon IM, DAS or PON 
treatment of CP CML CD34+ cells  
Western blotting was used for the analysis of LC3-II levels following 4h treatment of CML CD34+ 
cells with (A) 5µM IM±10µM CQ, (B) 150nM DAS±10µM CQ, or (C) 100nM PON±10µM CQ. 
Combined analysis of the data presented in (B) and (C) is depicted in (D). Densitometry 
calculations for western blot data shown were performed by using the Quantity One software 
(verifying for non-saturation and subtracting background). The graphs represent the relative LC3-II 
levels (normalised to β-tubulin levels) compared to the NDC. (ns; not significant) 
  
C D 
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3.1.2.4 Increased synthesis of LC3-positive punctae in K562 BC CML cells upon 
treatment with TKIs 
The most rigorous autophagy monitoring assays rely on two autophagy hallmarks, (i) 
lipidation of LC3, and (ii) changes in the subcellular distribution of LC3. As mentioned 
earlier, upon induction of autophagy, LC3 is lipidated and associated with autophagosome 
membranes; hence, coinciding with its lipidation, LC3 is redistributed within the cell into 
cytoplasmic punctae that can be visualised by immunofluorescence microscopy. 
In order to validate our protein analysis data demonstrating increased LC3 lipidation 
following TKI treatment, we performed immunofluorescence microscopy analysis on 
endogenous LC3 in TKI-treated CML BC cells. K562 cells were treated for 4h with 
150nM DAS or 100nM PON, followed by fixation onto slides and sequential staining with 
primary anti-LC3 antibody and Alexa-fluorochrome conjugated secondary antibody. DAPI 
was used for the counterstaining of nuclei.  
Figure 3-5A demonstrates the accumulation of LC3-positive punctae in the presence of 
DAS or PON. Enumeration of the LC3-positive punctae revealed that DAS- or PON-
treated cells presented >3-fold increase compared to the NDC (99 and 109 punctae/cell for 
DAS and PON respectively, versus 30 punctae/cell for the NDC) (Figure 3-5B). At this 
point it should also be mentioned that PON treatment was associated with accumulation of 
larger LC3-positive punctae (size >0.5µm2) compared to DAS-treated or NDC cells (size 
<0.5µm2). This could potentially indicate that PON affects kinases that regulate the size of 
the autophagosomes, such as the Rho-kinase 1 [345]. 
These data are in agreement with previous western blot data (§3.2.2), suggesting induction 
of autophagy within BC CML cells upon treatment with either of these TKIs. 
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Figure 3-5: Formation of LC3-positive punctae in DAS- and PON-treated K562 cells 
Immunofluorescence imaging on K562 cells treated for 4h with 150nM DAS, 100nM PON or 
NDC. Cells were stained with primary anti-LC3B antibody and secondary Alexa-fluorochrome 
conjugated antibody. (A) Photos represent Z-stack overlay after deconvolution by using the 
AxioVision software. Captions presented at 1000X magnification, DAPI used for nuclei staining. 
(B) Enumeration of the LC3-positive punctae was carried out by using the AxioVision 4 Module 
AutoMeasure software (n ≥30 cells). 
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3.1.2.5 Increased synthesis of LC3-positive punctae in CP CML CD34+ cells upon 
treatment with TKIs 
The question that next arose was if TKIs enhance the formation of LC3-positive punctae in 
CML CD34+ cells upon inhibition of BCR-ABL. 
Human CP CML CD34+ cells were cultured in SFM+PGFs and treated for 24h with 5µM 
IM, 150nM DAS, 100nM PON or NDC. Formation of LC3-positive punctae was assessed 
by immunofluorescence microscopy.  
Figure 3-6 demonstrates that treatment with IM (A), DAS or PON (B) resulted in an 
increase in LC3-positive punctae, suggesting enhanced synthesis of autophagosomes. 
Among the three TKIS, IM had the most moderate effect, whereas DAS and PON led to 
higher levels of autophagy induction. This could be attributed to more effective BCR-ABL 
targeting with 150nM DAS or 100nM PON compared to 5µM IM. 
Overall, these experiments illustrated visually the induction of autophagy in human 
primary CP CML stem and progenitor cells upon treatment with TKIs. 
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Figure 3-6: Formation of LC3-positive punctae in IM-, DAS- and PON-treated CP CML 
CD34+ cells 
Immunofluorescence imaging on CP CML CD34+ cells treated for 24h with 5µM IM (A), 150nM 
DAS, 100nM PON (B) or NDC. Cells were stained with primary anti-LC3 antibody and secondary 
Alexa-fluorochrome conjugated antibody. Photos represent Z-stack overlay after deconvolution by 
using the AxioVision software. Captions presented at 1000X magnification, DAPI used for nuclei 
staining.  
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3.1.2.6 Autophagy increase in K562 BC cells following TKI treatment measured by 
FACS 
Another approach in monitoring the effect of TKI-induced autophagy was by FACS 
analysis following staining with the Cyto-ID® Autophagy Detection Kit. The kit includes 
a dye that, according to the manufacturer’s instructions, stains specifically pre-
autophagosomes, autophagosomes, and autolysosomes, with minimal lysosomal staining. 
Incorporation of the dye to autophagic structures leads to bright fluorescence that can be 
detected by FACS analysis at the FL-1 channel (readout as FITC).  
K562 cells were treated for 4h with 5µM IM, 150nM DAS or 100nM PON, in the absence 
or presence of 10µM CQ or HCQ. Cells were then analysed by FACS for the detection of 
fluorescent Cyto-ID® dye (procedure described at §2.2.24). The geometrical mean 
(GeoMean) of FITC  (log scale) among different treatments was calibrated towards the 
NDC.  
Figure 3-7 demonstrates that all TKIs tested -IM (A), PON (B) and DAS (C) - induced 
autophagy upon BCR-ABL inhibition, since fluorescence was higher in the cells incubated 
with any TKI combined with autophagy inhibitor (CQ or HCQ) compared to treatment 
with autophagy inhibitor alone (n=2 for IM and PON and n=1 for DAS).  
An aliquot of the cells treated with 150nM DAS ± 10µM CQ was lysed and analysed by 
western blot. Figure 3-7D demonstrates the densitometry analysis on LC3-II protein levels 
measured by immunoblot. Comparison of the analysis of the same sample by 
CytoID®/FACS (Figure 3-7C) and immunoblot (Figure 3-7D) revealed an inconsistency in 
the data produced by these assays. Significant changes in LC3 lipidation at protein level 
(measured by immunoblot analysis) appeared as a subtle autophagy increase by CytoID® 
via FACS. For instance, a 36-fold increase in LC3-II protein levels between NDC and CQ, 
by CytoID®/FACS appeared as 1.78-fold relative increase.  
Our results suggest that monitoring autophagy via FACS following staining with CytoID® 
may be suitable for samples where a very low number of cells is available for 
experimenting (such as HSCs). Nevertheless, this assay appeared to be less sensitive 
compared to previously described methods. This should be kept in mind when analysing 
CytoID® data, since subtle changes by FACS could reflect significant changes at protein 
level.  
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Figure 3-7: Induction of autophagy in K562 cells upon TKI treatment measured by FACS 
K562 cells were treated for 4h with 5µM IM, 150nM DAS or 100nM PON ±10µM CQ or HCQ. 
Cells were then stained with the CytoID® Autophagy dye. Fluorescence was measured by FACS at 
the FL-1 channel as FITC. The graphs represent the GeoMean FITC of n=2 relative to the NDC for 
IM (A), PON (B) and n=1 for DAS (C). Western blot analysis was performed on an aliquot of the 
DAS±CQ-treated cells and densitometry analysis is presented at (D). Densitometry calculations for 
western blot data shown were performed by using the Quantity One software (verifying for non-
saturation and subtracting background). The graphs represent the relative LC3-II levels (normalised 
to β-tubulin levels) compared to the NDC. (ns; not significant) 
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3.1.3 Pharmacological inhibition of autophagy enhances TKI-induced 
effects in CML cells 
Experiments above demonstrated that TKIs induce autophagy in BC and CP CML cells 
upon inhibition of BCR-ABL. Hence, our next target was to explore if autophagy has a 
cytoprotective role within CML cells.  
In this series of experiments autophagy was suppressed in TKI-treated cells 
pharmacologically, by using inhibitors CQ or HCQ. Subsequently, it was investigated if 
TKIs are more effective with regards to apoptosis induction and suppression of the 
clonogenic ability of CML cells in an autophagy-inhibited background. 
 
3.1.3.1 TKI treatment in combination with CQ-mediated autophagy inhibition in 
K562  BC cells 
3.1.3.1.1 Analysis of apoptosis in K562 cells following TKI treatment in combination 
with CQ-mediated autophagy inhibition 
 
The apoptotic effect of the TKI/CQ combination versus single agent TKI was investigated 
in CML BC cells. K562 cells were treated for 72h with TKIs (5µM IM, 150nM DAS or 
100nM PON) ±10µM CQ. Apoptosis was analysed by FACS following annexin 
V/Viaprobe staining. 
Figure 3-8 demonstrates that CQ does not affect the apoptosis of K562 as a single agent, 
unlike TKIs that are targeted anti-CML drugs. Among the three TKIs tested, IM was the 
least potent in terms of apoptosis induction; despite increasing the mean levels of apoptosis 
(23.6±3.6% versus 11.6±2.2% in the NDC arm), statistical analysis revealed that this 
induction was not significant (p=0.13). However, CQ augmented the apoptotic effect of IM 
and the combination IM/CQ induced apoptosis at significant levels (49.2±8.4; p=0.04). 
DAS was more effective than IM, and as a single agent significantly induced the apoptotic 
rate within K562 cells (28.1±4.4%; p=0.04). CQ-mediated autophagy inhibition further 
promoted the apoptotic effect of DAS (58.8±11.4%; p=0.03).  
PON presented the highest activity among the three TKIs tested, targeting as a single agent 
almost half of the cells (43.7±4%; p=0.019). However, there was an obvious increase in the 
apoptotic percentage in the PON/CQ-treated arm (67.8±8.9%; p=0.006). 
Overall, these data suggest that TKI-induced apoptosis is enhanced in the presence of CQ-
mediated autophagy inhibition, with PON/CQ combination having the greatest effect. 
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Figure 3-8: CQ-mediated autophagy inhibition enhances TKI-induced apoptosis in K562 cells 
K562 cells were treated for 72h with 5µM IM or 150nM DAS or 100nM PON, with or without 
10µM CQ, and analysed by FACS following annexin V/Viaprobe staining. Graph represents 
apoptosis (early and late) relative to NDC and numbers are presented as mean±SEM (n=3). 
Statistical analysis was performed by using paired t-test. Annotation above a bar refers to statistical 
significance between the bar and the NDC. (ns; not significant, *; p≤0.05, **; p≤0.01) 
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3.1.3.1.2 Analysis of K562 clonogenic ability following TKI treatment in combination 
with CQ/HCQ-mediated autophagy inhibition 
 
The effect of CQ/HCQ-mediated autophagy inhibition in combination with TKIs was 
investigated by measuring the clonogenic ability of K562 cells.  
1000 K562 cells/treatment (in duplicate) were grown for two weeks in Methocult® that 
had been supplemented with 500nM IM or 5nM DAS or 1nM PON, in the absence or 
presence of 10µM CQ or HCQ.  
Figure 3-9A illustrates that 500nM IM significantly suppressed the clonogenic ability of 
the cells compared to NDC (p=0.0219). CQ significantly enhanced IM effect (p=0.0223 
IM/CQ versus IM), with the combination IM/CQ reducing colony numbers >50% 
(p=0.0131 IM/CQ versus NDC).  
Likewise, 5nM DAS inhibited efficiently the ability of K562 to form colonies (p=0.0028 
versus NDC). However, the combination DAS/CQ was much more potent in suppressing 
the clonogenicity of the cells (p=0.0032 DAS/CQ versus NDC). 
Figure 3-9B demonstrates that 1nM PON was not efficient in suppressing colony formation 
ability as a single agent (p=0.1195 PON versus NDC) (Figure 3-16B). Nevertheless, HCQ 
dramatically enhanced its effect (p=0.0159 PON/HCQ versus PON) and the combination 
of PON/HCQ was highly effective, suppressing >95% the clonogenic ability of K562 cells 
(p=0.0030 PON/HCQ versus NDC). 
In this experiment IM, DAS and PON were used in 10, 30 and 100 times, respectively, 
lower concentrations compared to the ones we previously identified to efficiently inhibit 
BCR-ABL activity (i.e. 5µM IM, 150nM DAS and 100nM PON). In all cases, CQ/HCQ-
mediated inhibition of autophagy enhanced the efficacy of the drugs against the 
clonogenicity of the K562 cells. This could suggest that cytoprotective autophagy is 
induced even upon incomplete BCR-ABL inhibition, allowing the cells to survive and 
proliferate.  
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Figure 3-9: CQ/HCQ enhance TKI-induced inhibition of the colony forming ability of K562 
cells 
1000 K562 cells/treatment (in duplicate) were grown for two weeks in Methocult® that contained 
500nM IM or 5nM DAS (A) or 1nM PON (B), with or without 10µM CQ. Colonies were counted 
after 14 days under light microscope. Number of colonies (No of colonies) /arm is presented as 
mean±SEM (n=3). Statistical analysis was performed by using paired t-test. Annotation above a bar 
refers to statistical significance between the bar and the NDC. (ns; not significant, *; p≤0.05, **; 
p≤0.01) 
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3.1.3.2 HCQ-mediated inhibition of autophagy enhances TKI-induced effects in 
CML CD34+ cells 
Having observed that CQ enhances TKI effects in Ph+ cell lines, the efficacy of the 
combination was investigated in human CML CD34+ cells.  
 
3.1.3.2.1 Analysis of CP CML CD34+ cell viability following TKI treatment in 
combination with HCQ-mediated autophagy inhibition 
 
CD34+ cells from CP CML patients were treated with 5µM IM, 150nM DAS or 100nM 
PON, in the presence or absence of 10µM HCQ and cell counts were performed after 3 and 
6 days. Cell viability was established by using the trypan blue exclusion method. 
Figure 3-10 demonstrates that 3 days following treatment initiation all TKIs mildly 
suppressed cell proliferation. HCQ-mediated inhibition did not enhance the 
antiproliferative effect of TKIs at significant levels at this time point. Nevertheless, the 
combination DAS/HCQ had a significant antiproliferative effect (p=0.02 versus NDC), 
which was associated with cytotoxicity (23% reduction of cell number compared to the 
input). 
Day 6 cell counts were performed on n=2 for IM and IM/HCQ; one of the biological 
triplicates for these treatment arms was contaminated with fungi and therefore, it was not 
taken into account for analysis. Statistical analysis at that time point revealed that DAS and 
PON were effective as single agents in suppressing the expansion of CP CML CD34+ cells 
(p=0.03 and p=0.04 respectively). Nevertheless, the combination of DAS or PON with 
HCQ revealed only slight enhancement of the TKI-mediated antiproliferative effect of the 
TKIs (p=0.03 for both DAS/HCQ and PON/HCQ versus NDC). A similar trend was 
observed in the IM versus IM/HCQ treatment arms as well. 
Overall, HCQ did not enhance the antiproliferative effect of IM, DAS and PON after 3 or 6 
days of treatment. In order to investigate if HCQ-mediated autophagy inhibition affects the 
long-term survival of CP CML CD34+ cells, the experiment in §3.1.3.2.2 was designed. 
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Figure 3-10: TKIs in combination with HCQ in the proliferation of CP CML CD34+ cells 
CML CD34+ cells were cultured in SFM+PGFs. Cell counts were performed at 3 and 6 days after 
treatment initiation and viability was determined by using the trypan blue exclusion method. The 
number of viable cells in each treatment was compared to input and the relative numbers are 
presented as mean±SEM (n=3-7), apart from IM and IM/HCQ (mean of n=2). Annotation above a 
bar refers to statistical significance between the bar and the NDC. (*; p≤0.05)  
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3.1.3.2.2 Analysis of CP CML CD34+ CFC potential following TKI treatment in 
combination with HCQ-mediated autophagy inhibition 
 
The committed progenitor potential of CP CML CD34+ cells was tested following TKI 
treatment, in the presence or absence of HCQ-mediated autophagy inhibition. 
CD34+ cells from three CP CML patients were treated in vitro with 150nM DAS or 
100nM PON, with or without 10µM HCQ. 3 days later, drugs were washed out and 2500 
cells/arm were transferred to Methocult®. Cell potential was measured by colony counts 
14 days later. 
Figure 3-11A provides data suggesting that HCQ potentiates the TKI-induced reduction of 
committed progenitor cell potential. DAS as a single agent did not significantly inhibit the 
cells’ clonogenic ability (p=0.1); however, the combination DAS/HCQ was significantly 
more effective (p=0.03). Similarly, PON was not potent in reducing the number of colonies 
(p=0.08), but HCQ enhanced its effect and the combination treatment resulted in 
significantly lower numbers of colonies (p=0.03). 
In order to assess the effect of prolonged HCQ-mediated exposure in the presence of TKIs, 
the following experiment was performed. 2500 CD34+ CP CML cells were transferred to 
Methocult® containing 5µM IM or 2µM NIL or 150nM DAS or 100nM PON, in the 
presence or absence of 10µM HCQ. Cell potential under prolonged TKI and HCQ 
exposure was measured by colony counts 14 days later. 
Figure 3-11B demonstrated that all TKIs significantly suppressed the clonogenic ability of 
the CML cells (p=0.04 for IM, p=0.01 for NIL, p=0.07 for DAS, p=0.01 for PON). 
However, the efficacy of all TKIs was enhanced by HCQ and all TKI/HCQ combinations 
were associated with superior effect compared to TKI-alone treatment (p=0.01 for 
IM/HCQ, p=0.009 for NIL/HCQ, p=0.006 for DAS/HCQ, p=0.009 for PON/HCQ). 
Taken together, these data support that pharmacological inhibition of autophagy augments 
the efficacy of TKIs against the colony-forming potential of CP CML cells.  
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Figure 3-11: HCQ-mediated autophagy inhibition enhances TKI effect against the clonogenic 
ability of CP CML CD34+ cells 
CP CML CD34+ cells were cultured in SFM+PGFs. (A) Cells were treated for 3 days with 150nM 
DAS or 100nM PON, with or without 10µM HCQ. Drugs were washed out and 2500 cells/arm 
were transferred to Methocult®. (B) 2500 CD34+ CP CML cells were transferred to Methocult® 
containing 5µM IM or 2µM NIL or 150nM DAS or 100nM PON, in the presence or absence of 
10µM HCQ. Colony counts were performed after 14 days under light microscope. No of colonies 
are presented as mean±SEM (n=3). Statistical analysis was performed by using paired t-test. 
Annotation above a bar refers to statistical significance between the bar and the NDC. (ns; not 
significant, *; p≤0.05, **; p≤0.01)  
 
CD34+_CML (n=3)
ND
C
HC
Q
DA
S
DA
S+
HC
Q
PO
N
PO
N+
HC
Q
0
100
200
300
400
ns
ns
** **
A
No
 o
f c
ol
on
ie
s
CD34+_CML (n=3)
ND
C
HC
Q IM
IM+
HC
Q NIL
NIL
+H
CQ DA
S
DA
S+
HC
Q
PO
N
PO
N+
HC
Q
0
100
200
300
400
500
*
*
* ** **
** * **
B
No
 o
f c
olo
nie
s
  142 
 
3.2 PON and mTOR inhibitors in the treatment of CML cells 
expressing BCR-ABLT315I 
CML clones carrying the T315I mutation are resistant to all first and second generation 
TKIs. More specifically, it has been suggested that BCR-ABLT315I clones are “selected” by 
sequential treatment with first and second generation TKIs due to their inherent resistance 
[346]. In this section we aimed to investigate TKI- and non-TKI drugs for the targeting of 
CML cells carrying the T315I mutation. 
 
3.2.1 Effect of PON on the proliferation of CML cells carrying BCR-
ABLT315I  
So far, PON is the only FDA approved TKI that has been reported to be active against 
BCR-ABLT315I. Hence, we designed a series of experiments in order to evaluate the 
efficacy of PON in inhibiting the proliferation of CML cells carrying the T315I mutation.  
BaF3T315 cells were treated with 0.1 to 10000nM PON and proliferation was evaluated by 
cell counts performed every 24h, for a total of 72h. Cell viability was established by using 
the trypan blue exclusion method. 
Figure 3-12 clearly demonstrates that PON concentrations within the range of 1 to 10nm 
effectively inhibited the proliferation of BaF3 cells carrying either native (A), or mutated 
BCR-ABL (B). PON was associated with increased cytotoxicity and concentrations 
≥10nM in BaF3WT cells and ≥100nM in BaF3T315I cells reduced the number of viable cells 
below the input (p=0.04 and p=0.001, respectively). Nevertheless, BaF3Parental cells were 
not significantly affected by PON and continued to proliferate even after exposure to 
increased concentrations of PON (Figure 3-12C).  
Based on the 72h cell counts, the proliferation IC50 of PON was evaluated in BaF3 cells. 
As depicted in Figure 3-12D, IC50 values were similar between BaF3WT (0.95nM) and 
BaF3T315I (7.6nM) cells, underlining the efficacy of the drug in cells carrying the T315I 
mutation. Nonetheless, these drug concentrations had no effect on BaF3Parental cells, which 
presented ≥100-fold increased IC50 value (177.7nM), highlighting the specificity of the 
drug. Overall, our data demonstrate the anti-proliferative/cytotoxic effect of PON against 
CML cells carrying the T315I mutation. 
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Figure 3-12: Comparison of PON treatment in BaF3WT, BaF3T315I and BaF3Parental cells 
BaF3WT (A), BaF3T315I (B) and BaF3Parental (C) cells were treated with increasing concentrations of 
PON. Cell counts were performed at 24, 48 and 72h after treatment initiation, and viability was 
determined by using the trypan blue exclusion method. The number of viable cells in each 
treatment was compared to the input and the relative numbers are presented as mean±SEM (n=3). 
(D) Proliferation IC50 values were estimated based on the proliferation data after 72h of TKI 
treatment. (θ; p≤0.05, ϕ; p≤0.01, δ; p≤0.001) 
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3.2.2 Effects of mTOR inhibitors’ treatment in CML cells 
During recent years a constantly growing number of studies has underlined the significance 
of the PI3K/AKT/mTOR pathway in the survival of cancer cells, making it a target for the 
development of potential anti-cancer drugs. Agents inhibiting the PI3K/AKT/mTOR 
pathway are currently being tested for the treatment of leukaemic patients, including CML 
[347]. These agents act downstream of BCR-ABL and hence, could benefit patients that do 
not respond to or are resistant to first and second generation TKIs (Figure 3-13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-13: The PI3K/AKT/mTOR pathway in cell survival 
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3.2.2.1 Effect of mTOR inhibitors in the proliferation of BCR-ABLT315I-expressing 
CML cells 
In order to investigate the effects of mTOR inhibition in the proliferation of resistant T315I 
cells, two inhibitors were used: (i) RAPA, which inhibits mTORC1 activity, and (ii) BEZ, 
a dual ATP-competitive PI3K and mTOR inhibitor. 
KCL22T315 cells were treated with 0.1 to 1000nM BEZ and proliferation was evaluated by 
cell counts performed every 24h, for a total of 72h. Cell viability was established by using 
the trypan blue exclusion method. 
Figure 3-14 demonstrates that within the first 48h of treatment, 100nM BEZ inhibited 50% 
the size of the viable population of KCL22 cells carrying either native (44.6±4.8%; 
p=0.007) (A), or BCR-ABLT315I  (48±6.3%; p=0.01) (B). Number of viable cells was 
further reduced within the next 24h of 100nM BEZ treatment; approximately 80% of the 
KCL22WT and KCL22T315I were eradicated, suggesting that the BEZ concentrations 
≥100nM had a cytotoxic effect. Hence, it was decided for subsequent experiments to use 
BEZ in the IC50 proliferation dose of 100nM. 
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Figure 3-14: Comparison of BEZ treatment in KCL22WT and KCL22T315I cells 
KCL22WT (A) and KCL22T315I (B) cells were treated with increasing concentrations of BEZ. Cell 
counts were performed at 48 and 72h after treatment initiation, and viability was determined by 
using the trypan blue exclusion method. The number of viable cells in each treatment was 
compared to the NDC and the relative numbers are presented as mean±SEM (n=3). (θ; p≤0.05, ϕ; 
p≤0.01, δ; p≤0.001) 
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KCL22T315 cells were also treated with 0.1 to 1000nM RAPA and proliferation was 
evaluated by cell counts performed every 24h, for a total of 72h. Cell viability was 
established by using the trypan blue exclusion method. 
Figure 3-15 illustrates that RAPA had an antiproliferative effect against both KCL22WT 
(A) and KCL22T315 (B) cells. Following 72h of treatment with 10nM RAPA the 
proliferation of KCL22T315 was reduced approximately 50% (53.7±2.8%; p=0.003), 
suggesting that this is the IC50 concentration of the drug. Nevertheless, treatment with 10- 
and 100-fold increased concentration did not achieve higher antiproliferative effects 
(50.4±2.9% for 100nM and 51.7±3.3% for 1000nM treatment). Hence, it was decided to 
use RAPA in the concentration of 10nM for subsequent experiments.  
Overall, these data suggest that mTOR inhibitors RAPA and BEZ suppress proliferation of 
KCL22 cells carrying the T315I mutation.  
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Figure 3-15: Comparison of RAPA treatment in KCL22WT and KCL22T315I cells 
KCL22WT (A) and KCL22T315I (B) cells were treated with increasing concentrations of RAPA. Cell 
counts were performed at 48 and 72h after treatment initiation, and viability was determined by 
using the trypan blue exclusion method. The number of viable cells in each treatment was 
compared to the NDC and the relative numbers are presented as mean±SEM (n=3). (θ; p≤0.05, ϕ; 
p≤0.01, δ; p≤0.001) 
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3.2.2.2 Effect of mTOR inhibitors in the autophagic flow of CML cells 
In §3.2.2.1 we demonstrated that BEZ and RAPA had antiproliferative effects against 
CML BC cells carrying either native or BCR-ABLT315I. Nevertheless, since these agents 
suppress mTOR, the major negative regulator of autophagy, they could induce autophagy. 
In order to further investigate the effect of BEZ and RAPA on the autophagic flow of CML 
cells, we performed the following experiment. 
Human CP CML CD34+ cells were cultured in SFM+PGFs and treated for 24h with 10nM 
RAPA or 100nM BEZ. Assessment of autophagy was carried out by immunofluorescence 
microscopy analysis on endogenous LC3 levels, following fixation of the treated cells onto 
slides and sequential staining with primary anti-LC3 antibody and Alexa-fluorochrome 
conjugated secondary antibody. DAPI was used for the counterstaining of nuclei.  
Figure 3-16 demonstrates the accumulation of LC3-positive punctae in the presence of 
RAPA or BEZ, suggesting the induction of autophagy upon treatment with these mTOR 
inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  151 
 
 
 
 
 
 
 
 
 
 
Figure 3-16: Formation of LC3-positive punctae in RAPA- and BEZ-treated CP CML CD34+ 
cells 
Immunofluorescence imaging on CP CML CD34+ cells treated for 24h with 10nM RAPA or 
100nM BEZ or NDC. Cells were stained with primary anti-LC3B antibody and secondary Alexa-
fluorochrome conjugated antibody. Photos represent Z-stack overlay after deconvolution by using 
the AxioVision software. Captions presented at 1000X magnification, DAPI used for nuclei 
staining. 
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3.2.2.3 Analysis of apoptosis in KCL22T315I cells following treatment with TKIs or 
mTOR inhibitors, in combination with CQ-mediated autophagy inhibition 
In order to evaluate if autophagy inhibition augments the effect of PON or mTOR pathway 
inhibitors, RAPA and BEZ, on CML cells carrying the T315I mutation, the following 
experiments were performed. 
KCL22WT and KCL22T315I were treated for 72h with 150nM DAS, 100nM PON, 10nM 
RAPA, 100nM BEZ or NDC, in the presence or absence of 10µM CQ. Apoptosis was 
measured by FACS after annexinV/Viaprobe staining. 
According to data presented in Figure 3-17A, PON (47.7±2.7%) was more effective than 
DAS (39.9±1.6%) in inducing apoptosis in KCL22WT cells, but none of these TKIs induced 
apoptosis at statistically significant levels as a single agent (p=0.056 and p=0.12, 
respectively). Nevertheless, CQ-mediated inhibition enhanced the apoptotic effect of PON 
at significant levels (p=0.02 PON/CQ versus NDC). RAPA did not induce significant 
levels of apoptosis, alone (22.9±9.2%; p=0.4) or in combination with CQ (33.6±10.1; p= 
0.36), but its effect was enhanced in the presence of CQ-mediated autophagy inhibition. 
Interestingly, our data underline the significance of mTOR signalling in cancer cells since 
BEZ (41.5±6.1; p=0.09) as single agent induced similar levels of apoptosis compared to 
DAS. Likewise, CQ enhanced the effect of BEZ (44.4±5.1%; p=0.06). 
As expected, DAS, alone (9.3±5.2%; p=0.6) or in combination with CQ (11.8±6.7%; 
p=0.9), did not affect the apoptosis of KCL22T315I cells since it is not active against the 
BCR-ABLT315I (Figure 3-17B). However, PON that has been suggested to target BCR-
ABLT315I activity, significantly induced apoptosis in KCL22T315I cells (30.9±7.3%; 
p=0.02). The apoptotic effect of PON was further boosted upon CQ-mediated autophagy 
inhibition with the PON/CQ combination (40.1±8.3%; p=0.01). RAPA (19.4±8%; p=0.09) 
was associated with higher levels of apoptosis in KCL22T315I cells compared to DAS, and 
CQ-mediated inhibition of autophagy enhanced its apoptotic effect (27.4±13.8%; p=0.17). 
BEZ, as a single agent was potent in inducing apoptosis in KCL22T315I cells (30.6±8.2%; 
p=0.04), to similar levels to PON. Interestingly, the BEZ/CQ combination induced the 
highest levels of apoptosis in these cells (45.6±4.3; p=0.0005), highlighting the 
significance of mTOR for the survival of these leukaemic blast cells.  
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Figure 3-17: CQ-mediated autophagy inhibition improves the apoptotic effect of PON and 
BEZ treatment in KCL22T315I cells 
KCL22WT (A) and KCL22T315I (B) were treated for 72h 150nM DAS, 100nM PON, 10nM RAPA, 
100nM BEZ or NDC, in the presence or absence of 10µM CQ. Apoptosis was measured by FACS 
after annexinV/Viaprobe staining. Graphs represent apoptosis percentages as mean±SEM (n=3). 
Statistical analysis was performed by using unpaired t-test. Annotation above a bar refers to 
statistical significance between the bar and the NDC. (*; p≤0.05, **; p≤0.01; ***; p≤0.001) 
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3.3 TKI treatment in the autophagy and survival of Ph- cells  
3.3.1.1 Treatment with IM, DAS or PON does not induce autophagy in 
Ph- CD34+ primary cells 
 
Experiments previously described, demonstrated that first (IM), second (DAS) and third 
(PON) generation TKIs induced autophagy upon treatment of Ph+ cells. In order to 
exclude that this was attributed to targeting of non-BCR-ABL related pathways, Ph- cells 
were treated with TKIs±CQ and the effect on the autophagic flux was monitored. 
Ph- CD34+ cells from a donor were cultured in SFM+5GFs and treated for 4h with 150nM 
DAS or 100nM PON, in the absence or presence of 10µM CQ. Cell aliquots from each 
treatment arm were used for (i) lysis and analysis by western blot for the measurement of 
LC3-II protein levels, and (ii) staining with CytoID® and analysis by FACS, for the 
detection of the autophagic activity.  
Figure 3-18A demonstrates that treatment with PON did not affect the levels of LC3 
lipidation in Ph-CD34+ cells; the PON/HCQ combination presented a 21% decrease in 
LC3-II compared to HCQ treatment arm. Nevertheless, DAS had a mild affect on 
autophagy; cells treated with DAS/HCQ combination presented a 20% increase in LC3 
lipidation compared to HCQ-treated cells. This may be attributed to the inhibition of non-
BCR-ABL targets, such as the SFKs.  
Furthermore, autophagy was monitored in the same samples by FACS after staining with 
CytoID®, as described in §2.2.2.4.  
Data presented in Figure 3-18B, illustrate that autophagy was not inducted upon TKI 
treatment of Ph- CD34+ cells since the FITC GeoMean was not increased in the TKI/HCQ 
combination compared to HCQ treatment alone. However, as discussed in §3.1.2.6, these 
data on their own could be inconclusive, but in combination with the protein analysis 
results, they demonstrate that TKIs do not induce autophagy in Ph- CD34+ cells. This 
observation further supports the notion that autophagy is induced in Ph+ cells upon TKI 
treatment due to BCR-ABL inhibition. 
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Figure 3-18: Treatment with DAS or PON does not induce autophagy in Ph- CD34+ cells 
(A) LC3-II levels were measured in Ph- CD34+ cells by western blot, following 4h treatment with 
150nM DAS or 100nM PON, ±10µM CQ. Densitometry calculations for western blot data shown 
were performed by using the Quantity One software (verifying for non-saturation and subtracting 
background). The graph represents the relative LC3-II levels (normalised to β-tubulin) compared to 
the NDC (n=1). (B) Cell aliquots from the same treatment arms were stained with the CytoID® 
Autophagy dye and FITC levels were determined by FACS analysis. The overlay of the logFITC 
FACS profiles is shown at the top, while the graphs below represent the FITC geometrical mean 
relative to the NDC (n=1).  
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3.3.2 Analysis of the effect of DAS/CQ combination treatment on a co-
culture of Ph-/Ph+ cells 
In order to investigate if CQ-mediated autophagy inhibition in combination with TKIs 
could potentially have a cytotoxic effect on Ph- cells, the following experiment was 
performed on IL-3-depended BaF3Parental cells (Ph-) and BaF3 cells that had been 
previously transfected with GFP-BCR-ABLp210 (BaF3p210) and could grow independently 
of the presence of IL-3.  
Equal amounts of BaF3Parental and BaF3p210 cells were used to initiate a co-culture where 
both populations were represented equally. Cells were maintained in RPMI+ supplemented 
with IL-3, and treated with or without 150nM DAS, in the presence or absence of 10µM 
CQ. The size of each population within the co-culture was monitored via FACS for a total 
of 96h following treatment initiation, based on the selection marker GFP expressed only by 
BaF3p210 cells. The experiment was repeated for n=3. 
As illustrated in Figure 3-19, FACS analysis verified that both BaF3p210 and BaF3Parental 
were equally represented at all time points examined in the NCD, underlining that both 
populations had the same viability under culture conditions. CQ-mediated inhibition of 
autophagy did not affect the BaF3Parental cells in the co-culture; however, it appeared to 
have a slight inhibitory effect on the growth kinetics of the BaF3p210 population. Exposure 
to DAS targeted specifically the BaF3p210 cells and significantly reduced their survival 
from the first 24h of treatment (p=0.03), leading to almost complete eradication of the 
population after 96h (p=0.004). Most importantly, the combination of DAS/CQ did not 
have any effect on the survival and proliferation of the BaF3Parental population, while it 
completely abolished the BaF3p210 population. 
Overall, these experiments demonstrate that the highest clinically achievable DAS 
concentration in combination with CQ has no cytotoxic effects on Ph- cells, and effectively 
targets only Ph+ cells in an in vitro co-culture. 
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Figure 3-19: DAS/CQ treatment is specifically targeting Ph+ cells and is not toxic for Ph- cells 
Equal amounts of BaF3Parental and BaF3p210 cells were maintained in RPMI+ supplemented with IL-
3, and treated with 150nM DAS, 10µM CQ, the combination of 10µM CQ, or NDC. The size of 
each population was monitored by FACS (BaF3p210 express GFP-BCR-ABLp210) for the total of 
96h. Representative FACS plots gated on the live cells’ population.
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4 Results (II): Investigation of ATG7 knock-down in 
combination with TKIs for the elimination of CP 
CML CD34+ primary cells 
In Chapter 3, by performing a series of autophagy monitoring assays, we demonstrated that 
first, second, and third generation TKIs induce autophagy upon inhibition of BCR-ABL 
activity. Furthermore, CQ and HCQ enhanced TKI-mediated apoptosis and suppression of 
the clonogenic ability in a BC CML cell line and CD34+ cells from CP CML patients, 
suggesting that TKI-induced autophagy has a cytoprotective role. 
CQ and HCQ inhibit the maturation of autophagosomes into degradative autolysosomes, 
and have been used widely for the pharmacological inhibition of autophagy. However, 
both drugs are lysosomotropic agents rather than exclusive autophagy inhibitors. Thus, 
based on these data we could not clarify if beneficial results observed upon combination of 
TKIs and CQ/HCQ were due to the inhibition of autophagy or attributed to effects on non-
related pathways/mechanisms. Furthermore, unpublished data from Ravi Amaravadi’s lab 
[348] demonstrate that clinically achievable concentrations of HCQ (1-10µM) do not 
inhibit autophagy sufficiently in vivo, highlighting the need for the development of potent 
inhibitors that specifically target autophagy for clinical use. 
In order to shed light on the aforementioned questions, in this chapter we inhibited 
autophagy in a specific manner, by knocking-down key autophagy gene ATG7 in CP CML 
CD34+ cells. Thereafter, cells were treated with TKIs and the significance of an 
autophagy-inhibited background was evaluated with regards to cell proliferation, apoptosis 
and clonogenic ability.  
The aims of these experiments were to determine:  
- if targeted inhibition of autophagy enhances the effects of TKIs in CP CML CD34+ cells 
- if ATG7 knock-down, alone or in the presence of TKI treatment, affects Ph- CD34+ cells  
-if ATG7 can serve as a potential therapeutic target in CML. ATG7 inhibitors are currently 
being developed in industry [349].  
In order to assess if ATG7 knock-down has an effect on Ph- CD34+ cells, non-CML cells 
and CB samples were also included in our experiments. 
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4.1 Optimisation of ATG7 knock-down techniques in human 
CD34+ progenitor cells 
Human CD34+ cells represent a powerful platform to study CML. More specifically, loss-
of-function studies in this cell population can offer an insight into disease mechanisms and 
reveal therapeutic targets. Nevertheless, primary cells are traditionally difficult to 
transduce and therefore, the technical part consists a major challenge. Several technologies 
that vary in complexity, efficiency, reliability and safety, have been developed for the 
manipulation and modification of HSCs. However, it remains unclear which protocol 
offers the most efficient and reliable method of gene knock-down in human CML CD34+ 
cells. 
In order to knock-down ATG7 in primary samples, two post-translational approaches were 
assessed; a) the non-viral nucleofection of siRNA that leads to transient ATG7 knock-
down, and b) the lentivirus-based shRNA-mediated stable ATG7 knock-down. These 
techniques are associated with different advantages and disadvantages and a direct 
comparison between them was performed so as to evaluate which one is more suitable for 
the CML system by means of effectiveness and efficiency, taking into account the low 
numbers of CML CD34+ samples that are available for research studies.  
 
4.1.1 Assessment of the siRNA nucleofection method for the knock-down 
of ATG7 in cell lines and CD34+ cells 
Nucleofection is an electroporation-based method that enables DNA to directly enter the 
nucleus and therefore, can be performed on non-dividing cells. This method is simple and 
fast and has been associated with high efficiency.  
K562 BC cells and Ph- CD34+ primary cells were transfected with a pool of four ATG7-
targeting siRNAs (siATG7) or non-targeting control siRNAs (siCtrl), along with a 
pmaxGFP® vector (to allow for monitoring of transfection via GFP expression), following 
the protocol described in §2.2.8.1.4. A pool of siRNAs was preferred over single siRNAs 
in order to mimic the natural silencing pathway and reduce the off-target effects. 
24h following nucleofection, 37.2 ± 14.4% of the siCtrl-transfected cells and 35.4 ± 13.3% 
of the siATG7-transfected cells were expressing GFP and, hence, were successfully 
transfected. In order to obtain a homogeneous population of transfected cells, siCtrl and 
siATG7 transfected cells were sorted from non-transfected cells based on expression of the 
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GFP marker. Monitoring of the sorted siCtrl and siATG7 populations by FACS every 24h 
following sorting, revealed that cell viability was not affected after DAPI staining (Figure 
4-1A); however, GFP expression was depleted in a time-dependent manner with a similar 
pattern within both siCtrl and siATG7 populations (Figure 4-1B). Furthermore, reduction 
in GFP expression was associated with lower ATG7 knock-down levels (Figure 4-1C). In 
an RT-PCR assay, while 24h post-sort siATG7-transfected cells showed significantly 
reduced ATG7 mRNA levels (68.1±2.8% compare to siCtrl; p=0.0003), 48h later siCtrl 
and siATG7 cells showed similar levels of ATG7 mRNA (p=0.33 siATG7 versus siCtrl).  
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Figure 4-1: Assessment of the siRNA nucleofection method in the viability, transfection 
efficiency and mRNA knock-down in K562 cells 
K562 cells were nucleofected with siCtrl or siATG7, along with a pmaxGFP® vector. Transfected 
cells were sorted and FACS analysis was performed (A) for the determination of cell viability after 
DAPI staining (n=1) and (B) for GFP expression monitoring (GFP levels presented as mean±SEM 
of n=3). (C) ATG7 mRNA levels were measured 24h and 48h post-sort by RT-PCR. Graph 
represents mean±SEM relative ATG7 mRNA levels compared to the siCtrl (n=3). Statistical 
analysis was performed by unpaired Student’s t-test. (ns; not significant, ***; p≤0.001) 
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The siRNA nucleofection method was also tested with regards to ATG7 knock-down in 
CD34+ cells.  
Ph- CD34+ cells were nucleofected with siCtrl and siATG7 along with pmaxGFP®, and 
cultured overnight in SFM+5GFs. FACS analysis was performed 24h later for the 
assessment of transfection efficiency by GFP measurement, and cell viability after DAPI 
staining. The transfected cells were sorted according to GFP expression levels to GFPHigh 
expressing cells, and GFPMedium expressing cells for both siCtrl and siATG7 populations. 
Figure 4-2A demonstrates that nucleofection severely affected the survival of CD34+ cells; 
the viability of siRNA-transfected cells was significantly reduced compared to cells of the 
same samples that had not been nucleofected (Figure 4-2B). Viability was affected in both 
siCtrl and siATG7 cells, suggesting that this was a method-associated disadvantage and not 
a knock-down induced effect. ATG7 mRNA levels were suppressed efficiently (>40%) 
within the GFPHigh siATG7 CD34+ cells compared to the GFPHigh siCtrl (Figure 4-2C). 
Nevertheless, GFPMedium siATG7 CD34+ cells did not show a significant reduction in 
ATG7 mRNA transcripts (<20%) compared to the GFPMedium siCtrl-transfected cells. 
Hence, even if the method was associated with high transfection levels, it was deemed 
unsuitable: 
(i) for prolonged assays in cell lines, since the overgrowth of untransfected cells would 
overwhelm and dilute transfected cells, 
(ii) for experiments with primary samples due to the low number of cells that would be 
available for experiments after nucleofection and sorting for high GFP-expressing cells. 
Therefore, alternative methods of knock-down were investigated. 
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Figure 4-2: Assessment of the siRNA nucleofection method in the viability, transfection and 
knock-down efficiency in Ph- CD34+ progenitor cells 
Ph- CD34+ cells were nucleofected with siCtrl or siATG7, along with a pmaxGFP® vector and 
cultured overnight in SFM+5GFs. Transfected cells were sorted into GFPHigh- and GFPMedium-
expressing populations. (A) FACS analysis for the determination of cell viability was performed 
24h post-nucleofection after DAPI staining. Graph values represent cell viability mean of n=2 
relative to non-nucleofected cells. (B) GFP expression was measured by FACS so as to determine 
transfection efficiency (n=2) (C) ATG7 mRNA levels were assessed 24h post-sort by qRT-PCR 
within GFPHigh and GFPMedium sorted cells. Graph values represent mean of n=2 compared to siCtrl.  
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4.1.2 Optimisation of the lentivirus-mediated shRNA delivery method 
for the knock-down of ATG7 in CP CML CD34+ primary cells 
4.1.2.1 Comparison of concentrated versus unconcentrated lentivirus in the viability 
and transduction efficiency of CD34+ cells 
In order to circumvent the problems of reduced cell viability and knock-down transiency 
following nucleofection, an HIV-based second generation lentivirus delivery system was 
used. The sequence-specific silencing of ATG7 was performed by two shRNAs targeting 
separate regions of ATG7 mRNA; shATG7_1 and shATG7_2. A scrambled shRNA 
(shCtrl) was used as negative control (no homology with any human mRNA). The shRNA 
hairpins were carried by a pGIPZ-based vector that uses a Pol II CMV promoter to drive 
expression of shRNA sequences. The vector also encodes a GFP marker, making the direct 
monitoring of transduced cells possible. 
In order to achieve high titer virus, the virus-containing supernatant medium of transfected 
HEK cells was ultracentrifuged at 625,000 x g for 2h in vacuum at 4oC, as described in 
§2.2.8.1.3, and resuspended in SFM in 1/100 of the medium volume used for the 
ultracentrifugation. The protocol followed for virus concentration was successful and virus 
titer was increased >100fold following ultracentrifugation (Figure 4-3A).  
Primary Ph- and Ph+ CD34+ cells were transduced with MOI10 in the presence of 
Transdux™, every 12h for a total of 36h accompanied by spinoculation, and transduction 
efficiency was measured 48h after the last round of incubation with virus (to allow for the 
expression of shRNA and gene silencing). Figure 4-3B demonstrates that cell viability of 
CD34+ cells was very low 48h after last transduction round with concentrated virus, as 
measured by FACS after DAPI staining (p= 0.00004 for siCtrl and p=0.001 for shATG7 
compared to untransduced cells from the same samples). This could be attributed to the 
presence of cellular debris that is received at the ultracentrifugation pellet along with the 
virions. Moreover, transduction efficiency was very low (Figure 4-3C); this could be due 
to the freeze-thaw procedure that reduces infectivity.  
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Figure 4-3: Assessment of the use of concentrated HIV-based lentiviral virus in the viability, 
and transduction efficiency in CD34+ progenitor cells 
Ph- and Ph+ CD34+ cells were transduced with 3 rounds of concentrated virus at MOI10 (A). Cell 
viability was measured 48h after the last transduction round by FACS after DAPI staining. Graph 
values represent cell viability mean±SEM (n=3) relative to untransduced cells. (C) GFP expression 
was measured by FACS so as to determine transduction efficiency. Graph values represent 
mean±SEM (n=3). (****; p<0.0001, ***; p≤0.001) 
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In an attempt to overcome this problem, unconcentrated virus was used for the infection of 
CD34+ cells. 
Primary Ph- and Ph+ CD34+ cells were transduced with freshly produced, filtered, virus-
containing medium, as described in §2.2.8.1.2. Transduction was performed in the 
presence of Transdux™, every 12h for a total of 36h accompanied by spinoculation, and 
transduction efficiency was measured 48h after the last round of incubation with virus.  
Figure 4-4A demonstrates that cell viability of CD34+ cells was not severely affected in 
both mock and ATG7-targeting populations, compared to untransduced cells from the 
same samples. Furthermore, as illustrated in Figure 4-4B, transduction efficiency 
associated with this method was relatively high (approximately 30% for both shCtrl and 
shATG7_2).  
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Figure 4-4: Assessment of the use of unconcentrated HIV-based lentiviral virus in the 
viability, and transduction efficiency in CD34+ cells 
Ph- and Ph+ CD34+ cells were transduced with 3 rounds of unconcentrated virus. (A) Cell viability 
was measured 48h after the last transduction round by FACS after DAPI staining. Graph values 
represent cell viability mean±SEM (n=3) relative to untransduced cells. (B) GFP expression was 
measured by FACS so as to determine transduction efficiency. Graph values represent mean±SEM 
(n=3). Statistical analysis was performed by paired Student’s t-test. (ns; not significant) 
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4.1.2.2 Assessment of the effect of ATG7 knock-down on basal and TKI-induced 
autophagy in K562 cells that have been stably transduced with pGIPZ-
shATG7-hairpins  
Having optimised the lentiviral shRNA-delivery technique, the efficacy of the ATG7-
targeting hairpins shATG7_1 and shATG7_2, was tested regarding the knock-down of 
ATG7. Protein analysis was performed in lysates from sorted K562 cells stably expressing 
shCtrl, shATG7_1 and shATG7_2 hairpins; GAPDH and actin were measured as loading 
controls. 
Figure 4-5A demonstrates that transduction with either shATG7_1 or shATG7_2 
significantly reduced ATG7 protein levels. Densitometry measurements on n=3 western 
blots revealed that shATG7_1 cells were expressing 59.5±7.1% ATG7 protein levels 
(p=0.01), while shATG7_2 64±4.4% (p=0.005) compared to the shCtrl. 
Reduction of ATG7 protein had an effect on lipidation of LC3, as illustrated in Figure 4-
5B. shATG7_1 and shATG7_2 K562 cells expressed approximately 45% and 35% less 
LC3-II protein levels compared to the shCtrl, respectively. Hence, knock-down of ATG7 at 
this level reduced lipidation of LC3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5: Measurement of ATG7 and LC3-II protein levels in K562 cells that stably express 
ATG7-targeting hairpins carried by pGIPZ vector 
Western blotting was used for the analysis of ATG7 (A) and LC3-II (B) protein levels. 
Densitometry calculations for western blot data shown were performed by using the Quantity One 
software (verifying for non-saturation and subtracting background). The graphs represent the 
relative ATG7 and LC3-II levels (normalised to actin or GAPDH loading levels) compared to the 
shCtrl. Replicates 1 and 2 refer to the same immunoblots. Graph values represent protein 
mean±SEM with n=3 for (A) and mean for n=2 for (B).  Statistical analysis was performed by 
paired Student’s t-test. (*; p≤0.05, **; p≤0.01). Arrowheads mark non-specific bands.  
  
sh
AT
G7
_1
)
sh
AT
G7
_2
)
sh
Ct
rl)
ATG7)
GAPDH)
REP3)
REP2)
ATG7)
ACTIN)
REP1)
ACTIN)
LC38I)
LC38II)
ACTIN)
LC38I)
LC38II)
REP1)
REP2)
sh
AT
G7
_1
)
sh
AT
G7
_2
)
sh
Ct
rl)
sh
Ct
rl
sh
AT
G7
_1
sh
AT
G7
_2
0
20
40
60
80
100
* **
R
el
at
iv
e 
AT
G
7 
pr
ot
ei
n 
le
ve
ls
sh
Ct
rl
sh
AT
G7
_1
sh
AT
G7
_2
0
20
40
60
80
100
R
el
at
iv
e 
LC
3I
I p
ro
te
in
 le
ve
ls
78)
Kd)
55)
ATG7)
ACTIN)
78)
55)
78)
37)
14)
55)
Kd)
16)
14)
55)
Kd)
16)
A B 
  172 
 
 
In order to investigate if the achieved levels of ATG7 knock-down would efficiently 
suppress autophagy upon TKI treatment, the following experiment was designed. 
Sorted K562 cells stably expressing shCtrl or shATG7_2 were treated with 150nM 
DAS±10µM CQ or NDC. 4h later, cells were lysed and analysed by western blotting. 
Levels of CrKL phosphorylation were measured as a marker of BCR-ABL activity; β-
tubulin was measured as a loading control. 
Figure 4-6 demonstrates that treatment of shCtrl with DAS induced autophagy, since LC3-
II levels were higher upon exposure to DAS/CQ compared to CQ treatment alone. 
However, shATG7_2 cells presented similar levels of LC3 lipidation upon DAS/CQ and 
CQ-alone treatment, suggesting that knock-down of ATG7 successfully inhibited DAS-
induced autophagy. 
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Figure 4-6: Measurement of DAS effect on the autophagic activity of K562 cells in the 
presence of ATG7 knock-down 
K562 shCtrl and shATG7_2 cells were treated for 4h with 150nM DAS±10µM CQ or NDC. (A) 
Cells were lysed and p-CrKL and LC3 protein levels were measured by western blot. B-tubulin was 
measured as loading control. (B) Densitometry calculations were performed by using the Quantity 
One software (verifying for non-saturation and subtracting background). The graph represents the 
relative LC3-II levels (normalised to β-tubulin) compared to NDC. 
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4.1.2.3 Assessment of the pGIPZ vector that drives shRNA expression under the 
CMV promoter 
K562 cells were transduced according to the protocol described in §2.2.8.1.3 and GFP+ 
cells were sorted 48h after the last transduction round. Based on previous experiments 
(Figure 4-2C) where higher GFP expression was associated with higher levels of knock-
down, a similar strategy was followed during sorting. The 5-10% highest GFP- expressing 
K562 cells (GFPHigh) were sorted in order to achieve a homogeneous population with high 
levels of knock-down. Sorted cells were maintained afterwards in RPMI+ liquid culture 
and monitored frequently by FACS for GFP expression. 
Within 5 days post-sort the GFP expression profile of the GFPHigh-sorted population 
(shCtrl, shATG7_1 or shATG7_2) was lower compared to the initial profile before sorting 
(Figure 4-7). In order to investigate if this was due to promoter silencing, the cells were 
treated with 5-azacytidine (AZA), a demethylation agent, and GFP expression was monitor 
every 24h for a total of 72h. Our data demonstrate that loss of GFP expression was 
reversed upon exposure to AZA, suggesting that the CMV promoter was methylated within 
K562 cells. Silencing of the CMV promoter would lead to inhibition of shRNA expression 
and abolishment of ATG7 knock-down. Hence, pGIPZ vector was deemed not suitable for 
experiments that require long-term and stable knock-down.  
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Figure 4-7: The CMV promoter of the pGIPZ vector is methylated in K562 cells 
K562 cells transduced with pGIPZ-GFP-shRNA via lentiviral delivery were sorted. GFP 
expression was monitored by FACS daily over a period of 7 days. The profile of shCtrl, shATG7_1 
and shATG7_2 K562 cells revealed reduction in GFP expression in a time-dependent manner. GFP 
expression was restored upon treatment with 5-azacytidine (AZA), a demethylation agent. 
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4.1.2.4 Assessment of ATG7 knock-down in CD34+ primitive cells, mediated by an 
ATG7-targeted hairpin carried by the pLKO.1 vector  
In an effort to achieve long-term stable knock-down, the pLKO.1 vector was tested. The 
shRNA in this vector is under the human U6 promoter that drives RNA Pol III 
transcription and published data have demonstrated that it is not silenced in human CD34+ 
cells [350, 351]. The commercially available vector carrying an ATG7-targeting hairpin, 
encodes as selection marker the resistance gene to puromycin. In order to avoid selecting 
infected primary CD34+ cells for 6 days in the presence of the antibiotic, it was decided to 
clone the control and ATG7-targeting hairpins from the pLKO.1-PURO backbone to a 
pLKO.1-GFP backbone where the puromycin resistance gene was replaced by the one 
encoding for GFP. At the end of the cloning procedure (described at §2.2.9), two plasmids 
were generated; the control pLKO-GFP-shCtrl, carrying the shCtrl non-targeting hairpin, 
and the pLKO.1-GFP-shATG7_E, which carried the shATG7_E hairpin against the ATG7 
mRNA. The functionality of the shATG7_E hairpin has been validated by the company 
and a series of publications, and is well described in the literature [309, 310, 352-354].  
In order to test the efficacy of the vector and the shATG7_E hairpin, CD34+ cells from 
two CP CML patients and one CB sample were incubated with freshly produced, filtered, 
virus-containing medium, as described in §2.2.8.1.2. Transduction was performed in the 
presence of Transdux™ every 12h for a total of 36h accompanied by spinoculation. Cells 
were sorted 48h after the last transduction round based on GFP expression, and knock-
down efficiency was measured in whole cell lysates by western blot analysis for ATG7.  
Figure 4-8A demonstrates that ATG7 protein levels were significantly reduced (≥60%) in 
shATG7_E CD34+ cells (p=0.002) compared to shCtrl. LC3-II levels were also measured 
in order to assess the effect of 60% ATG7 knock-down on the autophagic activity. As 
shown in Figure 4-8B, LC3 lipidation was inhibited at approximately 20% in the 
shATG7_E CD34+ cells compared to the shCtrl. 
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Figure 4-8: Measurement of ATG7 and LC3-II protein levels in CD34+ primitive cells that 
stably express an ATG7-targeting hairpin carried by the pLKO.1 vector 
Western blotting was used for the analysis of ATG7 (A) and LC3-II (B) protein levels in CD34+ 
cells transduced with shCtrl or shATG7_E pLKO.1 vector via lentiviral delivery. Densitometry 
calculations for western blot data shown were performed by using the Quantity One software 
(verifying for non-saturation and subtracting background). The graphs represent the relative ATG7 
and LC3-II levels (normalised to β–tubulin loading levels) compared to the shCtrl. Samples CB5 
and CML389 refer to the same immunoblot. Graph values represent protein mean±SEM with n=3 
for (A) and mean for n=2 for (B).  Statistical analysis was performed by paired Student’s t-test. (**; 
p≤0.01).  
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4.2 Investigation of ATG7 knock-down in combination with 
TKIs on CP CML CD34+ cells 
Having established stable and efficient knock-down of ATG7 in CP CML CD34+ cells, the 
efficacy of IM, NIL, DAS and PON was investigated in an autophagy suppressed 
background. Colleagues’ experiments within our laboratory have demonstrated that NIL 
induces autophagy upon inhibition of BCR-ABL. Hence, this second generation TKI was 
also included in this series of experiments.   
At this point it should also be mentioned that there have been published data supporting 
that ATG7 and autophagy are necessary for the maintenance of stemness in a mouse model 
[355]. Therefore, the inclusion of Ph- cells (derived from non-CML donors or CB samples) 
was necessary in order to investigate how autophagy inhibition, alone or in combination 
with TKIs, affects the fate of a normal stem cell. 
Ph+/Ph- CD34+ cells were transduced with shCtrl or shATG7_E and sorted, as previously 
described. Since the sorting procedure can be considered as a stress factor, the cells were 
left to recover in culture overnight and treatment initiation took place the following day (6-
7 days post-thaw). 
 
4.2.1 Analysis of CP CML CD34+ cell proliferation following ATG7 
knock-down and TKI treatment 
shCtrl and shATG7_E transduced cells were treated with 2µM NIL, 150nM DAS, 100nM 
PON or left untreated, and the population size was measured by cell counts 3 and 6 days 
later. Cell viability was assessed by the trypan blue exclusion method. 
As demonstrated in Figure 4-9, cell counts 3 days following treatment initiation revealed 
that ATG7 knock-down significantly affected the proliferation of shATG7_E CD34+ cells 
(p=0.008 compared to shCtrl). Day 3 or 6 drug treatments, in the presence or absence of 
ATG7 knock-down, did not inhibit cell proliferation at statistically significant levels. 
Nevertheless, ATG7 knock-down (i) enhanced the cytotoxicity of NIL, DAS and PON 
after 3 days of treatment, and (ii) increased the antiproliferative effect of all TKIs after 6 
days of treatment. Among the three drugs tested, PON was the most efficient TKI in 
suppressing the proliferation of CD34+ CML cells, and its effects were further enhanced 
upon ATG7 knock-down. 
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Figure 4-9: Comparison of NIL, DAS and PON treatments in combination with ATG7 knock-
down in CP CML CD34+ cells 
CP CML CD34+ cells stably expressing an ATG7-targeting (shATG7_E) or a mock hairpin 
(shCtrl) were treated with 2µM NIL, 150nM DAS, 100nM PON or NDC. Cell counts were 
performed at days 3 and 6 following treatment initiation and viability was determined by using the 
trypan blue exclusion method. The number of viable cells in each treatment was compared to the 
input and the relative numbers are presented as mean±SEM (n=3). Statistical analysis was 
performed by using paired t-test. Annotation above a bar refers to statistical significance between 
the bar and the NDC. (**; p≤0.001). 
  
CD34+_CML (n=3)
Inp
ut
ND
C NIL DA
S
PO
N
ND
C NIL DA
S
PO
N
0.0
0.5
1.0
1.5
2.0
2.5
shCtrl
shATG7_E
Day 3 Day 6
**
Re
lat
ive
 ce
ll n
um
be
r
  180 
 
4.2.2 Analysis of CP CML CD34+ cell apoptosis following ATG7 knock-
down and TKI treatment 
In order to further characterise the effect of ATG7 knock-down in the presence of different 
TKIs, the apoptosis of CP CML CD34+ cells (n=3) was measured. Transduced shCtrl and 
shATG7_E cells were cultured post-sort in SFM+PGFs in the presence of 2µM NIL, 
150nM DAS, 100nM PON or NDC. 6 days following treatment initiation, the cells were 
analysed by FACS after annexin V/Viaprobe staining for the evaluation of apoptotic cells 
(early and late). 
Figure 4-10 demonstrates that ATG7 knock-down moderately affected the survival of CP 
CML CD34+ cells; apoptosis levels within the shATG7_E NDC cells were similar to the 
ones observed in the shCtrl upon TKI treatment.  
Nevertheless, apoptosis within the TKI-treated cells was not augmented upon ATG7 
knock-down. It should be mentioned that these results refer solely to the induction of 
apoptosis (early and late) upon TKI treatment of shATG7 knock-down CML CD34+ cells. 
Hence, these data do not exclude the possibility of induction of non-apoptotic forms of 
death, such as necrosis.  
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Figure 4-10: Analysis of TKI-induced apoptosis in the presence of ATG7 knock-down in CP 
CML CD34+ cells 
CP CML CD34+ cells were treated for 6 days with 2µM NIL, 150nM DAS, 100nM PON or NDC. 
Apoptosis (early and late) was measured by FACS after annexinV/Viaprobe staining. Graph 
represents apoptosis relative to NDC and numbers are presented as mean±SEM (n=3).  
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4.2.3 Analysis of CML committed progenitor cell potential and 
differentiation following ATG7 knock-down and TKI treatment 
 
4.2.3.1 Analysis of CML committed progenitor cell potential following ATG7 knock-
down and short exposure TKIs 
The CFC assay is a rigorous method used for determining the clonogenic ability and the 
differentiation capacity of CD34+ progenitor cells. In order to investigate how inhibition of 
autophagy, alone or in combination with TKIs, affects the functionality of CML CD34+ 
cells, shCtrl and shATG7_E-transduced cells were treated in vitro for 3 or 6 days in the 
presence of 2µM NIL, 150nM DAS, 100nM PON or NDC. Thereafter, the drugs were 
washed out and the cells were plated in semi-solid methylcellulose-based medium at low 
density (2500 cells/1.5mL methycellulose, in duplicate). The medium was supplemented 
with GFs, including EPO, SCF, G-CSF, GM-CSF and IL-3, so as to support the 
proliferation and differentiation of the progenitor cells.  
Figure 4-11 demonstrates that in the NDC arm, ATG7 knock-down alone led to >50% 
reduction in the clonogenic ability of the cells (97±24.9 colonies) compared to the shCtrl 
(221.6±84 colonies), suggesting that basal levels of ATG7 and autophagy play an 
important role in the clonogenic potential of these cells.  
3 day exposure of shCtrl cells to TKIs significantly decreased the number of colonies; 10-
fold with DAS (p=0.04), 6-fold with PON (p=0.03), but only 4-fold with NIL (p=0.07). 
Likewise, TKI-treatment of shATG7_E cells significantly reduced the number of colonies 
compared to the NDC arm; 5.4-fold with NIL (p=0.01) or PON (p=0.02), and 6.5-fold with 
DAS (p=0.02). In both shCtrl and shATG7_E arms, DAS was the most potent TKI among 
the three.  
In order to assess if ATG7 knock-down enhanced TKI effect against the clonogenic ability 
of CD34+ cells, comparison was performed between TKI-treated shCtrl and shATG7_E 
cell. Student’s t-test paired analysis revealed that ATG7 knock-down significantly 
enhanced the effect of NIL (p=0.008) and DAS (p=0.02), but not PON (p=0.21). 
Taken together, ATG7 knock-down enhanced the effect of 3 day TKI treatment, reducing 
the number of progenitor colonies to 8% for NIL (18.6±8 colonies) and PON (18.3±5.5 
colonies), and 6% for DAS (15.6±8.7 colonies) compared to the shCtrl NDC arm (221±84 
colonies). 
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Figure 4-11: ATG7 knock-down-mediated autophagy inhibition enhances 3 day TKI 
treatment effect against the clonogenic ability of CP CML CD34+ cells 
CP CML CD34+ cells were cultured in SFM+PGFs. Cells were treated for 3 days with 2µM NIL, 
150nM DAS, 100nM PON, or NDC. Drugs were washed out and 2500 cells/arm were transferred 
to semi-solid medium. Colony counts were performed after 14 days under light microscope. 
Numbers of colonies are presented as mean±SEM (n=3). Statistical analysis was performed by 
using paired t-test. Annotation above a bar refers to statistical significance between the bar and the 
NDC. (ns; not significant, *; p≤0.05, **; p≤0.01) 
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CFC assay on cells that had been exposed for 6 days to TKIs, in the presence or absence of 
ATG7 knock-down, further supported these observations.  
Figure 4-12 demonstrates that the effect of all TKIs tested was enhanced in the presence of 
ATG7 knock-down. In the shCtrl cells, NIL (44±11.7 colonies; p=0.01) and DAS 
(26.3±5.1 colonies; p=0.01) suppressed the colony forming ability of the cells upon 
inhibition of BCR-ABL compared to the NDC (453±93.5 colonies). Treatment with PON 
followed the same trend (48.5±14.8, n=2).  
The ability of shATG7_E cells to form colonies was significantly disrupted in comparison 
to shCtrl cells within the NDC arm; the colony-forming potential of the cells was reduced 
approximately 50% (229±31.7 colonies in the shATG7_E arm versus 453±93.5 colonies in 
the shCtrl arm; p=0.02), highlighting the importance of basal ATG7 and autophagy levels 
for this cellular function.  
Likewise, proliferation of the TKI-treated shATG7_E cells was suppressed compared to 
the NDC (22.6±4 colonies for NIL, p=0.05; 9.3±1.5 colonies for DAS, p=0.006,). Most 
importantly, it was illustrated that inhibition of autophagy in the shATG7_E arm 
augmented the clonogenic inhibitory efficacy of all TKIs compared to their shCtrl 
counterparts (DAS, p=0.01; NIL, p=0.05). Most importantly, ATG7 knock-down in 
combination with NIL or DAS, reduced the number of progenitor colonies to 4% and 2% 
respectively, compared to the shCtrl NDC. This means that the majority of CP CML 
progenitors (96-98%) was successfully targeted by the TKI/ATG7 knock-down 
combination. DAS, was again more potent than NIL and PON in suppressing the 
clonogenicity of CP CML CD34+ cells, in the absence or presence of ATG7 knock-down.  
Based on these experiments, we report that inhibition of basal autophagy as a single 
approach significantly affects the functionality of the CML progenitor cells. Furthermore, 
we demonstrate that autophagy inhibition augments the efficacy of TKIs in reducing the 
colony forming ability of CD34+ cells from CP CML patients.  
Nevertheless, some progenitors managed to survive both ATG7 knock-down and TKI 
treatment and formed colonies (4% with NIL and 2% with DAS). In order to investigate if 
prolonged exposure to TKIs would eradicate these cells, the experiment described at 
§4.2.3.2 was designed. 
 
 
 
 
 
  185 
 
 
 
 
Figure 4-12: ATG7 knock-down-mediated autophagy inhibition enhances 6 day TKI 
treatment effect against the clonogenic ability of CP CML CD34+ cells 
CP CML CD34+ cells were cultured in SFM+PGFs. Cells were treated for 6 days with 2µM NIL, 
150nM DAS, 100nM PON (n=2), or NDC. Drugs were washed out and 2500 cells/arm were 
transferred to semi-solid medium. Colony counts were performed after 14 days under light 
microscope. Numbers of colonies for NIL and DAS are presented as mean±SEM (n=3) and for 
PON mean of n=2. Statistical analysis was performed by using paired t-test. Annotation above a 
bar refers to statistical significance between the bar and the NDC. (*; p≤0.05, **; p≤0.01) 
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CD34+CD38- cells from a CP CML CD34+ patient sample were isolated following the 
protocol described at §2.2.2.1. The cells were transduced with shCtrl or shATG7_E virus, 
isolated by sorting, and their functionality was investigated in a CFC assay. Cells from 
both arms were plated in semi-solid methylcellulose-based medium at low density (2500 
cells/1.5mL methycellulose, in duplicate).  
Figure 4-13A demonstrates that suppression of basal ATG7 levels had a detrimental effect 
on the clonogenicity of CD34+CD38- shATG7_E cells; they completely failed to 
proliferate and form colonies.  
In order to further investigate why CD34+CD38- cells are completely ablated upon ATG7 
knock-down contrast to CD34+CD38+ cells, we performed LTC-IC assays on shCtrl and 
shATG7_E-transduced CP CML CD34+ cells. Nevertheless, due to technical problems, the 
cells failed to give colonies at the end of the assay (in both control and ATG7 knock-
down). Future studies should focus on the evaluation of ATG7 knock-down effects on the 
most primitive population of stem cells, either by LTC-IC or serial replating assays. 
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Figure 4-13: Ablation of the clonogenic ability of CD34+CD38- cells from a CP CML patient 
upon ATG7 knock-down 
shCtrl and shATG7_E transduced CP CML CD34+CD38- cells were transferred to semi-solid 
medium (2500 cells/1.5mL medium). Colony counts were performed after 14 days under light 
microscope. Photos from representative colonies are included.  
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4.2.3.2 Analysis of CML committed progenitor cell potential and differentiation 
following ATG7 knock-down and prolonged exposure to TKIs 
In order to evaluate how CML progenitors respond under prolonged exposure to TKIs in 
the presence of ATG7 knock-down, shCtrl and shATG7_E CP CML CD34+ cells were 
plated in methycellulose (2500 cells/1.5mL methycellulose, in duplicate) in the presence of 
2µM NIL, 150nM DAS, 100nM PON or NDC.  
Data presented in Figure 4-14 further verify the pivotal role of basal autophagy in the 
survival of CML progenitors, with shATG7_E cells forming 64% less colonies compared 
to the shCtrl in the NDC arm (164±110 colonies for shATG7_E versus 452.7±122.6 
colonies for shCtrl; p=0.002, n=4). It should be highlighted that ATG7 knock-down in the 
shATG7_E NDC cells gave approximately the same number of colonies compared to the 
NIL-treated arm of the shCtrl cells (181±65.8 colonies). Hence, with regards to the colony 
forming capacity of CP CML CD34+ cells, inhibition of autophagy appeared to have the 
same effect as TKI-mediated specific targeting of BCR-ABL.  
The number of shCtrl colonies was reduced in all TKI-treated arms compared to NDC to 
40% with NIL (p=0.04), 16.5% with DAS (p=0.007), and 26.5% with PON (p=0.008). 
Likewise, the number of shATG7_E colonies was reduced upon TKI treatment; 49% with 
NIL (p=0.018), 25.6% with DAS (p=0.002) and 30% with PON (p=0.003), compared to 
the NDC. 
Most importantly, the efficacy of TKIs was potentiated in the presence of ATG7 knock-
down; NIL (p=0.017), DAS (p=0.009) and PON (p=0.012) reduced the number of colonies 
to 18%, 9% and 11%, respectively, compared to the shCtrl NDC, suggesting that the 
TKI/ATG7 knock-down combination eradicated the majority (82-91%) of the CML 
progenitors. 
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Figure 4-14: ATG7 knock-down-mediated autophagy inhibition enhances prolonged TKI 
treatment effect against the clonogenic ability of CP CML CD34+ cells 
shCtrl and shATG7_E transduced CP CML CD34+ cells were transferred to semi-solid medium 
containing 2µM NIL, 150nM DAS, 100nM PON, or NDC (n=4 for NDC and n=3 for TKI 
treatments). Colony counts were performed after 14 days under light microscope. Numbers of 
colonies presented as mean±SEM. Statistical analysis was performed by using paired t-test. 
Annotation above a bar refers to statistical significance between the bar and the NDC. (ns; not 
significant, *; p≤0.05, **; p≤0.01) 
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Furthermore, the potential of the progenitor cells to differentiate into different colonies was 
assessed morphologically and the cells of origin were classified based on the cellular 
composition and the size of each colony (Figure 4-15A).  
As demonstrated in Figure 4-15B, ATG7 knock-down was associated with suppression of 
erythroid colony formation; burst forming unit-erythroid (BFU-E) and colony-forming unit 
erythroid (CFU-E). shATG7_E cells produced significantly lower BFU-E/CFU-E colonies 
compared to the shCtrl under NDC conditions (8.8±4% versus 35.8±7.8%, p=0.008) and 
DAS treatment (8.7±5.8% versus 32.9±4%, p=0.05), while a non-statistically significant 
decrease was observed under NIL treatment (8.6±2% versus 29.6±12.5%, p=0.08) or PON 
treatment (18.4±4.9% versus 27.6±11.7, p=0.4). It should be also mentioned that in all 
cases, the colonies formed in the shATG7_E arm were morphologically similar to the ones 
in the shCtrl arm by means of size and cell number. 
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Figure 4-15: ATG7 knock-down-mediated autophagy inhibition is associated with reduced 
erythroid colony-formation potential in CP CML CD34+ cells 
shCtrl and shATG7_E transduced CP CML CD34+ cells were transferred to semi-solid medium 
containing 2µM NIL, 150nM DAS, 100nM PON, or NDC (n=5 for NDC and n=3 for TKI 
treatments). Colony counts were performed after 14 days and classification was carried out based 
on morphology under light microscope. Total colony numbers (A) and % relative number of 
erythroid colonies (compared to total number of colonies) (B) are presented. Graphs present 
number of colonies as mean±SEM. Statistical analysis was performed by using paired t-test. (ns; 
not significant, *; p≤0.05, **; p≤0.01) 
A 
 
B 
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Cells from 3-5 colonies were pooled from the shCtrl and shATG7_E NDC arms of the 
CML389 sample so as to investigate if the U6 promoter was still active in these cells, 
ensuring the transcription of the shRNA hairpins and the GFP protein. The pooled cells 
were analysed by FACS for the expression of GFP.  
As shown in Figure 4-16, almost 90% of the shCtrl cells and 95% of the shATG7_E cells 
were positive for GFP expression, suggesting that both mock and ATG7-targeting hairpins 
were expressed. 
Taken altogether, these results suggest that ATG7 is playing an important role in the 
survival of CD34+ CML progenitor cells. Furthermore, autophagy appears to have a 
cytoprotective role in the CML system upon inhibition of BCR-ABL, since ATG7 knock-
down enhanced the effects of TKIs. Finally, ATG7 and/or autophagy appear to take part in 
the differentiation decisions of CD34+ progenitors, as illustrated by reduced number of 
erythroid colonies in the shATG7_E cells, in the absence or presence of TKIs.  
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Figure 4-16: Assessment of GFP expression in cells from CML CD34+ progenitor colonies 
surviving ATG7 knock-down  
CD34+ cells from a CML patient were lentivirally transduced with a pLKO.1-GFP vector, carrying 
either a mock (shCtrl) or an ATG7-targeting hairpin (shATG7_E). GFP+ cells were sorted in order 
to obtain homogenous populations of transduced cells (GFP expression profile presented at the 
top). Following, the committed progenitor cell potential of these populations was tested; shCtrl and 
shATG7_E cells were transferred to semi-solid medium and colony counts were performed after 14 
days under light microscope. GFP expression analysis on pooled cells from 3-5 shCtrl or 
shATG7_E colonies was performed by FACS. Cells from a colony of the initial CD34+ non-
infected population were used as GFP- control. 
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4.3 Investigation of ATG7 knock-down in combination with 
TKIs on Ph- CD34+ cells 
Published studies have underlined the indispensible role of autophagy in the maintenance 
of stemness [356]. Hence, it was within the aims of this project to evaluate the effect of 
ATG7 knock-down in a non-BCR-ABL haemopoietic progenitor background and evaluate 
if targeted autophagy inhibition, in the presence or absence of TKIs, affects normal 
progenitors.  
non-CML CD34+ and CB cells were thawed and cultured overnight in SFM+5GFs and 
SFM+PGFs, respectively. Thereafter, the cells were transduced with virus carrying a 
shCtrl or an ATG7-targeting hairpin, as described in §2.2.8.1.2. Transduced cells were 
sorted based on the expression of GFP, and 24h later TKI treatment was initiated. 
 
 
4.3.1 Analysis of Ph- CD34+ cell proliferation following ATG7 knock-
down and TKI treatment 
shCtrl and shATG7_E transduced cells were treated with 2µM NIL, 150nM DAS, 100nM 
PON or NDC, and the population size was measured by cell counts 3 days later. Cell 
viability was assessed by trypan blue exclusion method. 
As demonstrated in Figure 4-17, day 3 cell counts revealed that ATG7 knock-down alone 
did not suppress the proliferation of the cells (p=0.21 shATG7_E versus shCtrl in the NDC 
arm). Moreover, TKIs, in the presence or absence of ATG7 knock-down, did not inhibit 
proliferation of the cells. 
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Figure 4-17: Comparison of NIL, DAS and PON treatments in combination with ATG7 
knock-down in Ph- CD34+ cells 
CD34+ progenitor cells from 2 non-CML donors and a CB sample, stably expressing an ATG7-
targeting (shATG7_E) or a mock hairpin (shCtrl) were treated with 2µM NIL, 150nM DAS, 
100nM PON or NDC. Cell counts were performed 3 days following treatment initiation and 
viability was determined by using the trypan blue exclusion method. The number of viable cells in 
each treatment was compared to the input and the relative numbers are presented as mean±SEM 
(n=3). Statistical analysis was performed by using paired t-test. (ns; not significant) 
  
CD34+_Non-CML (n=3)
Inp
ut
ND
C NI
L
DA
S
PO
N
1
2
shCtrl
shATG7_E
ns
ns
ns
ns
R
el
at
iv
e 
ce
ll 
nu
m
be
r
  196 
 
 
4.3.2 Analysis of Ph- CD34+ cell apoptosis following ATG7 knock-down 
and TKI treatment 
In order to further characterise the effect of ATG7 knock-down in the presence of different 
TKIs in Ph- CD34+ cells, apoptosis was measured in non-CML and CB CD34+ cells. 
Transduced shCtrl and shATG7_E cells were cultured post-sort in SFM+5GFs (for the 
non-CML samples) or SFM+PGFs (for the CB sample) in the presence of 2µM NIL, 
150nM DAS, 100nM PON or NDC. 6 days following treatment initiation, the cells were 
analysed by FACS after annexin V/7-AAD staining for the evaluation of apoptotic cells 
(early and late). 
Figure 4-18 illustrates that the survival of Ph- CD34+ samples was not affected by ATG7 
knock-down, as suggested by similar levels of apoptosis between the shCtrl and 
shATG7_E within the NDC arm. Furthermore, TKIs did not promote apoptosis in the Ph- 
CD34+ cells, with or without inhibition of ATG7. 
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Figure 4-18: Analysis of TKI-induced apoptosis in the presence of ATG7 knock-down in Ph-
CD34+ cells 
Transduced shCtrl and shATG7_E CD34+ cells from two non-CML donors and a CB sample were 
treated for 6 days with 2µM NIL, 150nM DAS, 100nM PON or NDC. Apoptosis (early and late) 
was measured by FACS after annexinV/Viaprobe staining. Graph represents apoptosis relative to 
NDC and numbers are presented as mean±SEM (n=3). Statistical analysis was performed by using 
paired t-test.  
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4.3.3 Analysis of Ph- committed progenitor cell potential following ATG7 
knock-down and exposure to TKIs 
In order to investigate how Ph- CD34+ cells respond under prolonged exposure to TKIs in 
the presence of ATG7 knock-down, two non-CML and one CB CD34+ samples were 
transduced with virus carrying either the shCtrl or the shATG7_E hairpin, as described in 
§2.2.8.1.2. Transduced cells were sorted and plated in methycellulose (2500 cells/1.5mL 
methycellulose, in duplicate), in the presence of 2µM NIL, 150nM DAS, 100nM PON or 
NDC.  
Data presented in Figure 4-19 demonstrate that knock-down of ATG7 did not affect the 
clonogenic ability of Ph- CD34+ cells (p=0.93 in the NDC arm). Furthermore, treatment 
with NIL, PON or DAS did not suppress the colony forming ability cells alone (p=0.2, 
p=0.13, p=0.44, respectively) or in combination with ATG7 knockdown (p=0.1, p=0.12, 
p=43, respectively).  
Overall, specific inhibition of autophagy via ATG7 knock-down did not affect the 
functionality of Ph- CD34+ stem/progenitor cells, in the absence or presence of TKI 
treatment.  
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Figure 4-19: ATG7 knock-down-mediated autophagy inhibition alone or in the presence of 
TKI treatment does not affect the clonogenic ability of Ph- CD34+ cells 
shCtrl and shATG7_E transduced Ph- CD34+ cells were transferred to semi-solid medium 
containing 2µM NIL, 150nM DAS, 100nM PON, or NDC. Colony counts were performed after 14 
days under light microscope. Numbers of colonies presented as mean±SEM. Statistical analysis 
was performed by using paired t-test. (ns; not significant) 
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4.3.4 Transcriptional analysis of key autophagy genes in Ph+ and Ph- 
CD34+ cells 
Data from experiments presented in this chapter pinpoint the importance of autophagy for 
the survival of cancer cells under steady state conditions. Cancer cells have been reported 
to have altered nutritional requirements and increased metabolic needs. This could possibly 
justify partially the addiction of CML stem/progenitor cells to basal autophagy for 
survival. Interestingly, our results suggest that inhibition of basal ATG7/autophagy levels 
specifically targets CML and not Ph- CD34+ cells.  
Single cell amplification (described at §2.2.5.4), followed by Fluidigm® analysis 
(described at §2.2.5.9), was utilised in order to investigate if there are transcriptional 
differences in autophagy under steady-state conditions between CML and non-CML 
CD34+ samples (n=3-5). mRNA expression levels were calibrated towards the house-
keeping gene GAPDH, and presented as relative fold-change compared to the non-CML 
samples (control). 
Figure 4-20 demonstrates that under normal conditions, CP CML CD34+ cells showed 
lower transcriptional levels of key autophagy genes ATG12, ATG7, BECLIN, 
GABARAPL and LC3. More specifically, ATG7 expression was approximately 3.5-fold 
reduced in CP CML CD34+ samples compared to Ph- CD34+ cells. Such observations 
have been further characterised by other members in our lab. 
These data, suggesting that CML stem/progenitor cells transcribe ATG7 and other 
autophagy genes at lower levels, could potentially explain why CML cells are more 
susceptible to ATG7 knock-down compared to non-CML cells. Reduction of ATG7 
mRNA levels by 70% within a Ph- CD34+ may not affect basal levels of autophagy; 
nevertheless, such a decrease could have a detrimental effect on a CML cell that by default 
has lower basal levels of ATG7 and/or autophagy. 
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Figure 4-20: Transcriptional analysis of key autophagy genes in Ph+ and Ph- CD34+ cells 
RNA extracted from CD34+ cells of CP CML patients and Ph- donors was analysed by Fluidigm® 
after PCR amplification (n=3-5). Graph represents mean±SEM relative autophagy genes’ mRNA 
levels in CML samples compared to non-CML samples. GAPDH was used calibrator. 
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5 Results (III): Investigation of the role of ATG7 and 
autophagy in the fate decision of leukaemic cells 
There is a crosstalk between autophagy and apoptosis, and many scientists view autophagy 
as a PCD type II. A recent study by Lee and colleagues demonstrated that ATG7 interacts 
directly with p53 during starvation, inducing p53-dependent apoptosis [287]. ATG5 is 
another autophagy protein that has been suggested to interplay with apoptosis [288].  
Autophagy is also a remodeling mechanism and it has been proposed to take part in 
mammalian differentiation from the very first stages of development, during the oocyte-to- 
embryo transition [357]. Recent studies reveal a role for autophagy proteins in the 
differentiation process of several cell types. For instance, ATG7 has been suggested to be 
an important component of the adipogenesis process [358], the terminal differentiation of 
reticulocytes to erythrocytes [359] and the differentiation of macrophages [360]. 
Additionally, ATG5 has been implicated in the hypoxia-induced osteoclastogenesis [361] 
and the differentiation of keratinocytes [362].   
Autophagy has also been proposed to play a role in the maintenance of the stem cell 
phenotype; deletion of Atg7 within the haemopoietic cell compartment in mouse models, 
lead to stem cell exhaustion, followed by anaemia and lymphopenia [355]. Furthermore, 
recent studies suggest that autophagy could affect ESCs maintenance and differentiation 
via regulation of the ATP levels within the cells [356]. 
In Chapter 4 we demonstrated that autophagy is important for the survival of primary CP 
CML CD34+ cells and its inhibition enhanced TKI-induced effects. Furthermore, 
inhibition of ATG7 and autophagy, disrupted partially the erythroid differentiation of the 
CD34+ progenitors, suggesting that autophagy plays a role in the differentiation of these 
cells. Therefore, in this chapter, we aimed to investigate the cell fate decisions of 
immortalised leukaemic cell lines upon ATG7 knock-down, and further characterise the 
role of autophagy in the survival, proliferation and differentiation of oncogene-transformed 
cells that carry additional secondary mutations.  
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5.1 Characterisation of BC CML cells following ATG7 knock-
down 
The natural history of CML progresses from the CP, which is relatively benign, through 
AP, to BC. BC is the final and fatal stage of the disease and clinically, presents similar 
features to acute leukaemia. Progression from CP to BC is associated with genetic 
instability, disrupted DNA repair, as well as altered proliferation, differentiation, and 
apoptosis (Figure 5-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1: CML development and disease progression 
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Secondary chromosomal abnormalities in BC CML include duplication of the Ph 
chromosome (38% of the patients), trisomy 8 (38% of the patients), isochromosome 17 
(20% of the patients), trisomy 19 (13% of the patients), and other less frequent changes 
[363].  Furthermore, BC is linked to the development of additional molecular changes; for 
example, 30% of the myeloid BC cases carry a p53 mutation, while almost half of the 
lymphoid BC patients have a mutation in p16/ARF. 
Unlike CP, where CML progenitor cells present only subtle defects in maturation, BC is 
characterised by a differentiation arrest. BCR-ABL has been suggested to be the driver of 
this differentiation blockade via interference with differentiation pathways, including the 
targeted activation of tissue-specific genes by transcription factors, such as the CEBPa 
[364], and p53-mediated events.   
In order to identify potential roles of autophagy in BC CML cells, the myelomonocytic BC 
cell line KCL22 and the erythromegakaryocytic BC cell line K562, were used as 
experimental models.  
 
5.1.1 Assessment of KCL22 viability following ATG7 knock-down 
KCL22 myelomonocytic BC cells carry the BCR-ABL1 e13-a2 (b2-a2) isoform, have p53 
loss-of-function, and additional cytogenetic which can include [365, 366]: 
- a hyperdiploid phenotype with 3.3% polyploidy (- 51(47-51)<2n>X, -X, +1, +6, +8, +8, 
+14, +22)  
- del(1)(p22) 
- t(9;22)(q34;q11) 
- add(17)(p12-13) 
- i(21q) 
- der(22)t(9;22)(q34;q11)  
 
KCL22 cells were transduced every 12h with DMEM+ virus-containing medium for a total 
of 36h, as described in §2.2.8.1.2. Transduced cells were sorted 48h after the last 
transduction round, based on the expression of the GFP marker, and cultured in RPMI+. 
In order to assess cell viability 4 days post-sort, cells were stained with DAPI and analysed 
by FACS.  
Figure 5-2 demonstrates that the viability of KCL22 cells transduced with the shATG7_E 
hairpin was severely affected by ATG7 knock-down compared to the shCtrl (p=0.004). 
Depriving the cells from ATG7 for ~96h had such a severe impact on the cells that 100% 
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of them died. On the other hand, shCtrl cells’ viability was not affected, suggesting that the 
enhanced cell death in the ATG7 knock-down cells was not attributed to GFP expression 
or transduction-associated toxicity.  
This experiment was repeated for a total of n=5; in all cases, the ATG7 knock-down 
population died within 4-5 days following sorting, demonstrating the indispensible role of 
ATG7 and autophagy for the survival of KCL22 cells. Hence, further characterisation was 
impossible.  
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Figure 5-2: Cell death analysis in KCL22 cells upon ATG7 knock-down 
KCLL22 cells were lentivirally transduced with a pLKO.1-GFP vector, carrying either a mock 
(shCtrl) or an ATG7-targeting hairpin (shATG7_E). GFP+ cells were sorted in order to obtain 
homogenous populations of transduced cells. 96h post-sort, cells were stained with DAPI and cell 
death was measured by FACS analysis. (A) Graph represents cell death levels as mean±SEM 
(n=3). (B) Representative DAPI/FSC (forward side scatter) plot after FACS analysis of shCtrl and 
shATG7_E cells; gates depict live cell percentages. Statistical analysis was performed by using 
paired t-test. (**; p≤0.01) 
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5.1.2 Characterisation of K562 cells following ATG7 knock-down 
K562 erythromegakaryocytic BC cells carry the BCR-ABL1 e14-a2 (b3-a2) fusion gene, 
have a p53 loss-of-function, and additional cytogenetic alterations that may include [367, 
368]: 
- 61-68<3n>XX 
- -X, -3, +7, -13, -18, +3mar 
- del(9)(p11/13) 
- der(14)t(14;?)(p11;?) 
- der(17)t(17;?)(p11/13;?) 
- der(?18)t(15;?18)(q21;?q12) 
- del(X)(p22) 
 
K562 cells were transduced with shCtrl or shATG7_E, as described in §2.2.8.1.2, and 
GFP+ cells were sorted 48h after the last transduction round.  
4 days post-sort, lysates from whole cells were prepared for the measurement of ATG7 
knock-down. Western blot analysis revealed a ≥60% reduction in ATG7 protein levels in 
the shATG7_E cells (Figure 5-3A). 
However, immunofluorescence analysis revealed that the formation of LC3-positive 
punctae was not completed inhibited, possibly suggesting the presence of residual 
autophagic activity (Figure 5-3B). Furthermore, accumulation of LC3II was observed 4 
weeks following ATG7 knock-down (Figure 5-3C). A potential explanation for this 
observation could be that the 30-40% of the remaining ATG7 protein is processing 
partially the lipidation of LC3 but it is not sufficient to allow for the completion of the 
autophagosome. Hence, incomplete autophagosomes may still form, and since the 
autophagic process is inhibited, they cannot be degraded and recycled. Hence lipidated 
LC3II could accumulate within the cells in a time-dependent manner. 
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Figure 5-3: ATG7 and LC3 monitoring in K562 cells that stably express an ATG7-targeting 
hairpin carried by pLKO.1 vector 
(A) Western blot was used for the analysis of ATG7 protein levels in shATG7_E-transduced K562 
cells. Densitometry calculations for data shown were performed by using the Quantity One 
software. The graph represents relative ATG7 levels (normalised to β-tubulin) compared to the 
shCtrl. (B) Immunofluorescence imaging on transduced K562 cells 4 days following sorting. Cells 
were stained with primary anti-LC3B antibody and secondary PE/Texas Red-fluorochrome 
conjugated antibody. Captions presented at 200X magnification, DAPI used for nuclei staining. (C) 
Western blot was used for the analysis of ATG7 and LC3 protein levels in shATG7_E-transduced 
K562 cells 4 weeks following sorting.  
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5.1.2.1 Assessment of K562 proliferation and cell viability following ATG7 knock-
down 
Proliferation of K562 cells transduced with either shCtrl or shATG7_E hairpin was 
assessed by performing cell counts every 24h following sorting. Cell viability was 
established by using the trypan blue exclusion method. 
Figure 5-4A demonstrates that cells with ATG7 knock-down had a strong anti-proliferative 
effect on K562 cells and shATG7_E cells presented significantly suppressed proliferation 
compared to the shCtrl (p=0.0005 at 25h, p=0.03 at 48h, p=0.008 at 72h). Furthermore, it 
was observed that the number of viable shATG7_E cells was decreased below the number 
of input cells, suggesting that ATG7 knock-down had a cytotoxic effect.  
The anti-proliferative/cytotoxic effect of ATG7 knock-down was further validated by the 
CellTiter-Glo® luminescence assay that detects metabolically active cells based on 
quantitation of the ATP present, which is directly proportional to the number of cells 
present in culture (described at §2.2.1.2.2) (Figure 5-4B). 
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Figure 5-4: Analysis of K562 cell proliferation upon ATG7 knock-down  
Cell proliferation was measured in shCtrl and shATG7_E cells by (A) cell counts (n=3) and (B) 
CellTiter-Glo® luminescence assay (n=2), every 24h post-sort, for a total of 72h. Graph values 
refer to viable cells (verified by trypan blue) and are presented as mean±SEM (n=3) relative to 
input. Statistical analysis was performed by using paired t-test. Annotation above a bar refers to 
statistical significance between the bar and the NDC. (*; p≤0.05, **; p≤0.01, ***; p≤0.001) 
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6 days post-sort, shCtrl and shATG7_E cells were stained with DAPI and analysed by 
FACS.  
Figure 5-5 reveals that induction of cell death correlated with ATG7 knock-down; while 
cell death rates in shCtrl cells were low (6.03±4.05%), shATG7_E cells presented a ≥10-
fold increase in death levels (68.56±11.47%, p=0.004 versus shCtrl). 
Overall, these data imply that ATG7 autophagy plays a vital role in the cellular integrity 
and survival of the K562 cells. 
 
  
  213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5: Cell death analysis in K562 cells upon ATG7 knock-down 
K562 cells were lentivirally transduced with a pLKO.1-GFP vector, carrying either a mock (shCtrl) 
or an ATG7-targeting hairpin (shATG7_E). GFP+ cells were sorted in order to obtain homogenous 
populations of transduced cells. 6 days post-sort, cells were stained with DAPI and cell death was 
measured by FACS analysis. Graph represents cell death levels as mean±SEM (n=3). Statistical 
analysis was performed by using paired t-test. (**; p≤0.01) 
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5.1.2.2 Effect of ATG7 knock-down in the erythroid differentiation of K562 cells 
and their mitochondrial potential 
K562 cells are bipotential and, after stimulation with a range of reagents, can be 
differentiated into cells with erythroid or megakaryocytic properties [369].  For example, 
treatment with hemin [370, 371], cytosine arabinoside [372], butyric acid [373] or AZA 
[374], induces erythroid differentiation while treatment with phorbol 12-myristate 13-
acetate (PMA) promotes megakaryocytic differentiation.  
According to data described in §5.1.2.1, the proliferation of K562 cells upon ATG7 knock-
down was severely disrupted during the first 72h following sorting and cell death was 
significantly increased. In order to explore the fate pathway of the remaining viable 
population of shATG7_E cells, cell counts were performed every 2 days so as to monitor 
the proliferation ability. Cell viability was assessed by the trypan blue exclusion method.  
Figure 5-6A demonstrates that shATG7_E cell population failed to efficiently expand up to 
10 days post-sort. Nevertheless, proliferation ability was restored afterwards. Interestingly, 
the ATG7 knock-down surviving population presented increased haemoglobin production 
compared to the shCtrl cells.  
The next question that arose was if increased haemoglobin production was associated with 
erythroid differentiation. Glycophorin A (GlyA) or CD235a (cluster of differentiation 
235a), is the major intrinsic sialoglycoprotein of the human erythrocyte and erythroid 
precursors membrane. Anti-GlyA antibodies have been used extensively in the 
characterisation of erythroid cell development and in the diagnosis of erythroid 
leukaemias. In order to explore if the ATG7 knock-down surviving K562 cells presented 
erythroid differentiation features, cells were stained with an anti-GlyA antibody (BD, PN 
555570) and analysed by FACS.  
As illustrated in Figure 5-6B, the FACS profile analysis of the shATG7_E cells revealed 
high levels of GlyA expression compared to the shCtrl. This increase in GlyA expression 
was not attributed to a corresponding increase in the size of shATG7_E cells (and 
therefore, cell membrane surface area) (Figure 5-6C). 
Taken altogether, these findings suggested that K562 cells that survived prolonged ATG7 
knock-down presented with a more differentiated phenotype.  
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Figure 5-6: Analysis of the erythroid differentiation potential of K562 cells upon ATG7 
knock-down 
(A) Cell proliferation was measured within the shATG7_E population by cell counts performed 
every 2 days, for the total of 12 days post-sort. Graph values refer to viable cells (verified by trypan 
blue) and are presented as mean±SEM (n=3) relative to input.  FACS analysis profile on the 
shATG7_E cells 12 days post-sort, regarding (B) GlyA expression and (C) cell size. 
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In order to examine the morphology of these cells, the "Diff-Quik" staining kit (DADE 
Behring, PN130832) was used according to the protocol described at §2.2.10.  
As depicted in Figure 5-7A, shCtrl and shATG7_E cells 12 days post-sort were not 
presenting significant morphological differences, despite the fact that shATG7_E cells 
expressed high levels of GlyA. Nonetheless, this could be attributed to the fact that 
inhibition of autophagy does not allow for terminal differentiation of reticulocytes. In a 
study published by Zhang and colleagues in 2009, it was reported that in the absence of 
ATG7, reticulocyte clearance of mitochondria was suppressed but not completely 
abolished [375]. Hence, it is likely that shATG7_E cells would not be able to undergo 
terminal differentiation due to suppressed mitophagy. 
In order to investigate this further, shCtrl and shATG7_E K562 cells were stained with 
MitoTracker® Red CMXRos (Invitrogen, PN M7512). This reduced probe does not 
fluoresce until it enters live cells, where it is oxidised and sequestered in functional 
mitochondria and starts emitting red fluorescence. The oxidised dye emits red fluorescence 
and can be detected by FACS analysis (emission maxima ~599nm).  
Figure 5-7B demonstrates that shATG7_E cells presented ~80% more functional 
mitochondria compared to the shCtrl (p=0.005). This is in agreement with other studies 
where knock-down of autophagy genes results to increased number of mitochondria due to 
suppression of autophagy [376].  
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Figure 5-7: Analysis of the morphology and the mitochondrial profile of K562 cells upon 
ATG7 knock-down 
K562 shCtrl and shATG7_E cells were stained 12 days post-sort with the "Diff-Quik" staining kit 
and examined morphologically under a light microscope. Representative captions of n=3 are 
presented at 400X magnification. (B) shCtrl and shATG7_E K562 cells were stained with 
MitoTracker® Red CMXRos and analysed by FACS for the quantification of functional 
mitochondria. Graph presents MitoTracker® levels relative to shCtrl as mean±SEM (n=3). 
Statistical analysis was performed by using paired t-test. (**; p≤0.01) 
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5.1.2.3 Effect of ATG7 knock-down in the megakaryocytic differentiation of K562 
cells and the levels of ROS 
K562 cells can differentiate either into erythroid cells or megakaryocytes. In order to 
explore if ATG7 knock-down promotes differentiation only towards the erythroid and not 
the megakaryocytic line, shATG7_E cells were maintained in culture for a total of 30 days 
post-sort and monitored frequently for the presence of megakaryocytic features. 
Progressively, shATG7_E cells proliferated with rates comparable to non-transduced K562 
and had increased cell size compared to the shCtrl cells. Moreover, cells within the 
shATG7_E arm appeared to attach on the plastic surface of the flask used for culture. 
Cytospin and staining with “Diff-Quik” revealed that a fraction of the cells presented 
morphologically megakaryocytic features including an apparent increase in cell size, 
multilobed nuclei, cytoplasmic blebs/pseudopods (Figure 5-8).  
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Figure 5-8: Analysis of the morphology K562 cells surviving prolonged ATG7 knock-down 
K562 shCtrl and shATG7_E cells were stained 30 days post-sort with the "Diff-Quik" staining kit 
and examined morphologically under light microscope. Representative captions on n=3 are 
presented at 200X magnification. Arrows point representative cells with meagakaryocytic features. 
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According to a study performed by Sardina and colleagues (2010), ROS production was 
required for the PMA-induced megakaryocytic differentiation of K562 cells [377]. During 
megakaryocytic differentiation ROS was transiently increased and its inhibition by 
antioxidants hindered differentiation. On the other hand autophagy/mitophagy inhibition 
has been suggested to lead to increased levels of ROS due to the accumulation of damaged 
mitochondria and the production of superoxide. Therefore, the next experiment aimed to 
measure the levels of superoxide produced by mitochondria in the shCtrl and shATG7_E 
populations that presented megakaryocytic features.  
shCtrl and shATG7_E cells were stained with MitoSOX™ Red (Invitrogen, PN M36008), 
according to the protocol described at §2.2.2.6. This reagent enters live cells and 
selectively localises to mitochondria where it is oxidised by superoxide but not by other 
ROS and reactive nitrogen species. As illustrated in Figure 5-9, shATG7_E cells presented 
almost 2-fold increased superoxide levels compared to the shCtrl (p=0.01).  
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Figure 5-9: Measurement of superoxide levels within K562 cells surviving prolonged ATG7 
knock-down 
30 days post-sort, shCtrl and shATG7_E K562 cells were stained with MitoSOX® Red and 
analysed by FACS for the quantification of superoxide levels. Graph presents MitoSOXTM levels 
relative to shCtrl as mean±SEM (n=3). Statistical analysis was performed by using paired t-test. 
(**; p≤0.01)   
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5.1.2.4 Investigation of ATG7 knock-down in erythroid and megakaryocytic 
differentiation at the single cell level  
In experiments described previously, 2 weeks following ATG7 knock-down K562 cells 
showed erythroid features and another 2 weeks later, a fraction of the population had 
megakaryocytic phenotype. The experiment described herein was designed in order to 
investigate: 
 i) if ATG7 knock-down “selects” for more differentiated cells within the initial culture or 
is the driver of the observed differentiation  
ii) if cells with megakaryocyte features were present in the culture 2 weeks following 
knock-down or developed at a later stage.  
K562 cells were transduced with shCtrl or shATG7_E virus, as described in §2.2.8.1.2. 
Transduced shCtrl and shATG7_E single cells were sorted 48h after the last transduction 
round into 96-well plates. The ability of each single cell to proliferate and initiate a culture 
in liquid medium was monitored frequently.  
10 days after sorting, shCtrl single cells had proliferated and initiated clones of >50 cells. 
Nevertheless, the shATG7_E cells did not appear to proliferate by that time. Since shCtrl 
cells were proliferating fast, each clone was isolated, washed and transferred in a well of a 
24-well plate for further examination.  
16-20 days following sorting, shATG7_E clones appeared in the knock-down arm. 
Nevertheless, as demonstrated in Figure 5-10A, the number of single cells that managed to 
proliferate and form clones in the shATG7_E arm was significantly lower compared to the 
shCtrl arm (p=0.002). Furthermore, in the shATG7_E arm, all clones presented either 
erythroid or megakaryocytic differentiation features. Erythroid clones consisted of >1000 
cells while all megakaryocytic clones contained 10-100 cells (Figure 5-10B). This 
difference in proliferation kinetics could explain why upon ATG7 knock-down, the cells 
with erythroid features appear first in the culture and the appearance of cells with 
megakaryocytic features is more delayed.  
Interestingly, none of the shCtrl isolated clones presented features of differentiation. This 
implies that ATG7 knock-down promoted the differentiation rather than selected for more 
differentiated cells in the initial culture. If this were the case, then differentiated clones 
should also be equally represented in the shCtrl arm. 
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Figure 5-10: Analysis of clone-initiating potential of single-sorted ATG7 knock-down K562 
cells  
shCtrl and shATG7_E single cells were sorted into a 96-well plate (n=3) and 20 days later, the 
wells were scored for the presence of cell clones. (A) The graph presents the per cent of sorted 
single cells that formed clones, relative to the shCtrl as mean±SEM (n=3). Statistical analysis was 
performed by using paired t-test. (**; p≤0.01). (B) Captions of the shCtrl and shATG7_E clones 
were examined under light microscope for the estimation of relative cell numbers within each 
clone.  
A B 
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To summarise, our experiments underline the significance of ATG7 in the cell fate 
decision of the K562 cell line. It was demonstrated that dependence on ATG7 for K562 
cell survival is strong, leading the majority of the population to cell death.  
Moreover, cells that evaded cell death upon ATG7 knock-down, presented a more 
differentiated phenotype. Failure of these cells to terminally differentiate could potentially 
be attributed to inhibition of autophagy and blockade of this “cell make-over” process. 
Nevertheless, our data are inconclusive in answering if ATG7 resolves the differentiation 
block within these blast cells rather than directly promoting differentiation.  
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5.2 Characterisation of CLL cells following ATG7 knock-down 
In order to explore if ATG7 is also playing a role in the cell fate decision of other 
transformed human leukaemic cells, the recently isolated CLL cell line HG3 was 
investigated. The HG3 cell line is a lymphoblastoid cell line with B1 cell characteristics. It 
was established from a CLL clone of a 70-year old man by in vitro Epstein-Barr virus 
infection, and it carries a biallelic chromosome 13q14 deletion, including the loss of 
DLEU7 and miR15a/16–1 [378]. 
HG3 cells were transduced with shCtrl or shATG7_E virus, as described in §2.2.8.1.2. 
GFP+ transduced cells were sorted 48h after the last transduction round and cultured in 
RPMI+. Western blot analysis on lysates from HG3 shCtrl and shATG7_E cells 4 days 
post-sort, revealed ≥50% reduction in ATG7 protein levels in the shATG7_E cells (Figure 
5-11). 
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Figure 5-11: Measurement of ATG7 protein levels in HG3 cells that stably express an ATG7-
targeting hairpin carried by pLKO.1 vector 
Western blot was used for the analysis of ATG7 protein levels in HG3 cells 4 days post-sort. 
Densitometry calculations for data shown were performed by using the Quantity One software. The 
graph represents relative ATG7 levels (normalised to β-tubulin) compared to the shCtrl.  
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5.2.1 Assessment of HG3 proliferation and cell viability following ATG7 
knock-down 
Proliferation of HG3 cells transduced with either shCtrl or shATG7_E hairpin, was 
assessed by performing cell counts every 24h after sorting. Cell viability was established 
by using the trypan blue exclusion method. 
Figure 5-12A illustrates that ATG7 knock-down significantly suppressed the proliferation 
of the HG3 cells compared to the shCtrl (p=0.018 at 24h, p=0.013 at 48h and p=0.0008 at 
72h). This was further validated by the CellTiter-Glo® luminescence assay (described at 
§2.2.1.2.2) that detects metabolically active cells based on quantitation of the ATP present, 
which is directly proportional to the number of cells present in culture (n=2) (Figure 5-
12B). 
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Figure 5-12: Analysis of HG3 cell proliferation upon ATG7 knock-down  
Cell proliferation was measured in shCtrl and shATG7_E cells by (A) cell counts (n=3) and (B) 
CellTiter-Glo® luminescence assay (n=2), every 24h post-sort, for a total of 72h. Graph values 
refer to viable cells (verified by trypan blue) and are presented as mean±SEM (n=3) relative to 
input. Statistical analysis was performed by using paired t-test. Annotation above a bar refers to 
statistical significance between the bar and the relative shCtrl. (*; p≤0.05, **; p≤0.01, ***; 
p≤0.001) 
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6 days post-sort, shCtrl and shATG7_E HG3 cells were stained with DAPI and analysed 
by FACS.  
Data presented in Figure 5-13 revealed that induction of cell death correlated with ATG7 
knock-down; while cell death rates in shCtrl cells were relatively low (26.63±8.79%), 
shATG7_E cells presented a ≥2-fold increase in death levels (68.50±4.23%, p=0.01). 
These data imply that autophagy plays a role in the survival of the HG3 lymphoblastoid 
cells.  
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Figure 5-13: Cell death analysis in HG3 cells upon ATG7 knock-down 
HG3 cells were lentivirally transduced with a pLKO.1-GFP vector, carrying either a mock (shCtrl) 
or an ATG7-targeting hairpin (shATG7_E). GFP+ cells were sorted in order to obtain homogenous 
populations of transduced cells. 6 days post-sort, cells were stained with DAPI and cell death was 
measured by FACS analysis. Graph presents cell death levels as mean±SEM (n=3). Statistical 
analysis was performed by using paired t-test. (**; p≤0.01) 
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5.2.2 Effect of ATG7 knock-down in the differentiation of HG3 cells 
HG3 that survived ATG7 knock-down were monitored frequently for the identification of 
morphological changes. Analysis by FACS revealed that shATG7_E HG3 cells that 
survived >10 days of ATG7 knock-down had increased cell size (Figure 5-14). 
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Figure 5-14: Increase in the cell size of HG3 cells upon ATG7 knock-down 
The geometrical mean of the FSC (forward side scatter) of shCtrl and shATG7_E cells was 
measured by FACS analysis 10 days post-sort. (A) The graph represents cell size relative to shCtrl 
as mean±SEM (n=3). (B) A representative FACS plot overlay of the FSC within shCtrl and 
shATG7_E cells. Statistical analysis was performed by using paired t-test. (*; p≤0.05) 
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Interestingly, ATG7 knock-down presented altered features compared to the control in 
liquid culture. Unlike HG3 WT or shCtrl-transduced cells that grow in clusters, HG3 
shATG7_E cells were growing as single cells (Figure 5-15A).  
In order to further investigate the morphology of the cells, shCtrl and shATG7_E HG3 
cells were adhered onto a slide and stained with the "Diff-Quik" kit. Figure 5-15B 
demonstrates that shCtrl and shATG7_E cells 15 days post-sort were presenting significant 
morphological differences. HG3 cells in the absence of ATG7 presented a clear increase in 
cell size, high proliferation rate (increased number of cells in mitosis in a single field), 
cytoplasmic blebs/pseudopods and prominent Golgi apparatus.  
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Figure 5-15: Morphological analysis of HG3 cells surviving ATG7 knock-down 
(A) HG3 shCtrl and shATG7_E cells 15-20 days post-sort presented different culture features after 
examination under light microscope. (B) Cell aliquots from these cultures were stained with the 
"Diff-Quik" staining kit and examined morphologically under light microscope. Black arrows point 
at representative cells with cytoplasmic blebs/pseudopods and prominent Golgi apparatus. Blue 
arrow points at a representative cell undergoing mitosis. Representative captions on n=3 are 
presented at 200X magnification. 
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Taken altogether, upon ATG7 knock-down the viability of the majority of HG3 cells was 
severely affected and approximately 70% of the population died within 6 days following 
sorting. However, the remaining shATG7_E cells that survived presented significantly 
altered phenotype regarding morphology and cell-cell adhesion habits in culture.   
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5.3 Effect of Atg7 knock-down in mouse c-kit enriched 
MLL-ENL transformed cells 
Previous experiments have demonstrated that ATG7 plays an important role in cell fate 
decisions of human CML and CLL cells. In order to further investigate how ATG7 knock-
down affects the cell fate of AML mouse cells, c-kit enriched mouse bone marrow cells 
transformed with the oncogene MLL-ENL were used.  
Mouse c-kit enriched MLL-ENL transformed cells were infected with a lentiviral system 
based on a pLKO.1 vector that encoded for the puromycin resistance gene and carried 
either an Atg7-targeting hairpin (shAtg7) or a mock hairpin (shCtrl). Following three 
rounds of transduction, cells were washed and cultured in IMDM supplemented with 10 
ng/ml of mIL3. Selection of transduced cells was initiated 48h after the last transduction 
round, by adding PURO (1µg/mL) in the culture. After 3 days of antibiotic selection, 
PURO was washed out, and the cells were examined under the light microscope.  
Figure 5-16A demonstrates that by the end of the selection process, Atg7 knock-down cells 
presented increased numbers of dead cells (viewed as condensed cellular debris). The 
shAtg7 population was maintained in culture for another 3 days, so as to allow for 
expansion of the live cells, and analysed by FACS after DAPI staining.  
Analysis 3 days post-selection termination revealed that all shAtg7 cells were dead, unlike 
the shCtrl cells that presented high viability (approx. 70%). Assuming equal efficacy of 
transduction between the shCtrl and shAtg7 virions, the complete eradication of the shAtg7 
cells was attributed to knock-down of Atg7. 
Overall, these data are in agreement with previously observed effects on human leukaemic 
cell lines. Viability of the mouse c-kit enriched MLL-ENL cells was completely ablated 
upon deprivation of the cells from the Atg7 protein and no cells survived in order to 
experiment further.  
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Figure 5-16: Cell death analysis in mouse c-kit enriched MLL-ENL transformed cells upon 
Atg7 knock-down 
Mouse c-kit enriched MLL-ENL transformed cells were lentivirally infected with a pLKO.1-PURO 
vector, carrying either a mock (shCtrl) or an Atg7-targeting hairpin (shAtg7). Infected cells were 
selected in PURO for 3 days at the end of the selection the cells were examined under a light 
microscope (captions at 200X) (A). 3 days post-selection, cells were stained with DAPI and cell 
death was measured by FACS analysis. FSC/DAPI plots are representative of n=2 and gate 
percentages refer to live cells.  
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6 Discussion 
The development of IM in the 1990s opened a new era in cancer cell targeted therapy; this 
2-phenylaminopyrimidine was the product of rational drug design, identified by high-
throughput screening and modified in order to inhibit the activity of the constitutively 
active BCR-ABL tyrosine kinase, the product of the chimeric BCR-ABL oncogene located 
on the Ph [379]. The 6-year follow-up data from the phase III IRIS study highlighted the 
clinical superiority of IM versus the combination of IFNα with cytarabine, which was used 
at that time as standard treatment [161]. Standard dose IM was associated with an EFS of 
83% and 93% estimated rate of freedom from progression to AP and BC, while the EOS 
was 88% (95% when only CML-related deaths were taken into account). The estimated 
cumulative rate of complete CyR for IM-treated patients was approximately 82%. Since 
then, IM has served as the frontline therapy for patients with newly diagnosed CP CML. 
However, it was observed that almost a quarter of the newly diagnosed CP patients on IM 
did not achieve complete CyR within the first 18 months of treatment. Interestingly, it has 
been reported that CML patients achieving complete CyR within the first two years of 
treatment have a favourable long-term outcome and a life expectancy comparable to the 
general population [380]. Another limitation of IM treatment was the restricted number of 
patients that achieve CMR and have undetectable BCR-ABL mRNA levels [166]. 
Furthermore, IM was not effective in advanced disease stages and any response to 
treatment was only transient [381]. Ultimately, the development of resistance was shown to 
be the Achilles’ heel of IM.  
So far, a plethora of mechanisms have been reported to lead to IM resistance, either BCR-
ABL-dependent (such as kinase domain mutations or BCR-ABL overexpression) or BCR-
ABL-independent (such as secondary mutations, drug delivery defects, and compliance 
issues). In an effort to override resistance, IM dose escalation (up to 800mg/day) was 
investigated in CML patients previously treated with 400mg/day that had relapsed or 
developed resistance [212, 213]. Unfortunately, even if responses were moderately 
improved, IM dose escalation was not sufficient to eliminate the issue of resistance. In 
order to tackle IM resistance, 2nd generation TKIs, DAS and NIL, were designed. 
DAS, a potent TKI that targets ABL kinases and SFKs, had in vitro high affinity for BCR-
ABL mutants refractory to IM. Likewise, NIL was demonstrated to be more potent than 
IM, targeting BCR-ABL conformations inaccessible to IM. Most importantly, both of these 
TKIs were superior to IM in the clinic; the DASISION clinical trial demonstrated in vivo 
that DAS is more efficacious over IM, while the ENESTnd trial illustrated that NIL was 
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associated with better responses compared to standard dose IM. However, both DAS and 
NIL were ineffective in targeting the gatekeeper T315I mutation [216, 222].  
Nevertheless, the major problem of all the above mentioned TKIs, and the reason why they 
fail to cure CML patients, is disease persistence. Two independent studies, the STIM [171] 
and the Australian group [172], demonstrated that discontinuation of IM in CMR patients 
led rapidly to relapse due to MRD. In vitro CML CD34+ can survive very high IM 
concentrations, indicating that LSCs are inherently refractory [173]. Additionally, this IM-
resistant fraction of LSCs that can replenish disease was not targeted by either DAS [221] 
or NIL [226]. At this point it should be highlighted that development of TKI resistance and 
molecular persistence is not always attributed to inaccessibility of BCR-ABL. For instance, 
the presence of BCR-ABL mutants does not always explain clinical resistance to IM [382], 
and CML patient cells resistant in vitro to TKIs may carry native, unmutated BCR-ABL 
[221].  
In 2011, Corbin and colleagues provided evidence suggesting that CML LT-HSCs and ST-
HSCs are not eradicated by IM treatment despite complete inhibition of BCR-ABL activity 
[234]. A few months later, a published study by our lab further validated these 
observations [235]. CML patient-derived CD34+ cells were lentivirally transduced in order 
to knock-down BCR-ABL. A fraction of these LSCs managed to escape cell death despite 
inhibition of BCR-ABL activity, even after DAS treatment and withdrawal of GFs. This 
observation was of great interest; it implied that the LSCs can override almost complete 
removal of internal (BCR-ABL) and external (GFs in culture medium) survival stimuli, 
and activate alternative pathways for evading cell death. Interestingly, this cell population 
was enriched for primitive leukemic cells that had LTC-IC potential.  
Taken together, these studies underlined that the leukaemia-initiating/repopulating TKI-
refractory fraction of LSCs does not depend on BCR-ABL for survival. Hence, it became 
clear that no TKI treatment would be effective in eradicating these cells, offering a curative 
option to CML patients. Based on such observations, scientists within the field of CML 
treatment research are trying to identify the BCR-ABL-independent alternative pathways 
that the LSC fraction is relying on for survival upon suppression of BCR-ABL signaling. 
Towards this direction, currently on-going clinical trials are evaluating the efficacy of 
single agents for the elimination of MRD in CML; examples include zileuton, panobinostat 
and BMS-833923, which are targeting fatty acid metabolism, histone acetylation and WNT 
signaling, respectively.  
On the other hand, high levels of BCR-ABL oncoprotein within CML CD34+ cells have 
been associated with disease progression and development of resistance [383]. This may 
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not be associated with BCR-ABL amplification since primitive CML HSCs have been 
reported to transcribe BCR-ABL at high levels despite the presence of a single gene copy 
[384]. It should also be highlighted that TKIs induce in general good responses during CP 
and, even if they do not eradicate the most primitive population of LSCs, they have a 
significant effect on more differentiated CML cells. Therefore, even if the above 
mentioned clinical trials reveal that non-BCR-ABL targeting single agents have a 
significant effect on the survival of LSCs, it is unlikely that they will be preferred as a first-
line treatment option over TKIs.  
An approach in developing a therapeutic strategy that (i) would have a stronger efficacy 
against refractory LSCs than TKIs alone, and (ii) could be used as first-line treatment, 
would be to combine TKIs with agents that target secondary pathways that are vital for the 
survival of LSCs. The success of such an approach would rely on the identification of 
appropriate targets within the primitive CML stem cells.  
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6.1 Autophagy in cancer 
Autophagy occurs at basal levels in the majority of mammalian cells, functioning as a 
quality control mechanism, maintaining homeostasis via the degradation of cytoplasmic 
contents, including damaged organelles and misfolded proteins. Nonetheless, under 
starvation or other stressful conditions, autophagy is induced as a survival mechanism in 
the cells in order to (i) sustain metabolism by breaking-down intracellular components and 
supplying the cells with building blocks to be used in energy replenishing pathways, and 
(ii) to remove damaged organelles and proteins generated under such stressful conditions.  
Autophagy has a paradoxical role in cancer, functioning as a tumour suppressor or 
promoter depending on the context. Mice genetically modified so as to have defective 
autophagy in their whole body or specific tissues have been reported to be susceptible to 
pathogen infection [385], muscle damage [386], neurodegeneration [387] and chronic 
inflammation, that can eventually lead to development of cancer [388]. In humans, defects 
in autophagy genes have been associated with the development of various pathologic 
conditions, including cancer. For example, haploinsufficiency in BECLIN [389] has been 
associated with tumourigenesis, and frameshift mutations in ATG2B, ATG5, ATG9B and 
ATG12 have been identified in gastric and colorectal cancers [390]. Nevertheless, it is not 
always clear if the defective phenotype is attributed to gene-specific autophagy-
independent functions or dysfunctional autophagy. UVRAG monoallelic mutations have 
been reported in almost a third of colon cancers; however, these mutations do not appear to 
have an effect on autophagy [391]. At this point it should be mentioned that UVRAG has 
also been reported to have extra-autophagic roles, taking part in membrane trafficking and 
regulation of endocytosis along with BECLIN [392]. Hence, caution must be taken when 
interpreting loss-of-function studies on autophagy genes and the role of autophagy in 
cancer, because these observations may be due to other functions of these genes.  
Nonetheless, defects in proteins that interplay with autophagy have also been linked to 
development of cancer and other diseases. For example, increased p62 levels have been 
associated with cancer development [393], and loss-of-function mutations in the PTEN-
induced putative kinase 1 (PINK1) or the E3 ligase parkin (PARK2) have been identified 
in Parkinson’s disease [394]. Interestingly, deletion of Park2 in mice has been reported to 
cause hepatocellular carcinoma that phenocopies loss of Beclin [296].   
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On the other hand, an increasing number of studies has highlighted that autophagy supports 
cancer cell survival. During the first steps in the process of tumour establishment, cancer 
cells have to overcome stress-inducing factors, such as hypoxia and limited nutrients, due 
to insufficient blood supply [395]. In 2006, Degenhardt and colleagues demonstrated that 
autophagy is induced in hypoxic tumour regions and is required for tumour cell survival, 
and inhibition of inflammation and metabolic crisis-induced necrosis [396]. Apoptosis-
defective cancer cells seem to rely on autophagy for evading necrosis [397]. 
Cancer cells have been reported to have high basal autophagy levels even under optimal 
conditions, suggesting that they may be autophagy-addicted [307, 311]. It has been 
reported that activation of oncogenic signals induces autophagy; for instance, activation of 
RAS at levels sufficient to induce tumourigenesis, leads to increased levels of basal 
autophagy. RAS-driven cancers require autophagy in order to induce/maintain 
transformation, and autophagy deficiency abolishes tumourigenesis [309, 310]. 
Mitochondria play a key role in cancer cells by supplying ATP and building blocks for 
other pathways (such as citrate for fatty acid synthesis). High levels of autophagy may be 
required in order to sustain increased mitochondrial metabolism within cancer cells.  
It has been suggested that pharmacological inhibition of autophagy facilitates the apoptotic 
effect of anticancer therapies such as irradiation, alkylating agents, and various targeted 
anticancer agents [398, 399]. Based on similar observations, where autophagy appears to 
support the survival of established cancer cells, recent clinical trials have investigated the 
effect of chemotherapeutic agents in combination with CQ/HCQ-mediated autophagy 
inhibition in a wide range of cancer types including breast, colorectal, lung, pancreatic, 
prostate cancer, as well as glioblastoma [318].  
Nevertheless, excessive autophagy can also lead to cell death, and there are studies 
suggesting that autophagy is required in order to allow for cell death in apoptosis-deficient 
cells [400, 401]. For example, RAPA-induced autophagy has been demonstrated to 
enhance radiation-mediated cell death in PTEN-defective prostate cancer cells [402]. 
Taken together, the role of autophagy and autophagy genes in the development of cancer 
still remains unclear. Autophagy appears to play different roles in different tissues, cancer 
types, and disease stages. Therefore, caution should be taken when deciding upon the 
modulation of the autophagic activity for the improvement of cancer treatment. 
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6.2 Is autophagy a survival factor for CML? 
In 2007, Ertmer and colleagues first reported that IM induces autophagy in a dose-
dependent manner, regardless of cell type or species [403]. A couple of months later, 
Carew and colleagues suggested that the HDAC inhibitor SAHA, among its other 
biological effects, induces autophagy in CML TKI-resistant cells [320]. Pharmacological 
inhibition of the SAHA-induced autophagy enhanced the anticancer efficacy of the drug, 
implying that autophagy may play a cytoprotective role in CML. In agreement with this 
observation, Mishima and colleagues reported that IM induces cytoprotective autophagy in 
CML cell lines [322]. 
However, in 2009, as part of a collaborative effort, our lab published the most rigorous 
evidence demonstrating induction of protective autophagy upon TKI treatment of CML 
cells [323]. Bellodi and colleagues aimed to investigate if TKI-mediated inhibition of 
BCR-ABL signaling, apart from inducing apoptosis, potentially has an effect on 
autophagy. As described in Chapter 1, the BCR-ABL oncoprotein is mimicking GF 
signaling, allowing the cells to survive and proliferate in the absence of extracellular GFs. 
By that time, a series of reports had already demonstrated that GF removal could lead to 
cellular autophagy in order to support survival [404-406]. On the basis of these 
observations, the authors hypothesised that a sudden withdrawal of the BCR-ABL GF 
mimicking signals could potentially induce cytoprotective autophagy.  
First of all, the authors demonstrated that treatment with 2µM IM induced LC3 lipidation 
and accumulation of LC3-positive punctae in K562 cells. Likewise, 1µM IM induced 
autophagy in 32D cells transformed with native BCR-ABLp210 (murine IL-3-independent 
myeloid cell line). The observed IM-mediated autophagic increase was attributed to 
suppression of survival signals upon BCR-ABL inhibition since addition of IL-3 to the 
culture disrupted IM-induced autophagy. Most importantly, IM-induced autophagy was 
observed only upon BCR-ABL inhibition; IM treatment did not induce autophagy in 32D 
cells transformed with the BCR-ABLT315I mutant, a conformation refractory to IM. These 
results appeared to be in contrast with the very first observations from Ertmer and 
colleagues, suggesting that IM induces autophagy even in BCR-ABL negative cells [403]. 
However, we should highlight that in the publication from Ertmer and colleagues (i) IM 
was used at doses up to 20µM, a concentration 10- to 20-fold higher compared to the ones 
in the Bellodi paper, and (ii) the authors reported that inhibition of ABL, but not PDGFR 
or KIT, induced autophagy. 
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Thereafter, Bellodi and colleagues performed a series of experiments in order to answer the 
question: is IM-induced autophagy protecting from cell death? CQ-mediated autophagy 
inhibition enhanced the effects of IM in IM-sensitive but not IM-insensitive 32D cells, 
indicating that BCR-ABL inhibition induces autophagy as a survival mechanism. To 
further validate if autophagy protects CML cells from TKI-induced death, the key 
autophagy genes ATG7 and ATG5 were targeted by RNAi in K562 cells. Specific 
autophagy inhibition augmented IM treatment, further supporting that TKI-induced 
autophagy prevents drug-mediated cell death. 
Subsequently, the authors investigated in vitro the role of autophagy in TKI-treated CD34+ 
cells from CML patients. Interestingly, CQ-mediated autophagy inhibition in combination 
with IM, DAS or NIL, suppressed the colony forming potential of CML CD34+ cells, 
including cells from patients carrying partially IM-resistant BCR-ABL mutants. Most 
significantly, pharmacological inhibition of autophagy enhanced the effect of IM and DAS 
in the most primitive fraction of CML HSCs, illustrated by reduction of colonies in LTC-
IC assays. Overall, this publication demonstrated for the first time that cytoprotective 
autophagy is induced in CML cell lines and primary samples upon TKI-induced BCR-ABL 
inhibition.  
Based on the data Bellodi and colleagues provided, CHOICES, a phase II Medical 
Research Council funded trial was initiated on March 2010 (and is currently ongoing). 
Despite the fact that in in vitro experiments described in the paper CQ was used for the 
pharmacological inhibition of autophagy, it was not the preferred autophagy inhibitor for 
the clinical trial because this drug has been associated with retinal toxicity [407]. 
Therefore, CQ was replaced in the clinic by HCQ, an agent with significantly lower 
toxicity, used extensively for the treatment of autoimmune diseases and malaria [408]. 
The aim of the CHOICES trial is to evaluate the responses of IM versus IM/HCQ for CML 
patients. Primary objectives of the trial include (i) providing preliminary evidence that the 
IM/HCQ combination is more effective than IM alone in terms of BCR-ABL levels in 
CML patients who are in major CyR with residual BCR-ABL+ cells after at least 12 
months of IM treatment, and (ii) to determine the safety and tolerability of HCQ when 
given in combination with IM to patients.  
In 2011, Altman and colleagues provided in vivo data further supporting the hypothesis 
behind the CHOICES clinical trial. The authors demonstrated that autophagy not only 
protects from TKI-induced cell death in established CML, but also plays an indispensible 
role in disease initiation. Transplantation of BCR-ABL-expressing HSCs where Atg3 was 
245 
 
conditionally knocked-out (KO) failed to induce leukaemia after transplantation to lethally 
irradiated mice.  
This study was launched a few months following the publication of Bellodi and colleagues. 
The primary objective was to investigate whether or not the enhancement of TKI treatment 
in the presence of CQ or HCQ is principally through inhibition of autophagy. Both CQ and 
HCQ are not exclusive autophagy inhibitors and affect lysosome-associated cellular 
processes, including immunosuppression. Therefore, it cannot be excluded that their 
beneficial properties are attributed to off target effects on non-autophagic mechanisms. In 
order to override problems of non-specificity and give direct answers regarding the role of 
autophagy in the survival of CML cells, autophagy was specifically targeted by knocking-
down the key autophagy gene ATG7.  
As described earlier, in the study published by Bellodi and colleagues [323], IM induced 
autophagy in cells carrying BCR-ABLp210 but not in BCR-ABLT315I; this suggests that 
induction of autophagy upon TKI treatment is due to inhibition of BCR-ABL. 
Nevertheless, induction of cytoprotective autophagy has been reported in CML cells 
following treatment with anti-CML agents that do not inhibit BCR-ABL; these include the 
histone deacetylase inhibitor SAHA [320], the dual mTORC1/2 inhibitor OSI-027 [326], 
the AKT inhibitor perifosine [329], as well as  IFNα [409]. Hence, CQ/HCQ-mediated 
autophagy inhibition could prove beneficial for CML patient treatment based on non-TKI 
agents.  
The maximum dose of HCQ currently used in most of the anticancer clinical trials, 
including CHOICES, is 800mg. Nonetheless, unpublished data from our collaborator Ravi 
Amaravadi suggest that administration of 800mg HCQ/day may not significantly inhibit 
autophagy in all patients, raising questions about the achievable levels of autophagy 
inhibition in vivo mediated by non-specific autophagy inhibitors. Consequently, ATG7 
knock-down studies would also elucidate if ATG7 is a promising target for clinical use, 
especially since specific ATG7 inhibitors are in development [349]. Therefore, this study is 
original and important for the investigation of this novel approach in CML treatment, as 
well as for the role of autophagy in the survival of cancer cells. 
The first part of this project included the investigation of the effects of TKIs on autophagy 
upon inhibition of BCR-ABL. Our data from the BC CML cell lines and CP CML CD34+ 
cells verify previously published observations, suggesting that IM and DAS induce 
autophagy [323, 410].  
PON is a novel multitargeted TKI that in our experiments had high specificity against 
BaF3 cells carrying either BCR-ABLp210 or BCR-ABLT315I, while not affecting parental 
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Ph- BaF3 cells. This is in agreement with previously published studies reporting that in 
vitro PON is effective against all tested BCR-ABL mutants that are refractory to IM, 
including the ones carrying the gatekeeper T315I mutation [227, 411, 412]. 
In the clinic PON has successfully progressed from a phase I [413], to the phase II PACE 
trial [229], and in July 2012 ARIAD announced the launch of the phase III EPIC trial for 
the investigational treatment of newly diagnosed CP CML adult patients with PON [230]. 
In December 2012, based on the auspicious results of the PACE trial, PON received FDA 
approval for clinical use in resistant or intolerant CML patients.  
Recently, Cortes and colleagues [228] provided data supporting the in vivo efficacy of 
PON in heavily pretreated CML patients that had previously failed two or three first and 
second generation TKIs. Overall, PON has been reported to be potent against all BCR-
ABL mutants and could potentially be the most effective TKI available in the clinic. 
Despite its effectiveness against all BCR-ABL mutants, PON treatment alone is unlikely to 
cure CML since the most refractory fraction of CML stem cells has been reported to 
survive and proliferate independent of BCR-ABL signaling [234, 235]. There have been no 
published papers so far monitoring the autophagy flow upon PON treatment of CML cells; 
this study is the first one to demonstrate that PON-mediated BCR-ABL inhibition induces 
autophagy in CML cells.  
At the time this project was initiated, there were no published reports regarding the 
molecular mechanism by which TKI treatment induces autophagy. However, in 2011, 
Sheng and colleagues deciphered a part of this complex mechanism [324]. They suggested 
that under steady state conditions BCR-ABL is suppressing autophagy via activation of the 
ATF5 transcription factor and mTOR. However, treatment with IM inhibits BCR-ABL 
signaling and therefore, suppresses the ATF5/mTOR pathway, leading to induction of 
autophagy (Figure 6-1). This mechanism is in agreement with data presented in this report, 
demonstrating induction of autophagy upon IM-, DAS- and PON-mediated BCR-ABL 
inhibition, and possibly explains why in the hereby-described experiments Ph+ CD34+ 
cells had lower levels of autophagy gene transcription under steady state conditions 
compared to Ph- CD34+ cells. Furthermore, it should be mentioned that other members in 
our lab have demonstrated that TKIs lead to upregulation of the transcription of autophagy 
genes in CP CML CD34+ cells compared to NDC (unpublished data). 
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Figure 6-1: The BCR-ABL/PI3K/AKT/FOXO4/ATF5/mTOR-mediated autophagy-inhibition 
pathway 
Fading of a protein indicates loss of function. (Modified from [324]) 
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Our data from the BC CML cell lines and CP CML CD34+ cells suggest that autophagy 
plays a cytoprotective role in CML and its suppression via CQ/HCQ enhances TKI 
treatment (Figure 6-2). These observations are in agreement with reports previously 
published by our [323] and other labs [322, 325, 328].  
 
 
 
 
 
 
Figure 6-2: Induction of cytoprotective autophagy upon TKI-treatment of CML cells 
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On the other hand, a number of studies support that autophagy induction mediated by non-
TKI investigational agents is enhancing CML cell death. Reagents such as acadesine [414], 
the plant phytoalexin resveratrol [331] and lapatinib (dual TKI of EGFRs and HER2) [415] 
have been suggested to increase the apoptosis of CML cells via induction of autophagy. 
Nevertheless, it has not been clarified yet if the chemotherapeutic effect of these agents is 
the critical mechanism of action of these reagents and further investigation has to be 
carried out before supporting the up-regulation of autophagy for the treatment of CML. 
Recently, Goussetis and colleagues [416] suggested that autophagy induction mediated by 
arsenic trioxide enhances the drug’s effects via degradation of BCR-ABL in the cells of 
CML patients. It would be interesting, therefore, to investigate the levels of BCR-ABL 
protein in autophagy-ablated CML cells; blockade of the autophagy recycling mechanism 
could lead to accumulation of BCR-ABL and hence, lead to toxic death of the cells.  
Autophagic targeting of specific proteins has been implicated with cancer cell survival; 
Sandilands and colleagues [417] reported that upon disruption of FAK signalling, c-Cbl 
mediates the autophagic targeting of Src to a Src/LC3 complex. Inhibition of autophagy 
restores Src at peripheral adhesions, and ultimately leads to cancer cell death. 
A growing number of published studies are highlighting the significance of the 
PI3K/AKT/mTOR pathway in the survival of TKI-refractory CML cells. Hence, an 
alternative approach for the treatment of leukaemic cells includes inhibition of the 
PI3K/AKT/mTOR pathway by using drugs such as RAPA and BEZ.  Nevertheless, since 
these drugs inhibit mTOR, they ultimately induce autophagy. This was also demonstrated 
by our experiments, where treatment with RAPA or BEZ IC50 values was associated with 
accumulation of LC3-positive punctae in the CD34+ cells of CP CML patient.  
A recent study by Bray and colleagues [353] suggests that activation of autophagy upon 
mTOR inhibition enables the survival of cancer cells by suppressing RIP kinase-dependent 
necrosis and promoting cellular integrity by ROS reduction, since mTOR inhibition 
abolishes NRF2 antioxidant defense. In order to investigate if inhibition of autophagy 
could potentiate the effects of these drugs, apoptosis was measured in KCL22T315I cells 
treated with PON, BEZ or RAPA ± CQ. PON, which can target the BCR-ABLT315I 
mutants, significantly enhanced apoptosis and CQ further augmented its effect. 
Interestingly, CQ-mediated autophagy inhibition enhanced the apoptotic effect of both 
RAPA and BEZ (used in proliferation IC50 concentrations), with BEZ/CQ having the most 
auspicious effects among all the treatment arms. These observations highlight the 
promising role of these drugs in the treatment of CML. Further experiments should be 
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carried out to identify RAPA and BEZ concentrations that completely inhibit mTOR 
activity, and investigate the effect of these concentrations in the proliferation, survival and 
clonogenic ability of CML cells carrying the T315I mutation. 
One of the greatest challenges when designing knock-down experiments within stem and 
progenitor cells, is the technical part. First of all these cells are hard to transfect and 
secondly, the number of cells available for experiments is limited. Different gene silencing 
techniques are linked to different advantages and disadvantages, efficacy, reliability and 
safety, which can be altered depending on the type of cell. Therefore, a major factor in the 
success of our experiments relied on choosing the best fitting gene silencing method for 
CD34+ cells, and optimising it for the scope of our experiments. The hairpins we used 
(mock and targeting) were carried by a pLKO.1 vector under the expression of a U6 
promoter, establishing long-term knock-down. Western blot analysis on shATG7_E-
transduced cells 24-48h post-sort revealed a 60-70% reduction in ATG7 levels and 25% 
reduction in LC3 lipidation. A study by Komatsu and colleagues has reported that ATG7 is 
a long-lived protein with a half-life of approximately a week [418]. Hence, it is possible 
that if we had performed the analysis at a later point we could have detected even lower 
levels of ATG7 protein and LC3 lipidation. 
In this study we first demonstrate the dependence of CML stem/progenitor cells on basal 
levels of ATG7 for their proliferation and survival; ATG7 knock-down alone significantly 
inhibited the proliferation of CP CML CD34+ cells and induced apoptosis at comparable 
levels to TKI treatment. The committed progenitor cell potential of CD34+ cells from CP 
CML patients was also reduced consistently at levels ≥50% compared to the control, 
suggesting that basal ATG7 and autophagy levels are required for the clonogenicity of the 
cells.  
These observations pinpoint the importance of autophagy for the survival of cancer cells 
under steady state conditions. Cancer cells have been reported to have altered nutritional 
requirements and increased metabolic needs [419]. This could possibly justify partially the 
addiction of CML stem/progenitor cells to basal autophagy for survival. Interestingly, our 
data suggest that CML cells express lower basal levels of ATG7 compared to non-CML 
CD34+ cells. This could partially explain why similar levels of ATG7 knock-down have a 
significant impact on CML cells and not Ph- CD34+ cells. 
The differentiation potential of shATG7_E-transduced CML CD34+ cells was also altered, 
compared to the control. ATG7 knock-down-mediated autophagy inhibition was associated 
with an approximate 75% decrease in the erythroid colony-formation potential of the cells. 
Autophagy has been reported to be essential for the maturation of erythroid cells through 
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the promotion of mitochondrial clearance [420] and recently, ATG7 was demonstrated to 
be essential for the maturation and maintenance of the cellular integrity of erythroid cells 
[375, 421]. In our experiments, it remains unclear if ATG7 knock-down (i) drove 
differentiation of CML CD34+ stem/progenitor cells, or (ii) preferentially eradicated or 
suppressed the maturation of cells committed to erythroid lineage. Future studies will shed 
more light on these questions. 
In any case, our observations on the proliferation, survival and differentiation of CML 
CD34+ cells upon ATG7 knock-down have to be further validated by knock-down studies 
of other indispensible ATG genes since our data cannot exclude a potential dependence on 
autophagy-independent roles of ATG7.  
Autophagy and ATG7 have been suggested to be vital for the maintenance of embryonic 
and adult HSCs; loss of autophagy within this fraction of cells has been demonstrated to 
lead to severe anaemia, lymphopenia, haemopoietic malignancies and exhaustion of the 
stem cell population. In 2011 Liu and colleagues reported that FIP200 is vital for the 
function and maintenance of foetal murine HSCs in a cell-autonomous manner [422]. 
HSCs with ablated FIP200 presented high levels of proliferation, increased mitochondrial 
mass and ROS levels, and failed to reconstitute haemopoiesis in lethally irradiated mice. 
Subsequently, Mortensen and colleagues reported that adult Atg7-deficient HSCs fail to 
engraft lethally irradiated recipients, further underlining the significance of autophagy in 
HSC maintenance [355]. Recently, similar observations were made upon KO of Atg5 
[423]. Thus, a range of experiments was designed in our study in order to investigate if the 
therapeutic approach of combined TKI/autophagy inhibition could affect Ph- haemopoietic 
stem/progenitor cells.  
Our data are in contrast to the above mentioned published studies. Our observations 
suggested that ATG7 knock-down, alone or in combination with TKIs, did not 
significantly affect the proliferation, survival, and clonogenic ability of Ph- CD34+ cells. 
However, it should be underlined that there is a major difference between KO and 
knocking-down a gene. KO of any key autophagy genes leads to complete ablation of the 
targeted protein and almost 100% inhibition of LC3 lipidation. In our experiments we used 
a knock-down approach that resulted in 70% reduction of ATG7 at protein level and 25% 
reduction of LC3 lipidation. This could explain why in our system the normal HSCs were 
not affected by ATG7 knock-down. However, our data cannot exclude a possible loss of 
the stemness within the primitive cells, followed by extended proliferation. In order to 
address this question robustly, we performed LTC-IC assays on shCtrl and shATG7_E-
transduced Ph+ and Ph- CD34+ cells. Nevertheless, due to technical problems, the cells 
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failed to give colonies at the end of the assay (in both control and ATG7 knock-down). 
Future studies should focus on the evaluation of ATG7 knock-down effects on the most 
primitive population of Ph- and Ph+ HSCs, either by LTC-IC or serial replating assays.  
Apoptosis is a programmed cell process, associated with a range of biochemical and 
cellular changes. Unlike apoptosis, necrosis is a less regulated and controlled procedure, 
and its patterns change according to the factor that triggered the mechanism. In 2006, 
Degenhardt and colleagues [396] demonstrated that inhibition of autophagy in apoptosis-
defective cells could restore cell death by inducing necrosis, in vitro and in vivo. Hence, it 
was suggested that the cytoprotective role of autophagy in cancer cells might be attributed 
to the ablation of necrotic cell death. Furthermore, in 2008 Wu and colleagues [424] 
provided evidence supporting that pharmacological inhibition of autophagy can enhance 
zVAD-induced necrosis. Finally, a recent study by Bray and colleagues [353] suggested 
that increase in autophagic flow upon mTOR inhibition supports cell survival and 
autophagy inhibition allows for necroptosis. Altogether, these studies suggest that in the 
presence of defective apoptosis, cancer cells rely on autophagy for their survival; inhibition 
of autophagy leads to a “metabolic catastrophe”, where the cells cannot overcome stress 
and die by necrosis [425]. This could explain why in our experiments ATG7 knock-down 
did not enhance TKI-induced apoptosis in CML CD34+ cells. Specific targeting of 
autophagy in a BCR-ABL-inhibited background could lead to a disproportional increase of 
necrotic versus apoptotic cell death. Hence, for future experiments, it would be 
recommended to also monitor necrosis, in addition to apoptosis. 
Data from this study demonstrate that ATG7 knock-down significantly augments TKI 
treatment regarding the suppression of colony forming ability of CML CD34+ cells. The 
combination of TKI/ATG7 knock-down reduced by 92-98% the potential of CP CML 
CD34+ cells to form colonies, compared to NDC shCtrl cells. These observations suggest 
that within CML CD34+ cells TKI-mediated autophagy induction is important for evading 
cell death upon inhibition of BCR-ABL signaling.  
In order to evaluate the effect of specific autophagy inhibition in the presence of prolonged 
TKI exposure, CML CD34+ stem/progenitor cells were cultured for 2 weeks in semi-solid 
medium containing NIL, DAS or PON. Interestingly, the number of colonies within the 
prolonged TKI treatment arms was higher compared to that followed by 6-day TKI 
treatment. This could be attributed to deactivation of the TKIs’ activity in the semi-solid 
medium before the completion of the assay (14 days). Even so, the effects of all TKIs 
tested were augmented in the presence of ATG7 knock-down, suppressing by 82-91%  the 
clonogenic potential of these cells compared to NDC shCtrl cells.  
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Overall, our experiments demonstrate the significance of basal autophagy for the survival, 
proliferation and differentiation potential of the CML stem/progenitor cells under steady 
state conditions. Furthermore, we illustrate that ATG7 knock-down and inhibition of 
autophagy in the presence of TKIs, potentiate treatment and enhance TKI effects.  
Nevertheless, TKIs failed to completely eradicate the colony forming potential of the 
progenitor cells alone or in combination with ATG7 knock-down. FACS analysis of such 
colonies revealed that the cells expressed GFP, suggesting that the shRNA hairpins were 
expressed. Therefore, supplementary investigation should be carried out for the 
characterisation of the cells that evade both autophagy and BCR-ABL inhibition. A 
possible explanation could be that within these cells autophagy was not sufficiently 
inhibited due to lower levels of ATG7 knock-down.  
Autophagy has been suggested to be vital for the maintenance and differentiation of stem 
cells [356, 426]. A recent study by Oliver and colleagues [427] proposed that stem cells 
have high levels of autophagy while differentiated cells have very low levels of basal 
autophagy. Preliminary studies from our lab are in agreement with these data; from our 
observations, CD34- cells have lower levels of autophagy compared to CD34+ cells. It 
should be mentioned that within CD34+ cells of a CML patient we observed that even if 
ATG7 knock-down did not induce apoptosis, the percentage of CD34+ cells within the 
double negative annexin/DAPI compartment was decreased compared to the control (data 
not shown). Further investigation is required in order to elucidate if this reduction in 
CD34+ cells upon ATG7 knock-down is attributed to cell cycle arrest, differentiation or 
cell death. A potential explanation could be that ATG7 knock-down and inhibition of 
autophagy lead to eradication of primitive cells because they gravely depend on this 
mechanism for their survival. On the other hand, autophagy inhibition would not equally 
affect more differentiated cells under stress free conditions, since these cells do not 
exclusively rely on autophagy for their survival. In order to answer these questions, stem 
cell assays, such as LTC-IC, should be performed in order to evaluate the effect of ATG7 
knock-down in the presence of TKIs and investigate if this therapeutic approach can 
eliminate the persistent CML stem cells. 
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Autophagy has been suggested to interplay with many cellular processes, including cell 
death (apoptosis and necrosis), differentiation [357-362] and stem cell maintenance [355, 
422, 426] (Figure 6-2).  
 
 
 
 
 
 
Figure 6-3: Autophagy takes part in many cellular processes 
 
Previous experiments demonstrated the importance of ATG7 and autophagy for the 
survival and differentiation of CP CML cells. Hence, in this section we aimed to explore 
the cell fate decisions of BC leukaemic cells upon ATG7 knock-down.  
As a model of BC CML study, the human myelomonocytic cell line KCL22 was 
employed. Surprisingly, ATG7 proved to be indispensible for the survival of these cells 
and the complete population of shATG7_E transduced cells was rapidly eradicated upon 
ATG7 knock-down. Similarly, the total population of murine c-kit enriched MLL-ENL-
transformed cells died upon inhibition of Atg7. Further investigation should be carried out 
regarding the mechanisms of cell death induction upon ATG7 knock-down. 
Subsequently, ATG7 was knocked-down in K562 cells, a BC CML erythromegakaryocytic 
cell line. K562 cells transduced with shATG7_E presented ≥60% reduced ATG7 protein 
levels compared to the control and their ability to proliferate was severely impaired. 
Furthermore, cell survival was significantly affected, with ~ 70% of the ATG7 knock-
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down cells staining positive for DAPI. Interestingly, K562 cells that survived ATG7 
knock-down 12 days post-sort were producing higher levels of haemoglobin and GlyA 
compared to the control, suggesting that the cells were more differentiated and committed 
to the erythroid lineage. However, as mentioned earlier, autophagy and ATG7 have been 
reported to be essential for the erythroid differentiation. Morphologic examination of K562 
shATG7_E-transduced cells after staining with “Diff Quik” revealed that the cells did not 
present erythroid cell features. Failure of K562 cells to terminally differentiate upon ATG7 
knock-down could be attributed to suppressed mitophagy and inability to clear the 
mitochondria (a vital step for reticulocyte maturation), since these cells presented 
accumulation of mitochondria. Remarkably, a fraction of K562 cells that survived 
prolonged ATG7 knock-down (4 weeks), presented morphologically megakaryocytic 
features, had altered adhesion properties, and produced elevated levels of ROS. Sardina 
and colleagues [377] suggested that increased ROS levels are necessary for the 
megakaryocytic differentiation of K562. Hence, a possible hypothesis is that upon ATG7 
knock-down, mitophagy is inhibited and a subsequent increase in ROS levels could favour 
the megakaryocytic differentiation of the cells. 
These experiments could not answer if ATG7 knock-down is the driver of the observed 
erythroid/megakaryocytic differentiation of the K562 cells, or if it is “selecting” for more 
differentiated cells within the initial culture. Hence, the survival and differentiation 
potential upon ATG7 knock-down was investigated at the single-cell level, by sorting 
shATG7_E and shCtrl K562 cells into single wells. The results suggested that less than 
20% of K562 cells managed to survive and proliferate upon ATG7 knock-down, compared 
to the control. Interestingly, all the clones generated within the ATG7 knock-down arm 
presented either erythroid or megakaryocytic features. Erythroid clones consisted of 
significantly higher cell numbers compared to the megakaryocytic clones, and this 
difference in proliferation kinetics could possibly explain why upon ATG7 knock-down 
K562 cells with erythroid features precede the appearance of cells with megakaryocytic 
features. On the other hand, none of the clones produced by shCtrl cells presented features 
of differentiation. This is in support with the notion that ATG7 knock-down promotes the 
differentiation observed in K562 cells; however, more experiments have to be carried out 
in order to clarify this. Both hypotheses are very interesting to study; if autophagy 
interplays with differentiation, the underlying mechanism of the crosstalk has not been 
investigated. On the other hand, if these ATG7 "survivors" pre-existed and they manage to 
outgrow, it is important to investigate why these cells can survive and proliferate with 
accelerated rates in the absence of ATG7 and/or autophagy. 
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Stem cells have been reported to differentiate upon increased levels of ROS and DNA 
damage [428]. In our experiments ATG7 knock-down was linked to increased levels of 
ROS. Hence, it would be interesting to perform assays evaluating the cellular integrity by 
means of mitochondrial potential, levels of ROS and DNA damage on K562 ATG7 knock-
down cells. Finally, future studies should elucidate if ATG7 knock-down is directly 
implicated in the differentiation process or ATG7/autophagy suppression is abolishing the 
differentiation block these BC cells present and consequently, allows for their 
differentiation.  
In order to investigate the role of ATG7 and autophagy in other transformed leukaemic 
cells, ATG7 was knocked down in HG3 cells, a human CLL cell line. Reduction of ATG7 
protein to ≥50% levels was associated with significantly suppressed proliferation and 
increased cell death, underlining the significance of ATG7 and autophagy for the survival 
of these cells. Interestingly, HG3 cells surviving for 15 days ATG7 knock-down presented 
a very different phenotype compared to the control; HG3 shATG7_E cells had increased 
cell size, prominent Golgi apparatus and presented cytoplasmic blebbing (pseudopods). 
Moreover, HG3 shATG7_E cells had altered cell-to-cell adhesion features and were 
growing in culture as single cells, unlike the shCtrl cell that were growing in clusters. This 
observation, in combination with the fact that K562 shATG7_E cells were partially 
attaching to the substrate, reflects that ATG7 knock-down may be associated with changes 
in the cytoskeleton.  
Taken altogether, ATG7 and autophagy appear to affect the cell fate decisions of 
transformed human leukaemic cells. Survival of these cells relies significantly on ATG7 
and its inhibition, as a single event, was consistently associated with a dramatic increase in 
cell death. The dependence of transformed cells lines on ATG7/autophagy appeared to be 
greater compared to CML CD34+ stem/progenitor cells, but this may reflect differences in 
metabolic needs due to higher proliferation rates. 
Future studies should focus on knock-down of other ATGs within leukaemic cells and 
clarify if the observed differentiation upon ATG7 knock-down is attributed to inhibition of 
autophagy or other non-autophagy related roles of ATG7. A possible explanation could be 
that the observed molecular, biochemical and morphological changes in BC cells upon 
ATG7 knock-down reflect inhibition of differentiation arrest rather than induction of 
differentiation per se. Additionally, the role of ATG7 knock-down should be investigated 
within non-transformed cells in order to identify if this protein is affecting the 
differentiation of normal cells.  
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6.3 Summary and future directions 
The findings from the present study demonstrate that all three generation TKIs (IM, DAS 
and PON) induce cytoprotective autophagy upon inhibition of BCR-ABL and 
pharmacological inhibition of autophagy via CQ or HCQ potentiates the effects of TKIs.  
Most importantly, this study first demonstrates that specific targeting of basal autophagy in 
CP CML CD34+ cells via ATG7 knock-down significantly impairs their survival, 
proliferation and differentiation. ATG7 knock-down reduced the total number of CP CML 
CD34+ colonies (50%) as well the relative number of erythroid colonies (75%) compared 
to the control. Interestingly, ATG7 knock-down enhanced TKI-induced effects, eradicating 
98% of the clonogenic ability of CP CML stem and progenitors compared to the control. 
Future studies should focus on the most primitive fraction of the CML stem cells and 
evaluate the effects of autophagy inhibition, alone or in combination with TKIs. However, 
knocking-down ATG7 or any other indispensible autophagy gene in vitro has two main 
drawbacks: (i) technically achievable knock-down levels do not completely abolish 
autophagy and residual autophagy levels may be sufficient for cell survival, and (ii) the 
cells are investigated under optimum, controlled conditions that differ considerably from 
the hypoxic niche of HSCs in vivo. It would be interesting to investigate in in vivo mouse 
models if Atg7 knock-out HSCs (i) will repopulate the haemopoiesis of NOD/SCID mice, 
(ii) will lead to development of CML upon expression/transduction with Bcr-Abl, and if 
yes, if the disease will progress with faster or slower rates.  
Nevertheless, our results reveal a contradictory role for ATG7 in the differentiation of 
CML cells; ATG7 knock-down suppressed the erythroid differentiation of CP CML cells, 
while within BC cells it promoted differentiation. This possibly reflects the different roles 
of ATG7 and/or autophagy within different stages of the disease or the technical cell 
differences between primary samples and immortalised cell lines (such as BCR-ABL copy 
number, presence of secondary mutation etc). More specifically, it has to be clarified if the 
observed erythroid differentiation of K562 cells upon ATG7 knock-down is attributed to a 
“true” induction of differentiation or release of blocks that inhibit differentiation in BC 
cells.  
ATG7 knock-down surviving cells had high levels of superoxide and increased numbers of 
functional mitochondria, potentially due to inhibition of mitophagy. It would be interesting 
to further characterise the mitochondrial profile of these cells, as well as monitor cellular 
integrity by means of DNA damage. Such changes have been associated in other studies 
with initiation of differentiation and, could be the case here. For example, it should be 
explored if NAC-mediated ROS reduction can abolish differentiation upon ATG7 knock-
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down. Another suggestion would be to transduce the cells with inducible ATG7-hairpin 
and explore if the ATG7 knock-down-induced differentiation is reversible upon recovery 
of ATG7 levels. Most importantly, it should be further investigated if the observed effects 
on cell differentiation upon ATG7 knock-down are attributed to reduced autophagy levels 
or ATG7 autophagy-independent roles. Hence, these experiments should be validated by 
knock-down other ATG genes, such as ATG5 or BECLIN.  
In conclusion, the data we provide in this study suggest that basal autophagy is 
indispensible for the survival of CP CML cell and inhibition of TKI-induced autophagy 
can augment therapy. Therefore, the development of specific autophagy inhibitors is 
critical since, in combination with TKIs, they could potentially lead to eradication of CML 
stem cells and cure of the disease. Further studies are required for the unravelling of the 
mechanism by which autophagy inhibition sensitises CML cells to TKIs. 
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Figure 6-4: Overview of the observed effects upon ATG7 knock-down in CP and BC CML 
cells 
 
 
 
 
 
 
BCR$ABL'
Ph+'CD34+''
cells'
CP'CM
L'
TKI'
AU
TO
PHAGY'
40$70%
'reducAon''
in'clonogenic'ability'
M
ature'cells''
AU
TO
PHAGY'
! 50%
'reducAon'''
'in'clonogenic'ability'
$'suppression'of'
erythroid'diﬀerenAaAon'
ATG7''
knock$dow
n'
BCR$ABL'
TKI'
AU
TO
PHAGY'
$'90%
'reducAon''
in'clonogenic'ability'
$'suppression'of'
erythroid'diﬀerenAaAon''
ATG7''
knock$dow
n'
TKIs'ATG7'KD'TKIs'+'ATG7'KD'
BC'CM
L'
Genom
ic'
Instability'
?'?'
KCL22'cells'ATG7'knock$dow
n'
100%
'
eradicaAon'of'
the'populaAon'
K562'cells'
! diﬀerenAaAon'arrest'
! 'increased'proliferaAon'
! 'reduced'apoptosis'%'Erythroid'diﬀerenAaAon'
4'days'
6'days'
70%
'cell'death'
2'w
eeks'
%
'M
egakaryocyte'diﬀerenAaAon'
4'w
eeks'
ATG7'
KD'?'
diﬀerenAaAon''
arrest'
'
""Progression"
260 
 
Appendix 
 
 
 
 
 
 
261 
 
  
262 
 
 
 
 
  
263 
 
List of References 
1. Passegue, E., et al., Global analysis of proliferation and cell cycle gene 
expression in the regulation of hematopoietic stem and progenitor cell fates. J 
Exp Med, 2005. 202(11): p. 1599-611. 
2. Spangrude, G.J., S. Heimfeld, and I.L. Weissman, Purification and 
characterization of mouse hematopoietic stem cells. Science, 1988. 241(4861): p. 
58-62. 
3. Morrison, S.J. and I.L. Weissman, The long-term repopulating subset of 
hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity, 
1994. 1(8): p. 661-73. 
4. Baum, C.M., et al., Isolation of a candidate human hematopoietic stem-cell 
population. Proc Natl Acad Sci U S A, 1992. 89(7): p. 2804-8. 
5. Osawa, M., et al., Long-term lymphohematopoietic reconstitution by a single 
CD34-low/negative hematopoietic stem cell. Science, 1996. 273(5272): p. 242-5. 
6. Muller, A.M., et al., Development of hematopoietic stem cell activity in the 
mouse embryo. Immunity, 1994. 1(4): p. 291-301. 
7. Morrison, S.J., N. Uchida, and I.L. Weissman, The biology of hematopoietic 
stem cells. Annu Rev Cell Dev Biol, 1995. 11: p. 35-71. 
8. Orkin, S.H., Diversification of haematopoietic stem cells to specific lineages. Nat 
Rev Genet, 2000. 1(1): p. 57-64. 
9. Marley, S.B. and M.Y. Gordon, Chronic myeloid leukaemia: stem cell derived 
but progenitor cell driven. Clin Sci (Lond), 2005. 109(1): p. 13-25. 
10. Schofield, R., The relationship between the spleen colony-forming cell and the 
haemopoietic stem cell. Blood Cells, 1978. 4(1-2): p. 7-25. 
11. Sutherland, H.J., et al., Characterization and partial purification of human 
marrow cells capable of initiating long-term hematopoiesis in vitro. Blood, 1989. 
74(5): p. 1563-70. 
12. Sutherland, H.J., et al., Functional characterization of individual human 
hematopoietic stem cells cultured at limiting dilution on supportive marrow 
stromal layers. Proc Natl Acad Sci U S A, 1990. 87(9): p. 3584-8. 
13. Wang, J.C., M. Doedens, and J.E. Dick, Primitive human hematopoietic cells 
are enriched in cord blood compared with adult bone marrow or mobilized 
peripheral blood as measured by the quantitative in vivo SCID-repopulating cell 
assay. Blood, 1997. 89(11): p. 3919-24. 
14. Morrison, S.J., et al., Identification of a lineage of multipotent hematopoietic 
progenitors. Development, 1997. 124(10): p. 1929-39. 
15. Suda, T., J. Suda, and M. Ogawa, Proliferative kinetics and differentiation of 
murine blast cell colonies in culture: evidence for variable G0 periods and 
constant doubling rates of early pluripotent hemopoietic progenitors. J Cell 
Physiol, 1983. 117(3): p. 308-18. 
16. Leary, A.G., et al., Survival of hemopoietic progenitors in the G0 period of the 
cell cycle does not require early hemopoietic regulators. Proc Natl Acad Sci U S 
A, 1989. 86(12): p. 4535-8. 
17. Leary, A.G., et al., Growth factor requirements for survival in G0 and entry into 
the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci U 
S A, 1992. 89(9): p. 4013-7. 
18. Vickers, M., et al., Modelling haemopoietic stem cell division by analysis of 
mutant red cells. Br J Haematol, 2000. 110(1): p. 54-62. 
264 
 
19. Terstappen, L.W., et al., Sequential generations of hematopoietic colonies 
derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood, 
1991. 77(6): p. 1218-27. 
20. DiGiusto, D., et al., Human fetal bone marrow early progenitors for T, B, and 
myeloid cells are found exclusively in the population expressing high levels of 
CD34. Blood, 1994. 84(2): p. 421-32. 
21. Link, H., et al., Transplantation of allogeneic CD34+ blood cells. Blood, 1996. 
87(11): p. 4903-9. 
22. Krause, D.S., et al., CD34: structure, biology, and clinical utility. Blood, 1996. 
87(1): p. 1-13. 
23. Kung, P., et al., Monoclonal antibodies defining distinctive human T cell surface 
antigens. Science, 1979. 206(4416): p. 347-9. 
24. Hogan, C.J., E.J. Shpall, and G. Keller, Differential long-term and multilineage 
engraftment potential from subfractions of human CD34+ cord blood cells 
transplanted into NOD/SCID mice. Proc Natl Acad Sci U S A, 2002. 99(1): p. 
413-8. 
25. Trumpp, A., M. Essers, and A. Wilson, Awakening dormant haematopoietic 
stem cells. Nat Rev Immunol, 2010. 10(3): p. 201-9. 
26. Sipkins, D.A., et al., In vivo imaging of specialized bone marrow endothelial 
microdomains for tumour engraftment. Nature, 2005. 435(7044): p. 969-73. 
27. Calvi, L.M., et al., Osteoblastic cells regulate the haematopoietic stem cell niche. 
Nature, 2003. 425(6960): p. 841-6. 
28. Zhang, J., et al., Identification of the haematopoietic stem cell niche and control 
of the niche size. Nature, 2003. 425(6960): p. 836-41. 
29. Yoshihara, H., et al., Thrombopoietin/MPL signaling regulates hematopoietic 
stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell, 
2007. 1(6): p. 685-97. 
30. Kiel, M.J. and S.J. Morrison, Maintaining hematopoietic stem cells in the 
vascular niche. Immunity, 2006. 25(6): p. 862-4. 
31. Lo Celso, C., et al., Live-animal tracking of individual haematopoietic 
stem/progenitor cells in their niche. Nature, 2009. 457(7225): p. 92-6. 
32. Bonnet, D. and J.E. Dick, Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997. 
3(7): p. 730-7. 
33. Visvader, J.E. and G.J. Lindeman, Cancer stem cells in solid tumours: 
accumulating evidence and unresolved questions. Nat Rev Cancer, 2008. 8(10): 
p. 755-68. 
34. Reya, T., et al., Stem cells, cancer, and cancer stem cells. Nature, 2001. 
414(6859): p. 105-11. 
35. Ito, M., et al., NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse 
model for engraftment of human cells. Blood, 2002. 100(9): p. 3175-82. 
36. Passegue, E., et al., Normal and leukemic hematopoiesis: are leukemias a stem 
cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U 
S A, 2003. 100 Suppl 1: p. 11842-9. 
37. Turhan, A.G., et al., Highly purified primitive hematopoietic stem cells are 
PML-RARA negative and generate nonclonal progenitors in acute promyelocytic 
leukemia. Blood, 1995. 85(8): p. 2154-61. 
38. Cozzio, A., et al., Similar MLL-associated leukemias arising from self-renewing 
stem cells and short-lived myeloid progenitors. Genes Dev, 2003. 17(24): p. 3029-
35. 
39. Jamieson, C.H., et al., Granulocyte-macrophage progenitors as candidate 
leukemic stem cells in blast-crisis CML. N Engl J Med, 2004. 351(7): p. 657-67. 
265 
 
40. Deshpande, A.J., et al., Acute myeloid leukemia is propagated by a leukemic 
stem cell with lymphoid characteristics in a mouse model of CALM/AF10-
positive leukemia. Cancer Cell, 2006. 10(5): p. 363-74. 
41. Kirstetter, P., et al., Modeling of C/EBPalpha mutant acute myeloid leukemia 
reveals a common expression signature of committed myeloid leukemia-initiating 
cells. Cancer Cell, 2008. 13(4): p. 299-310. 
42. Huntly, B.J., et al., MOZ-TIF2, but not BCR-ABL, confers properties of 
leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell, 
2004. 6(6): p. 587-96. 
43. Domingo-Domenech, J., et al., Suppression of Acquired Docetaxel Resistance in 
Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-
Initiating Cells. Cancer Cell, 2012. 22(3): p. 373-88. 
44. Nowell, P.C. and D.A. Hungerford, Chromosome studies on normal and 
leukemic human leukocytes. J Natl Cancer Inst, 1960. 25: p. 85-109. 
45. Rowley, J.D., Letter: A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa 
staining. Nature, 1973. 243(5405): p. 290-3. 
46. Daley, G.Q., R.A. Van Etten, and D. Baltimore, Induction of chronic 
myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia 
chromosome. Science, 1990. 247(4944): p. 824-30. 
47. Elefanty, A.G., I.K. Hariharan, and S. Cory, bcr-abl, the hallmark of chronic 
myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. 
EMBO J, 1990. 9(4): p. 1069-78. 
48. Heisterkamp, N., et al., Acute leukaemia in bcr/abl transgenic mice. Nature, 
1990. 344(6263): p. 251-3. 
49. Kelliher, M.A., et al., Induction of a chronic myelogenous leukemia-like 
syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A, 1990. 
87(17): p. 6649-53. 
50. Fialkow, P.J., S.M. Gartler, and A. Yoshida, Clonal origin of chronic 
myelocytic leukemia in man. Proc Natl Acad Sci U S A, 1967. 58(4): p. 1468-71. 
51. Fialkow, P.J., et al., Chronic myelocytic leukemia. Origin of some lymphocytes 
from leukemic stem cells. J Clin Invest, 1978. 62(4): p. 815-23. 
52. Martin, P.J., et al., Involvement of the B-lymphoid system in chronic 
myelogenous leukaemia. Nature, 1980. 287(5777): p. 49-50. 
53. Faderl, S., et al., The biology of chronic myeloid leukemia. N Engl J Med, 1999. 
341(3): p. 164-72. 
54. Kantarjian, H.M., et al., Characteristics of accelerated disease in chronic 
myelogenous leukemia. Cancer, 1988. 61(7): p. 1441-6. 
55. Kantarjian, H.M., et al., Chronic myelogenous leukemia: a concise update. 
Blood, 1993. 82(3): p. 691-703. 
56. Wong, S. and O.N. Witte, Modeling Philadelphia chromosome positive 
leukemias. Oncogene, 2001. 20(40): p. 5644-59. 
57. Smith, D.L., J. Burthem, and A.D. Whetton, Molecular pathogenesis of chronic 
myeloid leukaemia. Expert Rev Mol Med, 2003. 5(27): p. 1-27. 
58. Perrotti, D., et al., Chronic myeloid leukemia: mechanisms of blastic 
transformation. J Clin Invest, 2010. 120(7): p. 2254-64. 
59. Voncken, J.W., et al., Increased neutrophil respiratory burst in bcr-null mutants. 
Cell, 1995. 80(5): p. 719-28. 
60. Reuther, G.W., et al., Association of the protein kinases c-Bcr and Bcr-Abl with 
proteins of the 14-3-3 family. Science, 1994. 266(5182): p. 129-33. 
61. McWhirter, J.R., D.L. Galasso, and J.Y. Wang, A coiled-coil oligomerization 
domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. 
Mol Cell Biol, 1993. 13(12): p. 7587-95. 
266 
 
62. Boguski, M.S. and F. McCormick, Proteins regulating Ras and its relatives. 
Nature, 1993. 366(6456): p. 643-54. 
63. Diekmann, D., et al., Bcr encodes a GTPase-activating protein for p21rac. 
Nature, 1991. 351(6325): p. 400-2. 
64. Van Etten, R.A., P. Jackson, and D. Baltimore, The mouse type IV c-abl gene 
product is a nuclear protein, and activation of transforming ability is associated 
with cytoplasmic localization. Cell, 1989. 58(4): p. 669-78. 
65. Wetzler, M., et al., Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in 
normal and leukemic cells and correlation of expression with myeloid 
differentiation. J Clin Invest, 1993. 92(4): p. 1925-39. 
66. Ren, R., Z.S. Ye, and D. Baltimore, Abl protein-tyrosine kinase selects the Crk 
adapter as a substrate using SH3-binding sites. Genes Dev, 1994. 8(7): p. 783-95. 
67. Kipreos, E.T. and J.Y. Wang, Cell cycle-regulated binding of c-Abl tyrosine 
kinase to DNA. Science, 1992. 256(5055): p. 382-5. 
68. McWhirter, J.R. and J.Y. Wang, An actin-binding function contributes to 
transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive 
human leukemias. EMBO J, 1993. 12(4): p. 1533-46. 
69. Van Etten, R.A., et al., The COOH terminus of the c-Abl tyrosine kinase 
contains distinct F- and G-actin binding domains with bundling activity. J Cell 
Biol, 1994. 124(3): p. 325-40. 
70. Kharbanda, S., et al., The stress response to ionizing radiation involoves c-Abl-
dependent phosphorylation of SHPTP1. Proc Natl Acad Sci U S A, 1996. 93(14): 
p. 6898-901. 
71. Raitano, A.B., Y.E. Whang, and C.L. Sawyers, Signal transduction by wild-type 
and leukemogenic Abl proteins. Biochim Biophys Acta, 1997. 1333(3): p. F201-
16. 
72. Pendergast, A.M., et al., Evidence for regulation of the human ABL tyrosine 
kinase by a cellular inhibitor. Proc Natl Acad Sci U S A, 1991. 88(13): p. 5927-
31. 
73. Kharbanda, S., et al., Activation of the c-Abl tyrosine kinase in the stress 
response to DNA-damaging agents. Nature, 1995. 376(6543): p. 785-8. 
74. Liu, Z.G., et al., Three distinct signalling responses by murine fibroblasts to 
genotoxic stress. Nature, 1996. 384(6606): p. 273-6. 
75. Welch, P.J. and J.Y. Wang, A C-terminal protein-binding domain in the 
retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. 
Cell, 1993. 75(4): p. 779-90. 
76. Lewis, J.M., et al., Integrin regulation of c-Abl tyrosine kinase activity and 
cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A, 1996. 93(26): p. 
15174-9. 
77. Copland, M., H.G. Jorgensen, and T.L. Holyoake, Evolving molecular therapy 
for chronic myeloid leukaemia--are we on target? Hematology, 2005. 10(5): p. 
349-59. 
78. Deininger, M.W., et al., The prognosis for patients with chronic myeloid 
leukemia who have clonal cytogenetic abnormalities in philadelphia 
chromosome-negative cells. Cancer, 2007. 110(7): p. 1509-19. 
79. Bedi, A., et al., BCR-ABL-mediated inhibition of apoptosis with delay of G2/M 
transition after DNA damage: a mechanism of resistance to multiple anticancer 
agents. Blood, 1995. 86(3): p. 1148-58. 
80. Pendergast, A.M., et al., BCR-ABL-induced oncogenesis is mediated by direct 
interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 1993. 75(1): 
p. 175-85. 
267 
 
81. Million, R.P. and R.A. Van Etten, The Grb2 binding site is required for the 
induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl 
tyrosine kinase. Blood, 2000. 96(2): p. 664-70. 
82. Puil, L., et al., Bcr-Abl oncoproteins bind directly to activators of the Ras 
signalling pathway. EMBO J, 1994. 13(4): p. 764-73. 
83. Chang, E.H., et al., Human genome contains four genes homologous to 
transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl 
Acad Sci U S A, 1982. 79(16): p. 4848-52. 
84. Sattler, M., et al., Critical role for Gab2 in transformation by BCR/ABL. Cancer 
Cell, 2002. 1(5): p. 479-92. 
85. Wohrle, F.U., et al., Gab2 signaling in chronic myeloid leukemia cells confers 
resistance to multiple Bcr-Abl inhibitors. Leukemia, 2013. 27(1): p. 118-29. 
86. Kapeller, R. and L.C. Cantley, Phosphatidylinositol 3-kinase. Bioessays, 1994. 
16(8): p. 565-76. 
87. Divecha, N. and R.F. Irvine, Phospholipid signaling. Cell, 1995. 80(2): p. 269-
78. 
88. Alessi, D.R., et al., Mechanism of activation of protein kinase B by insulin and 
IGF-1. EMBO J, 1996. 15(23): p. 6541-51. 
89. Alessi, D.R., et al., Characterization of a 3-phosphoinositide-dependent protein 
kinase which phosphorylates and activates protein kinase Balpha. Curr Biol, 
1997. 7(4): p. 261-9. 
90. Koo, E.H. and S.L. Squazzo, Evidence that production and release of amyloid 
beta-protein involves the endocytic pathway. J Biol Chem, 1994. 269(26): p. 
17386-9. 
91. Bhaskar, P.T. and N. Hay, The two TORCs and Akt. Dev Cell, 2007. 12(4): p. 
487-502. 
92. Wullschleger, S., R. Loewith, and M.N. Hall, TOR signaling in growth and 
metabolism. Cell, 2006. 124(3): p. 471-84. 
93. Kim, D.H., et al., mTOR interacts with raptor to form a nutrient-sensitive 
complex that signals to the cell growth machinery. Cell, 2002. 110(2): p. 163-75. 
94. Kim, D.H., et al., GbetaL, a positive regulator of the rapamycin-sensitive 
pathway required for the nutrient-sensitive interaction between raptor and 
mTOR. Mol Cell, 2003. 11(4): p. 895-904. 
95. Pullen, N., et al., Phosphorylation and activation of p70s6k by PDK1. Science, 
1998. 279(5351): p. 707-10. 
96. Peterson, R.T. and S.L. Schreiber, Translation control: connecting mitogens 
and the ribosome. Curr Biol, 1998. 8(7): p. R248-50. 
97. Chiang, G.G. and R.T. Abraham, Phosphorylation of mammalian target of 
rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem, 2005. 
280(27): p. 25485-90. 
98. Pause, A., et al., Insulin-dependent stimulation of protein synthesis by 
phosphorylation of a regulator of 5'-cap function. Nature, 1994. 371(6500): p. 
762-7. 
99. Guertin, D.A. and D.M. Sabatini, Defining the role of mTOR in cancer. Cancer 
Cell, 2007. 12(1): p. 9-22. 
100. Frias, M.A., et al., mSin1 is necessary for Akt/PKB phosphorylation, and its 
isoforms define three distinct mTORC2s. Curr Biol, 2006. 16(18): p. 1865-70. 
101. Sarbassov, D.D., et al., Rictor, a novel binding partner of mTOR, defines a 
rapamycin-insensitive and raptor-independent pathway that regulates the 
cytoskeleton. Curr Biol, 2004. 14(14): p. 1296-302. 
102. Sarbassov, D.D., et al., Phosphorylation and regulation of Akt/PKB by the rictor-
mTOR complex. Science, 2005. 307(5712): p. 1098-101. 
268 
 
103. Sarbassov, D.D., et al., Prolonged rapamycin treatment inhibits mTORC2 
assembly and Akt/PKB. Mol Cell, 2006. 22(2): p. 159-68. 
104. Maira, S.M., et al., Identification and characterization of NVP-BEZ235, a new 
orally available dual phosphatidylinositol 3-kinase/mammalian target of 
rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 
2008. 7(7): p. 1851-63. 
105. Fan, Q.W., et al., A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy 
in glioma. Cancer Cell, 2006. 9(5): p. 341-9. 
106. Ghaffari, S., et al., Cytokines and BCR-ABL mediate suppression of TRAIL-
induced apoptosis through inhibition of forkhead FOXO3a transcription factor. 
Proc Natl Acad Sci U S A, 2003. 100(11): p. 6523-8. 
107. Salomoni, P., et al., Versatility of BCR/ABL-expressing leukemic cells in 
circumventing proapoptotic BAD effects. Blood, 2000. 96(2): p. 676-84. 
108. Mayo, L.D. and D.B. Donner, A phosphatidylinositol 3-kinase/Akt pathway 
promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl 
Acad Sci U S A, 2001. 98(20): p. 11598-603. 
109. Goetz, A.W., et al., Requirement for Mdm2 in the survival effects of Bcr-Abl and 
interleukin 3 in hematopoietic cells. Cancer Res, 2001. 61(20): p. 7635-41. 
110. Trotta, R., et al., BCR/ABL activates mdm2 mRNA translation via the La 
antigen. Cancer Cell, 2003. 3(2): p. 145-60. 
111. ten Hoeve, J., et al., Tyrosine phosphorylation of CRKL in Philadelphia+ 
leukemia. Blood, 1994. 84(6): p. 1731-6. 
112. Reichman, C.T., et al., The product of the cellular crk gene consists primarily of 
SH2 and SH3 regions. Cell Growth Differ, 1992. 3(7): p. 451-60. 
113. Oda, T., et al., Crkl is the major tyrosine-phosphorylated protein in neutrophils 
from patients with chronic myelogenous leukemia. J Biol Chem, 1994. 269(37): 
p. 22925-8. 
114. de Jong, R., et al., Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. 
Oncogene, 1997. 14(5): p. 507-13. 
115. de Jong, R., et al., Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-
positive leukemia. J Biol Chem, 1995. 270(37): p. 21468-71. 
116. Sattler, M., et al., Steel factor induces tyrosine phosphorylation of CRKL and 
binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, 
and p120(CBL). J Biol Chem, 1997. 272(15): p. 10248-53. 
117. Salgia, R., et al., CRKL links p210BCR/ABL with paxillin in chronic 
myelogenous leukemia cells. J Biol Chem, 1995. 270(49): p. 29145-50. 
118. Grumbach, I.M., et al., Engagement of the CrkL adaptor in interferon alpha 
signalling in BCR-ABL-expressing cells. Br J Haematol, 2001. 112(2): p. 327-
36. 
119. Druker, B.J., et al., Efficacy and safety of a specific inhibitor of the BCR-ABL 
tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 2001. 344(14): p. 
1031-7. 
120. Hamilton, A., et al., BCR-ABL activity and its response to drugs can be 
determined in CD34+ CML stem cells by CrkL phosphorylation status using flow 
cytometry. Leukemia, 2006. 20(6): p. 1035-9. 
121. Hebenstreit, D., J. Horejs-Hoeck, and A. Duschl, JAK/STAT-dependent gene 
regulation by cytokines. Drug News Perspect, 2005. 18(4): p. 243-9. 
122. Ilaria, R.L., Jr. and R.A. Van Etten, P210 and P190(BCR/ABL) induce the 
tyrosine phosphorylation and DNA binding activity of multiple specific STAT 
family members. J Biol Chem, 1996. 271(49): p. 31704-10. 
123. Chai, S.K., G.L. Nichols, and P. Rothman, Constitutive activation of JAKs and 
STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from 
leukemic patients. J Immunol, 1997. 159(10): p. 4720-8. 
269 
 
124. Ye, D., et al., STAT5 signaling is required for the efficient induction and 
maintenance of CML in mice. Blood, 2006. 107(12): p. 4917-25. 
125. Hoelbl, A., et al., Stat5 is indispensable for the maintenance of bcr/abl-positive 
leukaemia. EMBO Mol Med, 2010. 2(3): p. 98-110. 
126. Gesbert, F. and J.D. Griffin, Bcr/Abl activates transcription of the Bcl-X gene 
through STAT5. Blood, 2000. 96(6): p. 2269-76. 
127. Huang, M., et al., Inhibition of Bcr-Abl kinase activity by PD180970 blocks 
constitutive activation of Stat5 and growth of CML cells. Oncogene, 2002. 
21(57): p. 8804-16. 
128. Warsch, W., et al., High STAT5 levels mediate imatinib resistance and indicate 
disease progression in chronic myeloid leukemia. Blood, 2011. 117(12): p. 3409-
20. 
129. Klejman, A., et al., The Src family kinase Hck couples BCR/ABL to STAT5 
activation in myeloid leukemia cells. EMBO J, 2002. 21(21): p. 5766-74. 
130. Steelman, L.S., et al., JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in 
cell cycle progression and leukemogenesis. Leukemia, 2004. 18(2): p. 189-218. 
131. Roberts, A.W., G-CSF: a key regulator of neutrophil production, but that's not 
all! Growth Factors, 2005. 23(1): p. 33-41. 
132. Holyoake, T.L., et al., Primitive quiescent leukemic cells from patients with 
chronic myeloid leukemia spontaneously initiate factor-independent growth in 
vitro in association with up-regulation of expression of interleukin-3. Blood, 
2001. 97(3): p. 720-8. 
133. Holyoake, T.L., et al., Elucidating critical mechanisms of deregulated stem cell 
turnover in the chronic phase of chronic myeloid leukemia. Leukemia, 2002. 
16(4): p. 549-58. 
134. Jiang, X., et al., Autocrine production and action of IL-3 and granulocyte 
colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S 
A, 1999. 96(22): p. 12804-9. 
135. Chang, J.M., et al., Nonneoplastic hematopoietic myeloproliferative syndrome 
induced by dysregulated multi-CSF (IL-3) expression. Blood, 1989. 73(6): p. 
1487-97. 
136. Wong, P.M., et al., Retrovirus-mediated transfer and expression of the 
interleukin-3 gene in mouse hematopoietic cells result in a myeloproliferative 
disorder. Mol Cell Biol, 1989. 9(2): p. 798-808. 
137. Just, U., et al., Targeted in vivo infection with a retroviral vector carrying the 
interleukin-3 (multi-CSF) gene leads to immortalization and leukemic 
transformation of primitive hematopoietic progenitor cells. Growth Factors, 
1993. 9(1): p. 41-55. 
138. Arai, F., et al., Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell 
quiescence in the bone marrow niche. Cell, 2004. 118(2): p. 149-61. 
139. Teixido, J., et al., Role of beta 1 and beta 2 integrins in the adhesion of human 
CD34hi stem cells to bone marrow stroma. J Clin Invest, 1992. 90(2): p. 358-67. 
140. Hurley, R.W., J.B. McCarthy, and C.M. Verfaillie, Direct adhesion to bone 
marrow stroma via fibronectin receptors inhibits hematopoietic progenitor 
proliferation. J Clin Invest, 1995. 96(1): p. 511-9. 
141. Gordon, M.Y., et al., Altered adhesive interactions with marrow stroma of 
haematopoietic progenitor cells in chronic myeloid leukaemia. Nature, 1987. 
328(6128): p. 342-4. 
142. Verfaillie, C.M., et al., Integrin-mediated regulation of hematopoiesis: do 
BCR/ABL-induced defects in integrin function underlie the abnormal circulation 
and proliferation of CML progenitors? Acta Haematol, 1997. 97(1-2): p. 40-52. 
270 
 
143. Geay, J.F., et al., p210BCR-ABL inhibits SDF-1 chemotactic response via 
alteration of CXCR4 signaling and down-regulation of CXCR4 expression. 
Cancer Res, 2005. 65(7): p. 2676-83. 
144. Jin, L., et al., CXCR4 up-regulation by imatinib induces chronic myelogenous 
leukemia (CML) cell migration to bone marrow stroma and promotes survival of 
quiescent CML cells. Mol Cancer Ther, 2008. 7(1): p. 48-58. 
145. Geary, C.G., The story of chronic myeloid leukaemia. Br J Haematol, 2000. 
110(1): p. 2-11. 
146. Waxman, S. and K.C. Anderson, History of the development of arsenic 
derivatives in cancer therapy. Oncologist, 2001. 6 Suppl 2: p. 3-10. 
147. Galton, D.A., Myleran in chronic myeloid leukaemia; results of treatment. 
Lancet, 1953. 264(6753): p. 208-13. 
148. Thomas, E.D., et al., Marrow transplantation for acute nonlymphoblastic 
leukemia in first remission. N Engl J Med, 1979. 301(11): p. 597-9. 
149. Goldman, J.M., et al., Bone marrow transplantation for patients with chronic 
myeloid leukemia. N Engl J Med, 1986. 314(4): p. 202-7. 
150. Goldman, J., Hematopoietic stem cell transplantation. Curr Opin Hematol, 
1998. 5(6): p. 417-8. 
151. Gratwohl, A., et al., Risk assessment for patients with chronic myeloid 
leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia 
Working Party of the European Group for Blood and Marrow Transplantation. 
Lancet, 1998. 352(9134): p. 1087-92. 
152. Faderl, S., et al., Chronic myelogenous leukemia: biology and therapy. Ann 
Intern Med, 1999. 131(3): p. 207-19. 
153. Sawyers, C.L., Chronic myeloid leukemia. N Engl J Med, 1999. 340(17): p. 
1330-40. 
154. Talpaz, M., et al., Leukocyte interferon-induced myeloid cytoreduction in 
chronic myelogenous leukemia. Blood, 1983. 62(3): p. 689-92. 
155. Bhatia, R., et al., Interferon-alpha restores normal adhesion of chronic 
myelogenous leukemia hematopoietic progenitors to bone marrow stroma by 
correcting impaired beta 1 integrin receptor function. J Clin Invest, 1994. 94(1): 
p. 384-91. 
156. Druker, B.J., et al., Effects of a selective inhibitor of the Abl tyrosine kinase on 
the growth of Bcr-Abl positive cells. Nat Med, 1996. 2(5): p. 561-6. 
157. Buchdunger, E., et al., Inhibition of the Abl protein-tyrosine kinase in vitro and 
in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 1996. 56(1): p. 
100-4. 
158. Deininger, M.W., et al., The tyrosine kinase inhibitor CGP57148B selectively 
inhibits the growth of BCR-ABL-positive cells. Blood, 1997. 90(9): p. 3691-8. 
159. Kantarjian, H., et al., Hematologic and cytogenetic responses to imatinib 
mesylate in chronic myelogenous leukemia. N Engl J Med, 2002. 346(9): p. 645-
52. 
160. Daley, G.Q. and D. Baltimore, Transformation of an interleukin 3-dependent 
hematopoietic cell line by the chronic myelogenous leukemia-specific 
P210bcr/abl protein. Proc Natl Acad Sci U S A, 1988. 85(23): p. 9312-6. 
161. O'Brien, S.G., et al., Imatinib compared with interferon and low-dose cytarabine 
for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 
2003. 348(11): p. 994-1004. 
162. Hochhaus, A., et al., Six-year follow-up of patients receiving imatinib for the 
first-line treatment of chronic myeloid leukemia. Leukemia, 2009. 23(6): p. 
1054-61. 
271 
 
163. Li, S., et al., The P190, P210, and P230 forms of the BCR/ABL oncogene induce 
a similar chronic myeloid leukemia-like syndrome in mice but have different 
lymphoid leukemogenic activity. J Exp Med, 1999. 189(9): p. 1399-412. 
164. Pane, F., et al., Neutrophilic-chronic myeloid leukemia: a distinct disease with a 
specific molecular marker (BCR/ABL with C3/A2 junction). Blood, 1996. 88(7): 
p. 2410-4. 
165. O'Brien, S.G. and M.W. Deininger, Imatinib in patients with newly diagnosed 
chronic-phase chronic myeloid leukemia. Semin Hematol, 2003. 40(2 Suppl 2): 
p. 26-30. 
166. Druker, B.J., et al., Five-year follow-up of patients receiving imatinib for 
chronic myeloid leukemia. N Engl J Med, 2006. 355(23): p. 2408-17. 
167. Branford, S., et al., Imatinib produces significantly superior molecular 
responses compared to interferon alfa plus cytarabine in patients with newly 
diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 2003. 17(12): 
p. 2401-9. 
168. Hughes, T.P., et al., Frequency of major molecular responses to imatinib or 
interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N 
Engl J Med, 2003. 349(15): p. 1423-32. 
169. Tokarski, J.S., et al., The structure of Dasatinib (BMS-354825) bound to 
activated ABL kinase domain elucidates its inhibitory activity against imatinib-
resistant ABL mutants. Cancer Res, 2006. 66(11): p. 5790-7. 
170. Alvarado, Y., et al., Significance of suboptimal response to imatinib, as defined 
by the European LeukemiaNet, in the long-term outcome of patients with early 
chronic myeloid leukemia in chronic phase. Cancer, 2009. 115(16): p. 3709-18. 
171. Mahon, F.X., et al., Discontinuation of imatinib in patients with chronic myeloid 
leukaemia who have maintained complete molecular remission for at least 2 
years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 
2010. 11(11): p. 1029-35. 
172. Ross, D.M., et al., Patients with chronic myeloid leukemia who maintain a 
complete molecular response after stopping imatinib treatment have evidence of 
persistent leukemia by DNA PCR. Leukemia, 2010. 24(10): p. 1719-24. 
173. Graham, S.M., et al., Primitive, quiescent, Philadelphia-positive stem cells from 
patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 
2002. 99(1): p. 319-25. 
174. Michor, F., et al., Dynamics of chronic myeloid leukaemia. Nature, 2005. 
435(7046): p. 1267-70. 
175. Holtz, M.S., et al., Imatinib mesylate (STI571) inhibits growth of primitive 
malignant progenitors in chronic myelogenous leukemia through reversal of 
abnormally increased proliferation. Blood, 2002. 99(10): p. 3792-800. 
176. le Coutre, P., et al., Induction of resistance to the Abelson inhibitor STI571 in 
human leukemic cells through gene amplification. Blood, 2000. 95(5): p. 1758-
66. 
177. Mahon, F.X., et al., Selection and characterization of BCR-ABL positive cell 
lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse 
mechanisms of resistance. Blood, 2000. 96(3): p. 1070-9. 
178. Weisberg, E. and J.D. Griffin, Mechanism of resistance to the ABL tyrosine 
kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. 
Blood, 2000. 95(11): p. 3498-505. 
179. Quintas-Cardama, A., H.M. Kantarjian, and J.E. Cortes, Mechanisms of 
primary and secondary resistance to imatinib in chronic myeloid leukemia. 
Cancer Control, 2009. 16(2): p. 122-31. 
180. Stoklosa, T., et al., BCR/ABL inhibits mismatch repair to protect from apoptosis 
and induce point mutations. Cancer Res, 2008. 68(8): p. 2576-80. 
272 
 
181. Gorre, M.E., et al., Clinical resistance to STI-571 cancer therapy caused by 
BCR-ABL gene mutation or amplification. Science, 2001. 293(5531): p. 876-80. 
182. von Bubnoff, N., et al., A cell-based screen for resistance of Bcr-Abl-positive 
leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase 
inhibitor. Blood, 2005. 105(4): p. 1652-9. 
183. Corbin, A.S., et al., Several Bcr-Abl kinase domain mutants associated with 
imatinib mesylate resistance remain sensitive to imatinib. Blood, 2003. 101(11): 
p. 4611-4. 
184. Nicolini, F.E., et al., Mutation status and clinical outcome of 89 imatinib 
mesylate-resistant chronic myelogenous leukemia patients: a retrospective 
analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). 
Leukemia, 2006. 20(6): p. 1061-6. 
185. Soverini, S., et al., Contribution of ABL kinase domain mutations to imatinib 
resistance in different subsets of Philadelphia-positive patients: by the GIMEMA 
Working Party on Chronic Myeloid Leukemia. Clin Cancer Res, 2006. 12(24): p. 
7374-9. 
186. O'Hare, T., C.A. Eide, and M.W. Deininger, Bcr-Abl kinase domain mutations, 
drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 
2007. 110(7): p. 2242-9. 
187. Karvela, M., G.V. Helgason, and T.L. Holyoake, Mechanisms and novel 
approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid 
leukemia. Expert Rev Anticancer Ther, 2012. 12(3): p. 381-92. 
188. Hochhaus, A., Cytogenetic and molecular mechanisms of resistance to imatinib. 
Semin Hematol, 2003. 40(2 Suppl 2): p. 69-79. 
189. Tang, C., et al., Tyrosine kinase inhibitor resistance in chronic myeloid leukemia 
cell lines: investigating resistance pathways. Leuk Lymphoma, 2011. 52(11): p. 
2139-47. 
190. Hochhaus, A., et al., Molecular and chromosomal mechanisms of resistance to 
imatinib (STI571) therapy. Leukemia, 2002. 16(11): p. 2190-6. 
191. Brusa, G., et al., P210 Bcr-abl tyrosine kinase interaction with histone 
deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic 
myeloid leukaemia haematopoietic progenitors. Br J Haematol, 2006. 132(3): p. 
359-69. 
192. Lee, S.M., et al., Bcr-Abl-independent imatinib-resistant K562 cells show 
aberrant protein acetylation and increased sensitivity to histone deacetylase 
inhibitors. J Pharmacol Exp Ther, 2007. 322(3): p. 1084-92. 
193. Carette, J.E., et al., Generation of iPSCs from cultured human malignant cells. 
Blood, 2010. 115(20): p. 4039-42. 
194. Fioretos, T., et al., Isochromosome 17q in blast crisis of chronic myeloid 
leukemia and in other hematologic malignancies is the result of clustered 
breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood, 
1999. 94(1): p. 225-32. 
195. Schutte, J., et al., Analysis of the p53 gene in patients with isochromosome 17q 
and Ph1-positive or -negative myeloid leukemia. Leuk Res, 1993. 17(6): p. 533-9. 
196. Donato, N.J., et al., Imatinib mesylate resistance through BCR-ABL 
independence in chronic myelogenous leukemia. Cancer Res, 2004. 64(2): p. 
672-7. 
197. Donato, N.J., et al., BCR-ABL independence and LYN kinase overexpression in 
chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 
2003. 101(2): p. 690-8. 
198. Wang, Y., et al., Adaptive secretion of granulocyte-macrophage colony-
stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in 
273 
 
BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood, 2007. 
109(5): p. 2147-55. 
199. Nishioka, C., et al., Long-term exposure of leukemia cells to multi-targeted 
tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling 
via epigenetic silencing of the PTEN gene. Leukemia, 2010. 24(9): p. 1631-40. 
200. de Lavallade, H., et al., A gene expression signature of primary resistance to 
imatinib in chronic myeloid leukemia. Leuk Res, 2010. 34(2): p. 254-7. 
201. Mahon, F.X., et al., MDR1 gene overexpression confers resistance to imatinib 
mesylate in leukemia cell line models. Blood, 2003. 101(6): p. 2368-73. 
202. Hatziieremia, S., et al., Inhibition of MDR1 does not sensitize primitive chronic 
myeloid leukemia CD34+ cells to imatinib. Exp Hematol, 2009. 37(6): p. 692-
700. 
203. Gambacorti-Passerini, C., et al., Role of alpha1 acid glycoprotein in the in vivo 
resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J 
Natl Cancer Inst, 2000. 92(20): p. 1641-50. 
204. Gambacorti-Passerini, C., et al., Alpha1 acid glycoprotein binds to imatinib 
(STI571) and substantially alters its pharmacokinetics in chronic myeloid 
leukemia patients. Clin Cancer Res, 2003. 9(2): p. 625-32. 
205. Jorgensen, H.G., et al., Alpha1-acid glycoprotein expressed in the plasma of 
chronic myeloid leukemia patients does not mediate significant in vitro resistance 
to STI571. Blood, 2002. 99(2): p. 713-5. 
206. Thomas, J., et al., Active transport of imatinib into and out of cells: implications 
for drug resistance. Blood, 2004. 104(12): p. 3739-45. 
207. Wang, L., et al., Expression of the uptake drug transporter hOCT1 is an 
important clinical determinant of the response to imatinib in chronic myeloid 
leukemia. Clin Pharmacol Ther, 2008. 83(2): p. 258-64. 
208. Giannoudis, A., et al., The hOCT1 SNPs M420del and M408V alter imatinib 
uptake and M420del modifies clinical outcome in imatinib-treated chronic 
myeloid leukaemia. Blood, 2012. 
209. Green, H., et al., CYP3A activity influences imatinib response in patients with 
chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin 
Pharmacol, 2010. 66(4): p. 383-6. 
210. Noens, L., et al., Prevalence, determinants, and outcomes of nonadherence to 
imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. 
Blood, 2009. 113(22): p. 5401-11. 
211. Marin, D., et al., Adherence is the critical factor for achieving molecular 
responses in patients with chronic myeloid leukemia who achieve complete 
cytogenetic responses on imatinib. J Clin Oncol, 2010. 28(14): p. 2381-8. 
212. Kantarjian, H.M., et al., Dose escalation of imatinib mesylate can overcome 
resistance to standard-dose therapy in patients with chronic myelogenous 
leukemia. Blood, 2003. 101(2): p. 473-5. 
213. Jabbour, E., et al., Imatinib mesylate dose escalation is associated with durable 
responses in patients with chronic myeloid leukemia after cytogenetic failure on 
standard-dose imatinib therapy. Blood, 2009. 113(10): p. 2154-60. 
214. Lombardo, L.J., et al., Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-
hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-
carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent 
antitumor activity in preclinical assays. J Med Chem, 2004. 47(27): p. 6658-61. 
215. O'Hare, T., et al., In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-
354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. 
Cancer Res, 2005. 65(11): p. 4500-5. 
216. Shah, N.P., et al., Overriding imatinib resistance with a novel ABL kinase 
inhibitor. Science, 2004. 305(5682): p. 399-401. 
274 
 
217. Hochhaus, A., et al., Dasatinib induces durable cytogenetic responses in patients 
with chronic myelogenous leukemia in chronic phase with resistance or 
intolerance to imatinib. Leukemia, 2008. 22(6): p. 1200-6. 
218. Kantarjian, H., et al., Dasatinib versus imatinib in newly diagnosed chronic-
phase chronic myeloid leukemia. N Engl J Med, 2010. 362(24): p. 2260-70. 
219. Cortes, J., et al., Efficacy and safety of dasatinib in imatinib-resistant or -
intolerant patients with chronic myeloid leukemia in blast phase. Leukemia, 
2008. 22(12): p. 2176-83. 
220. Apperley, J.F., et al., Dasatinib in the treatment of chronic myeloid leukemia in 
accelerated phase after imatinib failure: the START a trial. J Clin Oncol, 2009. 
27(21): p. 3472-9. 
221. Copland, M., et al., Dasatinib (BMS-354825) targets an earlier progenitor 
population than imatinib in primary CML but does not eliminate the quiescent 
fraction. Blood, 2006. 107(11): p. 4532-9. 
222. O'Hare, T., et al., AMN107: tightening the grip of imatinib. Cancer Cell, 2005. 
7(2): p. 117-9. 
223. Golemovic, M., et al., AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, 
has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin 
Cancer Res, 2005. 11(13): p. 4941-7. 
224. Weisberg, E., et al., Characterization of AMN107, a selective inhibitor of native 
and mutant Bcr-Abl. Cancer Cell, 2005. 7(2): p. 129-41. 
225. Kantarjian, H.M., et al., Nilotinib versus imatinib for the treatment of patients 
with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic 
myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised 
ENESTnd trial. Lancet Oncol, 2011. 12(9): p. 841-51. 
226. Jorgensen, H.G., et al., Nilotinib exerts equipotent antiproliferative effects to 
imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 2007. 
109(9): p. 4016-9. 
227. O'Hare, T., et al., AP24534, a pan-BCR-ABL inhibitor for chronic myeloid 
leukemia, potently inhibits the T315I mutant and overcomes mutation-based 
resistance. Cancer Cell, 2009. 16(5): p. 401-12. 
228. Cortes, J.E., et al., Ponatinib in refractory Philadelphia chromosome-positive 
leukemias. N Engl J Med, 2012. 367(22): p. 2075-88. 
229. Jorge E. Cortes, D.-W.K., Javier Pinilla-Ibarz, Ronald Paquette, Philipp D. le 
Coutre, Charles Chuah, Franck E. Nicolini, Jane Apperley, Hanna Jean 
Khoury, Moshe Talpaz, John F DiPersio, Daniel J DeAngelo, Delphine Rea, 
Elisabetta Abruzzese, Martin C Müller, Michele Baccarani, Carlo 
Gambacorti-Passerini, Christopher D. Turner, Frank G. Haluska, Hagop 
Kantarjian; University of Texas M. D. Anderson Cancer Center, Houston, TX; 
The Catholic University of Korea, Seoul, South Korea; H. Lee Moffitt Cancer 
Center & Research Institute, Tampa, FL; Ronald Reagan UCLA Medical 
Center, Los Angeles, CA; Charité University of Medicine Berlin, Berlin, 
Germany; Singapore General Hospital, Singapore, Singapore; Centre 
Hospitalier Lyon Sud, Pierre Bénite, France; Hammersmith Hospital, 
Imperial College London, London, United Kingdom; Emory Winship Cancer 
Institute, Atlanta, GA; Comprehensive Cancer Center, University of 
Michigan, Ann Arbor, MI, J Clin Oncol 30, 2012: p. suppl; abstr 6503) 
. 
230. ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed 
CML. July 28, 2012 [cited 2012 18 Septermber]. 
231. Zhang, J., et al., Targeting Bcr-Abl by combining allosteric with ATP-binding-
site inhibitors. Nature, 2010. 463(7280): p. 501-6. 
275 
 
232. Chan, W.W., et al., Conformational control inhibition of the BCR-ABL1 
tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control 
inhibitor DCC-2036. Cancer Cell, 2011. 19(4): p. 556-68. 
233. Smahel, M., Antigens in chronic myeloid leukemia: implications for vaccine 
development. Cancer Immunol Immunother, 2011. 60(12): p. 1655-68. 
234. Corbin, A.S., et al., Human chronic myeloid leukemia stem cells are insensitive 
to imatinib despite inhibition of BCR-ABL activity. J Clin Invest, 2011. 121(1): 
p. 396-409. 
235. Hamilton, A., et al., Chronic myeloid leukemia stem cells are not dependent on 
Bcr-Abl kinase activity for their survival. Blood, 2012. 119(6): p. 1501-10. 
236. Zhang, B., et al., Effective targeting of quiescent chronic myelogenous leukemia 
stem cells by histone deacetylase inhibitors in combination with imatinib 
mesylate. Cancer Cell, 2010. 17(5): p. 427-42. 
237. Preudhomme, C., et al., Imatinib plus peginterferon alfa-2a in chronic myeloid 
leukemia. N Engl J Med, 2010. 363(26): p. 2511-21. 
238. Chen, Y., et al., Loss of the Alox5 gene impairs leukemia stem cells and prevents 
chronic myeloid leukemia. Nat Genet, 2009. 41(7): p. 783-92. 
239. Zhao, C., et al., Hedgehog signalling is essential for maintenance of cancer stem 
cells in myeloid leukaemia. Nature, 2009. 458(7239): p. 776-9. 
240. Kundu, M. and C.B. Thompson, Autophagy: basic principles and relevance to 
disease. Annu Rev Pathol, 2008. 3: p. 427-55. 
241. Rosenfeldt, M.T. and K.M. Ryan, The multiple roles of autophagy in cancer. 
Carcinogenesis, 2011. 32(7): p. 955-63. 
242. Huang, J. and D.J. Klionsky, Autophagy and human disease. Cell Cycle, 2007. 
6(15): p. 1837-49. 
243. Nakatogawa, H., et al., Dynamics and diversity in autophagy mechanisms: 
lessons from yeast. Nat Rev Mol Cell Biol, 2009. 10(7): p. 458-67. 
244. Rubinsztein, D.C., et al., Potential therapeutic applications of autophagy. Nat 
Rev Drug Discov, 2007. 6(4): p. 304-12. 
245. He, C. and D.J. Klionsky, Regulation mechanisms and signaling pathways of 
autophagy. Annu Rev Genet, 2009. 43: p. 67-93. 
246. Helgason, G.V., M. Karvela, and T.L. Holyoake, Kill one bird with two stones: 
potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood, 2011. 
118(8): p. 2035-43. 
247. Kim, J., et al., AMPK and mTOR regulate autophagy through direct 
phosphorylation of Ulk1. Nat Cell Biol, 2011. 13(2): p. 132-41. 
248. Hara, T., et al., FIP200, a ULK-interacting protein, is required for 
autophagosome formation in mammalian cells. J Cell Biol, 2008. 181(3): p. 497-
510. 
249. Jung, C.H., et al., ULK-Atg13-FIP200 complexes mediate mTOR signaling to 
the autophagy machinery. Mol Biol Cell, 2009. 20(7): p. 1992-2003. 
250. Hosokawa, N., et al., Nutrient-dependent mTORC1 association with the ULK1-
Atg13-FIP200 complex required for autophagy. Mol Biol Cell, 2009. 20(7): p. 
1981-91. 
251. Vanhaesebroeck, B., et al., Synthesis and function of 3-phosphorylated inositol 
lipids. Annu Rev Biochem, 2001. 70: p. 535-602. 
252. Lindmo, K. and H. Stenmark, Regulation of membrane traffic by 
phosphoinositide 3-kinases. J Cell Sci, 2006. 119(Pt 4): p. 605-14. 
253. Kihara, A., et al., Beclin-phosphatidylinositol 3-kinase complex functions at the 
trans-Golgi network. EMBO Rep, 2001. 2(4): p. 330-5. 
254. Liang, X.H., et al., Induction of autophagy and inhibition of tumorigenesis by 
beclin 1. Nature, 1999. 402(6762): p. 672-6. 
276 
 
255. Sun, Q., et al., Identification of Barkor as a mammalian autophagy-specific 
factor for Beclin 1 and class III phosphatidylinositol 3-kinase. Proc Natl Acad 
Sci U S A, 2008. 105(49): p. 19211-6. 
256. Itakura, E., et al., Beclin 1 forms two distinct phosphatidylinositol 3-kinase 
complexes with mammalian Atg14 and UVRAG. Mol Biol Cell, 2008. 19(12): p. 
5360-72. 
257. Itakura, E. and N. Mizushima, Characterization of autophagosome formation 
site by a hierarchical analysis of mammalian Atg proteins. Autophagy, 2010. 
6(6): p. 764-76. 
258. Matsunaga, K., et al., Autophagy requires endoplasmic reticulum targeting of 
the PI3-kinase complex via Atg14L. J Cell Biol, 2010. 190(4): p. 511-21. 
259. Maiuri, M.C., et al., Functional and physical interaction between Bcl-X(L) and a 
BH3-like domain in Beclin-1. EMBO J, 2007. 26(10): p. 2527-39. 
260. Pattingre, S., et al., Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent 
autophagy. Cell, 2005. 122(6): p. 927-39. 
261. Liang, C., et al., Autophagic and tumour suppressor activity of a novel Beclin1-
binding protein UVRAG. Nat Cell Biol, 2006. 8(7): p. 688-99. 
262. Di Bartolomeo, S., et al., The dynamic interaction of AMBRA1 with the dynein 
motor complex regulates mammalian autophagy. J Cell Biol, 2010. 191(1): p. 
155-68. 
263. Tooze, S.A. and T. Yoshimori, The origin of the autophagosomal membrane. 
Nat Cell Biol, 2010. 12(9): p. 831-5. 
264. Mizushima, N., et al., Mouse Apg16L, a novel WD-repeat protein, targets to the 
autophagic isolation membrane with the Apg12-Apg5 conjugate. J Cell Sci, 2003. 
116(Pt 9): p. 1679-88. 
265. He, H., et al., Post-translational modifications of three members of the human 
MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. 
J Biol Chem, 2003. 278(31): p. 29278-87. 
266. Xin, Y., et al., Cloning, expression patterns, and chromosome localization of 
three human and two mouse homologues of GABA(A) receptor-associated 
protein. Genomics, 2001. 74(3): p. 408-13. 
267. Kirisako, T., et al., The reversible modification regulates the membrane-binding 
state of Apg8/Aut7 essential for autophagy and the cytoplasm to vacuole 
targeting pathway. J Cell Biol, 2000. 151(2): p. 263-76. 
268. Kabeya, Y., et al., LC3, a mammalian homologue of yeast Apg8p, is localized in 
autophagosome membranes after processing. EMBO J, 2000. 19(21): p. 5720-8. 
269. Fujita, N., et al., The Atg16L complex specifies the site of LC3 lipidation for 
membrane biogenesis in autophagy. Mol Biol Cell, 2008. 19(5): p. 2092-100. 
270. Hanada, T., et al., The Atg12-Atg5 conjugate has a novel E3-like activity for 
protein lipidation in autophagy. J Biol Chem, 2007. 282(52): p. 37298-302. 
271. Pankiv, S., et al., p62/SQSTM1 binds directly to Atg8/LC3 to facilitate 
degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem, 
2007. 282(33): p. 24131-45. 
272. Wang, Q.J., et al., Induction of autophagy in axonal dystrophy and 
degeneration. J Neurosci, 2006. 26(31): p. 8057-68. 
273. Nakai, A., et al., The role of autophagy in cardiomyocytes in the basal state and 
in response to hemodynamic stress. Nat Med, 2007. 13(5): p. 619-24. 
274. Kirkin, V., et al., A role for NBR1 in autophagosomal degradation of 
ubiquitinated substrates. Mol Cell, 2009. 33(4): p. 505-16. 
275. Geng, J. and D.J. Klionsky, The Atg8 and Atg12 ubiquitin-like conjugation 
systems in macroautophagy. 'Protein modifications: beyond the usual suspects' 
review series. EMBO Rep, 2008. 9(9): p. 859-64. 
277 
 
276. Jager, S., et al., Role for Rab7 in maturation of late autophagic vacuoles. J Cell 
Sci, 2004. 117(Pt 20): p. 4837-48. 
277. Tanaka, Y., et al., Accumulation of autophagic vacuoles and cardiomyopathy in 
LAMP-2-deficient mice. Nature, 2000. 406(6798): p. 902-6. 
278. Liang, C., et al., Beclin1-binding UVRAG targets the class C Vps complex to 
coordinate autophagosome maturation and endocytic trafficking. Nat Cell Biol, 
2008. 10(7): p. 776-87. 
279. Tanida, I., et al., Lysosomal turnover, but not a cellular level, of endogenous 
LC3 is a marker for autophagy. Autophagy, 2005. 1(2): p. 84-91. 
280. Bursch, W., et al., Programmed cell death (PCD). Apoptosis, autophagic PCD, 
or others? Ann N Y Acad Sci, 2000. 926: p. 1-12. 
281. Hotchkiss, R.S., et al., Cell death. N Engl J Med, 2009. 361(16): p. 1570-83. 
282. Hollstein, M., et al., p53 mutations in human cancers. Science, 1991. 253(5015): 
p. 49-53. 
283. Sigal, A. and V. Rotter, Oncogenic mutations of the p53 tumor suppressor: the 
demons of the guardian of the genome. Cancer Res, 2000. 60(24): p. 6788-93. 
284. Crighton, D., et al., DRAM, a p53-induced modulator of autophagy, is critical 
for apoptosis. Cell, 2006. 126(1): p. 121-34. 
285. Crighton, D., S. Wilkinson, and K.M. Ryan, DRAM links autophagy to p53 and 
programmed cell death. Autophagy, 2007. 3(1): p. 72-4. 
286. Tasdemir, E., et al., A dual role of p53 in the control of autophagy. Autophagy, 
2008. 4(6): p. 810-4. 
287. Lee, I.H., et al., Atg7 modulates p53 activity to regulate cell cycle and survival 
during metabolic stress. Science, 2012. 336(6078): p. 225-8. 
288. Yousefi, S., et al., Calpain-mediated cleavage of Atg5 switches autophagy to 
apoptosis. Nat Cell Biol, 2006. 8(10): p. 1124-32. 
289. Qu, X., et al., Promotion of tumorigenesis by heterozygous disruption of the 
beclin 1 autophagy gene. J Clin Invest, 2003. 112(12): p. 1809-20. 
290. Yue, Z., et al., Beclin 1, an autophagy gene essential for early embryonic 
development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A, 
2003. 100(25): p. 15077-82. 
291. Mizushima, N. and M. Komatsu, Autophagy: renovation of cells and tissues. 
Cell, 2011. 147(4): p. 728-41. 
292. Levine, B., N. Mizushima, and H.W. Virgin, Autophagy in immunity and 
inflammation. Nature, 2011. 469(7330): p. 323-35. 
293. Kirkin, V., et al., A role for ubiquitin in selective autophagy. Mol Cell, 2009. 
34(3): p. 259-69. 
294. Wang, G., Z.Q. Yang, and K. Zhang, Endoplasmic reticulum stress response in 
cancer: molecular mechanism and therapeutic potential. Am J Transl Res, 2010. 
2(1): p. 65-74. 
295. Jin, S.M., et al., Mitochondrial membrane potential regulates PINK1 import and 
proteolytic destabilization by PARL. J Cell Biol, 2010. 191(5): p. 933-42. 
296. Fujiwara, M., et al., Parkin as a tumor suppressor gene for hepatocellular 
carcinoma. Oncogene, 2008. 27(46): p. 6002-11. 
297. Mathew, R., et al., Autophagy suppresses tumorigenesis through elimination of 
p62. Cell, 2009. 137(6): p. 1062-75. 
298. Komatsu, M., et al., The selective autophagy substrate p62 activates the stress 
responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell 
Biol, 2010. 12(3): p. 213-23. 
299. Lau, A., et al., A noncanonical mechanism of Nrf2 activation by autophagy 
deficiency: direct interaction between Keap1 and p62. Mol Cell Biol, 2010. 
30(13): p. 3275-85. 
278 
 
300. Komatsu, M., et al., Homeostatic levels of p62 control cytoplasmic inclusion 
body formation in autophagy-deficient mice. Cell, 2007. 131(6): p. 1149-63. 
301. Takamura, A., et al., Autophagy-deficient mice develop multiple liver tumors. 
Genes Dev, 2011. 25(8): p. 795-800. 
302. Lau, A., et al., Dual roles of Nrf2 in cancer. Pharmacol Res, 2008. 58(5-6): p. 
262-70. 
303. Colotta, F., et al., Cancer-related inflammation, the seventh hallmark of cancer: 
links to genetic instability. Carcinogenesis, 2009. 30(7): p. 1073-81. 
304. Cadwell, K., et al., A key role for autophagy and the autophagy gene Atg16l1 in 
mouse and human intestinal Paneth cells. Nature, 2008. 456(7219): p. 259-63. 
305. Mareninova, O.A., et al., Impaired autophagic flux mediates acinar cell vacuole 
formation and trypsinogen activation in rodent models of acute pancreatitis. J 
Clin Invest, 2009. 119(11): p. 3340-55. 
306. Funderburk, S.F., Q.J. Wang, and Z. Yue, The Beclin 1-VPS34 complex--at the 
crossroads of autophagy and beyond. Trends Cell Biol, 2010. 20(6): p. 355-62. 
307. White, E., Deconvoluting the context-dependent role for autophagy in cancer. 
Nat Rev Cancer, 2012. 12(6): p. 401-10. 
308. Cuervo, A.M., Autophagy: in sickness and in health. Trends Cell Biol, 2004. 
14(2): p. 70-7. 
309. Guo, J.Y., et al., Activated Ras requires autophagy to maintain oxidative 
metabolism and tumorigenesis. Genes Dev, 2011. 25(5): p. 460-70. 
310. Lock, R., et al., Autophagy facilitates glycolysis during Ras-mediated oncogenic 
transformation. Mol Biol Cell, 2011. 22(2): p. 165-78. 
311. Yang, S., et al., Pancreatic cancers require autophagy for tumor growth. Genes 
Dev, 2011. 25(7): p. 717-29. 
312. Solomon, V.R. and H. Lee, Chloroquine and its analogs: a new promise of an 
old drug for effective and safe cancer therapies. Eur J Pharmacol, 2009. 625(1-
3): p. 220-33. 
313. Levy, G.D., et al., Incidence of hydroxychloroquine retinopathy in 1,207 patients 
in a large multicenter outpatient practice. Arthritis Rheum, 1997. 40(8): p. 
1482-6. 
314. Blommaart, E.F., et al., The phosphatidylinositol 3-kinase inhibitors 
wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J 
Biochem, 1997. 243(1-2): p. 240-6. 
315. Caro, L.H., et al., 3-Methyladenine, an inhibitor of autophagy, has multiple 
effects on metabolism. Eur J Biochem, 1988. 175(2): p. 325-9. 
316. Kochl, R., et al., Microtubules facilitate autophagosome formation and fusion of 
autophagosomes with endosomes. Traffic, 2006. 7(2): p. 129-45. 
317. Klionsky, D.J., et al., Guidelines for the use and interpretation of assays for 
monitoring autophagy in higher eukaryotes. Autophagy, 2008. 4(2): p. 151-75. 
318. Townsend, K.N., et al., Autophagy inhibition in cancer therapy: metabolic 
considerations for antitumor immunity. Immunol Rev, 2012. 249(1): p. 176-94. 
319. Yan, C.H., et al., Contributions of autophagic and apoptotic mechanisms to 
CrTX-induced death of K562 cells. Toxicon, 2006. 47(5): p. 521-30. 
320. Carew, J.S., et al., Targeting autophagy augments the anticancer activity of the 
histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug 
resistance. Blood, 2007. 110(1): p. 313-22. 
321. Kamitsuji, Y., et al., The Bcr-Abl kinase inhibitor INNO-406 induces autophagy 
and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell 
Death Differ, 2008. 15(11): p. 1712-22. 
322. Mishima, Y., et al., Autophagy and autophagic cell death are next targets for 
elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci, 2008. 
99(11): p. 2200-8. 
279 
 
323. Bellodi, C., et al., Targeting autophagy potentiates tyrosine kinase inhibitor-
induced cell death in Philadelphia chromosome-positive cells, including primary 
CML stem cells. J Clin Invest, 2009. 119(5): p. 1109-23. 
324. Sheng, Z., et al., BCR-ABL suppresses autophagy through ATF5-mediated 
regulation of mTOR transcription. Blood, 2011. 118(10): p. 2840-8. 
325. Crowley, L.C., et al., Autophagy induction by Bcr-Abl-expressing cells facilitates 
their recovery from a targeted or nontargeted treatment. Am J Hematol, 2011. 
86(1): p. 38-47. 
326. Carayol, N., et al., Critical roles for mTORC2- and rapamycin-insensitive 
mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic 
cells. Proc Natl Acad Sci U S A, 2010. 107(28): p. 12469-74. 
327. Carella, A.M., et al., Clarithromycin potentiates tyrosine kinase inhibitor 
treatment in patients with resistant chronic myeloid leukemia. Leuk Lymphoma, 
2012. 53(7): p. 1409-11. 
328. Yu, Y., et al., Targeting microRNA-30a-mediated autophagy enhances imatinib 
activity against human chronic myeloid leukemia cells. Leukemia, 2012. 26(8): 
p. 1752-60. 
329. Tong, Y., et al., Perifosine induces protective autophagy and upregulation of 
ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol 
Sin, 2012. 33(4): p. 542-50. 
330. Altman, B.J., et al., Autophagy is essential to suppress cell stress and to allow 
BCR-Abl-mediated leukemogenesis. Oncogene, 2011. 30(16): p. 1855-67. 
331. Puissant, A., et al., Resveratrol promotes autophagic cell death in chronic 
myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and 
AMPK activation. Cancer Res, 2010. 70(3): p. 1042-52. 
332. Goussetis, D.J., E. Gounaris, and L.C. Platanias, BCR-ABL1-induced 
leukemogenesis and autophagic targeting by arsenic trioxide. Autophagy, 2012. 
9(1). 
333. Goussetis, D.J., et al., Autophagic degradation of the BCR-ABL oncoprotein and 
generation of antileukemic responses by arsenic trioxide. Blood, 2012. 
334. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 
2001. 25(4): p. 402-8. 
335. Deguchi, T., et al., Comparison of the intrusion effects on the maxillary incisors 
between implant anchorage and J-hook headgear. Am J Orthod Dentofacial 
Orthop, 2008. 133(5): p. 654-60. 
336. Shah, N.P., et al., Transient potent BCR-ABL inhibition is sufficient to commit 
chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell, 2008. 
14(6): p. 485-93. 
337. Mauro, M.J. and B.J. Druker, STI571: targeting BCR-ABL as therapy for 
CML. Oncologist, 2001. 6(3): p. 233-8. 
338. Deguchi, Y., et al., Comparison of imatinib, dasatinib, nilotinib and INNO-406 
in imatinib-resistant cell lines. Leuk Res, 2008. 32(6): p. 980-3. 
339. Klionsky, D.J., et al., Guidelines for the use and interpretation of assays for 
monitoring autophagy. Autophagy, 2012. 8(4): p. 445-544. 
340. Eskelinen, E.L., et al., Seeing is believing: the impact of electron microscopy on 
autophagy research. Autophagy, 2011. 7(9): p. 935-56. 
341. Rubinsztein, D.C., et al., In search of an "autophagomometer". Autophagy, 
2009. 5(5): p. 585-9. 
342. Kimura, S., et al., Monitoring autophagy in mammalian cultured cells through 
the dynamics of LC3. Methods Enzymol, 2009. 452: p. 1-12. 
280 
 
343. Kimura, S., T. Noda, and T. Yoshimori, Dissection of the autophagosome 
maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. 
Autophagy, 2007. 3(5): p. 452-60. 
344. Mizushima, N., T. Yoshimori, and B. Levine, Methods in mammalian 
autophagy research. Cell, 2010. 140(3): p. 313-26. 
345. Mleczak, A., et al., Regulation of autophagosome formation by Rho kinase. Cell 
Signal, 2013. 25(1): p. 1-11. 
346. Shah, N.P., et al., Sequential ABL kinase inhibitor therapy selects for compound 
drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin 
Invest, 2007. 117(9): p. 2562-9. 
347. Schuster, K., et al., Selective targeting of the mTORC1/2 protein kinase 
complexes leads to antileukemic effects in vitro and in vivo. Blood Cancer J, 
2011. 1(9): p. e34. 
348. Amaravadi, R. Autophagy Inhibition in Cancer Therapy: Progress and 
Unanswered 
Questions in AAAS Annual Meeting, Autophagy: An Emerging Therapeutic Target in 
Human 
Disease. 2012. 
349. Zhang, W.H., KB. Spelman, J. LeRoy, P., et al, Identification of small molecule 
inhibitors of ATG7, in Keystone Symposia2011,  
. 
350. Wilber, A., et al., Therapeutic levels of fetal hemoglobin in erythroid progeny of 
beta-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. 
Blood, 2011. 117(10): p. 2817-26. 
351. Modi, H., et al., Inhibition of Grb2 expression demonstrates an important role in 
BCR-ABL-mediated MAPK activation and transformation of primary human 
hematopoietic cells. Leukemia, 2011. 25(2): p. 305-12. 
352. Yang, D., et al., Therapeutic potential of a synthetic lethal interaction between 
the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci 
U S A, 2010. 107(31): p. 13836-41. 
353. Bray, K., et al., Autophagy suppresses RIP kinase-dependent necrosis enabling 
survival to mTOR inhibition. PLoS One, 2012. 7(7): p. e41831. 
354. Wilson, E.N., et al., A switch between cytoprotective and cytotoxic autophagy in 
the radiosensitization of breast tumor cells by chloroquine and vitamin D. Horm 
Cancer, 2011. 2(5): p. 272-85. 
355. Mortensen, M., et al., The autophagy protein Atg7 is essential for hematopoietic 
stem cell maintenance. J Exp Med, 2011. 208(3): p. 455-67. 
356. Vessoni, A.T., A.R. Muotri, and O.K. Okamoto, Autophagy in stem cell 
maintenance and differentiation. Stem Cells Dev, 2012. 21(4): p. 513-20. 
357. Tsukamoto, S., A. Kuma, and N. Mizushima, The role of autophagy during the 
oocyte-to-embryo transition. Autophagy, 2008. 4(8): p. 1076-8. 
358. Singh, R., et al., Autophagy regulates adipose mass and differentiation in mice. J 
Clin Invest, 2009. 119(11): p. 3329-39. 
359. Takano-Ohmuro, H., et al., Autophagy in embryonic erythroid cells: its role in 
maturation. Eur J Cell Biol, 2000. 79(10): p. 759-64. 
360. Jacquel, A., et al., Autophagy is required for CSF-1-induced macrophagic 
differentiation and acquisition of phagocytic functions. Blood, 2012. 119(19): p. 
4527-31. 
281 
 
361. Zhao, Y., et al., Autophagy regulates hypoxia-induced osteoclastogenesis 
through the HIF-1alpha/BNIP3 signaling pathway. J Cell Physiol, 2012. 227(2): 
p. 639-48. 
362. Aymard, E., et al., Autophagy in human keratinocytes: an early step of the 
differentiation? Exp Dermatol, 2011. 20(3): p. 263-8. 
363. Calabretta, B. and D. Perrotti, The biology of CML blast crisis. Blood, 2004. 
103(11): p. 4010-22. 
364. Perrotti, D., et al., BCR-ABL suppresses C/EBPalpha expression through 
inhibitory action of hnRNP E2. Nat Genet, 2002. 30(1): p. 48-58. 
365. Kubonishi, I. and I. Miyoshi, Establishment of a Ph1 chromosome-positive cell 
line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning, 1983. 
1(2): p. 105-17. 
366. Rosenhahn, J., et al., Cytogenetic characterisation and proteomic profiling of the 
Imatinib-resistant cell line KCL22-R. Int J Oncol, 2007. 31(1): p. 121-8. 
367. Law, J.C., et al., Mutational inactivation of the p53 gene in the human erythroid 
leukemic K562 cell line. Leuk Res, 1993. 17(12): p. 1045-50. 
368. Naumann, S., et al., Complete karyotype characterization of the K562 cell line by 
combined application of G-banding, multiplex-fluorescence in situ hybridization, 
fluorescence in situ hybridization, and comparative genomic hybridization. Leuk 
Res, 2001. 25(4): p. 313-22. 
369. Lockhart, D.J., et al., Expression monitoring by hybridization to high-density 
oligonucleotide arrays. Nat Biotechnol, 1996. 14(13): p. 1675-80. 
370. Rutherford, T.R., J.B. Clegg, and D.J. Weatherall, K562 human leukaemic 
cells synthesise embryonic haemoglobin in response to haemin. Nature, 1979. 
280(5718): p. 164-5. 
371. Gambari, R., et al., Predominant expression of zeta and epsilon globin genes in 
human leukemia K-562(S6) variant cell line. Experientia, 1983. 39(4): p. 415-6. 
372. Bianchi Scarra, G.L., et al., Terminal erythroid differentiation in the K-562 cell 
line by 1-beta-D-arabinofuranosylcytosine: accompaniment by c-myc messenger 
RNA decrease. Cancer Res, 1986. 46(12 Pt 1): p. 6327-32. 
373. Cioe, L., et al., Differential expression of the globin genes in human leukemia 
K562(S) cells induced to differentiate by hemin or butyric acid. Cancer Res, 
1981. 41(1): p. 237-43. 
374. Gambari, R., et al., Human leukemia K-562 cells: induction of erythroid 
differentiation by 5-azacytidine. Cell Differ, 1984. 14(2): p. 87-97. 
375. Zhang, J., et al., Mitochondrial clearance is regulated by Atg7-dependent and -
independent mechanisms during reticulocyte maturation. Blood, 2009. 114(1): p. 
157-64. 
376. Tal, M.C., et al., Absence of autophagy results in reactive oxygen species-
dependent amplification of RLR signaling. Proc Natl Acad Sci U S A, 2009. 
106(8): p. 2770-5. 
377. Sardina, J.L., et al., p22phox-dependent NADPH oxidase activity is required for 
megakaryocytic differentiation. Cell Death Differ, 2010. 17(12): p. 1842-54. 
378. Rosen, A., et al., Lymphoblastoid cell line with B1 cell characteristics established 
from a chronic lymphocytic leukemia clone by in vitro EBV infection. 
Oncoimmunology, 2012. 1(1): p. 18-27. 
379. Druker, B.J. and N.B. Lydon, Lessons learned from the development of an abl 
tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest, 2000. 
105(1): p. 3-7. 
380. Gambacorti-Passerini, C., et al., Multicenter independent assessment of 
outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl 
Cancer Inst, 2011. 103(7): p. 553-61. 
282 
 
381. Druker, B.J., et al., Activity of a specific inhibitor of the BCR-ABL tyrosine 
kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic 
leukemia with the Philadelphia chromosome. N Engl J Med, 2001. 344(14): p. 
1038-42. 
382. Khorashad, J.S., et al., The presence of a BCR-ABL mutant allele in CML does 
not always explain clinical resistance to imatinib. Leukemia, 2006. 20(4): p. 658-
63. 
383. Barnes, D.J., et al., Bcr-Abl expression levels determine the rate of development 
of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res, 
2005. 65(19): p. 8912-9. 
384. Jiang, X., et al., Chronic myeloid leukemia stem cells possess multiple unique 
features of resistance to BCR-ABL targeted therapies. Leukemia, 2007. 21(5): p. 
926-35. 
385. Yuk, J.M., T. Yoshimori, and E.K. Jo, Autophagy and bacterial infectious 
diseases. Exp Mol Med, 2012. 44(2): p. 99-108. 
386. Masiero, E., et al., Autophagy is required to maintain muscle mass. Cell Metab, 
2009. 10(6): p. 507-15. 
387. Jaeger, P.A. and T. Wyss-Coray, All-you-can-eat: autophagy in 
neurodegeneration and neuroprotection. Mol Neurodegener, 2009. 4: p. 16. 
388. White, E., et al., Role of autophagy in suppression of inflammation and cancer. 
Curr Opin Cell Biol, 2010. 22(2): p. 212-7. 
389. Liang, X.H., et al., Protection against fatal Sindbis virus encephalitis by beclin, a 
novel Bcl-2-interacting protein. J Virol, 1998. 72(11): p. 8586-96. 
390. Kang, M.R., et al., Frameshift mutations of autophagy-related genes ATG2B, 
ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite 
instability. J Pathol, 2009. 217(5): p. 702-6. 
391. Knaevelsrud, H., et al., UVRAG mutations associated with microsatellite 
unstable colon cancer do not affect autophagy. Autophagy, 2010. 6(7): p. 863-
70. 
392. Liang, C., et al., Beyond autophagy: the role of UVRAG in membrane 
trafficking. Autophagy, 2008. 4(6): p. 817-20. 
393. Moscat, J. and M.T. Diaz-Meco, p62 at the crossroads of autophagy, apoptosis, 
and cancer. Cell, 2009. 137(6): p. 1001-4. 
394. Cheung, Z.H. and N.Y. Ip, The emerging role of autophagy in Parkinson's 
disease. Mol Brain, 2009. 2: p. 29. 
395. Harris, A.L., Hypoxia--a key regulatory factor in tumour growth. Nat Rev 
Cancer, 2002. 2(1): p. 38-47. 
396. Degenhardt, K., et al., Autophagy promotes tumor cell survival and restricts 
necrosis, inflammation, and tumorigenesis. Cancer Cell, 2006. 10(1): p. 51-64. 
397. Mathew, R., V. Karantza-Wadsworth, and E. White, Role of autophagy in 
cancer. Nat Rev Cancer, 2007. 7(12): p. 961-7. 
398. Amaravadi, R.K., et al., Autophagy inhibition enhances therapy-induced 
apoptosis in a Myc-induced model of lymphoma. J Clin Invest, 2007. 117(2): p. 
326-36. 
399. Sasaki, K., et al., Chloroquine potentiates the anti-cancer effect of 5-fluorouracil 
on colon cancer cells. BMC Cancer, 2010. 10: p. 370. 
400. Mujumdar, N. and A.K. Saluja, Autophagy in pancreatic cancer: an emerging 
mechanism of cell death. Autophagy, 2010. 6(7): p. 997-8. 
401. Shimizu, S., et al., Role of Bcl-2 family proteins in a non-apoptotic programmed 
cell death dependent on autophagy genes. Nat Cell Biol, 2004. 6(12): p. 1221-8. 
402. Cao, C., et al., Inhibition of mammalian target of rapamycin or apoptotic 
pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. 
Cancer Res, 2006. 66(20): p. 10040-7. 
283 
 
403. Ertmer, A., et al., The anticancer drug imatinib induces cellular autophagy. 
Leukemia, 2007. 21(5): p. 936-42. 
404. Lum, J.J., et al., Growth factor regulation of autophagy and cell survival in the 
absence of apoptosis. Cell, 2005. 120(2): p. 237-48. 
405. Codogno, P. and A.J. Meijer, Autophagy and signaling: their role in cell 
survival and cell death. Cell Death Differ, 2005. 12 Suppl 2: p. 1509-18. 
406. Lum, J.J., R.J. DeBerardinis, and C.B. Thompson, Autophagy in metazoans: 
cell survival in the land of plenty. Nat Rev Mol Cell Biol, 2005. 6(6): p. 439-48. 
407. Finbloom, D.S., et al., Comparison of hydroxychloroquine and chloroquine use 
and the development of retinal toxicity. J Rheumatol, 1985. 12(4): p. 692-4. 
408. Munster, T., et al., Hydroxychloroquine concentration-response relationships in 
patients with rheumatoid arthritis. Arthritis Rheum, 2002. 46(6): p. 1460-9. 
409. Zhu, S., et al., Inhibiting autophagy potentiates the anticancer activity of 
IFN1@/ IFNalpha in chronic myeloid leukemia cells. Autophagy, 2012. 9(3). 
410. Schafranek, L., et al., Clarithromycin enhances dasatinib-induced cell death in 
chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leuk 
Lymphoma, 2012. 
411. Huang, W.S., et al., Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-
methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-
(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-
inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the 
T315I gatekeeper mutant. J Med Chem, 2010. 53(12): p. 4701-19. 
412. Cassuto, O., et al., All tyrosine kinase inhibitor-resistant chronic myelogenous 
cells are highly sensitive to Ponatinib. Oncotarget, 2012. 
413. Eiring, A.M., et al., Advances in the treatment of chronic myeloid leukemia. 
BMC Med, 2011. 9: p. 99. 
414. Robert, G., et al., Acadesine kills chronic myelogenous leukemia (CML) cells 
through PKC-dependent induction of autophagic cell death. PLoS One, 2009. 
4(11): p. e7889. 
415. Huang, H.L., et al., Lapatinib induces autophagy, apoptosis and megakaryocytic 
differentiation in chronic myelogenous leukemia K562 cells. PLoS One, 2011. 
6(12): p. e29014. 
416. Goussetis, D.J., et al., Autophagic degradation of the BCR-ABL oncoprotein and 
generation of antileukemic responses by arsenic trioxide. Blood, 2012. 120(17): 
p. 3555-62. 
417. Sandilands, E., et al., Autophagic targeting of Src promotes cancer cell survival 
following reduced FAK signalling. Nat Cell Biol, 2012. 14(1): p. 51-60. 
418. Komatsu, M., et al., Impairment of starvation-induced and constitutive 
autophagy in Atg7-deficient mice. J Cell Biol, 2005. 169(3): p. 425-34. 
419. Cairns, R.A., I.S. Harris, and T.W. Mak, Regulation of cancer cell metabolism. 
Nat Rev Cancer, 2011. 11(2): p. 85-95. 
420. Chen, M., H. Sandoval, and J. Wang, Selective mitochondrial autophagy during 
erythroid maturation. Autophagy, 2008. 4(7): p. 926-8. 
421. Mortensen, M., et al., Loss of autophagy in erythroid cells leads to defective 
removal of mitochondria and severe anemia in vivo. Proc Natl Acad Sci U S A, 
2010. 107(2): p. 832-7. 
422. Liu, F. and J.L. Guan, FIP200, an essential component of mammalian 
autophagy is indispensible for fetal hematopoiesis. Autophagy, 2011. 7(2): p. 
229-30. 
423. Kelli P.A. MacDonald, L.L., Therese Vu, Claudia Bruedigam, Geoffrey R. Hill 
and Steven W. Lane. Autophagy is a constitutively active process in long-term 
hematopoietic stem cells and is essential for their survival and function. in 
284 
 
Keystone Symposia, Autophagy, Inflammation and Immunity. 2013. Montreal, 
Canada. 
424. Wu, Y.T., et al., Autophagy plays a protective role during zVAD-induced 
necrotic cell death. Autophagy, 2008. 4(4): p. 457-66. 
425. Jin, S., et al., Metabolic catastrophe as a means to cancer cell death. J Cell Sci, 
2007. 120(Pt 3): p. 379-83. 
426. Salemi, S., et al., Autophagy is required for self-renewal and differentiation of 
adult human stem cells. Cell Res, 2012. 22(2): p. 432-5. 
427. Oliver, L., et al., Basal autophagy decreased during the differentiation of human 
adult mesenchymal stem cells. Stem Cells Dev, 2012. 21(15): p. 2779-88. 
428. Wang, J., et al., A differentiation checkpoint limits hematopoietic stem cell self-
renewal in response to DNA damage. Cell, 2012. 148(5): p. 1001-14. 
 
 
